"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 1288796 A,134-019-725-507-44X,1918-12-24,1918,US 23558618 A,1918-05-20,US 23558618 A,1918-05-20,LAMP CHIMNEY AND BURNER.,,ANDERSON LAURA,ANDERSON LAURA,,https://lens.org/134-019-725-507-44X,Granted Patent,no,0,0,1,1,0,F21V17/00;;F21V17/00,,,0,0,,,,EXPIRED
2,US,A,US 5286152 A,041-045-825-592-108,1994-02-15,1994,US 98697492 A,1992-12-08,US 98697492 A,1992-12-08,Rivet fastener with push-in releasable drive pin,A rivet fastener which can be readily and repeatedly removed and reinstalled including a rivet body and a drive pin where the drive pin can be inserted within the rivet body so as to retain the fastener within an article and upon further insertion of the drive pin the fastener is released from an article where the drive pin does not protrude from the back side of the rivet body either during fastening or removal thereof.,ILLINOIS TOOL WORKS,ANDERSON LAURA A,ILLINOIS TOOL WORKS INC (1992-12-07),https://lens.org/041-045-825-592-108,Granted Patent,yes,8,42,3,3,0,F16B19/1081;;F16B19/1081,F16B19/10,411/45;;411/41,0,0,,,,EXPIRED
3,FR,B1,FR 2698922 B1,178-080-671-969-284,1995-11-17,1995,FR 9314658 A,1993-12-07,US 98697492 A,1992-12-08,ORGANE DE FIXATION A RIVETER.,,ILLINOIS TOOL WORKS,ANDERSON LAURA A,,https://lens.org/178-080-671-969-284,Granted Patent,no,0,0,3,3,0,F16B19/1081;;F16B19/1081,F16B19/10,,0,0,,,,EXPIRED
4,FR,A1,FR 2698922 A1,147-049-000-175-125,1994-06-10,1994,FR 9314658 A,1993-12-07,US 98697492 A,1992-12-08,Organe de fixation à riveter.,"<P>L'invention concerne un organe de fixation à riveter qui peut être posé et enlevé de façon répétée et aisée. <BR/> Il comprend un corps (16) de rivet et une broche (18) de pose pouvant être insérées dans le corps pour retenir l'organe de fixation sur un article (12, 14). La poursuite de l'insertion de la broche de pose permet de libérer l'organe de fixation de l'article, la broche de pose ne dépassant jamais du côté arrière du corps du rivet durant la fixation ou son enlèvement. <BR/> Domaine d'application: rivetage de panneaux, etc.</P>",ILLINOIS TOOL WORKS,ANDERSON LAURA A,,https://lens.org/147-049-000-175-125,Patent Application,no,4,0,3,3,0,F16B19/1081;;F16B19/1081,F16B19/10,,0,0,,,,EXPIRED
5,US,A1,US 2014/0120580 A1,049-666-765-004-548,2014-05-01,2014,US 201314019399 A,2013-09-05,US 201314019399 A;;US 201113033521 A;;US 43848406 A;;US 35188606 A;;US 22769402 A;;US 31520901 P,2001-08-27,SYSTEM FOR ANTIBODY EXPRESSION AND ASSEMBLY,"The present invention provides methods and compositions for expression and production of recombinant antibodies in a host cell system, such as prokaryotic and eukaryotic expression systems. Particularly contemplated are recombinant systems for temporally separated expression of light chain and heavy chain of antibodies. The antibody products including antibody fragments can be used in various aspects of biological research, diagnosis and medical treatment.",GENENTECH INC,SIMMONS LAURA;;ANDERSON DANA,,https://lens.org/049-666-765-004-548,Patent Application,yes,0,8,25,26,6,C07K16/00;;C07K16/2845;;C07K16/2896;;C07K2317/54;;C07K16/36;;C07K16/00;;C07K16/00;;C07K16/2845;;C07K16/2896;;C07K2317/54;;C07K16/36,C07K16/36;;C12N15/09;;C07K16/00;;C07K16/28;;C12N1/21;;C12N15/13;;C12P21/02;;C12P21/08,435/69.6;;435/252.33;;435/320.1,0,0,,,,EXPIRED
6,US,A1,US 2007/0224664 A1,141-953-451-322-347,2007-09-27,2007,US 62707107 A,2007-01-25,US 62707107 A;;US 35188606 A;;US 22769402 A;;US 31520901 P,2001-08-27,System for Antibody Expression and Assembly,"The present invention provides methods and compositions for expression and production of recombinant antibodies in a host cell system, such as prokaryotic and eukaryotic expression systems. Particularly contemplated are recombinant systems for temporally separated expression of light chain and heavy chain of antibodies. The antibody products including antibody fragments can be used in various aspects of biological research, diagnosis and medical treatment.",GENENTECH INC,SIMMONS LAURA C;;ANDERSON DANA,,https://lens.org/141-953-451-322-347,Patent Application,yes,30,9,25,26,6,C07K16/00;;C07K16/2845;;C07K16/2896;;C07K2317/54;;C07K16/36;;C07K16/00;;C07K16/00;;C07K16/2845;;C07K16/2896;;C07K2317/54;;C07K16/36,C12N15/09;;C12P21/02;;C07K16/00;;C07K16/28;;C07K16/36;;C12N1/21;;C12N15/00;;C12N15/13;;C12P21/08,435/69.6;;435/252.3;;435/252.33;;435/320.1,0,0,,,,DISCONTINUED
7,EP,B1,EP 3495461 B1,149-591-638-251-097,2022-06-22,2022,EP 18197140 A,2018-09-27,US 201715836990 A,2017-12-11,AUTOMOTIVE TRANSMISSION FLUID COMPOSITIONS FOR IMPROVED ENERGY EFFICIENCY,,INFINEUM INT LTD,KIM HAHNSOO;;KAHSAR LAURA ANDERSON,,https://lens.org/149-591-638-251-097,Granted Patent,yes,4,0,10,10,0,C10M141/08;;C10M141/10;;C10M161/00;;C10M2215/28;;C10M2219/062;;C10M2219/066;;C10M2223/045;;C10N2030/54;;C10N2040/042;;C10N2030/06;;C10N2070/02;;C10M169/04;;C10M125/04;;C10M149/22;;C10M2201/06;;C10M2215/24;;C10N2040/042;;C10N2040/04;;C10N2030/54;;C10M141/10;;C10M161/00;;C10M2215/28;;C10M141/08;;C10M2219/062;;C10M2223/045;;C10M2219/066;;C10N2030/06;;C10N2030/54;;C10N2040/042;;C10N2070/02;;C10M141/12;;C10M2215/223;;C10M2227/09,C10M141/08;;C10M141/10;;C10M161/00;;C10N30/00;;C10N30/06;;C10N40/04;;C10N70/00,,0,0,,,,ACTIVE
8,EP,A1,EP 3495461 A1,046-190-411-222-564,2019-06-12,2019,EP 18197140 A,2018-09-27,US 201715836990 A,2017-12-11,AUTOMOTIVE TRANSMISSION FLUID COMPOSITIONS FOR IMPROVED ENERGY EFFICIENCY,"An automatic transmission fluid comprises a major amount of an oil of lubricating viscosity and minor amounts of (a) one or more oil-soluble or dispersible molybdenum-containing compounds, and (b) a reaction product of an isomerized alkenyl-substituted succinic anhydride and a polyamine characterized by structure (II):
  In structure (II) x and y are independently zero or integers from 1 to 30, where x + y is from 1 to 30, and z is zero or an integer from 1 to 10.",INFINEUM INT LTD,KIM HAHNSOO;;KAHSAR LAURA ANDERSON,,https://lens.org/046-190-411-222-564,Patent Application,yes,25,0,10,10,0,C10M141/08;;C10M141/10;;C10M161/00;;C10M2215/28;;C10M2219/062;;C10M2219/066;;C10M2223/045;;C10N2030/54;;C10N2040/042;;C10N2030/06;;C10N2070/02;;C10M169/04;;C10M125/04;;C10M149/22;;C10M2201/06;;C10M2215/24;;C10N2040/042;;C10N2040/04;;C10N2030/54;;C10M141/10;;C10M161/00;;C10M2215/28;;C10M141/08;;C10M2219/062;;C10M2223/045;;C10M2219/066;;C10N2030/06;;C10N2030/54;;C10N2040/042;;C10N2070/02;;C10M141/12;;C10M2215/223;;C10M2227/09,C10M141/08;;C10M141/10;;C10M161/00,,1,0,,,"C.V. SMALLHEER; R. KENNEDY SMITH, LUBRICANT ADDITIVES, 1967, pages 1 - 11",ACTIVE
9,US,A1,US 2003/0069758 A1,029-613-220-632-89X,2003-04-10,2003,US 24444302 A,2002-09-16,US 24444302 A;;US 32835401 P,2001-10-10,System and method for use in providing a healthcare information database,"
   A method for providing accessibility to an information database by users of application software is presented, comprising the steps of retrieving desired data from a first source; processing the data to be suitable for incorporation in a transitional database by using industry specific starter data to aid in merging the desired data; applying a predetermined rule to the processed data to ensure compatibility of the processed data with the transitional database; incorporating the processed data into the transitional database in response to the determination; and communicating transitional database data to a targeted information database. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope of meaning of the claims. 
",ANDERSON LAURA M.;;DENNY ROBERT C.,ANDERSON LAURA M;;DENNY ROBERT C,SIEMENS MEDICAL SOLUTIONS HEALTH SERVICES CORPORATION (2002-11-06),https://lens.org/029-613-220-632-89X,Patent Application,yes,16,54,5,5,0,G16H40/63;;G16H10/60;;G16H40/20;;G16H50/20;;G16H70/00;;G16H40/63;;G16H10/60;;G16H50/20;;G16H40/20;;G16H70/00,G16H10/60;;G16H70/00;;A61B5/00,705/3;;707/102,0,0,,,,DISCONTINUED
10,US,A1,US 2019/0380853 A1,107-894-065-839-188,2019-12-19,2019,US 201916553567 A,2019-08-28,US 201916553567 A;;US 201715411494 A,2017-01-20,VALVE PROSTHESIS HAVING A RADIALLY EXPANDABLE SLEEVE INTEGRATED THEREON FOR DELIVERY AND PREVENTION OF PARAVALVULAR LEAKAGE,"A delivery system includes an elongated shaft component, a self-expanding valve prosthesis, at least one cinching suture, and a radially-expandable sleeve. The valve prosthesis is disposed over a distal portion of the elongated shaft component and includes a compressed configuration for delivery and an expanded configuration for deployment. The at least one cinching suture removably couples the valve prosthesis to the elongated shaft component and radially compresses the valve prosthesis into the compressed configuration for delivery. The sleeve is secured to and encircles an outer surface of the valve prosthesis. The sleeve has a delivery state with a first diameter extending over a full length of the valve prosthesis in the compressed configuration and a deployed state with a greater second diameter extending over the full length of the valve prosthesis in the expanded configuration. The sleeve is configured to prevent paravalvular leakage in situ in the deployed state.",MEDTRONIC VASCULAR INC,ANDERSON MARC;;RUDDY LAURA;;CARROLL GRAINNE,MEDTRONIC VASCULAR INC (2017-01-25),https://lens.org/107-894-065-839-188,Patent Application,yes,1,0,6,6,0,A61F2/2439;;A61F2210/0057;;A61F2230/0069;;A61F2/2466;;A61F2/844;;A61F2210/0057;;A61F2230/0069;;A61F2/2439;;A61F2/2466,A61F2/962;;A61F2/24;;A61F2/844,,0,0,,,,ACTIVE
11,EP,A1,EP 3674385 A1,169-208-990-581-31X,2020-07-01,2020,EP 19213431 A,2019-12-04,US 201816233528 A,2018-12-27,DISPERSANTS FOR LUBRICATING OIL COMPOSITIONS,"A lubricating oil composition comprises a major amount of an oil of lubricating viscosity and a minor amount of an unsymmetrical bis-succinimide, or a mixture of unsymmetrical bis-succinimides, of the structure (I):
  One of R 1  and R 2  is a polyisobutylene group having a weight average molecular weight of 400 to 5,000, as determined by GPC with reference to linear polystyrene standards, and the other of R 1  and R 2  is a hydrocarbon group made by the metallocene-catalysed polymerisation of an α-olefin feedstock. Value x is from 1 to 10 and is the same for all molecules of structure (I) or an average of all molecules of structure (I) in a mixture of molecules of structure (I).",INFINEUM INT LTD,GORDA KEITH RAYMOND;;KAHSAR LAURA ANDERSON,,https://lens.org/169-208-990-581-31X,Patent Application,yes,22,2,8,8,0,C10M169/041;;C10M169/044;;C10M133/16;;C08F8/32;;C10M2215/086;;C10M133/56;;C10M2215/28;;C10N2040/042;;C10N2030/06;;C10N2040/042;;C08G81/024;;C10M149/22;;C10M169/041;;C10M2203/003;;C10M2217/046,C10M105/68;;C10M133/56,,1,0,,,"C.V. SMALLHEERR. KENNEDY SMITH, LUBRICANT ADDITIVES, 1967, pages 1 - 11",ACTIVE
12,EP,A3,EP 1302888 A3,175-807-300-301-176,2006-11-22,2006,EP 02256921 A,2002-10-04,US 32835401 P;;US 24444302 A,2001-10-10,A system and method for use in providing a healthcare information database,"A method for providing accessibility to an information database by users of application software is presented, comprising the steps of retrieving desired data from a first source; processing the data to be suitable for incorporation in a transitional database (40) by using industry specific starter data (35) to aid in merging the desired data; applying a predetermined rule (22) to the processed data to ensure compatibility of the processed data with the transitional database (40); incorporating the processed data into the transitional database in response to the determination; and communicating transitional database data to a targeted information database (62).
",SIEMENS MED SOLUTIONS HEALTH,ANDERSON LAURA M;;DENNY ROBERT C,,https://lens.org/175-807-300-301-176,Search Report,yes,0,0,5,5,0,G16H40/63;;G16H10/60;;G16H40/20;;G16H50/20;;G16H70/00;;G16H40/63;;G16H10/60;;G16H50/20;;G16H40/20;;G16H70/00,A61B5/00;;G16H10/60;;G16H70/00,,1,1,080-097-195-237-37X,11187645,"ABIDI S S R; MANICKAM S: ""Transforming XML-based electronic patient records for use in medical case based reasoning systems."", MEDICAL INFOBAHN FOR EUROPE. PROCEEDINGS OF MIE2000 AND GMDS2000, 2000, Amsterdam, Netherlands, pages 709 - 713, XP001247168",DISCONTINUED
13,ES,T3,ES 2357093 T3,046-474-655-953-827,2011-04-18,2011,ES 06759891 T,2006-05-16,US 68226905 P,2005-05-18,ELUCION DE FARMACO PARA DISPOSITIVOS PARA LA INCONTINENCIA IMPLANTABLES.,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,TIMM GERALD;;ANDERSON DAVID;;SKADSBERG LAURA,,https://lens.org/046-474-655-953-827,Granted Patent,no,0,0,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F2/00;;A61F5/00,,0,0,,,,ACTIVE
14,EP,B1,EP 3674385 B1,075-832-580-750-134,2021-03-10,2021,EP 19213431 A,2019-12-04,US 201816233528 A,2018-12-27,DISPERSANTS FOR LUBRICATING OIL COMPOSITIONS,,INFINEUM INT LTD,GORDA KEITH RAYMOND;;KAHSAR LAURA ANDERSON,,https://lens.org/075-832-580-750-134,Granted Patent,yes,3,0,8,8,0,C10M169/041;;C10M169/044;;C10M133/16;;C08F8/32;;C10M2215/086;;C10M133/56;;C10M2215/28;;C10N2040/042;;C10N2030/06;;C10N2040/042;;C08G81/024;;C10M149/22;;C10M169/041;;C10M2203/003;;C10M2217/046,C10M105/68;;C10M133/56,,0,0,,,,ACTIVE
15,CN,A,CN 111378517 A,068-117-529-911-506,2020-07-07,2020,CN 201911365752 A,2019-12-26,US 201816233528 A,2018-12-27,DISPERSANTS FOR LUBRICATING OIL COMPOSITIONS,"A lubricating oil composition comprises a major amount of an oil of lubricating viscosity and a minor amount of an unsymmetrical bis-succinimide, or a mixture of unsymmetrical bis-succinimides, of thestructure (I):One of R1and R2is a polyisobutylene group having a weight average molecular weight of 400 to 5,000, as determined by GPC with reference to linear polystyrene standards, and the other ofR1and R2is a hydrocarbon group made by the metallocene-catalysed polymerisation of an alpha-olefin feedstock. Value x is from 1 to 10 and is the same for all molecules of structure (I) or an averageof all molecules of structure (I) in a mixture of molecules of structure (I).",LNFINEUM INT LTD,GORDA KEITH RAYMOND;;KAHSAR LAURA ANDERSON,,https://lens.org/068-117-529-911-506,Patent Application,no,2,0,8,8,0,C10M169/041;;C10M169/044;;C10M133/16;;C08F8/32;;C10M2215/086;;C10M133/56;;C10M2215/28;;C10N2040/042;;C10N2030/06;;C10N2040/042;;C08G81/024;;C10M149/22;;C10M169/041;;C10M2203/003;;C10M2217/046,C10M169/04;;C08F8/32;;C08F110/10;;C08F210/14;;C10M133/16;;C10N30/04;;C10N30/06,,0,0,,,,PENDING
16,US,B2,US 11666443 B2,069-881-172-016-532,2023-06-06,2023,US 201916553567 A,2019-08-28,US 201916553567 A;;US 201715411494 A,2017-01-20,Valve prosthesis having a radially expandable sleeve integrated thereon for delivery and prevention of paravalvular leakage,"A delivery system includes an elongated shaft component, a self-expanding valve prosthesis, at least one cinching suture, and a radially-expandable sleeve. The valve prosthesis is disposed over a distal portion of the elongated shaft component and includes a compressed configuration for delivery and an expanded configuration for deployment. The at least one cinching suture removably couples the valve prosthesis to the elongated shaft component and radially compresses the valve prosthesis into the compressed configuration for delivery. The sleeve is secured to and encircles an outer surface of the valve prosthesis. The sleeve has a delivery state with a first diameter extending over a full length of the valve prosthesis in the compressed configuration and a deployed state with a greater second diameter extending over the full length of the valve prosthesis in the expanded configuration. The sleeve is configured to prevent paravalvular leakage in situ in the deployed state.",MEDTRONIC VASCULAR INC,ANDERSON MARC;;RUDDY LAURA;;CARROLL GRAINNE,MEDTRONIC VASCULAR INC (2017-01-25),https://lens.org/069-881-172-016-532,Granted Patent,yes,183,0,6,6,0,A61F2/2439;;A61F2210/0057;;A61F2230/0069;;A61F2/2466;;A61F2/844;;A61F2210/0057;;A61F2230/0069;;A61F2/2439;;A61F2/2466,A61F2/24;;A61F2/844,,1,0,,,"PCT Communication issued in PCT Application No. PCT/US2017/066199, dated Mar. 23, 2018.",ACTIVE
17,AT,T1,AT E489052 T1,122-990-825-748-582,2010-12-15,2010,AT 06759891 T,2006-05-16,US 68226905 P;;US 2006/0018830 W,2005-05-18,WIRKSTOFFELUIERUNG FÜR IMPLANTIERBARE INKONTINENZGERÄTE,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,TIMM GERALD;;ANDERSON DAVID;;SKADSBERG LAURA,,https://lens.org/122-990-825-748-582,Granted Patent,no,0,0,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,,,0,0,,,,INACTIVE
18,EP,A2,EP 1302888 A2,196-565-295-152-42X,2003-04-16,2003,EP 02256921 A,2002-10-04,US 32835401 P;;US 24444302 A,2001-10-10,A system and method for use in providing a healthcare information database,"A method for providing accessibility to an information database by users of application software is presented, comprising the steps of retrieving desired data from a first source; processing the data to be suitable for incorporation in a transitional database (40) by using industry specific starter data (35) to aid in merging the desired data; applying a predetermined rule (22) to the processed data to ensure compatibility of the processed data with the transitional database (40); incorporating the processed data into the transitional database in response to the determination; and communicating transitional database data to a targeted information database (62).",SIEMENS MED SOLUTIONS HEALTH,ANDERSON LAURA M;;DENNY ROBERT C,,https://lens.org/196-565-295-152-42X,Patent Application,yes,0,1,5,5,0,G16H40/63;;G16H10/60;;G16H40/20;;G16H50/20;;G16H70/00;;G16H40/63;;G16H10/60;;G16H50/20;;G16H40/20;;G16H70/00,G16H10/60;;A61B5/00;;G16H70/00,,0,0,,,,DISCONTINUED
19,JP,A,JP 2003208472 A,137-457-375-167-025,2003-07-25,2003,JP 2002297649 A,2002-10-10,US 32835401 P;;US 24444302 A,2001-10-10,"METHOD OF GIVING ACCESS RIGHT OF HEALTH CARE INFORMATION DATABASE, AND METHOD OF GIVING USER INTERFACE FOR SUPPORTING INTEGRATION OF DATA ELEMENTS RELATED TO PATIENT","<P>PROBLEM TO BE SOLVED: To construct a database for health care information related to a patient to support a health care information system used in a hospital and an enterprise related to health care. <P>SOLUTION: (a) A patient-related data is acquired, (b) the acquired patient- related data is processed to be suitable to integration to a transition database having prescribed initial structure and a prescribed data, (c) a prescribed rule is applied to the processed patient-related data to ensure compatibility between the patient-related data and the transition database, (d) the processed patient- related data is integrated to the transition database in response to a determined result, and (e) a data in the transition database is communicated to a user health care information database. <P>COPYRIGHT: (C)2003,JPO",SIEMENS MED SOLUTIONS HEALTH,ANDERSON LAURA M;;DENNY ROBERT C JR,,https://lens.org/137-457-375-167-025,Patent Application,no,0,3,5,5,0,G16H40/63;;G16H10/60;;G16H40/20;;G16H50/20;;G16H70/00;;G16H40/63;;G16H10/60;;G16H50/20;;G16H40/20;;G16H70/00,G16H10/60;;G16H70/00;;A61B5/00,,0,0,,,,DISCONTINUED
20,WO,A2,WO 2010/083501 A2,130-559-785-674-938,2010-07-22,2010,US 2010/0021356 W,2010-01-19,US 14535709 P,2009-01-16,"ALPHA-HELIX MIMETIC USING A 2,5-OLIGOPYRIMIDINE SCAFFOLD","Alpha-helix mimetics and associated methods of making are provided. These compounds are constructed using a 2,5-oligopyrimidine scaffold. The semi-rigid scaffold holds individual side chain-like residues in orientations that mimic the orientations of side chain residues of an ?-helical protein domain. The new scaffold is easier to make than previous scaffolds and has much more favorable physical properties than previous alpha-helix mimics. The amphiphilic alpha-helix mimetics have application for making libraries and for treating diseases or conditions effected by the inhibition or disruption of interactions with the alpha helix of a protein.",UNIV SOUTH FLORIDA;;H LEE MOFFITT CANCER CT AND RE;;MCLAUGHLIN MARK L;;ANDERSON LAURA;;ZHOU MINGZHOU,MCLAUGHLIN MARK L;;ANDERSON LAURA;;ZHOU MINGZHOU,,https://lens.org/130-559-785-674-938,Patent Application,yes,0,19,2,2,0,A61K31/435;;A61P35/00;;C07D403/14,C07D403/14;;A61K31/435;;A61P35/00,,0,0,,,,PENDING
21,CA,A1,CA 2407168 A1,110-309-780-430-734,2003-04-10,2003,CA 2407168 A,2002-10-08,US 32835401 P;;US 24444302 A,2001-10-10,A SYSTEM AND METHOD FOR USE IN PROVIDING A HEALTHCARE INFORMATION DATABASE,"A method for providing accessibility to an information database by users of application software is presented, comprising the steps of retrieving desired data from a first source; processing the data to be suitable for incorporation in a transitional database by using industry specific starter data to aid in merging the desired data; applying a predetermined rule to the processed data to ensure compatibility of the processed data with the transitional database; incorporating the processed data into the transitional database in response to the determination; and communicating transitional database data to a targeted information database. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope of meaning of the claims.",SIEMENS MED SOLUTIONS HEALTH,DENNY ROBERT C JR;;ANDERSON LAURA M,,https://lens.org/110-309-780-430-734,Patent Application,no,0,0,5,5,0,G16H40/63;;G16H10/60;;G16H40/20;;G16H50/20;;G16H70/00;;G16H40/63;;G16H10/60;;G16H50/20;;G16H40/20;;G16H70/00,G16H10/60;;G16H70/00;;A61B5/00,,0,0,,,,DISCONTINUED
22,WO,A3,WO 2010/083501 A3,174-427-486-484-757,2011-03-31,2011,US 2010/0021356 W,2010-01-19,US 14535709 P,2009-01-16,"ALPHA-HELIX MIMETIC USING A 2,5-OLIGOPYRIMIDINE SCAFFOLD","Alpha-helix mimetics and associated methods of making are provided. These compounds are constructed using a 2,5-oligopyrimidine scaffold. The semi-rigid scaffold holds individual side chain-like residues in orientations that mimic the orientations of side chain residues of an ?-helical protein domain. The new scaffold is easier to make than previous scaffolds and has much more favorable physical properties than previous alpha-helix mimics. The amphiphilic alpha-helix mimetics have application for making libraries and for treating diseases or conditions effected by the inhibition or disruption of interactions with the alpha helix of a protein.",UNIV SOUTH FLORIDA;;H LEE MOFFITT CANCER CT & RES;;MCLAUGHLIN MARK L;;ANDERSON LAURA;;ZHOU MINGZHOU,MCLAUGHLIN MARK L;;ANDERSON LAURA;;ZHOU MINGZHOU,,https://lens.org/174-427-486-484-757,Search Report,yes,2,0,2,2,0,A61K31/435;;A61P35/00;;C07D403/14,C07D403/14;;A61K31/435;;A61P35/00,,3,3,050-935-819-480-709;;101-404-468-723-814;;034-703-101-786-968,10.1042/bst0361414;;19021566;;10.1016/j.bmcl.2008.06.074;;18639452;;16763614;;10.1038/sj.cdd.4401992,"SARAPGI, SHU ET AL.: ""a-Helix mimetics as inhibitors of protein-protein interactions."", BIOCHEM. SOC. TRANS., vol. 36, 2008, pages 1414 - 1417;;RESTORP. PER ET AL.: ""Synthesis of a-helix mimetics with four side-chains."", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 18, 2008, pages 5909 - 5911, XP025627167, DOI: doi:10.1016/j.bmcl.2008.06.074;;WALENSKY, LD.: ""BCL-2 in the crosshairs: tipping the balance of life and death."", CELL DEATH AND DIFFERENTIATION., vol. 13, 2006, pages 1339 - 1350",PENDING
23,WO,A1,WO 2018/136174 A1,095-855-980-790-802,2018-07-26,2018,US 2017/0066199 W,2017-12-13,US 201715411494 A,2017-01-20,VALVE PROSTHESIS HAVING A RADIALLY-EXPANDABLE SLEEVE INTEGRATED THEREON FOR DELIVERY AND PREVENTION OF PARAVALVULAR LEAKAGE,"A delivery system includes an elongated shaft component, a self-expanding valve prosthesis, at least one cinching suture, and a radially-expandable sleeve. The valve prosthesis is disposed over a distal portion of the elongated shaft component and includes a compressed configuration for delivery and an expanded configuration for deployment. The at least one cinching suture removably couples the valve prosthesis to the elongated shaft component and radially compresses the valve prosthesis into the compressed configuration for delivery. The sleeve is secured to and encircles an outer surface of the valve prosthesis. The sleeve has a delivery state with a first diameter extending over a full length of the valve prosthesis in the compressed configuration and a deployed state with a greater second diameter extending over the full length of the valve prosthesis in the expanded configuration. The sleeve is configured to prevent paravalvular leakage in situ in the deployed state.",MEDTRONIC VASCULAR INC,ROTHSTEIN PAUL;;ANDERSON MARC;;RUDDY LAURA;;CARROLL GRAINNE,,https://lens.org/095-855-980-790-802,Patent Application,yes,5,0,6,6,0,A61F2/2439;;A61F2210/0057;;A61F2230/0069;;A61F2/2466;;A61F2/844;;A61F2210/0057;;A61F2230/0069;;A61F2/2439;;A61F2/2466,A61F2/24,,0,0,,,,PENDING
24,US,A1,US 2018/0207011 A1,017-557-334-209-003,2018-07-26,2018,US 201715411494 A,2017-01-20,US 201715411494 A,2017-01-20,VALVE PROSTHESIS HAVING A RADIALLY-EXPANDABLE SLEEVE INTEGRATED THEREON FOR DELIVERY AND PREVENTION OF PARAVALVULAR LEAKAGE,"A delivery system includes an elongated shaft component, a self-expanding valve prosthesis, at least one cinching suture, and a radially-expandable sleeve. The valve prosthesis is disposed over a distal portion of the elongated shaft component and includes a compressed configuration for delivery and an expanded configuration for deployment. The at least one cinching suture removably couples the valve prosthesis to the elongated shaft component and radially compresses the valve prosthesis into the compressed configuration for delivery. The sleeve is secured to and encircles an outer surface of the valve prosthesis. The sleeve has a delivery state with a first diameter extending over a full length of the valve prosthesis in the compressed configuration and a deployed state with a greater second diameter extending over the full length of the valve prosthesis in the expanded configuration. The sleeve is configured to prevent paravalvular leakage in situ in the deployed state.",MEDTRONIC VASCULAR INC,ROTHSTEIN PAUL;;ANDERSON MARC;;RUDDY LAURA;;CARROLL GRAINNE,MEDTRONIC VASCULAR INC (2017-01-25),https://lens.org/017-557-334-209-003,Patent Application,yes,0,3,6,6,0,A61F2/2439;;A61F2210/0057;;A61F2230/0069;;A61F2/2466;;A61F2/844;;A61F2210/0057;;A61F2230/0069;;A61F2/2439;;A61F2/2466,A61F2/962;;A61F2/24;;A61F2/844,,0,0,,,,ACTIVE
25,AU,A,AU 2000/039388 A,102-309-069-678-383,2000-12-21,2000,AU 2000/039388 A,2000-06-08,US 33340999 A,1999-06-15,Optical ring network having enhanced security and reduced loss,,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/102-309-069-678-383,Patent Application,no,0,0,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,DISCONTINUED
26,EP,B1,EP 1063802 B1,184-376-028-555-023,2002-04-10,2002,EP 00304779 A,2000-06-06,US 33340999 A,1999-06-15,Optical ring network having enhanced security and reduced loss,,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/184-376-028-555-023,Granted Patent,yes,3,3,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,EXPIRED
27,TW,B,TW 466842 B,061-908-628-216-927,2001-12-01,2001,TW 89111429 A,2000-06-12,US 33340999 A,1999-06-15,Optical ring network having enhanced security and reduced loss,"A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. The WDM ring includes an optical add-drop module (OADM) at each node for adding and dropping signals associated with that node. The WDM ring also includes active terminal equipment at each node for conditioning incoming and outgoing data and for converting between the optical and electrical domains. The OADM at each of at least some nodes, to be referred to as enhanced nodes, is situated at a site physically separated from the powered terminal equipment, and is coupled to the powered terminal equipment via an optical medium. At each enhanced node, traffic not destined for that node is routed through no more than one enclosure on subscriber premises that requires a connection. If there is such enclosure, it contains the OADM.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/061-908-628-216-927,Granted Patent,no,0,0,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,EXPIRED
28,JP,A,JP 2001044944 A,061-698-402-108-648,2001-02-16,2001,JP 2000178072 A,2000-06-14,US 33340999 A,1999-06-15,COMMUNICATION NETWORK,"PROBLEM TO BE SOLVED: To reduce patch panel loss applied to the traffic of another receiver by taking the optical multiplexing and demultiplexing module (OADM) of a double ring two-way optical fiber transmission system out of an electronic cabinet and arranging the optical multiplexing and demultiplexing module at a place where an access possibility is low. SOLUTION: A WDM ring has an OADM that multiplexes and demultiplexes the signal of each node in the node. The WDM ring also has a power terminal device adjusting input - output data and performing conversion between a light area and an electricity area in each node. The OADM 501 of a node is arranged at a place that is physically separated from the power terminal device and connected to the power terminal device through an optical medium. In each node, traffic that is not to the node is subjected to routing through only one housing in the in-house of a subscriber requesting connection. In the case such a housing exists, the housing includes the OADM.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/061-698-402-108-648,Patent Application,no,0,2,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,EXPIRED
29,DE,D1,DE 60000119 D1,058-164-958-162-418,2002-05-16,2002,DE 60000119 T,2000-06-06,US 33340999 A,1999-06-15,Optisches Ringnetzwerk mit erhöhtem Schutz und vermindertem Verlust,,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/058-164-958-162-418,Granted Patent,no,0,0,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,EXPIRED
30,EP,A1,EP 1063802 A1,176-195-890-889-310,2000-12-27,2000,EP 00304779 A,2000-06-06,US 33340999 A,1999-06-15,Optical ring network having enhanced security and reduced loss,"A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. The WDM ring includes an optical add-drop module (OADM) at each node for adding and dropping signals associated with that node. The WDM ring also includes active terminal equipment at each node for conditioning incoming and outgoing data and for converting between the optical and electrical domains. The OADM at each of at least some nodes, to be referred to as enhanced nodes, is situated at a site physically separated from the powered terminal equipment, and is coupled to the powered terminal equipment via an optical medium. At each enhanced node, traffic not destined for that node is routed through no more than one enclosure on subscriber premises that requires a connection. If there is such enclosure, it contains the OADM.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/176-195-890-889-310,Patent Application,yes,3,4,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,EXPIRED
31,US,B1,US 6748175 B1,160-346-577-263-324,2004-06-08,2004,US 33340999 A,1999-06-15,US 33340999 A,1999-06-15,Optical ring network having enhanced security and reduced loss,"
    A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. The WDM ring includes an optical add-drop module (OADM) at each node for adding and dropping signals associated with that node. The WDM ring also includes active terminal equipment at each node for conditioning incoming and outgoing data and for converting between the optical and electrical domains. The OADM at each of at least some nodes, to be referred to as enhanced nodes, is situated at a site physically separated from the powered terminal equipment, and is coupled to the powered terminal equipment via an optical medium. At each enhanced node, traffic not destined for that node is routed through no more than one enclosure on subscriber premises that requires a connection. If there is such enclosure, it contains the OADM. 
",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,LUCENT TECHNOLOGIES INC (1999-08-20),https://lens.org/160-346-577-263-324,Granted Patent,yes,10,10,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,398/82;;398/58;;398/59;;398/83,0,0,,,,EXPIRED
32,DE,T2,DE 60000119 T2,121-816-773-832-132,2002-10-31,2002,DE 60000119 T,2000-06-06,US 33340999 A,1999-06-15,Optisches Ringnetzwerk mit erhöhtem Schutz und vermindertem Verlust,,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/121-816-773-832-132,Granted Patent,no,0,0,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,EXPIRED
33,EP,A1,EP 3570781 A1,048-670-267-115-70X,2019-11-27,2019,EP 17822533 A,2017-12-13,US 201715411494 A;;US 2017/0066199 W,2017-01-20,VALVE PROSTHESIS HAVING A RADIALLY-EXPANDABLE SLEEVE INTEGRATED THEREON FOR DELIVERY AND PREVENTION OF PARAVALVULAR LEAKAGE,,MEDTRONIC VASCULAR INC,ROTHSTEIN PAUL;;ANDERSON MARC;;RUDDY LAURA;;CARROLL GRAINNE,,https://lens.org/048-670-267-115-70X,Patent Application,yes,0,0,6,6,0,A61F2/2439;;A61F2210/0057;;A61F2230/0069;;A61F2/2466;;A61F2/844;;A61F2210/0057;;A61F2230/0069;;A61F2/2439;;A61F2/2466,A61F2/24,,0,0,,,,PENDING
34,KR,A,KR 20010015020 A,051-935-041-705-511,2001-02-26,2001,KR 20000032658 A,2000-06-14,US 33340999 A,1999-06-15,Optical ring network having enhanced security and reduced loss,"PURPOSE: A patch panel loss is reduced applied to the traffic of another receiver by taking the optical multiplexing and demultiplexing module(OADM) of a double ring two-way optical fiber transmission system out of an electronic cabinet and arranging the optical multiplexing and demultiplexing module at a place where an access possibility is low. CONSTITUTION: A WDM ring has an OADM that multiplexes and demultiplexes the signal of each node in the node. The WDM ring also has a power terminal device adjusting input - output data and performing conversion between a light area and an electricity area in each node. The OADM a node is arranged at a place that is physically separated from the power terminal device and connected to the power terminal device through an optical medium. In each node, traffic that is not to the node is subjected to routing through only one housing in the in-house of a subscriber requesting connection. In the case such a housing exists, the housing includes the OADM.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO,,https://lens.org/051-935-041-705-511,Patent Application,no,0,0,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,EXPIRED
35,US,A1,US 2024/0074862 A1,110-836-215-246-613,2024-03-07,2024,US 18308062,2023-04-27,,,VALVE PROSTHESIS HAVING A RADIALLY EXPANDABLE SLEEVE INTEGRATED THEREON FOR DELIVERY AND PREVENTION OF PARAVALVULAR LEAKAGE,"A delivery system includes an elongated shaft component, a self-expanding valve prosthesis, at least one cinching suture, and a radially-expandable sleeve. The valve prosthesis is disposed over a distal portion of the elongated shaft component and includes a compressed configuration for delivery and an expanded configuration for deployment. The at least one cinching suture removably couples the valve prosthesis to the elongated shaft component and radially compresses the valve prosthesis into the compressed configuration for delivery. The sleeve is secured to and encircles an outer surface of the valve prosthesis. The sleeve has a delivery state with a first diameter extending over a full length of the valve prosthesis in the compressed configuration and a deployed state with a greater second diameter extending over the full length of the valve prosthesis in the expanded configuration. The sleeve is configured to prevent paravalvular leakage in situ in the deployed state.","Medtronic Vascular, Inc.",Paul Rothstein;;Marc Anderson;;Laura Ruddy;;Grainne Carroll,,https://lens.org/110-836-215-246-613,Patent Application,yes,0,0,1,1,0,A61F2/2466;;A61F2/2439;;A61F2/844;;A61F2210/0057;;A61F2230/0069,A61F2/24;;A61F2/844,,0,0,,,,UNKNOWN
36,CA,A1,CA 2311144 A1,145-350-276-452-875,2000-12-15,2000,CA 2311144 A,2000-06-02,US 33340999 A,1999-06-15,OPTICAL RING NETWORK HAVING ENHANCED SECURITY AND REDUCED LOSS,"A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. The WDM ring includes an optical add-drop module (OADM) at each node for adding and dropping signals associated with that node. The WDM ring also includes active terminal equipment at each node for conditioning incoming and outgoing data and for converting between the optical and electrical domains. The OADM at each of at least some nodes, to be referred to as enhanced nodes, is situated at a site physically separated from the powered terminal equipment, and is coupled to the powered terminal equipment via an optical medium. At each enhanced node, traffic not destined for that node is routed through no more than one enclosure on subscriber premises that requires a connection. If there is such enclosure, it contains the OADM.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;BROBERG ROBERT MARIO;;ANDERSON JON,,https://lens.org/145-350-276-452-875,Patent Application,no,0,0,12,12,0,H04J14/0206;;H04J14/0213;;H04B10/2581;;H04J14/0213;;H04J14/0206,H04B10/27;;H04B10/2581;;H04B10/275;;H04B10/29;;H04B10/291;;H04J14/00;;H04J14/02;;H04L12/42,,0,0,,,,DISCONTINUED
37,WO,A2,WO 2012/083183 A2,001-774-084-754-577,2012-06-21,2012,US 2011/0065520 W,2011-12-16,US 201061424200 P,2010-12-17,SWELLABLE COSMETIC SYSTEMS,The invention relates to a cosmetic system comprising a basecoat composition comprising at least one acrylic thickener and a topcoat composition comprising at least one aqueous polyurethane dispersion.,OREAL;;LI CHUNHUA;;BUI HY SI;;ANDERSON LAURA;;KANJI MOHAMED,LI CHUNHUA;;BUI HY SI;;ANDERSON LAURA;;KANJI MOHAMED,,https://lens.org/001-774-084-754-577,Patent Application,yes,0,3,3,3,0,A61K8/027;;A61K8/375;;A61K8/731;;A61K8/8152;;A61K8/8164;;A61K8/922;;A61K2800/31;;A61K2800/884;;A61Q1/10;;A61Q1/10;;A61K2800/884;;A61K8/922;;A61K8/027;;A61K8/8152;;A61K2800/31;;A61K8/375;;A61K8/8164;;A61K8/731;;A61K8/8188,A61K8/34;;A61K8/41;;A61K8/72;;A61K8/87;;A61K8/92;;A61Q19/00,,0,0,,,,PENDING
38,EP,A1,EP 1898848 A1,030-931-931-378-989,2008-03-19,2008,EP 06759891 A,2006-05-16,US 2006/0018830 W;;US 68226905 P,2005-05-18,DRUG ELUTION FOR IMPLANTABLE INCONTINENCE DEVICES,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,TIMM GERALD W;;ANDERSON DAVID W;;SKADSBERG LAURA B,,https://lens.org/030-931-931-378-989,Patent Application,yes,0,0,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F2/00;;A61F5/00,,0,0,,,,ACTIVE
39,US,A1,US 2023/0411724 A1,081-515-302-748-382,2023-12-21,2023,US 202118250136 A,2021-10-20,GB 202016722 A;;GB 2021052701 W,2020-10-21,BATTERY RECYCLING,"A method ( 2800 ) of selectively leaching one or more manganese-containing phases from a mixed-phase battery electrode material comprises treating ( 2802 ) the mixed-phase battery electrode material with a solution of an acid, the acid acting as both a leaching agent and a reducing agent, so as to form a manganese-containing leachate whilst leaving at least one phase of the battery electrode material unleached, wherein the acid has a pKa greater than or equal to −2. Either or both of the leachate and the remaining electrode material may then be regenerated ( 2806, 2808 ).",UNIV BIRMINGHAM,DRISCOLL LAURA LOUISE;;SLATER PETER RAYMOND;;ANDERSON PAUL ALEXANDER,THE UNIVERSITY OF BIRMINGHAM (2023-04-17),https://lens.org/081-515-302-748-382,Patent Application,yes,0,0,5,5,0,C22B47/0063;;C01G53/50;;C01G53/006;;C22B3/165;;H01M10/54;;Y02P10/20;;Y02W30/84;;C22B7/007;;C22B47/0063;;H01M4/0471;;H01M4/505;;H01M4/525;;H01M10/54,H01M10/54;;C22B7/00;;C22B47/00;;H01M4/04;;H01M4/505;;H01M4/525,,0,0,,,,PENDING
40,CN,B,CN 101175458 B,132-256-795-727-831,2010-08-18,2010,CN 200680017026 A,2006-05-16,US 2006/0018830 W;;US 68226905 P,2005-05-18,Drug elution for implantable incontinence devices,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,SKADSBERG LAURA B;;TIMM GERALD W;;ANDERSON DAVID W,,https://lens.org/132-256-795-727-831,Granted Patent,no,0,0,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F5/44,,0,0,,,,INACTIVE
41,US,B2,US 8062205 B2,044-956-189-692-103,2011-11-22,2011,US 43496606 A,2006-05-16,US 43496606 A;;US 68226905 P,2005-05-18,Drug elution for implantable incontinence devices,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",TIMM GERALD W;;ANDERSON DAVID W;;SKADSBERG LAURA B;;GT UROLOGICAL LLC,TIMM GERALD W;;ANDERSON DAVID W;;SKADSBERG LAURA B,GT UROLOGICAL LLC (2006-05-16),https://lens.org/044-956-189-692-103,Granted Patent,yes,11,11,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F2/02,600/30;;600/37,1,0,,,"Supplementary European Search Report issued by the European Patent Office Apr. 22, 2009 in co-pending European Patent Application No. 06759891.",INACTIVE
42,WO,A3,WO 2012/083183 A3,014-077-720-131-37X,2012-10-26,2012,US 2011/0065520 W,2011-12-16,US 201061424200 P,2010-12-17,SWELLABLE COSMETIC SYSTEMS,The invention relates to a cosmetic system comprising a basecoat composition comprising at least one acrylic thickener and a topcoat composition comprising at least one aqueous polyurethane dispersion.,OREAL;;LI CHUNHUA;;BUI HY SI;;ANDERSON LAURA;;KANJI MOHAMED,LI CHUNHUA;;BUI HY SI;;ANDERSON LAURA;;KANJI MOHAMED,,https://lens.org/014-077-720-131-37X,Search Report,yes,4,0,3,3,0,A61K8/027;;A61K8/375;;A61K8/731;;A61K8/8152;;A61K8/8164;;A61K8/922;;A61K2800/31;;A61K2800/884;;A61Q1/10;;A61Q1/10;;A61K2800/884;;A61K8/922;;A61K8/027;;A61K8/8152;;A61K2800/31;;A61K8/375;;A61K8/8164;;A61K8/731;;A61K8/8188,A61K8/41;;A61K8/34;;A61K8/72;;A61K8/87;;A61K8/92;;A61Q19/00,,0,0,,,,PENDING
43,EP,B1,EP 1898848 B1,059-269-931-326-723,2010-11-24,2010,EP 06759891 A,2006-05-16,US 2006/0018830 W;;US 68226905 P,2005-05-18,DRUG ELUTION FOR IMPLANTABLE INCONTINENCE DEVICES,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,TIMM GERALD W;;ANDERSON DAVID W;;SKADSBERG LAURA B,,https://lens.org/059-269-931-326-723,Granted Patent,yes,10,0,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F2/00;;A61F5/00,,0,0,,,,ACTIVE
44,US,A1,US 2008/0004671 A1,019-149-305-288-240,2008-01-03,2008,US 76840007 A,2007-06-26,US 76840007 A;;US 80606506 P,2006-06-28,VAGUS NERVE STIMULATION VIA ORALLY DELIVERED APPARATUS,"Apparatus, systems and methods for stimulation of a vagus nerve of a patient are disclosed. An element that can be deployed and retained inside the patient's stomach without surgery and having a power supply and electrodes is associated with the expandable element. The electrodes are capable of stimulating the vagus nerve while the expandable element remains in the stomach for an extended period of time.",ALZA CORP,ANDERSON ROLFE;;DE LA SERNA PEDRO E;;MAURER LAURA,ALZA CORPORATION (2007-07-16),https://lens.org/019-149-305-288-240,Patent Application,yes,63,4,1,1,0,A61N1/36007;;A61N1/36007;;A61N1/0551;;A61N1/0551;;A61N1/37518;;A61N1/37518;;A61N1/3756;;A61N1/3756,A61N1/05,607/40,0,0,,,,DISCONTINUED
45,EP,A1,EP 4232612 A1,164-568-969-771-669,2023-08-30,2023,EP 21801608 A,2021-10-20,GB 202016722 A;;GB 2021052701 W,2020-10-21,BATTERY RECYCLING,,UNIV BIRMINGHAM,DRISCOLL LAURA LOUISE;;SLATER PETER RAYMOND;;ANDERSON PAUL ALEXANDER,,https://lens.org/164-568-969-771-669,Patent Application,yes,0,0,5,5,0,C22B47/0063;;C01G53/50;;C01G53/006;;C22B3/165;;H01M10/54;;Y02P10/20;;Y02W30/84;;C22B7/007;;C22B47/0063;;H01M4/0471;;H01M4/505;;H01M4/525;;H01M10/54,C22B47/00;;C01G45/12;;C01G51/00;;C01G53/00,,0,0,,,,PENDING
46,DE,D1,DE 602006018460 D1,112-569-640-093-178,2011-01-05,2011,DE 602006018460 T,2006-05-16,US 68226905 P;;US 2006/0018830 W,2005-05-18,WIRKSTOFFELUIERUNG FÜR IMPLANTIERBARE INKONTINENZGERÄTE,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,TIMM GERALD W;;ANDERSON DAVID W;;SKADSBERG LAURA B,,https://lens.org/112-569-640-093-178,Granted Patent,no,0,0,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F5/44;;A61F5/00,,0,0,,,,ACTIVE
47,WO,A1,WO 2022/084668 A1,070-965-620-734-030,2022-04-28,2022,GB 2021052701 W,2021-10-20,GB 202016722 A,2020-10-21,BATTERY RECYCLING,"A method (2800) of selectively leaching one or more manganese-containing phases from a mixed-phase battery electrode material comprises treating (2802) the mixed-phase battery electrode material with a solution of an acid, the acid acting as both a leaching agent and a reducing agent, so as to form a manganese-containing leachate whilst leaving at least one phase of the battery electrode material unleached, wherein the acid has a pKa greater than or equal to -2. Either or both of the leachate and the remaining electrode material may then be regenerated (2806, 2808).",UNIV BIRMINGHAM,DRISCOLL LAURA LOUISE;;SLATER PETER RAYMOND;;ANDERSON PAUL ALEXANDER,,https://lens.org/070-965-620-734-030,Patent Application,yes,1,1,5,5,0,C22B47/0063;;C01G53/50;;C01G53/006;;C22B3/165;;H01M10/54;;Y02P10/20;;Y02W30/84;;C22B7/007;;C22B47/0063;;H01M4/0471;;H01M4/505;;H01M4/525;;H01M10/54,C22B47/00;;C01G45/12;;C01G51/00;;C01G53/00,,15,8,018-228-684-379-511;;009-257-412-021-977;;027-177-055-039-345;;010-021-891-524-217;;007-713-335-499-929;;004-159-195-972-483;;022-900-210-606-118;;082-551-279-679-95X,10.1016/j.cej.2020.124321;;10.1002/cey2.29;;10.1021/acsenergylett.8b00833;;10.1016/s0378-7753(01)00753-4;;28365275;;10.1016/j.wasman.2017.03.037;;10.1107/s0021889813003531;;10.1107/s0021889801002242;;10.1016/j.jhazmat.2007.10.048;;18054156,"CHEN DONGDONG ET AL: ""Synergistic leaching of valuable metals from spent Li-ion batteries using sulfuric acid- l-ascorbic acid system"", CHEMICAL ENGENEERING JOURNAL, vol. 388, 15 May 2020 (2020-05-15), AMSTERDAM, NL, pages 124321, XP055876328, ISSN: 1385-8947, DOI: 10.1016/j.cej.2020.124321;;OR TYLER ET AL: ""Recycling of mixed cathode lithium-ion batteries for electric vehicles: Current status and future outlook"", CARBON ENERGY, vol. 2, no. 1, 10 January 2020 (2020-01-10), pages 6 - 43, XP055876308, ISSN: 2637-9368, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cey2.29> [retrieved on 20220106], DOI: 10.1002/cey2.29;;SHI YANG ET AL: ""Resolving the Compositional and Structural Defects of Degraded LiNi x Co y Mn z O 2 Particles to Directly Regenerate High-Performance Lithium-Ion Battery Cathodes"", ACS ENERGY LETTERS, vol. 3, no. 7, 26 June 2018 (2018-06-26), pages 1683 - 1692, XP055876538, ISSN: 2380-8195, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsenergylett.8b00833> [retrieved on 20220106], DOI: 10.1021/acsenergylett.8b00833;;W. LVZ. WANGH. CAOY. SUNY. ZHANGZ. SUN: ""A Critical Review and Analysis on the Recycling of Spent Lithium-Ion Batteries"", ACS SUSTAIN. CHEM. ENG., vol. 6, 2018, pages 1504 - 1521;;T. NUMATAC. AMEMIYAT. KUMEUCHI, ADVANTAGES OF BLENDING LINI . CO . O INTO LI ,MN -.0 CATHODES, vol. 98, 2001, pages 358 - 360;;R. GOLMOHAMMADZADEHF. RASHCHIE. VAHIDI, WASTE MANAG, vol. 64, 2017, pages 244 - 254;;B. MUSARIRIG. AKDOGANC. DORFLINGS. BRADSHAW, MINER. ENG., vol. 137, 2019, pages 108 - 117;;L. YAOY. XIH. HANW. LIC. WANGY. FENG, J. ALLOYS COMPD., vol. 868, 2021, pages 159222;;B. H. TOBYR. B. VON DREELE, J. APPL. CRYSTALLOGR., vol. 46, 2013, pages 544 - 549;;I. BELHAROUAKW. LUD. VISSERSK. AMINE, ELECTROCHEM. COMMUN., vol. 8, 2006, pages 329 - 335;;GSAS, J. APPL. CRYSTALLOGR., vol. 34, 2001, pages 210 - 213;;A.C. LARSONR.B. VON DREELE: ""General Structure Analysis System"", STRUCTURE, vol. 748, 2004, pages 86 - 748;;J.F. PAULINON.G. BUSNARDOJ.C. AFONSO: ""Recovery of valuable elements from spent Li-batteries"", J. HAZARD. MATER., vol. 150, 2008, pages 843 - 849, XP022424344, DOI: 10.1016/j.jhazmat.2007.10.048;;M.F. RABUNIN.M.N. SULAIMANM.K. AROUAN.A. HASHIM, EFFECTS OF ALKALINE ENVIRONMENTS AT MILD CONDITIONS ON THE STABILITY OF PVDF MEMBRANE : AN EXPERIMENTAL STUDY, 2013;;L. PAGLIAROD. LOWRY, INTERACTION OF POLYVINYLIDENE FLUORIDE (PVDF)-BASED BINDERS WITH STRONGLY ALKALINE SOLUTIONS, vol. 29, 2019, pages 18 - 32",PENDING
48,US,A1,US 2006/0264697 A1,111-361-780-698-890,2006-11-23,2006,US 43496606 A,2006-05-16,US 43496606 A;;US 68226905 P,2005-05-18,Drug elution for implantable incontinence devices,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,TIMM GERALD W;;ANDERSON DAVID W;;SKADSBERG LAURA B,GT UROLOGICAL LLC (2006-05-16),https://lens.org/111-361-780-698-890,Patent Application,yes,10,38,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F2/02;;A61F2/00,600/29;;600/31,0,0,,,,INACTIVE
49,EP,A4,EP 1898848 A4,020-913-580-746-863,2009-06-17,2009,EP 06759891 A,2006-05-16,US 2006/0018830 W;;US 68226905 P,2005-05-18,DRUG ELUTION FOR IMPLANTABLE INCONTINENCE DEVICES,"An implantable incontinence device and method provides for occluding the urethra in preventing urine leakage. The device includes an occluding member connected to a control mechanism. The occluding member is movable from a contracted (occlusive) condition to an expansive (non-occlusive) condition by activating and deactivating the control mechanism. A drug coating is disposed on a portion of the implantable incontinence device. The drug coating elutes a bioaffecting or pharmaceutical composition to minimize capsular tissue formation, so that prevention of urine leakage can be facilitated.",GT UROLOGICAL LLC,TIMM GERALD W;;ANDERSON DAVID W;;SKADSBERG LAURA B,,https://lens.org/020-913-580-746-863,Search Report,no,6,0,11,11,0,A61B2018/00154;;A61F2/0036;;A61F5/005;;A61F5/0079;;A61F2002/009;;A61F2250/0067;;A61F2310/0097;;A61F2/0036;;A61F5/0079;;A61F5/005;;A61F2250/0067;;A61B2018/00154;;A61F2002/009;;A61F2310/0097,A61F2/00;;A61F5/00,,0,0,,,,ACTIVE
50,US,A1,US 2013/0230477 A1,184-593-143-197-373,2013-09-05,2013,US 201113884122 A,2011-12-16,US 201113884122 A;;US 201061424200 P;;US 2011/0065520 W,2010-12-17,SWELLABLE COSMETIC SYSTEMS,The invention relates to a cosmetic system comprising a basecoat composition comprising at least one acrylic thickener and a topcoat composition comprising at least one aqueous polyurethane dispersion.,LI CHUNHUA;;BUI HY SI;;ANDERSON LAURA;;KANJI MOHAMED;;OREAL,LI CHUNHUA;;BUI HY SI;;ANDERSON LAURA;;KANJI MOHAMED,L'OREAL (2013-04-25),https://lens.org/184-593-143-197-373,Patent Application,yes,2,4,3,3,0,A61K8/027;;A61K8/375;;A61K8/731;;A61K8/8152;;A61K8/8164;;A61K8/922;;A61K2800/31;;A61K2800/884;;A61Q1/10;;A61Q1/10;;A61K2800/884;;A61K8/922;;A61K8/027;;A61K8/8152;;A61K2800/31;;A61K8/375;;A61K8/8164;;A61K8/731;;A61K8/8188,A61K8/81;;A61Q1/10,424/70.7,1,0,,,"Super Volume Mascara, The Body Shop, Retrieved from URL:, 2009",DISCONTINUED
51,TW,U,TW 309754 U,179-770-605-770-810,1997-07-01,1997,TW 83215430 U,1992-03-17,US 73158991 A,1991-07-17,Absorbent article exhibiting improved fluid management,"An absorbent article is disclosed which exhibits improved fluid management. The article includes an absorbent having first and second oppositely aligned surfaces and a longitudinally extending central axis. A bicomponent cover is positioned over the first surface of the absorbent and includes a first and a second material. The first material has openings formed therein and is aligned along the longitudinally extending central axis of the absorbent. The second material is nonapertured and is secured to, or positioned adjacent to, the outer periphery of the first material. The first and second materials cooperate to enclose the absorbent. Positioned between the first material and the first surface of the absorbent is a separation means. The separation means directs fluid from the body downward, in the z direction, away from the bicomponent cover, and outward in the x and y directions to provide a more efficient use of the absorbent material. The absorbent article further contains a liquid-impermeable baffle which is positioned adjacent to the second surface of the absorbent.",KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONAR;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;LAURA JANE ANDERSON;;MARY LEONARD KASPAR,,https://lens.org/179-770-605-770-810,Limited Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F5/44;;A61F13/511;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
52,EP,A1,EP 1061683 A1,155-034-028-819-189,2000-12-20,2000,EP 00304775 A,2000-06-06,US 33340799 A,1999-06-15,Optical add-drop module with low loss and high isolation,"An optical add-drop module (OADM) includes in the through-path exactly two thin-film filters (TFFs) having respective passbands that approximately coincide in wavelength. Each TFF has a respective across-the-band isolation level, representing the smallest isolation achieved at any wavelength within the passband. The respective reflection characteristic curves of the two TFFs are at least partially complementary, such that the OADM isolation level exceeds the logarithmic sum of the across-the-band isolation levels of the respective TFFs.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;LENZ GADI,,https://lens.org/155-034-028-819-189,Patent Application,yes,3,6,8,8,0,H04J14/0206;;H04J14/0213;;H04B10/00;;H04J14/0213;;H04J14/0206,H04J14/00;;H04B10/27;;H04B10/29;;H04J14/02,,0,0,,,,DISCONTINUED
53,CN,A,CN 114587609 A,041-124-164-858-356,2022-06-07,2022,CN 202210249259 A,2017-06-22,US 201662362431 P;;CN 201780054873 A;;US 2017/0038674 W,2016-07-14,Multi-cable medical device,"The invention relates to a multi-cable medical device. A medical device includes pairs of cables each wound about an input spindle and connected to actuate a degree of freedom of a device shaft structure. The cables may be connected such that rotating the input spindle will actuate a respective degree of freedom. A first pulley in the instrument may receive a first cable from the input spindle and redirect the first cable toward the instrument shaft, and a second pulley may receive a second cable from the input spindle and redirect the second cable toward the instrument shaft. In one configuration, the first and second pulleys are mounted on the first and second horizontal planes, respectively, and the second pulley redirects the second cable through the first horizontal plane. Additionally or alternatively, the cables of one horizontal plane may intersect, while the cables of the other horizontal plane do not intersect.",INTUITIVE SURGICAL OPERATION COMPANY,LAMBRECHT BRAM GILBERT ANTOON;;ANDERSON STEVEN C;;JOHNSON LAURA T,,https://lens.org/041-124-164-858-356,Patent Application,no,5,0,13,13,0,A61B34/30;;A61B34/71;;A61B2017/2929;;A61B17/29;;A61B2017/00477;;A61B2034/715;;A61B2017/2903;;A61B2017/00477;;A61B34/71;;A61B34/30;;A61B2090/371;;A61B34/00;;A61B34/30;;A61B34/71;;A61B34/30;;A61B34/71;;A61B2034/715;;A61B17/29;;A61B2017/2903;;A61B2017/2929;;A61B34/00;;A61B2090/371;;A61B2017/00477,A61B34/30,,0,0,,,,PENDING
54,CA,A1,CA 2310972 A1,008-604-395-715-252,2000-12-15,2000,CA 2310972 A,2000-06-05,US 33340799 A,1999-06-15,OPTICAL ADD-DROP MODULE WITH LOW LOSS AND HIGH ISOLATION,"An optical add-drop module (OADM) includes in the through-path exactly two thin-film filters (TFFs) having respective passbands that approximately coincide in wavelength. Each TFF has a respective across-the-band isolation level, representing the smallest isolation achieved at and wavelength within the passband. The respective reflection characteristic curves of the two TFFs are at least partially complementary, such that the OADM isolation level exceeds the logarithmic sum of the across-the-band isolation levels of the respective TFFs.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;LENZ GADI;;BROBERG ROBERT MARIO;;ANDERSON JON,,https://lens.org/008-604-395-715-252,Patent Application,no,0,0,8,8,0,H04J14/0206;;H04J14/0213;;H04B10/00;;H04J14/0213;;H04J14/0206,H04J14/00;;H04B10/27;;H04B10/29;;H04J14/02,,0,0,,,,DISCONTINUED
55,US,S,US D0659839 S,133-706-465-147-211,2012-05-15,2012,US 36793010 F,2010-08-16,US 36793010 F,2010-08-16,Support for a pneumatic compression controller,,ANDERSON JULIA-ROSE;;KEITH LAURA E;;LONGAN JOHN;;BOOZER BRAD;;TYCO HEALTHCARE,ANDERSON JULIA-ROSE;;KEITH LAURA E;;LONGAN JOHN;;BOOZER BRAD,COVIDIEN LP (2012-09-28);;KPR U.S. LLC (2017-07-28),https://lens.org/133-706-465-147-211,Design Right,no,0,2,1,1,0,,,0201;;D24/186,0,0,,,,ACTIVE
56,JP,A,JP 2001053723 A,168-748-068-111-237,2001-02-23,2001,JP 2000177065 A,2000-06-13,US 33340799 A,1999-06-15,OPTICAL ADD/DROP MODULE (OADM) AND ITS MANUFACTURE,PROBLEM TO BE SOLVED: To obtain an optical add/drop module to improve isolation without increasing cost and a storage loss due to increase of components in a network. SOLUTION: This optical add/drop module(OADM) is constituted by including exactly two thin film filters (TFF) with respective path band wavelength of which approximately coincide with each other in a through path. Each TFF is provided with each across-the-band isolation level to indicate the minimum isolation to be achieved in either wavelength in the path bands. Reflection characteristic curves of each of the two TFFs are at least partially complementary so that an OADM isolation level exceeds logarithmic sum of the across-the- band isolation levels of each of the TFFs.,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;LENZ GADI,,https://lens.org/168-748-068-111-237,Patent Application,no,0,0,8,8,0,H04J14/0206;;H04J14/0213;;H04B10/00;;H04J14/0213;;H04J14/0206,H04J14/00;;H04B10/27;;H04B10/29;;H04J14/02,,0,0,,,,EXPIRED
57,US,B1,US 6253205 B1,004-877-362-711-931,2001-06-26,2001,US 13705298 A,1998-08-20,US 13705298 A,1998-08-20,"Object oriented translation framework method, apparatus, and program","The invention is a translation framework which performs data conversions in an object oriented environment from clipboards, drag, and drop tend entire files and entire objects into compound documents. There are three primary classes: the translator, the translator surrogates, and the translation query. Translators are heavy objects that may include the translator's shared library and supporting libraries. The framework uses light weight surrogate translators as stand-ins for translators. The surrogates do not pull in the translators unless there is a request to do an actual translation. When a translation is requested, the translator must be streamed into the address space of the repeating client. Clients desiring a document object be translated for inclusion in a compound document interact with the framework by using queries to access a translation surrogate.",OBJECT TECH LICENSING CORP,QUARATO JAMES A;;ANDERSON DAVID R;;WERNER LAURA;;ADLER MITCH,APPLE INC (2009-12-10);;OBJECT TECHNOLOGY LICENSING CORP (1998-10-02),https://lens.org/004-877-362-711-931,Granted Patent,yes,3,12,1,1,0,G06F8/51;;G06F8/51;;Y10S707/99944;;Y10S707/99943,G06F9/44;;G06F17/00,707/103;;707/102,3,2,046-956-469-926-245;;011-452-625-783-575,10.1049/el:20000639;;10.1049/ip-sen:20000460,"Kwon et al., Threshold-type call admission control in wireless/mobile multimedia networks using prioritised adaptive framework, Apr. 2000.;;IEEE, IEEE Recommended practice for architectural description of software-intensive systems, p. 1-23, Sep. 2000.*;;Lee et al., ""Qualitative formal methods for requirements specification and validation of hybrid real-time safety systems"", Software, IEE Proceedings, vol. 147, Issue 1, Feb. 2000.*",EXPIRED
58,TW,B,TW 521508 B,027-629-489-865-825,2003-02-21,2003,TW 89111431 A,2000-06-12,US 33340799 A,1999-06-15,Optical add-drop module with low loss and high isolation,"An optical add-drop module (OADM) includes in the through-path exactly two thin-film filters (TFFs) having respective passbands that approximately coincide in wavelength. Each TFF has a respective across-the-band isolation level, representing the smallest isolation achieved at any wavelength within the passband. The respective reflection characteristic curves of the two TFFs are at least partially complementary, such that the OADM isolation level exceeds the logarithmic sum of the across-the-band isolation levels of the respective TFFs.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;LENZ GADI,,https://lens.org/027-629-489-865-825,Granted Patent,no,0,0,8,8,0,H04J14/0206;;H04J14/0213;;H04B10/00;;H04J14/0213;;H04J14/0206,H04J14/00;;H04B10/27;;H04B10/29;;H04J14/02,,0,0,,,,EXPIRED
59,US,B1,US 6577415 B1,075-258-486-323-220,2003-06-10,2003,US 33340799 A,1999-06-15,US 33340799 A,1999-06-15,Optical add-drop module with low loss and high isolation,"
    An optical add-drop module (OADM) includes in the through-path exactly two thin-film filters (TFFs) having respective passbands that approximately coincide in wavelength. Each TFF has a respective across-the-band isolation level, representing the smallest isolation achieved at any wavelength within the passband. The respective reflection characteristic curves of the two TFFs are at least partially complementary, such that the OADM isolation level exceeds the logarithmic sum of the across-the-band isolation levels of the respective TFFs. 
",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;LENZ GADI,WSOU INVESTMENTS LLC (2017-07-22);;LUCENT TECHNOLOGIES INC (1999-07-19),https://lens.org/075-258-486-323-220,Granted Patent,yes,8,0,8,8,0,H04J14/0206;;H04J14/0213;;H04B10/00;;H04J14/0213;;H04J14/0206,H04J14/00;;H04B10/27;;H04B10/29;;H04J14/02,359/127;;359/110;;359/124;;359/130,4,1,144-623-309-475-411,10.1887/0750306882,"Rancourt, J. D., Optical Thin Films Users' Handbook, McGraw-Hill, New York, (1987).;;Macleod, H.A., Thin-Film Optical Filters, 2nd Ed., McGraw-Hill, New York, (1989).;;Scobey, M.A. et al., ""Stable ultra-narrow bandpass filters,"" Proceedings of SPIE's International Symposium, (1994).;;Scobey, M.A. et al., ""Improved Temperature and Humidity Stability of Ultra-Narrow Band Filters,"" Proceedings of Society of Vacuum Coaters (1994).",EXPIRED
60,AU,A,AU 2000/039389 A,195-587-083-495-456,2000-12-21,2000,AU 2000/039389 A,2000-06-08,US 33340799 A,1999-06-15,Optical add-drop module with low loss and high isolation,,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;LENZ GADI,,https://lens.org/195-587-083-495-456,Patent Application,no,0,0,8,8,0,H04J14/0206;;H04J14/0213;;H04B10/00;;H04J14/0213;;H04J14/0206,H04J14/00;;H04B10/27;;H04B10/29;;H04J14/02,,0,0,,,,DISCONTINUED
61,EP,A1,EP 2192963 A1,155-324-960-899-722,2010-06-09,2010,EP 08795368 A,2008-08-15,US 2008/0009784 W;;US 96497007 P,2007-08-16,CHROMATOGRAPHY COLUMN ASSEMBLIES,,ALL TECH ASSOCIATES INC,ANDERSON SCOTT C;;KAEPPLINGER LAURA T;;MAIER-ROSENKRANZ JUERGEN T,,https://lens.org/155-324-960-899-722,Patent Application,yes,0,0,2,2,0,B01D15/1864;;G01N30/461;;G01N2030/085,B01D15/18;;G01N30/46,,1,0,,,See references of WO 2009023268A1,DISCONTINUED
62,WO,A1,WO 2009/023268 A1,168-914-897-616-372,2009-02-19,2009,US 2008/0009784 W,2008-08-15,US 96497007 P,2007-08-16,CHROMATOGRAPHY COLUMN ASSEMBLIES,"Chromatography column assemblies are disclosed. Methods of making chromatography column assemblies and methods of using chromatography column assemblies are also disclosed. The chromatography column assembly comprises an analytical column comprising a first packing media having a first average particle size; and a guard column in-line with said analytical column, said guard column comprising a second packing media having a second average particle size; said second average particle size being greater than said first average particle size; said chromatography column assembly having a system efficiency greater than a similar chromatography column assembly in which said second average particle size is equal to or less than said first average particle size.",ALLTECH ASSOCIATES INC;;ANDERSON SCOTT C;;KAEPPLINGER LAURA T;;MAIER-ROSENKRANZ JUERGEN T,ANDERSON SCOTT C;;KAEPPLINGER LAURA T;;MAIER-ROSENKRANZ JUERGEN T,,https://lens.org/168-914-897-616-372,Patent Application,yes,6,2,2,2,0,B01D15/1864;;G01N30/461;;G01N2030/085,B01D15/18;;G01N30/46,,1,0,,,"RONALD E MAJORS: ""New Chromatography Columns and Accessories at the 2003 Pittsburgh Conference, Part I"", LCGC EUROPE, ADVANSTAR COMMUNICATIONS (UK) LTD, UNITED KINGDOM, 1 April 2003 (2003-04-01), pages 202 - 214, XP007906554, ISSN: 1471-6577",PENDING
63,KR,A,KR 20010007392 A,094-917-473-543-174,2001-01-26,2001,KR 20000032954 A,2000-06-15,US 33340799 A,1999-06-15,Optical add-drop module with low loss and high isolation,PURPOSE: An optical add/drop module is provided to improve isolation without increasing cost and a storage loss due to increase of components in a network. CONSTITUTION: This optical add/drop module(OADM) includes exactly two thin film filters(TFF) with respective path band wavelength of which approximately coincide with each other in a through path. Each TFF is provided with each across-the-band isolation level to indicate the minimum is isolation to be achieved in either wavelength in the path bands. Reflection characteristic curving each of the two TFFs are at least partially complementary so that an OADM isolation level exceeds logarithmic sum of the across-the-band isolation levels of each of the TFFs.,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;LENZ GADI,,https://lens.org/094-917-473-543-174,Patent Application,no,5,0,8,8,0,H04J14/0206;;H04J14/0213;;H04B10/00;;H04J14/0213;;H04J14/0206,H04J14/00;;H04B10/27;;H04B10/29;;H04J14/02,,0,0,,,,DISCONTINUED
64,US,S,US D0675741 S,105-703-236-473-583,2013-02-05,2013,US 36793210 F,2010-08-16,US 36793210 F,2010-08-16,Pneumatic compression controller,,COVIDIEN LP;;ANDERSON JULIA-ROSE;;KEITH LAURA E;;LONGAN JOHN;;BOOZER BRAD,ANDERSON JULIA-ROSE;;KEITH LAURA E;;LONGAN JOHN;;BOOZER BRAD,COVIDIEN LP (2012-09-28);;KPR U.S. LLC (2017-07-28),https://lens.org/105-703-236-473-583,Design Right,no,0,4,1,1,0,,,0201;;D24/186,0,0,,,,ACTIVE
65,EP,A1,EP 2486141 A1,078-514-061-422-37X,2012-08-15,2012,EP 10822699 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,"MACROGENICS, INC. (2016-10-12)",https://lens.org/078-514-061-422-37X,Patent Application,yes,0,0,32,32,48,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08;;A61K39/00;;C07K16/28;;C07K16/32;;C07K16/44;;C12P21/00,,0,0,,,,INACTIVE
66,JP,A,JP 2001036557 A,142-762-750-216-354,2001-02-09,2001,JP 2000178068 A,2000-06-14,US 33340699 A,1999-06-15,WIDE BAND OPTICAL PACKET RING NETWORK SYSTEM,"PROBLEM TO BE SOLVED: To efficiently increase capacity of operation by connecting a series of nodes with hubs by a dual ring bi-directional optical fiber transmission system and constituting an optical additional drop module of a broad band filter like a dielectric thin film filter at each node. SOLUTION: Nodes are connected together to make a ring 101 to connect only one of optical transmission rings with three additional/drop nodes 110 to 112 and a hub 130 transmit a packet in the clockwise direction and to make a similar ring to transmit the packet in the counterclockwise direction. Each of the nodes 110 to 112 is provided with corresponding optical additional drop modules OADM 210 to 212. Namely, in a specified wavelength band corresponding to a specified widely spaced C-WAM channel, only a signal is extracted from a wavelength division multiplexed signal existing in the ring 101 and inserted into the same wavelength band and a C-WDM channel so as to be returned on the ring 101.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BRINKMAN WILLIAM FRANK;;BROBERG ROBERT MARIO,,https://lens.org/142-762-750-216-354,Patent Application,no,0,8,6,6,0,H04J14/0206;;H04J14/0213;;H04J14/0219;;H04J14/0283;;H04J14/0294;;H04Q11/0062;;H04Q11/0066;;H04Q11/0071;;H04L12/42,H04B10/27;;H04B10/032;;H04B10/038;;H04B10/275;;H04B10/29;;H04J14/00;;H04J14/02;;H04L12/42;;H04Q11/00,,0,0,,,,PENDING
67,CA,A1,CA 2776385 A1,139-607-034-063-563,2011-04-14,2011,CA 2776385 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by Fc?R is desired (e.g., inflammation, autoimmunde disease).",MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/139-607-034-063-563,Patent Application,no,0,0,32,32,48,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,,,0,0,,,,ACTIVE
68,AU,A,AU 2000/039349 A,179-412-603-509-336,2000-12-21,2000,AU 2000/039349 A,2000-06-07,US 33340699 A,1999-06-15,Wideband optical packet ring network,,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;BRINKMAN WILLIAM FRANK;;BROBERG ROBERT MARIO;;ANDERSON JON,,https://lens.org/179-412-603-509-336,Patent Application,no,0,0,6,6,0,H04J14/0206;;H04J14/0213;;H04J14/0219;;H04J14/0283;;H04J14/0294;;H04Q11/0062;;H04Q11/0066;;H04Q11/0071;;H04L12/42,H04B10/27;;H04B10/032;;H04B10/038;;H04B10/275;;H04B10/29;;H04J14/00;;H04J14/02;;H04L12/42;;H04Q11/00,,0,0,,,,DISCONTINUED
69,PT,T,PT 2486141 T,057-080-631-065-363,2018-05-09,2018,PT 10822699 T,2010-10-07,US 24951009 P,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,SERGEY GORLATOV;;JLESLIE S JOHNSON;;ANDERSON RAINEY GODFREY JONAH;;LAURA LERNER,,https://lens.org/057-080-631-065-363,Patent Application,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,A61K39/00;;C12P21/08;;C07K16/28;;C07K16/32;;C07K16/44;;C12P21/00,,0,0,,,,PENDING
70,CA,A1,CA 2310949 A1,139-476-949-462-450,2000-12-15,2000,CA 2310949 A,2000-06-05,US 33340699 A,1999-06-15,WIDEBAND OPTICAL PACKET RING NETWORK,"A dual-ring, bi-directional optical fiber transmission system interconnects a series of add/drop nodes with a hub, such that multiple, widely spaced coarse wavelength division multiplexed (C-WDM) channels are established on each ring. At each node, an optical add/drop module (OADM) includes broadband filters (BBF's), such as dielectric thin film filters, arranged to (a) extract, for the purposes of a receiver, or (b) insert, for the purposes of a transmitter, information in one or more of the channels. The signals in the one or more channels are coupled to the OADM's by a standard optical transceiver, which performs modulation and demodulation. Each filter passband can be populated with multiple dense wavelength division multiplexed (D-WDM) channels, so that the capacity of traffic that can be handled at each node can be easily upgraded. The transceiver is, in turn, coupled to packet framer, such as an IP packet over SONET framer, which supplies received packets to, and receives outgoing packets from, a conventional Layer 3 routing engine. While in most instances, endpoints at each of the nodes communicate with other endpoints connected to the hub, if desired, endpoints at one or more nodes can communicate directly with endpoints on other nodes, using a direct or bypass connection through the hub. The bypass can be ""permanent"" or controlled via a switch, such as a micro-electro-mechanical switch (MEMS).",LUCENT TECHNOLOGIES INC,ANDERSON JON;;BRINKMAN WILLIAM FRANK;;ADAMS LAURA ELLEN;;BROBERG ROBERT MARIO,,https://lens.org/139-476-949-462-450,Patent Application,no,0,0,6,6,0,H04J14/0206;;H04J14/0213;;H04J14/0219;;H04J14/0283;;H04J14/0294;;H04Q11/0062;;H04Q11/0066;;H04Q11/0071;;H04L12/42,H04B10/27;;H04B10/032;;H04B10/038;;H04B10/275;;H04B10/29;;H04J14/00;;H04J14/02;;H04L12/42;;H04Q11/00,,0,0,,,,DISCONTINUED
71,IL,B,IL 219059 B,137-300-047-302-683,2018-06-28,2018,IL 21905912 A,2012-04-04,US 2010/0051831 W;;US 24951009 P,2009-10-07,Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation and methods for their use,,MACROGENICS INC;;LESLIE S JOHNSON;;LAURA LERNER;;SERGEY GORLATOV;;GODFREY JONAH ANDERSON RAINEY,LESLIE S JOHNSON;;LAURA LERNER;;SERGEY GORLATOV;;GODFREY JONAH ANDERSON RAINEY,,https://lens.org/137-300-047-302-683,Unknown,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,,,0,0,,,,ACTIVE
72,TW,B,TW 496055 B,013-333-448-576-110,2002-07-21,2002,TW 89111430 A,2000-06-12,US 33340699 A,1999-06-15,Wideband optical packet ring network,"A dual-ring, bi-directional optical fiber transmission system interconnects a series of add/drop nodes with a hub, such that multiple, widely spaced coarse wavelength division multiplexed (C-WDM) channels are established on each ring. At each node, an optical add/drop module (OADM) includes broadband filters (BBF's), such as dielectric thin film filters, arranged to (a) extract, for the purposes of a receiver, or (b) insert, for the purposes of a transmitter, information in one or more of the channels. The signals in the one or more channels are coupled to the OADM's by a standard optical transceiver, which performs modulation and demodulation. Each filter passband can be populated with multiple dense wavelength division multiplexed (D-WDM) channels, so that the capacity of traffic that can be handled at each node can be easily upgraded. The transceiver is, in turn, coupled to packet framer, such as an IP packet over SONET framer, which supplies received packets to, and receives outgoing packets from, a conventional Layer 3 routing engine. While in most instances, endpoints at each of the nodes communicate with other endpoints connected to the hub, if desired, endpoints at one or more nodes can communicate directly with endpoints on other nodes, using a direct or bypass connection through the hub. The bypass can be """"permanent"""" or controlled via a switch, such as a micro-electro-mechanical switch (MEMS).",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BRINKMAN WILLIAM FRANK;;BROBERG ROBERT MARIO,,https://lens.org/013-333-448-576-110,Granted Patent,no,0,1,6,6,0,H04J14/0206;;H04J14/0213;;H04J14/0219;;H04J14/0283;;H04J14/0294;;H04Q11/0062;;H04Q11/0066;;H04Q11/0071;;H04L12/42,H04B10/27;;H04B10/032;;H04B10/038;;H04B10/275;;H04B10/29;;H04J14/00;;H04J14/02;;H04L12/42;;H04Q11/00,,0,0,,,,EXPIRED
73,US,B2,US 7246424 B2,029-890-353-443-924,2007-07-24,2007,US 82315304 A,2004-04-13,US 82315304 A,2004-04-13,Magnetic devices having magnetic features with CMP stop layers,"A magnetic device having a magnetic feature, the magnetic feature including a magnetic portion comprising a magnetic material, a region of non-magnetic material adjacent to the magnetic portion, and a stop layer disposed above the region of non-magnetic material, defining a planar upper boundary of the magnetic portion.",SEAGATE TECHNOLOGY LLC,HUANG PICHENG;;ANDERSON PAUL E;;STEARNS LAURA C;;XUE SONG S,SEAGATE TECHNOLOGY LLC (2004-04-09),https://lens.org/029-890-353-443-924,Granted Patent,yes,23,9,3,3,0,G11C11/16;;Y10T29/49052;;Y10T29/49043;;Y10T29/49046;;Y10T29/49002;;Y10T29/49224;;Y10T29/49044;;Y10T29/49048;;H10N50/85;;Y10T29/49052;;Y10T29/49043;;Y10T29/49046;;Y10T29/49002;;Y10T29/49224;;Y10T29/49044;;Y10T29/49048;;G11C11/16;;H10N50/85,H01S4/00;;G11B5/127;;G11B5/147;;G11B5/17;;H04R31/00,29/592.1;;29/603.13;;29/603.14;;29/603.15;;29/603.16;;29/603.18;;29/885;;216/22;;216/38;;216/41;;216/48;;427/127;;427/128;;438/633;;438/692;;438/693;;451/5;;451/9;;451/10;;451/16;;451/41,0,0,,,,INACTIVE
74,SI,T1,SI 2486141 T1,104-320-987-646-92X,2018-06-29,2018,SI 201031668 T,2010-10-07,US 24951009 P;;US 2010/0051831 W;;EP 10822699 A,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/104-320-987-646-92X,Granted Patent,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,A61K39/00;;C12P21/00;;C07K16/00,,0,0,,,,ACTIVE
75,EP,A4,EP 2486141 A4,117-365-646-735-212,2013-04-17,2013,EP 10822699 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,"MACROGENICS, INC. (2016-10-12)",https://lens.org/117-365-646-735-212,Search Report,no,2,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08;;C07K16/28;;C12P21/00,,3,2,094-082-569-858-098;;026-158-168-209-734,17875730;;10.1158/0008-5472.can-07-0696;;17012310;;10.1093/glycob/cwl057,"STAVENHAGEN JEFFREY B ET AL: ""Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fc gamma receptors"", 1 September 2007, CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, PAGE(S) 8882 - 8890, ISSN: 0008-5472, XP002489883;;KANDA YUTAKA ET AL: ""Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types"", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 17, no. 1, 29 September 2006 (2006-09-29), pages 104 - 118, XP002443679, ISSN: 0959-6658, DOI: 10.1093/GLYCOB/CWL057;;See also references of WO 2011044368A1",INACTIVE
76,AU,B2,AU 2010/303415 B2,003-049-860-671-207,2015-02-19,2015,AU 2010/303415 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by FcγR is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by FcγR is desired (e.g., inflammation, autoimmunde disease).",MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/003-049-860-671-207,Granted Patent,no,1,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C07K16/00;;C07K16/28;;C07K16/30;;C12P21/08,,1,1,094-082-569-858-098,17875730;;10.1158/0008-5472.can-07-0696,"STAVENHAGEN J.B. et al., Cancer Research, 15 September 2007, Vol. 67, No. 18, pages 8882-8890",INACTIVE
77,ES,T3,ES 2672121 T3,149-091-871-620-820,2018-06-12,2018,ES 10822699 T,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso","Uso de una sustitución de aminoácido en una región Fc de IgG humana para atenuar la fucosilación postraduccional de la región Fc de IgG humana, en el que la región Fc de IgG humana así modificada: (A) comprende una sustitución de aminoácido en relación con una región Fc de tipo natural, en el que dicha sustitución de aminoácido es en una o más de posiciones L234, L235, F243, R292, Y300, V305 o P396; y (B) presenta una razón de glicosilación de oligosacárido con alto contenido en manosa con respecto a glicosilación de oligosacárido complejo que es mayor de 0,2.",MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/149-091-871-620-820,Granted Patent,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08;;A61K39/00;;C07K16/28;;C07K16/32;;C07K16/44;;C12P21/00,,0,0,,,,ACTIVE
78,US,A1,US 2005/0225898 A1,196-178-727-741-376,2005-10-13,2005,US 82315304 A,2004-04-13,US 82315304 A,2004-04-13,Magnetic devices having magnetic features with CMP stop layers,"A magnetic device having a magnetic feature, the magnetic feature including a magnetic portion comprising a magnetic material, a region of non-magnetic material adjacent to the magnetic portion, and a stop layer disposed above the region of non-magnetic material, defining a planar upper boundary of the magnetic portion.",SEAGATE TECHNOLOGY LLC,HUANG PICHENG;;ANDERSON PAUL E;;STEARNS LAURA C;;XUE SONG S,SEAGATE TECHNOLOGY LLC (2004-04-09),https://lens.org/196-178-727-741-376,Patent Application,yes,22,8,3,3,0,G11C11/16;;Y10T29/49052;;Y10T29/49043;;Y10T29/49046;;Y10T29/49002;;Y10T29/49224;;Y10T29/49044;;Y10T29/49048;;H10N50/85;;Y10T29/49052;;Y10T29/49043;;Y10T29/49046;;Y10T29/49002;;Y10T29/49224;;Y10T29/49044;;Y10T29/49048;;G11C11/16;;H10N50/85,G11B5/127;;G11B5/147;;G11B5/17;;H04R31/00,360/126;;29/603.15,0,0,,,,INACTIVE
79,CA,C,CA 2776385 C,199-844-615-398-674,2019-04-09,2019,CA 2776385 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by Fc?R is desired (e.g., inflammation, autoimmunde disease).",MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/199-844-615-398-674,Granted Patent,no,0,0,32,32,48,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,,,0,0,,,,ACTIVE
80,HR,T1,HR P20180574 T1,014-805-089-019-820,2018-06-01,2018,HR P20180574 T,2018-04-10,US 24951009 P;;EP 10822699 A;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/014-805-089-019-820,Granted Patent,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08;;A61K39/00;;C07K16/28;;C07K16/32;;C07K16/44;;C12P21/00,,0,0,,,,ACTIVE
81,RU,C2,RU 2583298 C2,151-290-765-216-094,2016-05-10,2016,RU 2012118865 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,POLYPEPTIDES CONTAINING Fc-SECTION THAT DISPLAY INCREASED EFFECTOR FUNCTION OWING TO VARYING FUCOSYLATION LEVEL AND THEIR APPLICATIONS,"FIELD: biotechnologies.SUBSTANCE: claimed invention discloses the attenuation of post-translational fucosylation of the molecule containing a modified Fc-section. The claimed process comprises the Fc-section modification, molecule-candidate expression, evaluation of the ratio between the glycosylation of oligosaccharides with the high content of mannose and the glycosylation of complex oligosaccharides and identification of the molecule-candidate as a suitable one at the ratio over 0.2. The proposed invention can be used in medicine.EFFECT: higher efficiency of purification.15 cl, 95 dwg, 35 tbl, 7 ex",MAKRODZHENIKS INK,DZHONSON LESLI S;;REJNI GODFRI DZHOUNA ANDERSON;;LERNER LAURA;;GORLATOV SERGEJ,,https://lens.org/151-290-765-216-094,Granted Patent,no,0,3,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08,,0,0,,,,ACTIVE
82,US,B2,US 9096877 B2,039-918-449-426-082,2015-08-04,2015,US 201013499007 A,2010-10-07,US 201013499007 A;;US 24951009 P;;US 2010/0051831 W,2009-10-07,"Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by FcγR is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by FcγR is desired (e.g., inflammation, autoimmune disease).",JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;GORLATOV SERGEY;;LERNER LAURA;;MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;GORLATOV SERGEY;;LERNER LAURA,MACROGENICS INC (2010-10-22),https://lens.org/039-918-449-426-082,Granted Patent,yes,102,33,32,32,48,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,A61K39/395;;A61K39/00;;C07K16/00;;C07K16/28;;C12P21/00,,102,99,094-082-569-858-098;;094-082-569-858-098;;009-483-512-107-343;;091-262-869-424-290;;003-650-786-098-12X;;020-576-792-007-611;;033-343-140-348-124;;020-789-896-622-570;;020-750-167-506-977;;075-555-351-927-589;;033-401-440-963-789;;014-776-651-048-814;;002-007-578-507-698;;027-117-540-018-519;;035-802-558-039-698;;073-222-313-095-672;;036-720-275-917-363;;026-384-386-494-532;;169-186-375-773-817;;033-990-313-560-010;;049-307-661-382-363;;004-375-613-873-442;;045-523-629-709-160;;007-008-151-758-101;;123-934-383-563-555;;027-913-674-497-110;;153-697-003-263-81X;;026-542-912-820-248;;071-073-635-453-103;;054-793-648-765-383;;077-767-979-415-033;;024-713-126-014-389;;041-522-636-975-061;;003-259-714-971-039;;009-998-798-409-381;;111-219-040-927-726;;007-165-098-021-088;;018-694-440-454-632;;001-159-651-167-076;;080-174-984-018-360;;108-262-256-096-760;;086-407-380-072-326;;003-849-961-384-35X;;036-929-348-767-907;;007-551-089-881-647;;004-695-024-784-866;;054-250-934-559-758;;021-221-106-931-817;;016-709-591-901-870;;029-486-077-444-570;;027-453-843-545-386;;086-049-106-202-274;;039-889-533-551-521;;000-499-911-678-177;;009-483-512-107-343;;023-774-521-222-455;;019-486-597-805-058;;045-942-104-775-903;;007-301-518-002-478;;032-051-920-489-349;;075-247-958-346-33X;;113-882-985-226-72X;;035-504-753-072-607;;001-779-867-387-972;;077-451-267-180-896;;024-423-452-023-533;;058-706-555-349-273;;066-645-742-509-803;;013-742-087-776-842;;008-274-774-541-556;;016-480-590-824-962;;029-611-134-469-353;;021-506-129-296-050;;076-090-519-318-074;;006-618-536-567-519;;014-268-591-389-367;;028-677-787-189-119;;052-806-662-716-147;;079-109-121-457-433;;088-886-544-277-170;;050-646-523-937-465;;014-113-432-888-031;;026-156-177-050-56X;;130-680-203-388-320;;008-017-330-278-198;;081-969-406-101-221;;042-869-707-573-852;;014-710-159-963-322;;011-842-849-963-456;;071-305-244-060-783;;071-474-587-354-086;;104-492-368-133-050;;078-132-684-581-98X;;110-094-292-858-47X;;101-575-504-070-651;;097-033-715-916-451;;023-767-491-654-250;;003-337-413-216-452;;017-441-437-559-036,17875730;;10.1158/0008-5472.can-07-0696;;17875730;;10.1158/0008-5472.can-07-0696;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;10.1081/lpr-120004770;;12604032;;10.1002/ijc.21219;;16003736;;10.1097/00007890-199457110-00001;;10.1097/00007890-199406150-00001;;8009586;;10.1016/j.nucmedbio.2006.09.003;;17127172;;10413102;;10.1016/s0014-5793(99)00782-6;;10.1126/science.274.5284.94;;8810254;;10.1126/science.2426778;;2426778;;8417368;;10.1016/0161-5890(93)90432-b;;12196122;;10.1042/bst0300495;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;14597161;;10.1016/j.molimm.2003.08.004;;3038161;;10.1111/j.1365-2141.1987.tb01308.x;;16177115;;10.4049/jimmunol.175.7.4677;;10.1007/bf01941181;;3053230;;10.1111/j.1525-1438.2005.00441.x;;16343244;;16956823;;2492278;;10.1016/s0021-9258(18)94224-9;;10.2165/00063030-200115040-00002;;11437687;;2432048;;10.1016/0198-8859(86)90299-5;;18957413;;10.1074/jbc.m803584200;;8756631;;pmc231474;;10.1128/mcb.16.9.4735;;2899603;;10.4049/jimmunol.141.4.1398;;pmc150845;;11805126;;10.1172/jci14843;;10.1172/jci0214843;;10.1038/nbt0697-553;;9181578;;10858036;;10.1021/bp970144q;;11075358;;10.1016/s0076-6879(00)28410-3;;10.1073/pnas.170297297;;pmc27086;;10984501;;12171503;;10.1517/14712598.2.6.577;;10.1084/jem.20020165;;pmc2193704;;11994421;;10.1016/s0065-2776(08)60019-x;;10361574;;16167082;;pmc1201664;;10.1172/jci24772;;10404066;;10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j;;10.4049/jimmunol.167.1.204;;11418650;;7875742;;pmc1415059;;10.1002/eji.1830241042;;7925582;;9815920;;11710535;;10.1016/s1567-5769(01)00129-1;;10.1016/s0091-679x(08)61850-6;;7707984;;3049306;;10.1089/hyb.1988.7.407;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;10.2210/pdb1frt/pdb;;10.1038/372379a0;;7969498;;10.1016/s0065-2776(08)60486-1;;1502974;;10.1016/0161-5890(88)90153-8;;2975762;;10.1016/0161-5890(85)90151-8;;3889592;;16616063;;10.1053/j.seminoncol.2006.01.010;;10.1073/pnas.97.1.309;;pmc26659;;10618414;;12095707;;10.1016/s0165-2478(02)00118-9;;14675408;;10.1046/j.1365-2141.2003.04737.x;;10.1016/s0268-960x(03)00005-5;;12818224;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;10.1084/jem.176.4.1191;;1402660;;pmc2119390;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;11806974;;10.1182/blood.v99.3.754;;12438452;;10.1172/jci15454;;pmc151807;;10.1172/jci0215454;;10.1172/jci200215454;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1002/(sici)1097-4652(200003)182:3<323::aid-jcp2>3.0.co;2-;;10.1002/(sici)1097-4652(200003)182:3<323::aid-jcp2>3.0.co;2-#;;10653598;;7561063;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;8227075;;10.1016/s0021-9258(19)74578-5;;10.1007/s002620050038;;10.1007/bf01526201;;8306369;;10.1006/jmbi.1999.3192;;10543973;;10.1097/00022744-200106000-00001;;pmc432698;;1056014;;10.1073/pnas.72.6.2081;;10.1016/1074-7613(95)90155-8;;7621075;;10.1084/jem.189.1.179;;9874574;;pmc1887693;;10742152;;10.1038/74704;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;10.1126/science.279.5353.1052;;9461440;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1016/1074-7613(95)90134-5;;7584153;;9143687;;10.1146/annurev.immunol.15.1.203;;12010811;;10.1182/blood.v99.11.4087;;10.1002/bit.1119.abs;;11410853;;10.1002/bit.1119;;10.1038/nbt0595-475;;9634788;;11732118;;10.2210/pdb1fc1/pdb;;7236608;;10.2210/pdb1fc2/pdb;;10.1021/bi00512a001;;10580127;;10.1016/s0304-4165(99)00167-1;;10.1016/s0167-5699(97)01007-4;;9078685;;12218124;;10.4049/jimmunol.169.6.3076;;1348016;;10.1038/nbt0394-320;;16877060;;10.1016/s0065-3527(06)66003-x;;10.1016/s1074-7613(00)80546-4;;9586631;;10.1046/j.1365-2567.2001.01275.x;;pmc1783287;;11576217;;pmc2373476;;10.1110/ps.34602;;11847273;;3258649;;10.1038/332738a0;;2965792;;10.1038/332563a0;;10.4049/jimmunol.152.12.5826;;8207210;;15868901;;16397206;;10.1158/0008-5472.can-05-3389;;10.1016/0076-6879(91)02017-4;;1784180;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;2918553;;10.1093/jnci/81.6.445;;8069530;;10.1006/immu.1994.1009;;14563637;;10.1182/blood-2003-07-2548;;9488147;;10.1093/protein/10.10.1221,"Stavenhagen et al (Cancer Res, 2007, 67:8882-8890).;;Stavenhagen et al (Cancer Research, 2007, 67:8882-8890).;;Carter et al (Proceedings of the National Academy of Sciences, 1992, 89:4285-4289).;;US 6,339,069, 01/2002, Wittrup et al. (withdraw).;;Abra et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. Feb.-May 2002;12(1-2):1-3.;;Akcakanat et al. (2006) ""Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy"" Int. J. Cancer 118(1):123-8.;;Alegre et al. (1994) ""A non-activating 'humanized' anti-CD3 Monoclonal Antibody Retains Immunosuppressive Properties In Vivo,"" Transplantation 57:1537-1543.;;Almqvist (2006) ""In vitro and in vivo characterization of 177Lu-huA33 A radioimmunoconjugate against colorectal cancer,"" Nucl. Med. Biol. Nov. 33(8):991-998.;;Alt et al., ""Novel Tetravalent and Bispecific IgG-Like Antibody Molecules Combining Single-Chain Diabodies With the Immunoglobin Gamma 1 Fc or CH3 Region,"" FEBS Letters 454: 90-94, 1999.;;Altman et al., ""Phenotypic Analysis of Antigen-Specific T Lymphocytes"", Science 274:94-96, 1996.;;Amit et al. (1986) Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution.; Science 233:747-753.;;Angal et al., ""A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,"" Mol Immunol 30 .105-108, 1993.;;Armour et al., ""The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors,"" Biochemical Society Transactions 30:495-500, 2002.;;Armour et al., ""Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,"" Eur J Immunol 29:2613-2624, 1999.;;Armour et al., ""Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies,"" Mol Immunol 40 :585-593, 2003.;;Armstrong, S. et al. ""Heterogeneity of IgG1 monoclonal anti-Rh(D): an investigation using ADCC and macrophage binding assays,"" Brit. J. Haematol. 66:257-262 (1987).;;Bachmann et al. (2005) ""Recall Proliferation of Memory CD8+ T Cells and Antiviral Protection,"" J. Immunol 175:4677-4685.;;Baggiolini M, Dewald B. ""Cellular models for the detection and evaluation of drugs that modulate human phagocyte activity,"" Experientia. Oct. 15;44(10):841-848, 1988.;;Bast et al. (2005) ""New tumor markers: CA125 and beyond,"" Int. J. Gynecol. Cancer 15 Suppl 3:274-81.;;Bataille (2006) ""The phenotype of normal, reactive and malignant plasma cells. Identification of ""many and multiple myelomas"" and of new targets for myeloma therapy,"" Haematologica 91(9):1234-40.;;Bedzyk, W.D. et al. (1989) ""Comparison of Variable Region Primary Structures Within An Anti-Fluorescein Idiotype Family,""J. Biol. Chem. 264(3):1565-1569.;;Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.;;Bernard et al. (1986) ""A unique epitope on the CD2 molecule defined by the monoclonal antibody 9-1: epitope-specific modulation of the E-rosette receptor and effects on T-cell functions,"" Hum. Immunol 17(4):388-405.;;Berntzen, G. et al. (2009) ""Identification of a High Affinity FcgammaRIIA-binding Peptide That Distinguishes FcgammaRIIA from FcgammaRIIB and Exploits FcgamaRIIA-mediated Phagocytosis and Degradation,"" J. Biol. Chem. 284(2):1126-1135.;;Bewarder et al., 1996, ""In vivo and in vitro specificity of protein tyrosine kinases for immunoglobulin G receptor (FcgammaRll) phosphorylation,"" Mol. Cell. Biol. 16 (9):4735-43.;;Bhattacharya-Chatteijee et al. (1988) ""Idiotype Vaccines Against Human T Cell Leukemia,"" J. Immun. 141:1398-1403.;;Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. Jan. 2002;109(2):161-8.;;Boder and Wittrup, 1997, ""Yeast surface display for screening combinatorial polypeptide libraries"", Nature Biotechnology 15:553-557.;;Boder and Wittrup, ""Optimal screening of surface-displayed polypeptide libraries,"" Biotechnol Prog 14:55-62, 1998.;;Boder and Wittrup, ""Yeast surface display for directed evolution of protein expression, affinity, and stability,"" Methods in Enzymology 328:430-444, 2000.;;Boder et al., ""Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,"" Proc. Natl. Acad. Sci. USA 97:10701-10705, 2000.;;Bodey (2002) ""Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy,"" Expert Opin Biol Ther. 2(6):577-84.;;Bolland et al., Genetic modifiers of systemic lupus erythematosus in Fc.gamma.RIIB(-/-) mice. J Exp Med. May 6, 2002;195(9):1167-74.;;Bolland and Ravetch., Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149-177.;;Boruchov et al. (2005) Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of Clinical Investigation 115(10):2914-2923.;;Boruchov et al., ""Expression and Modulation of the Inhibitory Fcgamma Receptor, FcgammaRIIB (CD32B), on Human Dendritic Cells (DCs),"" Blood 102(11):Abstract #1908, 2003.;;Boyer et al. (1999) ""Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185,"" Int. J. Cancer. 82(4):525-531.;;Brauweiler et al., Partially distinct molecular mechanisms mediate inhibitory Fc.gamma.RIIB signaling in resting and activated B cells. J Immunol 2001;167:204-211.;;Bredius et al., ""Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes,"" Immunology 83:624-630, 1994.;;Brekke et al., ""Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis.,"" Eur J Immunol 24:2542-2547, 1994.;;Brooks et al., Phase Ia Trial of Murine Immunoglobulin A Antitransferrin Receptor Antibody 42/6, Clinical Cancer Research 1: 1259-1265, Nov. 1995.;;Brown (2001) ""Factors Modifying the Migration of Lymphocytes Across the Blood-Brain Barrier,"" Int Immunopharmacol. Nov. 2001;1(12):2043-62.;;Brown EJ., ""In Vitro Assays of Phagocytic Function of Human Peripheral Blood Leukocytes: Receptor Modulation and Signal Transduction,"" vol. 45 (Microbes as Tools for Cell Biology) in Methods in Cell Biololgy, Russell ed. Academic Press Inc. pp. 147-164, 1994.;;Budde et al., Specificity of CD32 mAB for Fc.gamma.RIIa, Fc.gamma.RIIbl, and Fc.gamma.RIIb2 expressed in transfected mouse B cells and BHK-21 cells. Leukocyte Typing V: White cell differentiation antigens. 1995;828-832 (Schlossman, Boumsell, Gilks, Harlan, Kishomoto, eds.).;;Bumal (1988) ""Characterization of the Human Tumor and Normal Tissue Reactivity of the KS1/4 Monoclonal Antibody,"" Hybridoma 7(4):407-415.;;Burgess et al. (1990) ""Possible dissociation of the heparin-binding and mitogenic activities of the heparin-binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue,"" J. Cell Biol. 111:2129-2138.;;Burlmeister et al., ""Crystal structure of the complex of rat neonatal Fc receptor with Fc,"" Nature 372:379-383, 1994.;;Burton and Woof, ""Human antibody effector function,"" Advances in Immunology 51:1-84, 1992.;;Burton et al., ""Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI),"" Mol Immunol 25:1175-1181, 1988.;;Burton, ""Immunoglobulin G: functional sites,"" Mol Immunol 22:161-206, 1985.;;Calin et al. (2006) ""Genomics of Chronic Lymphocytic Leukemia MicroRNAs as New Players With Clinical Significance,"" Semin Oncol. 33(2):167-73.;;Callanan et al., The IgG Fc Receptor, Fc.gamma.RIIB is a target for deregulation by chromosomal translocation in malignant lymphoma. PNAS. Jan. 2000;97(1):309-314.;;Cameron et al., Differentiation of the human monocyte cell line, U937, with dibutyryl cyclicAMP induces the expression of the inhibitory Fc receptor, Fc.gamma.RIIb. Immunol Lett. Oct. 1, 2002;83(3):171-9.;;Camilleri-Broet et al., Fc.gamma.RIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol. 2004;124(1):55-62.;;Campbell et al. (2003) ""Monoclonal antibody therapy for lymphoma,"" Blood Rev. 17(3):143-152.;;Canfield and Morrison, ""The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region,"" J Exp Med 173:1483-1491, 1991.;;Caron et al., ""Engineered humanized dimeric forms of IgG are more effective antibodies,"" J Exp Med 176 :1191-5, 1992.;;Carter et al., ""Humanization of an anti-p185HER2 antibody for human cancer therapy,"" Proc. Natl. Acad. Sci. USA 89:4285-4289, 1992.;;Cartron et al., ""Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene,"" Blood 99 :754-758, 2002.;;Cassard et al., Modulation of tumor growth by inhibitory Fc.gamma. receptor expressed by human melanoma cells. The J Clin Invest. Nov. 2002;110(10):1549-1557.;;Casset et al. (2003) A peptide mimetic of an anti-CD4 monoclonal antibody by rational design, Biochem. Biophs. Res. Commun. 307:198-205.;;Castelli et al. (2000) ""T-Cell Recognition of Melanoma-Associated Antigens,"" J. Cell Physiol. 182(3):323-31.;;Cavacini et al. (1995) ""Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody,"" J Immunol 155(7):3638-3644.;;Chappel et al., ""Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgGl/IgG2 hybrid and point-mutated antibodies,"" Proc. Natl. Acad. Sci USA 88:9036-9040, 1991.;;Chappel et al., ""Identification of a secondary Fc gamma RI binding site within a genetically engineered human IgG antibody,"" J Biol. Chem 268:25124-25131, 1993.;;Chattergee et al. (1994) ""Idiotypic Antibody Immunotherapy of Cancer,"" Cancer Immuno Immunother. 38:75-82.;;Chen, et al. (1999) ""Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen,"" J. Molec. Biol. 293:865-881.;;Chu et al. (2001) ""CD79: A Review,"" Appl. Immunohistochem. Mol. Morphol. 9(2):97-106.;;Ciccimarra et al., ""Localization of the IgG effector site for monocyte receptors,"" Proc. Natl. Acad. Sci. U.S.A. 72 :2081-2083, 1975.;;Clynes and Ravetch, ""Cytotoxic antibodies trigger inflammation through Fc receptors,"" Immunity 3:21-26, 1995.;;Clynes et al., ""Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors,"" J Exp Med 189:179-185, 1999.;;Clynes et al , ""Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,"" Nature Medicine 6 :443-446, 2000.;;Clynes et al., ""Fc receptors are required in passive and active immunity to melanoma,"" Proc. Natl. Acad. Sci USA 95:652-656, 1998.;;Clynes et al., ""Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis,"" Science 279:1052-1054, 1998.;;Colman, P.M. (1994) ""Effects of amino acid sequence changes on antibody-antigen interactions,"" Res. Immunol 145:33-36.;;Daeron et al., The Same Tyrosine Based Inhibition Motif, in the Intracytoplasmic Domain of Fc.gamma.RIIB, regulates negatively BCR, TCR- and FcR dependent cell activation. Immunity Nov. 1995;3: 635-646.;;Daeron, m. ""Fc Receptor Biology,"" Ann. Rev. Immunol 15:203-234.;;Damle et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood Jun. 1, 2002;99(11):4087-4093.;;Davies et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC.sub..gamma. RIII. Biotechnol Bioeng. Aug. 20, 2001;74(4):288-94.;;Davies et al. (1995) Antibody VH domains as small recognition units, Bio/Technology 13:475-479.;;de Haas, Wien Kin ""IgG-Fc receptors and the clinical relevance of their polymorphisms,"" Wien Klin Wochenscha 113:825-831, 2001.;;Deisenhofer, ""Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution,"" Biochem. 20:2361-2370, 1981.;;Dennis (1999) ""Glycoprotein glycosylation and cancer progression,"" Biochim. Biophys. Acta. 1473(1):21-34.;;Deo et al., ""Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies,"" Immunology Today 18:127-135, 1997.;;DePascalis et al. (2002) ""Grafting of Abbreviated Complementarity Determining Regions Containing Specificity Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic humanized monoclonal antibody,"" J. Immunol 169:3076-3084.;;De Santes et al. (1992) ""Radiolabeled Antibody Targeting of the Her-2/neu Oncoprotein,"" Cancer Res. 52:1916-1923.;;Dermer (1994) ""Another Anniversary for the War on Cancer,"" Biotechnology 12:320 (1994).;;DiMaio et al. (2006) ""Human Papillomaviruses and Cervical Cancer,"" Adv. Virus Res. 66:125-59.;;Ding et al. (1998) ""Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Acids,"" Immunity 8:403-411.;;Ding et al., Inhibition of the function of the Fc.gamma.RIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen. Immunology. Sep. 2001;104(1):28-36.;;Dumoulin et al. (2002) Single-domain antibody fragments with high conformational stability, Protein Science 11:500-512.;;Duncan and Winter, ""The binding site for C1q on IgG,"" Nature 332 :738-740, 1988.;;Duncan and Winter, ""Localization of the binding site for the human high-affinity Fc receptor on IgG,"" Nature 332:563-564, 1988.;;Edberg et al., ""Modulation of Fcgamma and Complement Receptor Function by the Glycosyl-Phosphatidylinositol-Anchored Form of FcgammaRIII,"" Journal of Immunology 152: 5826-5835, 1994.;;Efferson et al. (2005) ""Stimulation of Human T Cells by an Influenza A Vector Expressing a CTL Epitope from the HER-2/neu Protooncogene Results in Higher Numbers of Antigen Specific TCRhi Cells than Stimulation with Peptide,"" Anticancer Research 25:715-724.;;Egloff et al. (2006) ""Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer,"" Cancer Res. 66(1):6-9.;;Ellman, J. et al. ""Biosynthetic Method for Introducing Unnatural Amino Acids Site-Specifically into Proteins,"" Methods Enzymol. 202:301-336, 1991.;;Eppstein et al., Biological activity of liposome-encapsulated murine interferon .gamma. is mediated by a cell membrane receptor. Proc Natl Acad Sci U S A. Jan. 1985;82(11):3688-9.;;Estin et al. (1989) ""Transfected Mouse Melanoma Lines That Express Various Levels of Human Melanoma-Associated Antigen p97,"" J. Natl. Cancer Instit. 81(6):445-446.;;Fanger et al., Production and use of anti-FcR bispecific antibodies. Immunomethods. Feb. 1994;4(1):72-81.;;Farag, et al., Fc.gamma.RIIIa and Fc.gamma.RIIIa polymorphisms do not predict response to Rituximab in B-cell chronic lymphocytic leukemia. Blood. Oct. 16, 2003 (15 pp.).;;FitzGerald, et al., ""Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris,"" Protein Engineering 10(10): 1221-1225, 1997.",ACTIVE
83,DK,T3,DK 2486141 T3,104-436-664-667-026,2018-04-23,2018,DK 10822699 T,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC-REGION-INDEHOLDENDE POLYPEPTIDER, DER UDVISER FORBEDRET EFFEKTOR-FUNKTION GRUNDET ÆNDRINGER AF OMFANGET AF FUKOSYLERING, OG FREMGANGSMÅDER TIL DERES ANVENDELSE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/104-436-664-667-026,Granted Patent,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,A61K39/00;;C12P21/08;;C07K16/28;;C07K16/32;;C07K16/44;;C12P21/00,,0,0,,,,ACTIVE
84,MX,A,MX 2012004029 A,143-568-163-113-040,2012-05-08,2012,MX 2012004029 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE.","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by FcÎ³R is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by FcÎ³R is desired (e.g., inflammation, autoimmunde disease).",MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/143-568-163-113-040,Patent Application,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08,,0,0,,,,ACTIVE
85,KR,A,KR 20140015138 A,039-577-529-012-258,2014-02-06,2014,KR 20127010978 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/039-577-529-012-258,Patent Application,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C07K16/28;;A61K39/395;;A61P35/00;;C12P21/08,,0,0,,,,ACTIVE
86,WO,A1,WO 2011/044368 A1,103-524-987-862-68X,2011-04-14,2011,US 2010/0051831 W,2010-10-07,US 24951009 P,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by FcγR is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by FcγR is desired (e.g., inflammation, autoimmunde disease).",MACROGENICS INC;;JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/103-524-987-862-68X,Patent Application,yes,164,61,32,32,48,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08,,332,253,094-082-569-858-098;;059-082-631-746-849;;008-868-436-749-205;;156-501-805-490-709;;008-999-877-271-403;;027-913-674-497-110;;055-264-094-145-870;;051-116-306-800-452;;031-358-399-679-87X;;011-859-803-472-492;;086-378-024-269-624;;039-822-207-928-876;;002-267-311-930-893;;026-158-168-209-734;;076-774-944-138-418;;071-305-244-060-783;;015-110-020-909-687;;051-120-152-684-314;;020-576-792-007-611;;135-761-430-417-685;;045-966-724-527-157;;049-106-712-009-69X;;007-729-295-724-605;;013-452-637-389-025;;002-007-578-507-698;;054-717-629-774-351;;026-221-045-144-327;;027-367-233-681-03X;;053-392-328-406-863;;004-458-031-333-650;;003-752-183-823-430;;097-637-621-469-520;;093-304-805-156-309;;040-833-896-641-924;;071-073-635-453-103;;009-483-512-107-343;;092-006-899-469-178;;113-882-985-226-72X;;075-247-958-346-33X;;017-695-622-077-055;;093-304-805-156-309;;053-392-328-406-863;;054-717-629-774-351;;026-221-045-144-327;;002-007-578-507-698;;007-729-295-724-605;;010-488-381-022-259;;013-452-637-389-025;;135-761-430-417-685;;020-576-792-007-611;;015-110-020-909-687;;071-305-244-060-783;;000-499-911-678-177;;083-019-407-395-691;;015-914-646-829-770;;115-440-304-483-056;;079-109-121-457-433;;045-966-724-527-157;;003-097-377-914-607;;021-283-800-780-039;;135-137-520-495-776;;020-343-106-176-355;;030-861-724-466-58X;;094-791-135-404-955;;018-312-064-455-300;;070-318-112-524-781;;014-268-591-389-367;;015-466-204-116-873;;012-268-510-926-843;;053-392-328-406-863;;054-717-629-774-351;;022-375-749-274-329;;104-212-297-137-759;;031-063-853-127-197;;037-711-371-585-567;;022-375-749-274-329;;023-676-781-371-861;;028-385-018-876-542;;042-204-626-457-327;;022-023-983-891-895;;010-157-107-750-37X;;039-004-732-914-566;;043-108-278-056-872;;040-701-579-915-050;;057-837-842-755-673;;019-270-209-846-374;;069-935-065-298-889;;050-508-960-693-969;;017-077-300-427-35X;;133-154-290-763-393;;014-793-548-895-526;;049-565-952-682-771;;050-367-412-649-24X;;044-211-341-870-853;;131-325-784-167-955;;041-100-339-266-381;;101-640-792-825-42X;;030-771-085-408-850;;181-460-978-724-129;;000-094-608-211-106;;021-590-982-383-404;;029-496-615-483-112;;039-637-342-948-023;;006-557-225-778-806;;010-617-983-092-447;;023-139-057-784-151;;040-891-671-774-625;;042-969-985-115-518;;004-102-362-470-775;;005-894-275-098-711;;008-564-079-644-575;;061-458-250-035-271;;092-707-624-827-265;;096-885-619-853-781;;101-620-080-356-321;;123-934-383-563-555;;016-181-439-241-916;;096-131-283-549-67X;;029-369-188-860-718;;033-343-140-348-124;;078-132-684-581-98X;;077-767-979-415-033;;049-139-166-786-483;;021-221-106-931-817;;163-424-374-760-881;;072-652-403-050-578;;107-906-915-546-126;;169-186-375-773-817;;011-990-796-934-989;;015-437-525-153-752;;024-463-524-141-376;;077-451-267-180-896;;135-579-118-581-789;;005-610-949-554-027;;016-862-277-703-762;;050-331-065-793-647;;012-905-578-343-379;;035-508-996-080-378;;003-650-786-098-12X;;077-947-902-225-141;;047-546-945-216-549;;002-109-732-460-38X;;008-017-330-278-198;;042-579-537-651-17X;;136-761-514-047-614;;007-301-518-002-478;;024-285-885-610-44X;;074-791-142-946-327;;036-874-797-397-539;;031-987-750-488-846;;004-169-180-602-454;;012-445-901-371-843;;114-469-280-121-327;;020-390-505-416-055;;062-493-033-998-805;;070-318-112-524-781;;014-268-591-389-367;;061-317-267-044-853;;037-104-018-004-405;;016-667-499-483-351;;036-720-275-917-363;;085-382-910-924-422;;108-262-256-096-760;;088-563-914-464-250;;009-370-444-509-525;;081-969-406-101-221;;108-262-256-096-760;;019-673-197-708-279;;033-990-313-560-010;;081-969-406-101-221;;045-391-526-515-919;;029-826-853-870-598;;003-203-289-113-355;;012-122-364-391-278;;008-274-774-541-556;;065-516-907-443-199;;048-580-962-676-163;;013-807-902-871-50X;;004-930-036-538-272;;001-973-539-951-983;;070-280-057-407-994;;030-094-646-061-709;;077-040-152-841-627;;053-151-351-393-311;;166-025-821-402-033;;052-448-118-559-881;;015-506-891-538-448;;094-361-353-812-80X;;073-920-878-473-157;;001-127-144-604-001;;053-607-213-075-289;;081-720-011-594-742;;022-890-295-989-907;;052-235-244-371-629;;064-758-125-126-733;;053-251-957-094-365;;090-530-046-937-847;;028-900-321-386-005;;049-193-575-982-626;;004-912-179-216-140;;147-162-083-899-675;;147-556-573-144-832;;003-931-599-928-408;;095-945-393-711-654;;017-432-979-461-610;;005-149-894-631-757;;061-244-313-648-46X;;014-341-665-487-807;;000-094-608-211-106;;021-590-982-383-404;;097-033-715-916-451;;028-875-918-643-762;;039-637-342-948-023;;008-564-079-644-575;;004-701-796-869-470;;045-149-256-448-908;;129-722-134-945-53X;;095-386-846-016-358;;018-846-180-145-197;;047-388-844-780-414;;058-206-259-826-732;;026-531-521-458-647;;043-425-934-172-29X;;129-722-134-945-53X;;137-933-044-086-604;;031-886-516-535-883;;158-702-773-779-180;;010-184-078-818-93X;;047-584-153-988-599;;013-742-087-776-842;;118-790-987-080-617;;014-254-720-413-443;;006-337-951-387-864;;002-383-720-885-024;;029-998-982-422-928;;072-086-006-519-340;;064-992-932-868-798;;138-931-536-237-445;;058-650-779-085-254;;006-082-974-700-153;;049-453-063-076-310;;042-197-857-911-133;;008-274-774-541-556;;037-370-421-486-098;;021-477-482-927-001;;066-369-350-073-678;;010-056-645-097-600;;049-905-255-640-830;;047-318-935-119-599;;066-369-350-073-678;;094-082-569-858-098;;106-613-224-263-471;;001-513-599-447-597,17875730;;10.1158/0008-5472.can-07-0696;;10.4161/mabs.1.3.8328;;20065644;;pmc2726589;;10.1158/1078-0432.ccr-06-1335;;17363544;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1016/s1286-4579(00)01360-5;;11251299;;pmc150845;;11805126;;10.1172/jci14843;;10.1172/jci0214843;;10.1126/science.290.5489.84;;11021804;;11244038;;10.1146/annurev.immunol.19.1.275;;8069908;;10.1016/0092-8674(94)90521-5;;10.1053/ctrv.2000.0176;;10913382;;10561017;;pmc138676;;11250751;;10.1186/bcr276;;10.1096/fasebj.5.10.1712326;;1712326;;17012310;;10.1093/glycob/cwl057;;pmc1389705;;10.1073/pnas.0508123103;;16537476;;2965792;;10.1038/332563a0;;1833457;;10.4049/jimmunol.147.8.2657;;1530984;;10.1016/0161-5890(92)90156-r;;10.1097/00007890-199457110-00001;;10.1097/00007890-199406150-00001;;8009586;;pmc40279;;10.1073/pnas.92.26.11980;;8618827;;7797239;;10.1016/0165-2478(94)00201-2;;10.1096/fasebj.9.1.7821750;;7821750;;9052861;;10.1016/s0165-2478(96)02656-9;;8943402;;10.4049/jimmunol.157.11.4963;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.4049/jimmunol.164.8.4178;;10754313;;10657642;;10.4049/jimmunol.164.4.1925;;10716879;;10.1006/cimm.2000.1617;;11160318;;10.4049/jimmunol.166.4.2571;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;10.1016/s0165-2478(02)00019-6;;12008035;;12196120;;10.1042/bst0300487;;10917521;;10.1038/35018508;;11075358;;10.1016/s0076-6879(00)28410-3;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;pmc6808100;;10.1002/1098-2825(2000)14:4<141::aid-jcla3>3.0.co;2-0;;10906767;;8227075;;10.1016/s0021-9258(19)74578-5;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;12196120;;10.1042/bst0300487;;11160318;;10.4049/jimmunol.166.4.2571;;10.4049/jimmunol.164.8.4178;;10754313;;10657642;;10.4049/jimmunol.164.4.1925;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;9052861;;10.1016/s0165-2478(96)02656-9;;14699147;;10.1074/jbc.c300470200;;8943402;;10.4049/jimmunol.157.11.4963;;pmc40279;;10.1073/pnas.92.26.11980;;8618827;;10.1097/00007890-199457110-00001;;10.1097/00007890-199406150-00001;;8009586;;1833457;;10.4049/jimmunol.147.8.2657;;2965792;;10.1038/332563a0;;10.1084/jem.176.4.1191;;1402660;;pmc2119390;;10.4049/jimmunol.148.9.2918;;1573276;;8495420;;2930624;;10.2210/pdb1fc1/pdb;;7236608;;10.2210/pdb1fc2/pdb;;10.1021/bi00512a001;;7797239;;10.1016/0165-2478(94)00201-2;;15903235;;10.1021/bp040016j;;3896128;;10.1146/annurev.biochem.54.1.631;;0003896128;;10.1146/annurev.bi.54.070185.003215;;10.1093/glycob/cwl040;;16973733;;19226457;;10.1186/1471-2407-9-58;;pmc2649154;;10.1126/science.1060077;;11313494;;12240211;;10.1039/b105185g;;11686725;;10.1021/ja016652k;;10.1038/6179;;10052355;;10.1002/bit.1119.abs;;11410853;;10.1002/bit.1119;;12427744;;10.1074/jbc.m210665200;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;11160318;;10.4049/jimmunol.166.4.2571;;10.4049/jimmunol.164.8.4178;;10754313;;1675655;;10.4049/jimmunol.147.1.60;;10.4049/jimmunol.148.5.1547;;1531669;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1016/0076-6879(86)21019-8;;3724461;;1675655;;10.4049/jimmunol.147.1.60;;10.1126/science.3929380;;3929380;;10.1016/0022-1759(89)90093-8;;2514231;;3127726;;10.1038/332323a0;;10.1016/0161-5890(91)90163-e;;1905784;;10.1093/protein/7.6.805;;7937712;;8302875;;pmc521435;;10.1073/pnas.91.3.969;;7494109;;10.3109/08830189509061738;;7521646;;10.1038/nbt0994-899;;1551402;;10.1002/eji.1830220422;;6276389;;10.1016/s0021-9258(19)68223-2;;7826947;;10.1093/intimm/6.10.1567;;pmc286569;;10.1073/pnas.86.3.821;;2536934;;6204768;;10.1016/0092-8674(84)90412-4;;7530459;;9425664;;10.1016/s0958-1669(97)80127-9;;10.1016/s0167-7799(97)01158-x;;9487735;;10080890;;10.1006/jmbi.1999.2607;;10.2144/98242rr03;;9494734;;9796981;;10.1021/bc990010t;;10411450;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;2469722;;1702359;;2395659;;pmc331993;;10.1093/nar/18.16.4928;;2470373;;10.1016/0006-291x(89)92520-5;;8417812;;3539308;;10.1002/1097-0142(19870101)59:1<55::aid-cncr2820590115>3.0.co;2-r;;pmc329854;;2254463;;10.1172/jci114952;;1596900;;10.1002/ijc.2910530508;;8449598;;7509655;;10.1182/blood.v83.5.1329.bloodjournal8351329;;7506951;;10.1182/blood.v83.2.435.bloodjournal832435;;10.1182/blood.v83.2.435.435;;8441034;;10.4049/jimmunol.151.6.3390;;8376782;;8500110;;10.1007/bf01742253;;10.1200/jco.1994.12.5.1036;;8164027;;7916649;;3986770;;3731064;;2899603;;10.4049/jimmunol.141.4.1398;;1412714;;10.1016/0968-0004(92)90315-z;;10.1038/314053a0;;2579340;;9532405;;10.1016/j.nucmedbio.2006.09.003;;17127172;;16397206;;10.1158/0008-5472.can-05-3389;;12171503;;10.1517/14712598.2.6.577;;14517842;;10.1002/path.1448;;16616063;;10.1053/j.seminoncol.2006.01.010;;9766918;;10.1016/j.hoc.2006.06.011;;16990112;;pmc2761061;;10.1208/aapsj080363;;17025272;;16956823;;15790550;;10.1532/lh96.04056;;16461788;;10.1196/annals.1358.008;;10.1007/s11912-005-0060-7;;16091194;;10.1097/00022744-200106000-00001;;16969111;;10.4161/cc.5.18.3218;;10.1016/j.gyobfe.2006.06.011;;16876456;;16708907;;10.1016/j.coi.2006.01.011;;16464564;;10.1038/sj.onc.1205984;;12483526;;15067357;;10.3892/ijo.24.5.1325;;10.1002/ijc.21219;;16003736;;10.1007/s00262-005-0663-8;;15926079;;pmc2174598;;10.1097/01.cji.0000211312.36363.56;;17063124;;16890794;;10.1053/j.seminoncol.2006.04.004;;16877060;;10.1016/s0065-3527(06)66003-x;;16211870;;10.1007/0-387-27545-2_7;;16091200;;10.1007/s11912-005-0065-2;;10.1002/(sici)1097-4652(200003)182:3<323::aid-jcp2>3.0.co;2-;;10.1002/(sici)1097-4652(200003)182:3<323::aid-jcp2>3.0.co;2-#;;10653598;;16921403;;10.1038/nrm1987;;16247351;;11728222;;10.1517/14712598.1.5.881;;16614236;;10.1634/theoncologist.11-4-397;;10.2174/1389450003349092;;11467075;;10.1634/theoncologist.11-9-992;;17030640;;6806261;;10.1016/s0021-9258(18)34527-7;;10.4049/jimmunol.139.10.3521;;3119711;;7719381;;10.1089/cbr.1994.9.341;;10.1038/6179;;10052355;;10.1002/bit.1119.abs;;11410853;;10.1002/bit.1119;;11567028;;10.1074/jbc.m107478200;;11297533;;10.1074/jbc.m100351200;;10818726;;10.1385/1-59259-044-6:179;;10.1007/bf01941181;;3053230;;10.1016/s0022-1759(00)00237-4;;10986417;;10.1016/s0091-679x(08)61850-6;;7707984;;10.1084/jem.172.1.231;;pmc2188164;;2193096;;11841694;;10.1046/j.1365-3083.2002.01024.x;;10.1016/s1074-7613(00)80546-4;;9586631;;10.1016/s0091-679x(08)61850-6;;7707984;;10781611;;10.1074/jbc.m909462199;;2492278;;10.1016/s0021-9258(18)94224-9;;10.1016/s1074-7613(00)80546-4;;9586631;;1709200;;10.1002/jlb.49.6.556;;10.1074/jbc.m110277200;;11741917;;8483949;;pmc46497;;10.1073/pnas.90.9.4314;;450085;;10.1038/279328a0;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;894031;;1013510;;10.1007/978-3-642-81043-5_5;;10.1093/jnci/34.2.231;;14293790;;4174339;;10.1016/0022-1759(96)00063-4;;8699033;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1016/0022-1759(83)90438-6;;6300286;;6199426;;3192948;;10.1016/0022-1759(88)90310-9;;11020321;;10.1006/meth.2000.1039;;10.1016/s0958-1669(98)80091-8;;9503595;;10.1016/s0958-1669(99)00054-3;;10679342;;10.1525/ac.2000.11.3-4.54;;10.1016/s0958-1669(97)80157-7;;9013659;;10.1016/0958-1669(94)90047-7;;7765171;;7764646;;10.1016/s0958-1669(05)80072-2;;1632507;;10.1016/0003-2697(92)90329-6;;10.1006/abio.1995.1268;;7668379;;10.1006/abio.1996.0167;;8660505;;9571064;;10.1006/jmbi.1998.1653;;10.1016/0092-8674(77)90333-6;;194704;;7460013;;10.1016/0092-8674(80)90558-9;;6262811;;10.1073/pnas.78.3.1527;;pmc319164;;7017722;;pmc319285;;10.1073/pnas.78.4.2072;;8354036;;10.1146/annurev.pharmtox.33.1.573;;8494352;;10.1146/annurev.pa.33.040193.003041;;10.1126/science.8493530;;8493530;;10.1146/annurev.bi.62.070193.001203;;10.1146/annurev.biochem.62.1.191;;8352589;;10.1007/978-1-349-11891-5;;10.1016/0022-2836(81)90321-1;;6271971;;10.1016/0378-1119(84)90115-x;;6096211;;10.1128/mcb.3.2.257;;10.1128/mcb.3.2.257-266.1983;;6835212;;pmc368530;;pmc348679;;6769123;;10.1073/pnas.77.4.2197;;12975461;;10.1200/jco.2003.05.013;;10.1128/iai.67.3.1172-1179.1999;;10024557;;pmc96443;;2395659;;pmc331993;;10.1093/nar/18.16.4928;;2470373;;10.1016/0006-291x(89)92520-5;;2918553;;10.1093/jnci/81.6.445;;2324688;;10.1084/jem.171.4.1375;;pmc2187848;;3539308;;10.1002/1097-0142(19870101)59:1<55::aid-cncr2820590115>3.0.co;2-r;;8500110;;10.1007/bf01742253;;10.1016/s0021-9258(18)61209-8;;3558345;;2218494;;10.1126/science.2218494;;10.1016/0167-8140(96)01718-5;;8735485;;9038083;;7423373;;2761602;;10.1056/nejm198908313210904;;10.1126/science.3919445;;3919445;;10.1002/ana.410250406;;2634975;;10.3171/jns.1989.71.1.0105;;2567778;;10.1016/0167-8140(96)01718-5;;8735485;;10.1073/pnas.88.5.1864;;1672046;;pmc51126;;8102322;;10.1007/bf01518520;;11448923;;7654026;;11684435;;10.1016/s0962-8924(01)02127-4;;10742152;;10.1038/74704;;10718116;;10.1023/a:1007033610430;;14001233;;10.3181/00379727-111-27849;;1641579;;10.3109/00365529209000116;;3905309;;10.1007/bf01296964;;10.3109/08916939908998537;;10433102;;10403183;;10.1016/s0300-9084(99)80103-5;;9952277;;10.1159/isbn.978-3-318-03437-0;;10.1201/9781351077217;;10.1007/978-1-4615-8152-9;;10.1182/blood.v90.3.1109.1109_1109_1114;;10.1182/blood.v90.3.1109;;9242542;;9276722;;pmc508280;;10.1172/jci119616;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;16757681;;10.1182/blood-2006-05-020602;;16322460;;10.1126/science.1118948;;10.1016/j.immuni.2005.05.010;;16039578;;pmc2192335;;10.1084/jem.183.3.1259;;8642269;;10.1002/eji.1830210226;;1825635;;14801344;;10.1038/bjc.1950.36;;pmc2007731;;10.1016/j.immuni.2005.05.010;;16039578;;17875730;;10.1158/0008-5472.can-07-0696;;6736648;;90108;;10.1084/jem.150.3.580;;pmc2185638,"STAVENHAGEN ET AL.: ""Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors."", CANCER RES., vol. 67, no. 18, 15 September 2007 (2007-09-15), pages 8882 - 8890, XP002489883;;YAMANE-OHNUKI ET AL.: ""Production of therapeutic antibodies with controlled fucosylation."", MABS., vol. 1, no. 3, May 2009 (2009-05-01), pages 230 - 236, XP002630025;;SUZUKI ET AL.: ""A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients."", CLIN. CANCER RES., vol. 13, no. 6, 15 March 2007 (2007-03-15), pages 1875 - 1882, XP002508365;;RAVETCH J.V. ET AL., ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 92;;GERBER J.S. ET AL., MICROBES AND INFECTION, vol. 3, 2001, pages 131 - 139;;BILLADEAU D.D. ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 2, no. 109, 2002, pages 161 - 1681;;RAVETCH J.V. ET AL., SCIENCE, vol. 290, 2000, pages 84 - 89;;RAVETCH J.V. ET AL., ANNU. REV. IMMUNOL., vol. 19, 2001, pages 275 - 90;;RAVETCH J.V., CELL, vol. 78, no. 4, 1994, pages 553 - 60;;""Immunobiology: The Immune System in Health and Disease, 4th ed."", 1999, ELSEVIER SCIENCE LTD/GARLAND PUBLISHING;;ROBBINS; ANGELL: ""Basic Pathology, 2nd ed."", 1976, W.B. SAUNDERS CO., pages: 68 - 122;;RUBENSTEIN AND FEDERMAN: ""Scientific American: Medicine"", vol. 3, 1998, article STOCKDALE: ""Principles of Cancer Patient Management (Chapter 12, Section IV)"";;GILMAN ET AL.: ""Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th ed."", 1990, PERGAMOM PRESS;;RUBENSTEIN AND FEDERMAN: ""Scientific American Medicine"", vol. 3, 1998, article STOCKDALE: ""Principles Of Cancer Patient Management (ch. 12, sect. 10)"";;GREEN M.C. ET AL., CANCER TREAT REV., vol. 26, 2000, pages 269 - 286;;WEINER LM, SEMIN ONCOL., vol. 26, no. 14, 1999, pages 43 - 51;;SUZANNE A. ECCLES, BREAST CANCER RES., vol. 3, 2001, pages 86 - 90;;BELSHE: ""Textbook of Human Virology"", 1984, PSG PUBLISHING;;WYNGAARDEN; SMITH: ""Cecil Textbook of Medicine, 18th ed."", 1988, W.B. SAUNDERS CO., pages: 1750 - 1753;;MITSUYA ET AL., FASEB J., vol. 5, 1991, pages 2369 - 2381;;KANDA ET AL., GLYCOBIOLOGY, vol. 17, no. 1, 2006, pages 104 - 118;;LAZAR, G.A. ET AL., PROC. NATL. ACAD. SCI. (USA, vol. 103, 2006, pages 4005 - 4010;;DUNCAN ET AL., NATURE, vol. 332, 1988, pages 563 - 564;;LUND ET AL., J. IMMUNOL, vol. 147, 1991, pages 2657 - 2662;;LUND ET AL., MOL IMMUNOL, vol. 29, 1992, pages 53 - 59;;ALEGRE ET AL., TRANSPLANTATION, vol. 57, 1994, pages 1537 - 1543;;HUTCHINS ET AL., PROC NATL. ACAD SCI U S A, vol. 92, 1995, pages 11980 - 11984;;JEFFERIS ET AL., IMMUNOL LETT., vol. 44, 1995, pages 111 - 117;;LUND ET AL., FASEB J, vol. 9, 1995, pages 115 - 119;;JEFFERIS ET AL., IMMUNOL LETT, vol. 54, 1996, pages 101 - 104;;LUND ET AL., J IMMUNOL, vol. 157, 1996, pages 4963 - 4969;;ARMOUR ET AL., EUR J IMMUNOL, vol. 29, 1999, pages 2613 - 2624;;IDUSOGIE ET AL., J IMMUNOL, vol. 164, 2000, pages 4178 - 4184;;REDDY ET AL., J IMMUNOL, vol. 164, 2000, pages 1925 - 1933;;XU ET AL., CELL IMMUNOL, vol. 200, 2000, pages 16 - 26;;IDUSOGIE ET AL., J IMMUNOL, vol. 166, 2001, pages 2571 - 2575;;SHIELDS ET AL., J BIOL CHEM, vol. 276, 2001, pages 6591 - 6604;;SHIELDS ET AL., J BIOL CHEM, vol. 277, 2002, pages 26733 - 26740;;JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65;;PRESTA ET AL., BIOCHEM SOC TRANS, vol. 30, 2002, pages 487 - 490;;LAZAR , G.A. ET AL., PROC. NATL. ACAD. SCI. (USA, vol. 103, 2006, pages 4005 - 4010;;SONDERMANN ET AL., NATURE, vol. 406, 2000, pages 267 - 273;;BODER; WITTRUP, METHODS IN ENZYMOLOGY, vol. 328, 2000, pages 430 - 444;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 - 9;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991;;FLESCH; NEPPERT, J. CLIN. LAB. ANAL., vol. 14, 1999, pages 141 - 156;;CHAPPEL ET AL., J. BIOL. CHEM., vol. 33, 1993, pages 25124 - 25131;;CHAPPEL ET AL., PROC. NATL. ACAD. SCI. (U.S.A., vol. 88, 1991, pages 9036 - 9040;;BRIIGGEMANN ET AL., J. EXP. MED, vol. 166, 1987, pages 1351 - 1361;;PRESTA ET AL., BIOCHEM SOC TRANS, vol. 30, 2002, pages 487 - 90;;IDUSOGIE ET AL., J IMMUNOL, vol. 166, 2001, pages 2571 - 75;;IDUSOGIE ET AL., J IMMUNOL, vol. 164, 2000, pages 4178 - 84;;REDDY ET AL., J IMMUNOL, vol. 164, 2000, pages 1925 - 33;;ARMOUR ET AL., EUR J IMMUNOL, vol. 29, 1999, pages 2613 - 24;;JEFFERIS ET AL., IMMUNOL LETT, vol. 54, 1996, pages 101 - 04;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6;;LUND ET AL., J IMMUNOL, vol. 157, 1996, pages 4963 - 69;;HUTCHINS ET AL., PROC. NATL. ACAD. SCI. (U.S.A., vol. 92, 1995, pages 11980 - 84;;JEFFERIS ET AL., IMMUNOL LETT., vol. 44, 1995, pages 111 - 17;;LUND ET AL., FASEB J, vol. 9, 1995, pages 115 - 19;;ALEGRE ET AL., TRANSPLANTATION, vol. 57, 1994, pages 1537 - 43;;LUND ET AL., J. IMMUNOL, vol. 147, 1991, pages 2657 - 62;;DUNCAN ET AL., NATURE, vol. 332, 1988, pages 563 - 64;;CARON ET AL., J. EXP MED., vol. 176, 1992, pages 1191 - 1195;;B. SHOPES, J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922;;WOLFF ET AL., CANCER RESEARCH, vol. 53, 1993, pages 2560 - 2565;;STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, vol. 3, 1989, pages 219 - 230;;DIESENHOFER ET AL., BIOCHEMISTRY, vol. 20, 1981, pages 2361 - 2370;;SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;JEFFERIS ET AL., IMMUNOLOGY LETTERS, vol. 44, 1995, pages 111 - 7;;JEFFERIS, R.: ""Glycosylation of Recombinant Antibody Therapeutics"", BIOTECHNOL. PROG., vol. 21, 2005, pages 11 - 16;;KOMFELD, R. ET AL.: ""Assembly Of Asparagine-Linked Oligosaccharides"", ANN. REV. BIOCHEM., vol. 54, 1985, pages 631 - 664;;J. D. WATSON, ET AL.: ""Recombinant DNA: A Short Course"", 1983, W.H. FREEMAN AND COMPANY, article ""In Vitro Mutagenesis (chapter 8)"", pages: 106 - 116;;MA, B. ET AL.: ""Fucosylation In Prokaryotes And Eukaryotes"", GLYCOBIOLOGY, vol. 16, no. 12, 14 September 2006 (2006-09-14), pages 158R - 184R;;IIDA, S. ET AL.: ""Ttvo Mechanisms Of The Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Efficacy Of Non-Fucosylated Therapeutic Antibodies In Human Blood"", BMC CANCER, vol. 18, no. 9, 2009, pages 58;;WANG ET AL., CHEM. COMM., vol. 1, 2002, pages 1 - 11;;WANG ET AL., SCIENCE, vol. 292, 2001, pages 498 - 500;;VAN HEST ET AL., CHEM. COMM., vol. 19, 2001, pages 1897 - 1904;;TANG ET AL., J. AM. CHEM., vol. 123, no. 44, 2001, pages 11089 - 11090;;KIICK ET AL., FEBS LETT., vol. 505, no. 3, 2001, pages 465;;HUTCHINS ET AL., PROC NATL. ACAD SCI USA, vol. 92, 1995, pages 11980 - 11984;;UMANA ET AL., NAT. BIOTECHNOL, vol. 17, 1999, pages 176 - 180;;DAVIES ET AL., BIOTECHNOL BIOENG, vol. 74, pages 288 - 294;;SHINKAWA ET AL., J BIOL CHEM, vol. 278, 2003, pages 3466 - 3473;;OKAZAKI ET AL., JMB, vol. 336, 2004, pages 1239 - 49;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", NATIONAL INSTITUTES OF HEALTH;;IDUSOGIE ET AL., J. IMMUNOL., vol. 166, no. 4, 2001, pages 2571 - 5;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, no. 8, 2000, pages 4178 - 4184;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659;;SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;MORRISON, SCIENCE, vol. 229, 1985, pages 1202;;OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214;;GILLIES ET AL., J. IMMUNOL. METHODS, vol. 125, 1989, pages 191 - 202;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323;;PADLAN, MOLECULAR IMMUNOLOGY, vol. 28, no. 4-5, 1991, pages 489 - 498;;STUDNICKA ET AL., PROTEIN ENGINEERING,, vol. 7, no. 6, 1994, pages 805 - 814;;ROGUSKA ET AL., PROC NATL. ACACL. SCI. USA, vol. 91, 1994, pages 969 - 973;;LONBERG; HUSZAR, INT. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;JESPERS ET AL., BIO/TECHNOLOGY,, vol. 12, 1988, pages 899 - 903;;AUSUBEL, F.M. ET AL.: ""Current Protocols in Molecular Biology"", vol. 1, 1989, GREEN PUBLISHING ASSOCIATES, INC. AND JOHN WILEY AND SONS, INC., pages: 6.3.1 - 6.3.6,2.;;LAUTNER-RIESKE ET AL., EUR. J. IMMUNOL., vol. 22, 1992, pages 1023 - 1029;;HIETER ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 1516 - 22;;TAKAHASHI ET AL., J. IMMUNOL., vol. 6, 1994, pages 1567 - 1574;;GENTZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 821 - 824;;WILSON ET AL., CELL, vol. 37, 1984, pages 767;;KNAPPIK ET AL., BIOTECHNIQUES, vol. 17, no. 4, 1994, pages 754 - 761;;PATTEN ET AL., CURR. OPINION BIOTECHNOL., vol. 8, 1997, pages 724 - 33;;HARAYAMA, TRENDS BIOTECHNOL., vol. 16, 1998, pages 76;;HANSSON ET AL., J. MOL. BIOL., vol. 287, 1999, pages 265;;LORENZO; BLASCO, BIOTECHNIQUES, vol. 24, 1998, pages 308;;DENARDO ET AL., CLIN CANCER RES., vol. 4, 1998, pages 2483 - 90;;PETERSON ET AL., BIOCONJUG. CHEM,, vol. 10, 1999, pages 553;;ZIMMERMAN ET AL., NUCL. MED. BIOL., vol. 26, 1999, pages 943 - 50;;ARNON ET AL.: ""Monoclonal Antibodies And Cancer Therapy"", 1985, ALAN R. LISS, INC., article ""Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy"", pages: 243 - 56;;ROBINSON ET AL.: ""Controlled Drug Delivery, 2nd ed."", 1987, MARCEL DEKKER, INC., article HELLSTROM ET AL.: ""Antibodies For Drug Delivery"", pages: 623 - 53;;PINCHERA ET AL.: ""Monoclonal Antibodies '84: Biological And Clinical Applications"", 1985, article THORPE ET AL.: ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;BALDWIN ET AL.: ""Monoclonal Antibodies For Cancer Detection And Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy"", pages: 303 - 16;;THORPE ET AL., IMMUNOL. REV., vol. 62, 1982, pages 119 - 58;;PEREZ; WALKER, J. IMMUNOL., vol. 142, 1990, pages 3662 - 3667;;BUMAL, HYBRIDOMA, vol. 7, no. 4, 1988, pages 407 - 415;;YU ET AL., CANCER RES., vol. 51, no. 2, 1991, pages 468 - 475;;TAILOR ET AL., NUCL. ACIDS RES., vol. 18, no. 16, 1990, pages 4928;;HENTTU; VIHKO, BIOCHEM. BIOPHYS. RES. COMM., vol. 160, no. 2, 1989, pages 903 - 910;;ISRAELI ET AL., CANCER RES., vol. 53, 1993, pages 227 - 230;;ESTIN ET AL., J. NATL. CANCER INSTIT., vol. 81, no. 6, 1989, pages 445 - 446;;VIJAYASARDAHL ET AL., J. EXP. MECL., vol. 171, no. 4, 1990, pages 1375 - 1380;;NATALI ET AL., CANCER, vol. 59, 1987, pages 55 - 63;;MITTELMAN ET AL., J. CLIN. INVEST., vol. 86, 1990, pages 2136 - 2144;;FOON ET AL., PROC. AM. SOC. CLIN. ONCOL., vol. 13, 1994, pages 294;;YOKATA ET AL., CANCER RES., vol. 52, 1992, pages 3402 - 3408;;RAGNHAMMAR ET AL., INT. J. CANCER, vol. 53, 1993, pages 751 - 758;;HERLYN ET AL., J. CLIN. IMMUNOL., vol. 2, 1982, pages 135;;GHETIE ET AL., BLOOD, vol. 83, 1994, pages 1329 - 1336;;REFF ET AL., BLOOD, vol. 83, 1994, pages 435 - 445;;SGOUROS ET AL., J. NUCL. MED., vol. 34, 1993, pages 422 - 430;;SALEH ET AL., J. IMMUNOL., vol. 151, 1993, pages 3390 - 3398;;SHITARA ET AL., CANCER IMMUNOL. IMMURTOTLIER., vol. 36, 1993, pages 373 - 380;;LIVINGSTON ET AL., J. CLIN. ONCOL., vol. 12, 1994, pages 1036 - 1044;;HOON ET AL., CANCER RES., vol. 53, 1993, pages 5244 - 5250;;HELLSTROM ET AL., CANCER. RES., vol. 45, 1985, pages 2210 - 2188;;HELLSTROM ET AL., CANCER RES., vol. 46, 1986, pages 3917 - 3923;;BHATTACHARYA-CHATTERJEE ET AL., J. OF IMMUN., vol. 141, 1988, pages 1398 - 1403;;HILKENS ET AL., TRENDS IN BIO. CHEM. SCI., vol. 17, 1992, pages 359;;BERNHARD ET AL., SCIENCE, vol. 245, 1989, pages 301 - 304;;FEIZI, NATURE, vol. 314, 1985, pages 53 - 57;;EDELSON, THE CANCER JOURNAL, vol. 4, 1998, pages 62;;ALMQVIST, Y., NUCL MED BIOL., vol. 33, no. 8, November 2006 (2006-11-01), pages 991 - 998;;EGLOFF, A.M. ET AL., CANCER RES., vol. 66, no. 1, 2006, pages 6 - 9;;BODEY, B., EXPERT OPIN BIOL THER., vol. 2, no. 6, 2002, pages 577 - 84;;PRANGE W. ET AL., J PATHOL., vol. 201, no. 2, 2003, pages 250 - 9;;BAST, R.C. JR. ET AL., INT J GYNECOL CANCER, vol. 15, no. 3, 2005, pages 274 - 81;;CALIN, G.A ET AL., SEMIN ONCOL., vol. 33, no. 2, 2006, pages 167 - 73;;TROUSSARD, X. ET AL., HEMATOL CELL THER., vol. 40, no. 4, 1998, pages 139 - 48;;THOMAS, D.A. ET AL., HEMATOL ONCOL CLIN NORTH AM., vol. 20, no. 5, 2006, pages 1125 - 36;;KREITMAN, R.J., AAPS J., vol. 8, no. 3, 18 December 2005 (2005-12-18), pages E532 - 51;;ROSATI, S. ET AL., CURR TOP MICROBIOL IMMUNOL., vol. 5, no. 294, 2005, pages 91 - 107;;BATAILLE, R., HAEMATOLOGICA, vol. 91, no. 9, 2006, pages 1234 - 40;;GE, Y., LAB HEMATOL., vol. 11, no. 1, 2005, pages 31 - 7;;MESSMER, D. ET AL., ANN N Y ACAD SCI., vol. 1062, 2005, pages 51 - 60;;JURCIC, J.G., CURR ONCOL REP., vol. 7, no. 5, 2005, pages 339 - 46;;TROUSSARD, X ET AL., HEMATOL CELL THER., vol. 40, no. 4, 1998, pages 139 - 48;;CHU, P.G. ET AL., APPL IMMUNOHISTOCHEM MOL MORPHOL., vol. 9, no. 2, 2001, pages 97 - 106;;LEE, Y.M. ET AL., CELL CYCLE, vol. 5, no. 18, 2006, pages 2110 - 4;;MATHELIN, C., GYNECOL OBSTET FERTIL., vol. 34, no. 7-8, 2006, pages 638 - 46;;TELLEZ-AVILA, F.I. ET AL., REV INVEST CLIN., vol. 57, no. 6, 2005, pages 814 - 9;;PEGGS, K.S. ET AL., CURR OPIN IMMUNOL., vol. 18, no. 2, 2006, pages 206 - 13;;ADENIS, A. ET AL., BULL CANCER., 2003;;ZHOU, H. ET AL., ONCOGENE, vol. 21, no. 57, 2002, pages 8732 - 40;;RIMON, E. ET AL., INT J ONCOL., vol. 24, no. 5, 2004, pages 1325 - 38;;AKCAKANAT, A. ET AL., INT J CANCER., vol. 118, no. 1, 2006, pages 123 - 8;;LIVINGSTON, P.O. ET AL., CANCER IMMUNOL IMMUNOTHER., vol. 54, no. 10, 2005, pages 1018 - 25;;LOTEM, M. ET AL., J IMMUNOTHER., vol. 29, no. 6, 2006, pages 616 - 27;;KUMAR, PAL S ET AL., SEMIN ONCOL., vol. 33, no. 4, 2006, pages 386 - 91;;DIMAIO, D. ET AL., ADV VIRUS RES., vol. 66, 2006, pages 125 - 59;;RAGUPATHI, G., CANCER TREAT RES., vol. 123, 2005, pages 157 - 80;;KOUNALAKIS, N. ET AL., CURR ONCOL REP., vol. 7, no. 5, 2005, pages 377 - 82;;CASTELLI, C. ET AL., J CELL PHYSIOL., vol. 182, no. 3, 2000, pages 323 - 31;;DENNIS, J.W., BIOCHIM BIOPHYS ACTA, vol. 1473, no. 1, 6 December 1998 (1998-12-06), pages 21 - 34;;GIL, J. ET AL., NAT REV MOL CELL BIOL., vol. 7, no. 9, 2006, pages 667 - 77;;CRACCO, C.M. ET AL., MINERVA UROL NEFROL., vol. 57, no. 4, 2005, pages 301 - 11;;HOLMBERG, L.A., EXPERT OPIN BIOL THER., vol. 1, no. 5, 2001, pages 881 - 91;;VAN HORSSEN, R. ET AL., ONCOLOGIST, vol. 11, no. 4, 2006, pages 397 - 408;;GARDNEROVA, M. ET AL., CURR DRUG TARGETS, vol. 1, no. 4, 2000, pages 327 - 64;;O'DWYER. P.J., ONCOLOGIST., vol. 11, no. 9, 2006, pages 992 - 8;;KRANZ ET AL., J. BIOL. CHEM., vol. 257, no. 12, 1982, pages 6987 - 6995;;LIU ET AL., JOURNAL OF IMMUNOLOGY, vol. 139, 1987, pages 3521 - 6;;SHA ET AL., CANCER BIOTHER., vol. 9, no. 4, 1994, pages 341 - 9;;UMAHA ET AL., NAT BIOTECHNOL, vol. 17, 1999, pages 176 - 180;;DAVIES ET AL., BIOTECHNOL BIOENG, vol. 74, 2001, pages 288 - 294;;MIMURA ET AL., J BIOL CHEM, vol. 276, 2001, pages 45539;;RADAEV ET AL., J BIOL CHEM, vol. 276, 2001, pages 16478 - 16483;;PERUSSIA ET AL., METHODS MOL. BIOL., vol. 121, 2000, pages 179 - 92;;BAGGIOLINI ET AL., EXPERIENTIA, vol. 44, no. 10, 1998, pages 841 - 8;;LEHMANN ET AL., J. IMMUNOL. METHODS, vol. 243, no. 1-2, 2000, pages 229 - 42;;BROWN EJ., METHODS CELL BIOL.,, vol. 45, 1994, pages 147 - 64;;MUNN ET AL., J. EXP. MED., vol. 172, 1990, pages 231 - 237;;ABDUL-MAJID ET AL., SCAND. J. IMMUNOL., vol. 55, 2002, pages 70 - 81;;DING ET AL., IMMUNITY, vol. 8, 1998, pages 403 - 411;;BROWN EJ., METHODS CELL BIOL., vol. 45, 1994, pages 147 - 164;;TRIDANDAPANI ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 20480 - 7;;BEDZYK ET AL., J. BIOL. CHEM, vol. 264, no. 3, 1989, pages 1565 - 1569;;DING ET AL., IMMUNITY, vol. 8, 1998, pages 403 - 11;;FLEIT ET AL., J. LEUK. BIOL., vol. 49, 1991, pages 556;;PRICOP ET AL., J. IMMUNOL., vol. 166, 2000, pages 531 - 7;;TRIDANDAPANI ET AL., J. BIOL CHEM., vol. 277, 2002, pages 5082 - 9;;PEARSE ET AL., PNAS USA, vol. 90, 1993, pages 4314 - 8;;KOREN ET AL., NATURE, vol. 279, 1979, pages 328 - 331;;CLYNES ET AL., PNAS USA, vol. 95, 1998, pages 652 - 656;;RALPH ET AL., J. IMMUNOL., vol. 119, pages 950 - 4;;TREMP ET AL., CANCER RES., 1976, pages 33 - 41;;EPSTEIN ET AL., J. NATL. CANCER INST., vol. 34, 1965, pages 231 - 240;;KLEIN ET AL., CANCER RES., vol. 28, 1968, pages 1300 - 10;;BLOMBERG ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 193, 1996, pages 199 - 206;;GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163;;KORZENIEWSKI ET AL., IMMUNOL. METHODS, vol. 64, no. 3, 1983, pages 313 - 20;;DECKER ET AL., J. IMMUNOL METHODS, vol. 115, no. 1, 1988, pages 61 - 9;;MULLET ET AL., METHODS, vol. 22, 2000, pages 77 - 91;;DONG ET AL., REVIEW IN MOL. BIOTECH.,, vol. 82, 2002, pages 303 - 23;;FIVASH ET AL., CURRENT OPINION IN BIOTECHNOLOGY, vol. 9, 1998, pages 97 - 101;;RICH ET AL., CURRENT OPINION IN BIOTECHNOLOGY, vol. 11, 2000, pages 54 - 61;;MYSZKA, CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 50 - 7;;FISHER ET AL., CURRENT OPINION IN BIOTECHNOLOGY, vol. 5, 1994, pages 389 - 95;;O'SHANNESSY, CURRENT OPINION IN BIOTECHNOLOGY, vol. 5, 1994, pages 65 - 71;;CHAIKEN ET AL., ANALYTICAL BIOCHEMISTRY, vol. 201, 1992, pages 197 - 210;;MORTON ET AL., ANALYTICAL BIOCHEMISTRY, vol. 227, 1995, pages 176 - 85;;O'SHANNESSY ET AL., ANALYTICAL BIOCHEMISTRY, vol. 236, 1996, pages 275 - 83;;SAMBROOK ET AL.: ""Molecular Cloning, A Laboratory Manual, 3rd ed."", 2001, COLD SPRING HARBOR LABORATORY;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1998, JOHN WILEY & SONS;;CHOTHIA ET AL., J. MOL. BIOL., vol. 278, 1998, pages 457 - 479;;SAMBROOK ET AL.: ""Molecular Cloning, A Laboratory Manual, 2nd ed."", 1990, COLD SPRING HARBOR LABORATORY;;FOECKING ET AL., GENE, vol. 45, 1998, pages 101;;COCKETT ET AL., BIOLTECHNOLOGY, vol. 8, 1990, pages 2;;RUTHER ET AL., EMBO J., vol. 2, 1983, pages 1791;;INOUYE; INOUYE, NUCLEIC ACIDS RES., vol. 13, 1985, pages 3101 - 3109;;VAN HEEKE; SCHUSTER, J. BIOL. CHEM., vol. 24, 1989, pages 5503 - 5509;;LOGAN; SHENK, PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 355 - 359;;BITTNER ET AL., METHODS IN ENZYMOL., vol. 153, 1987, pages 51 - 544;;WIGLER ET AL., CELL, vol. 11, 1977, pages 223;;SZYBALSKA; SZYBALSKI, PROC. NATL. ACAD. SCI. USA, vol. 48, 1992, pages 202;;LOWY ET AL., CELL, vol. 22, 1980, pages 817;;WIGLER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 357;;O'HARE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 1527;;MULLIGAN; BERG, PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 2072;;CLINICAL PHARMACY, vol. 12, pages 488 - 505;;TOLSTOSHEV, ANN. REV. PHARMACOL. TOXICOL., vol. 32, 1993, pages 573 - 596;;MULLIGAN, SCIENCE, vol. 260, 1993, pages 926 - 932;;MORGAN; ANDERSON, ANN. REV. BIOCHEM., vol. 62, 1993, pages 191 - 217;;MAY, TIB TECH, vol. 11, no. 5, 1993, pages 155 - 215;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1993, JOHN WILEY & SONS;;KRIEGLER: ""Gene Transfer and Expression, A Laboratory Manual"", 1990, STOCKTON PRESS;;DRACOPOLI ET AL.: ""Current Protocols in Human Genetics"", 1994, JOHN WILEY & SONS, article ""Chapters 12 and 13"";;COLBERRE-GARAPIN ET AL., J. MOL. BIOL., vol. 150, 1981, pages 1;;SANTERRE ET AL., GENE, vol. 30, 1984, pages 147;;""DNA cloning"", vol. 3, 1987, ACADEMIC PRESS;;CROUSE ET AL., MOL. CELL. BIOL., vol. 3, 1983, pages 257;;PROUDFOOT, NATURE, vol. 322, 1986, pages 52;;KOHLER, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 2197;;CARTON ET AL., BLOOD, vol. 99, 2002, pages 754 - 8;;WENG ET AL., J CLIN ONCOL, vol. 21, no. 21, 2003, pages 3940 - 7;;SUN ET AL., INFECTION AND IMMUNITY, vol. 67, no. 3, 1999, pages 1172 - 9;;PEREZ; WALKER, J. IMMUNOL., vol. 142, 1990, pages 32 - 37;;YU ET AL., CANCER RES., vol. 51, no. 2, 1991, pages 48 - 475;;TAILOR ET AL., NUCL. ACIDS RES., vol. 18, no. 1, 1990, pages 4928;;HENTTU; VIHKO, BIOCHEM. BIOPHYS. RES. COMM., vol. 10, no. 2, 1989, pages 903 - 910;;ESTIN ET AL., J. NATL. CANCER INSTIT., vol. 81, no. 6, 1989, pages 445 - 44;;VIJAYASARDAHL ET AL., J. EXP. MED., vol. 171, no. 4, 1990, pages 1375 - 1380;;NATALI ET AL., CANCER, vol. 59, 1987, pages 55 - 3;;SALEH ET AL., J.IMMUNOL., vol. 151, 1993, pages 3390 - 3398;;SHITARA ET AL., CANCER IMMUNOL. IMMUNOTHER, vol. 36, 1993, pages 373 - 380;;FISHMAN ET AL.: ""Medicine, 2nd ed."", 1985, J.B. LIPPINCOTT CO.;;MURPHY ET AL.: ""Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery"", 1997, PENGUIN BOOKS U.S.A., INC.;;""Physician's Desk Reference, 56th ed."", 2002, .;;WU; WU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432;;LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533;;LOPEZ-BERESTEIN AND FIDLER: ""Liposomes in the Therapy of Infectious Disease and Cancer"", 1989, LISS, article TREAT ET AL., pages: 353 - 365;;LOPEZ-BERESTEIN: ""LIPOSOMES IN THE THERAPY OF INFECTIOUS DISEASE AND CANCER"", 1989, LISS, pages: 317 - 327;;NING ET AL.: ""Intratumoral Radioimmunotheraphy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel"", RADIOTHERAPY & ONCOLOGY, vol. 39, 1996, pages 179 - 189;;SONG ET AL.: ""Antibody Mediated Lung Targeting of Long-Circulating Emulsions"", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 50, 1995, pages 372 - 397;;CLEEK ET AL.: ""Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application"", PRO. INT'L. SYMP. CONTROL. REL. BIOACT. MATER., vol. 24, 1997, pages 853 - 854;;LAM ET AL.: ""Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery"", PROC. INT'L. SYMP. CONTROL REL. BIOACT. MATER., vol. 24, 1997, pages 759 - 760;;SEFTON, CRC CRIT. REF BIOMECL. ENG., vol. 14, 1987, pages 20;;BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507;;SAUDEK ET AL., N. ENGL. J. MED., vol. 321, 1989, pages 574;;LANGER AND WISE: ""Medical Applications of Controlled Release"", 1974, CRC PRES.;;SMOLEN AND BALL: ""Controlled Drug Bioavailability, Drug Product Design and Performance"", 1984, WILEY;;RANGER; PEPPAS, J., MACROMOL. SCI. REV. MACROMOL. CHEM., vol. 23, 1983, pages 61;;LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190;;DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351;;HOWARD ET AL., J. NEUROSURG., vol. 7 1, 1989, pages 105;;GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138;;NING ET AL., RADIOTHERAPY & ONCOLOGY, vol. 39, 1996, pages 179 - 189;;SONG ET AL., PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 50, 1995, pages 372 - 397;;CLEEK ET AL., PRO. INT'L. SYMP. CONTROL. REL. BIOACT. MATER., vol. 24, 1997, pages 853 - 854;;LAM ET AL., PROC. INT'L. SYMP. CONTROL REL. BIOACT. MATER., vol. 24, 1997, pages 759 - 760;;JOLIOT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 1864 - 1868;;HUDSIAK ET AL., MOL. CELL BIOL., vol. 9, 1989, pages 1165 - 72;;LEWIS ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 37, 1993, pages 255 - 63;;BERGMAN ET AL., CLIN. CANCER RES., vol. 7, 2001, pages 2050 - 6;;JOHNSON ET AL., ANTICANCER RES., 1995, pages 1387 - 93;;WU ET AL., TRENDS CELL BIOL., vol. 11, 2001, pages 2 - 9;;CLYNES ET AL., NAT. MED., vol. 6, 2000, pages 443 - 6;;MCCARTY ET AL.: ""Arthritis and Allied Conditions: A Textbook of Rheumatology"", 1993, LEE AND FEBIGER, article CROFFORD L.J.; WILDER R.L. ET AL.: ""Arthritis and Autoimmunity in Animals (chapter 30)"";;MCCARTY ET AL.: ""Arthritis and Allied Conditions: A Textbook of Rheumatology"", 1993, LEE AND FEBIGER, article CROFFORD L.J.; WILDER R.L ET AL.: ""Arthritis and Autoimmunity in Animals (chapter 30)"";;HANSRA P. ET AL.: ""Carrageenan-Induced Arthritis in the Rat"", INFLAMMATION, vol. 24, no. 2, 2000, pages 141 - 155;;WINTER C. A. ET AL.: ""Carrageenan-Induced Edema in Hind Paw of the Rat as an Assay for Anti-inflammatory Drugs"", PROC. SOC. EXP. BIOL MECL., vol. 111, 1962, pages 544 - 547;;KIM ET AL., SCAND. J. GASTROENTROL., vol. 27, 1992, pages 529 - 537;;STROBER, DIG. DIS. SCI., vol. 30, no. 12, 1985, pages 3S - 10S;;FLANDERS ET AL., AUTOIMMUNI, vol. 29, 1999, pages 235 - 246;;KROGH ET AL., BIOCLIIMIE, vol. 81, 1999, pages 511 - 515;;FOSTER, SEMIN. NEPLIROL., vol. 19, 1999, pages 12 - 24;;FIEBIG AND BURGER: ""Relevance of Tumor Models for Anticancer Drug Development"", 1999;;""Contributions to Oncology"", 1999, KARGER;;BOVEN AND WINOGRAD: ""The Nude Mouse in Oncology Research"", 1991;;TEICHER: ""Anticancer Drug Development Guide"", 1997;;KOENE ET AL., BLOOD, vol. 90, 1997, pages 1109 - 1114;;WU ET AL., J. CLIN. INVEST., vol. 100, 1997, pages 1059 - 70;;CLYNES ET AL., PNAS USA, vol. 95, 1998, pages 652 - 6;;RANKIN, C.T. ET AL., BLOOD, vol. 108, 2006, pages 2384 - 2391;;NIMMERJAHN, F. ET AL., SCIENCE, vol. 310, 2005, pages 1510 - 1512;;NIMMERJAHN, F., IMMUNITY, vol. 23, 2005, pages 41 - 51;;LI, M. ET AL., J. EXP. MED., vol. 183, 1996, pages 1259 - 1263;;PERUSSIA, B. ET AL., EUR. J. IMMUTIOL., vol. 21, pages 425 - 429;;GORER, P.A., BRIT. J. CANE, vol. 4, no. 4, 1950, pages 372 - 379;;NIMMERJAHN, F. ET AL., IMMUNITY, vol. 23, 2005, pages 41 - 51;;STAVENHAGEN, J.B. ET AL.: ""Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcy Receptors"", CANCER RES., vol. 67, no. 18, 2007, pages 8882 - 8890;;KURLANDER ET AL.: ""The Blockade Of Fc Receptor-Mediated Clearance Of Immune Complexes In Vivo By A Monoclonal Antibody (2.4G2) Directed Against Fc Receptors On Murine Leukocytes"", J. IMMUNOL., vol. 133, no. 2, 1984, pages 855 - 862;;UNKELESS, J.C.: ""Characterization of a Mooclonal Antibody Directed Against Mouse Macrophage and Lymphocyte Fc Receptors"", J. EXPER. MED., vol. 150, 1979, pages 580 - 596;;See also references of EP 2486141A4",PENDING
87,PL,T3,PL 2486141 T3,105-210-038-427-476,2018-07-31,2018,PL 10822699 T,2010-10-07,US 24951009 P;;EP 10822699 A;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/105-210-038-427-476,Patent Application,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,A61K39/00;;C12P21/08;;C07K16/28;;C07K16/32;;C07K16/44;;C12P21/00,,0,0,,,,PENDING
88,AU,A1,AU 2010/303415 A1,189-504-307-537-94X,2012-04-19,2012,AU 2010/303415 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by FcγR is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by FcγR is desired (e.g., inflammation, autoimmunde disease).",MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,,https://lens.org/189-504-307-537-94X,Patent Application,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08,,0,0,,,,INACTIVE
89,EP,B1,EP 2486141 B1,054-135-882-997-196,2018-01-10,2018,EP 10822699 A,2010-10-07,US 24951009 P;;US 2010/0051831 W,2009-10-07,"FC REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE",,MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;LERNER LAURA;;GORLATOV SERGEY,"MACROGENICS, INC. (2016-10-12)",https://lens.org/054-135-882-997-196,Granted Patent,yes,24,24,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08;;A61K39/00;;C07K16/28;;C07K16/32;;C07K16/44;;C12P21/00,,10,10,094-082-569-858-098;;064-195-030-872-518;;037-370-421-486-098;;038-305-867-383-662;;042-467-037-806-132;;113-882-985-226-72X;;013-452-637-389-025;;097-187-829-414-793;;094-082-569-858-098;;057-224-929-124-944,17875730;;10.1158/0008-5472.can-07-0696;;10.1371/journal.pone.0008425;;20037630;;pmc2791859;;16757681;;10.1182/blood-2006-05-020602;;10.1006/bbrc.2001.5382;;11500028;;19494347;;10.1093/glycob/cwp079;;8227075;;10.1016/s0021-9258(19)74578-5;;8943402;;10.4049/jimmunol.157.11.4963;;18344326;;10.1073/pnas.0801192105;;pmc2393817;;17875730;;10.1158/0008-5472.can-07-0696;;23488770;;10.1111/sji.12046,"STAVENHAGEN, JEFFREY B. ET AL.: ""Fc optimization of 2007 therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor ex pansion in vivo via low-affinity activating Fcy receptors"", CANCER RESEARCH, vol. 67, no. 18, 1 September 2007 (2007-09-01), pages 8882 - 8890, XP002489883;;VOYNOV, VLADIMIR ET AL.: ""Dynamic fluctuations of protein- carbohydrate interactions promote protein aggregation"", PLOS ONE, vol. 4, no. 12, December 2009 (2009-12-01), pages e8425-1 - e8425-10, XP055523337;;RANKIN , CHRISTOPHER T. ET AL.: ""CD 32B, the human 2006 inhibitory Fc-y receptor IIB, as a target for monoclonal antibody therapy of B- cell lymphoma"", BLOOD, vol. 108, no. 7, October 2006 (2006-10-01), pages 2384 - 2391, XP002522503;;JASSAL, RAMESH ET AL.: ""Sialylation of human IgG-Fc 2001 carbohydrate by transfected rat a2, 6-sialyltransferase"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 243 - 249, XP002574380;;HOSSLER ET AL.: ""Optimal and consistent protein glycosylation in mammalian cell culture"", GLYCOBIOLOGY, vol. 19, no. 9, 3 June 2009 (2009-06-03), pages 936 - 949, XP055112498;;CHAPPEL M S; ET AL: ""Identification of a secondary FcyRI binding site within a genetically engineered human IgG antibody"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 33, 1993, pages 25124 - 25131, XP002337952;;LUND J; ET AL: ""Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains"", JOURNAL OF IMMUNOLOGY, vol. 157, no. 11, December 1996 (1996-12-01), pages 4963 - 4969, XP002484003;;SCANLAN CHRISTOPHER N; BURTON D R; DWEK R A: ""Making autoantibodies safe"", PNAS, vol. 105, no. 11, 14 March 2008 (2008-03-14), pages 4081 - 4082, XP002569096;;STAVENHAGEN JEFFREY B; ET AL: ""Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fc gamma receptors"", CANCER RESEARCH, vol. 67, no. 18, September 2007 (2007-09-01), pages 8882 - 8890, XP002489883;;A. C. VESTRHEIM, A. MOEN, W. EGGE-JACOBSEN, D. B. BRATLIE, T. E. MICHAELSEN: ""Different Glycosylation Pattern of Human lgG 1 and lgG3 Antibodies Isolated from Transiently as well as Permanently Transfected Cell Lines"", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 77, no. 5, May 2013 (2013-05-01), pages 419 - 428, XP055523377",INACTIVE
90,CN,A,CN 102666874 A,160-742-815-520-854,2012-09-12,2012,CN 201080055367 A,2010-10-07,US 2010/0051831 W;;US 24951009 P,2009-10-07,"Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by Fc?R is desired (e.g., inflammation, autoimmunde disease).",MACROGENICS INC,JOHNSON LESLIE S;;ANDERSON RAINEY GODFREY JONAH;;LAURA LERNER;;SERGEY GORLATOV,,https://lens.org/160-742-815-520-854,Patent Application,no,0,1,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C12P21/08,,1,0,,,"JEFFREY B. STAVENHAGEN等: ""Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors"", 《CANCER RESEARCH》",ACTIVE
91,EP,A1,EP 1063803 A1,160-406-079-073-802,2000-12-27,2000,EP 00304792 A,2000-06-06,US 33340699 A,1999-06-15,Wideband optical packet ring network,"A dual-ring, bi-directional optical fiber transmission system interconnects a series of add/drop nodes with a hub, such that multiple, widely spaced coarse wavelength division multiplexed (C-WDM) channels are established on each ring. At each node, an optical add/drop module (OADM) includes broadband filters (BBF's), such as dielectric thin film filters, arranged to (a) extract, for the purposes of a receiver, or (b) insert, for the purposes of a transmitter, information in one or more of the channels. The signals in the one or more channels are coupled to the OADM's by a standard optical transceiver, which performs modulation and demodulation. Each filter passband can be populated with multiple dense wavelength division multiplexed (D-WDM) channels, so that the capacity of traffic that can be handled at each node can be easily upgraded. The transceiver is, in turn, coupled to packet framer, such as an IP packet over SONET framer, which supplies received packets to, and receives outgoing packets from, a conventional Layer 3 routing engine. While in most instances, endpoints at each of the nodes communicate with other endpoints connected to the hub, if desired, endpoints at one or more nodes can communicate directly with endpoints on other nodes, using a direct or bypass connection through the hub. The bypass can be ""permanent"" or controlled via a switch, such as a micro-electro-mechanical switch (MEMS).",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BRINKMAN WILLIAM FRANK;;BROBERG ROBERT MARIO,,https://lens.org/160-406-079-073-802,Patent Application,yes,3,22,6,6,0,H04J14/0206;;H04J14/0213;;H04J14/0219;;H04J14/0283;;H04J14/0294;;H04Q11/0062;;H04Q11/0066;;H04Q11/0071;;H04L12/42,H04B10/27;;H04B10/032;;H04B10/038;;H04B10/275;;H04B10/29;;H04J14/00;;H04J14/02;;H04L12/42;;H04Q11/00,,0,0,,,,DISCONTINUED
92,KR,A,KR 20010015011 A,160-208-524-676-891,2001-02-26,2001,KR 20000032293 A,2000-06-13,US 33340699 A,1999-06-15,WIDEBAND OPTICAL PACKET RING NETWORK,"PURPOSE: A wide band optical packet ring network is provided to efficiently increase capacity of operation by connecting a series of nodes with hubs by a dual ring bi-directional optical fiber transmission system and constituting an optical additional drop module of a broad band filter like a dielectric thin film filter at each node. CONSTITUTION: Nodes are connected together to make a ring (101) to connect only one of optical transmission rings with three additional/drop nodes (110 to 112) and a hub (130) transmit a packet in the clockwise direction and to make a similar ring to transmit the packet in the counterclockwise direction. Each of the nodes (110 to 112) is provided with corresponding optical additional drop modules OADM (210 to 212). Namely, in a specified wavelength band corresponding to a specified widely spaced C-WAM channel, only a signal is extracted from a wavelength division multiplexed signal existing in the ring (101) and inserted into the same wavelength band and a C-WDM channel so as to be returned on the ring (101).",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BRINKMAN WILLIAM FRANK;;BROBERG ROBERT MARIO,,https://lens.org/160-208-524-676-891,Patent Application,no,0,3,6,6,0,H04J14/0206;;H04J14/0213;;H04J14/0219;;H04J14/0283;;H04J14/0294;;H04Q11/0062;;H04Q11/0066;;H04Q11/0071;;H04L12/42,H04B10/27;;H04B10/032;;H04B10/038;;H04B10/275;;H04B10/29;;H04J14/00;;H04J14/02;;H04L12/42;;H04Q11/00,,0,0,,,,DISCONTINUED
93,TR,T4,TR 201804897 T4,174-549-525-307-936,2018-06-21,2018,TR 201804897 T,2010-10-07,US 24951009 P,2009-10-07,FUKOSİLASYON ÖLÇÜSÜNÜN DEĞİŞİMLERİNDEN DOLAYI GELİŞMİŞ EFEKTÖR İŞLEVİ SERGİLEYEN FC BÖLGESİNİ İÇEREN POLİPEPTİTLER VE BUNLARIN KULLANIMLARINA YÖNELİK YÖNTEMLER,"FUKOSİLASYON ÖLÇÜSÜNÜN DEĞİŞİMLERİNDEN DOLAYI GELİŞMİŞ EFEKTÖR İŞLEVİ SERGİLEYEN FC BÖLGESİNİ İÇEREN POLİPEPTİTLER VE BUNLARIN KULLANIMLARINA YÖNELİK YÖNTEMLER Mevcut buluş, fukosilasyon ölçüsünün değişimlerinden dolayı gelişmiş efektör işlevi sergileyen Fc bölgesini içeren polipeptitlerle ve kanserin ve diğer hastalıkların tedavi edilmesine veya önlenmesine yönelik bu tarz polipeptitlerin kullanımına yönelik yöntemlerle ilgilidir. Fc bölgesini içeren polipeptitler tercihen immünoglobulinlerdir (örn. antikorlar), burada Fc bölgesi, bir sokak türü Fc bölgesinin ilgili amino asit sekansına göre en az bir aminoyu ve ikameyi içermektedir ve dönüşüm sonrası fukosilasyonu hafifletmek ve bir aktif hale getirici Fc reseptörüne gelişmiş bağlantıyı ve bir inhibitör Fc reseptörüne azaltılmış bağlantıyı yönlendirmek için yeterlidir. Buluşun yöntemleri, Fc&#947#&R ile yönlendirilen efektör hücre işlevinin gelişmiş bir verimliliğinin arzu edildiği (örn. kanser, bulaşıcı hastalık) veya Fc&#947#&R ile yönlendirilen bir inhibe edilmiş efektör hücresi yanıtının arzu edildiği (örn. inflamasyon, otoimmün hastalık) bir hastalıkla, rahatsızlıkla veya enfeksiyonla ilişkili bir veya birden fazla semptomun önlenmesinde, tedavi edilmesinde veya hafifletilmesinde özellikle kullanışlıdır.",MACROGENICS INC,LESLIE S JOHNSON;;GODFREY JONAH ANDERSON RAINEY;;LAURA LERNER;;SERGEY GORLATOV,,https://lens.org/174-549-525-307-936,Granted Patent,no,0,0,32,32,0,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,C07K16/28;;A61K39/00;;C07K16/32;;C07K16/44;;C12P21/00;;C12P21/08,,0,0,,,,ACTIVE
94,US,A1,US 2007/0263322 A1,042-211-573-677-11X,2007-11-15,2007,US 87963707 A,2007-07-18,US 87963707 A;;US 82315304 A,2004-04-13,Magnetic devices having magnetic features with CMP stop layers,"A magnetic device having a magnetic feature, the magnetic feature including a magnetic portion comprising a magnetic material, a region of non-magnetic material adjacent to the magnetic portion, and a stop layer disposed above the region of non-magnetic material, defining a planar upper boundary of the magnetic portion.",SEAGATE TECHNOLOGY LLC,HUANG PICHENG;;ANDERSON PAUL E;;STEARNS LAURA C;;XUE SONG S,SEAGATE TECHNOLOGY LLC (2004-04-09),https://lens.org/042-211-573-677-11X,Patent Application,yes,30,2,3,3,0,G11C11/16;;Y10T29/49052;;Y10T29/49043;;Y10T29/49046;;Y10T29/49002;;Y10T29/49224;;Y10T29/49044;;Y10T29/49048;;H10N50/85;;Y10T29/49052;;Y10T29/49043;;Y10T29/49046;;Y10T29/49002;;Y10T29/49224;;Y10T29/49044;;Y10T29/49048;;G11C11/16;;H10N50/85,G11B5/147;;G11B5/127;;G11B5/17;;H04R31/00,360/126;;29/603.13,0,0,,,,DISCONTINUED
95,US,A1,US 2012/0219551 A1,043-517-331-147-923,2012-08-30,2012,US 201013499007 A,2010-10-07,US 201013499007 A;;US 24951009 P;;US 2010/0051831 W,2009-10-07,"Fc Region-Containing Polypeptides That Exhibit Improved Effector Function Due To Alterations Of The Extent Of Fucosylation, And Methods For Their Use","The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by FcγR is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by FcγR is desired (e.g., inflammation, autoimmune disease).",JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;GORLATOV SERGEY;;LERNER LAURA;;MACROGENICS INC,JOHNSON LESLIE S;;RAINEY GODFREY JONAH ANDERSON;;GORLATOV SERGEY;;LERNER LAURA,MACROGENICS INC (2010-10-22),https://lens.org/043-517-331-147-923,Patent Application,yes,3,59,32,32,48,A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/2887;;C07K16/32;;C07K16/44;;C07K2317/41;;C07K2317/71;;C12P21/005;;A61P35/00;;A61K2039/505;;C07K2317/52;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K2317/71;;C07K16/2887;;C07K16/44;;C07K16/32;;C07K2317/41;;C07K16/283;;C12P21/005,A61K39/395;;A61P35/00;;C07K16/30;;C12P21/00,424/133.1;;435/69.6;;530/387.3,3,3,094-082-569-858-098;;094-082-569-858-098;;009-483-512-107-343,17875730;;10.1158/0008-5472.can-07-0696;;17875730;;10.1158/0008-5472.can-07-0696;;10.1073/pnas.89.10.4285;;1350088;;pmc49066,"Stavenhagen et al (Cancer Res, 2007, 67:8882-8890);;Stavenhagen et al (Cancer Research, 2007, 67:8882-8890);;Carter et al (Proceedings of the National Academy of Sciences, 1992, 89:4285-4289)",ACTIVE
96,WO,A1,WO 2008/147442 A1,042-532-499-999-328,2008-12-04,2008,US 2007/0083403 W,2007-11-02,US 94100707 P,2007-05-31,METHOD AND APPARATUS FOR MANUFACTURING AN ENDLESS LOOP SEAL,"An extrusion line (10) comprising an extrusion machine (14) operable to provide an extrusion (18) having a desired cross-section; and a fully automated device (22) operable to receive the extrusion, remove a piece of predetermined length, and form the piece into a finished endless loop (30).",BEMIS MFG CO;;BEMIS PETER F;;CYKANA DANIEL;;ANDERSON EINAR;;BROST TAMARA;;O'GRADY LAURA,BEMIS PETER F;;CYKANA DANIEL;;ANDERSON EINAR;;BROST TAMARA;;O'GRADY LAURA,,https://lens.org/042-532-499-999-328,Patent Application,yes,8,2,1,1,0,B29C65/2061;;B29C48/001;;B29C48/0022;;B29C48/09;;B29C48/12;;B29C53/36;;B29C65/7841;;B29C66/1142;;B29C66/52211;;B29C66/71;;B29C66/8221;;B29C66/83221;;B29C2793/0027;;B29D99/0082;;B29L2031/26;;B29L2031/709;;B29L2031/7096,B29C69/02;;B29C53/36;;B29C65/20;;B29C65/78;;B29L31/26,,0,0,,,,PENDING
97,CA,A1,CA 2389609 A1,133-746-551-677-020,2001-05-10,2001,CA 2389609 A,2000-10-31,US 43163999 A;;US 0029977 W,1999-11-01,FREEZER-TO-OVEN DOUGH PRODUCTS,"The present invention provides freezer-to-oven dough products, as well as methods for preparing the dough products. Specifically, the dough products o f the present invention include a chemical leavening system comprising a plurality of chemical leavening acids having different temperature ranges within which they are active as chemical leaveners. Such a chemical leavenin g system provides for the staged rising, i.e., rising that occurs over a wide temperature range and thus during a substantial portion of the cooking cycle , of the dough products of the present invention when cooked. By providing frozen dough products with such a leavening system, the need for a preproofi ng step prior to freezing, a thawing step or an intervening proofing step prior to cooking is avoided, and yet, the dough product is capable of substantial expansion upon cooking, thereby producing a cooked dough product with excellent visual and organoleptic properties.",PILLSBURY CO,REINKE JEFFREY D;;HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W,,https://lens.org/133-746-551-677-020,Patent Application,no,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,EXPIRED
98,US,B1,US 6589583 B1,123-762-260-425-592,2003-07-08,2003,US 43163999 A,1999-11-01,US 43163999 A,1999-11-01,Freezer to oven dough products,"
    The present invention provides freezer-to-oven dough products, as well as methods for preparing the dough products. Specifically, the dough products of the present invention include a chemical leavening system comprising a plurality of chemical leavening acids having different temperature ranges within which they are active as chemical leaveners. Such a chemical leavening system provides for the staged rising, i.e., rising that occurs over a wide temperature range and thus during a substantial portion of the cooking cycle, of the dough products of the present invention when cooked. By providing frozen dough products with such a leavening system, the need for a preproofing step prior to freezing, a thawing step or an intervening proofing step prior to cooking is avoided, and yet, the dough product is capable of substantial expansion upon cooking, thereby producing a cooked dough product with excellent visual and organoleptic properties. 
",PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,GENERAL MILLS INC (2012-07-11);;GENERAL MILLS MARKETING INC (2005-07-07);;PILLSBURY COMPANY THE (2000-01-27),https://lens.org/123-762-260-425-592,Granted Patent,yes,20,59,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/14;;A21D2/18;;A21D2/02;;A21D6/00;;A21D8/04;;A21D10/02,426/551;;426/549;;426/94;;426/553,1,0,,,International Search Report PCT/US00/29977.,EXPIRED
99,US,B1,US 10142255 B1,069-031-725-925-728,2018-11-27,2018,US 201615259912 A,2016-09-08,US 201615259912 A,2016-09-08,Allocating dynamic resources to service clusters,"Techniques for efficiently managing resources are described. In an example, a computer system may access a forecast for demand associated with utilizing a service during a time period, where the service is available from service sources grouped in clusters. The computer system may identify resources scheduled to facilitate the service. Based on a scheduled start time for utilizing a resource, the forecast, and an allocation of remaining resources to the clusters, the computer system may allocate the resource to a first cluster and may provide a notification about the allocation to an associated client device. At a subsequent time during the time period, the computer system may re-allocate the resource to a second cluster based on a current utilization of the resource, an update to the forecast, and the allocation of the remaining resources. A respective notification may be provided to the client device.",AMAZON TECH INC,PACHON JULIAN;;ANDERSON MARC JOSEPH;;HOUSLEY LAURA LYNN;;SINGH AMANDEEP;;TOMAY BERYL,AMAZON TECHNOLOGIES INC (2016-09-07),https://lens.org/069-031-725-925-728,Granted Patent,yes,10,31,1,1,0,G06Q10/083;;G08G1/202;;G06Q10/08355;;G06Q10/047;;G06Q10/0631;;G06F16/2379;;H04L67/52;;G06Q50/40;;G06F16/2379;;G08G1/202;;G06Q10/083;;G06Q10/08355;;G06Q10/047;;G06Q10/0631;;H04L67/52;;G06Q50/40,H04L12/911;;G06F17/30;;H04L29/08,,1,0,,,"U.S. Appl. No. 15/242,274, filed Aug. 19, 2016, Title: Allocating Resource Blocks to Dynamic Resources.",ACTIVE
100,CO,A1,CO 5221079 A1,124-940-372-835-348,2002-11-28,2002,CO 00082960 A,2000-10-31,US 43163999 A,1999-11-01,PRODUCTOS DE MASA DEL CONGELADOR AL HORNO,"Un producto de masa congelado no probado comprende:a) harina, agua y levadura; yb) un sistema fermentador químico que comprende una pluralidad de ácidos de fermentación química que tienen diferentes rangos de temperatura dentro de los cuales ellos son activos como fermentadores químicos.",PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,,https://lens.org/124-940-372-835-348,Patent Application,no,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/00;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,DISCONTINUED
101,US,B2,US 9271907 B2,085-951-177-937-18X,2016-03-01,2016,US 93262211 A,2011-03-01,US 93262211 A;;US 33918410 P,2010-03-01,Compositions and methods for protection of skin against thermal insult,"The present invention provides novel topically-applied skin and face coating and paint compositions comprising near infrared reflecting pigments and hydrogels swollen with aqueous solution and/or with simulated sweat. The invention further provides methods of making and using the compositions. The novel compositions protect the skin of the wearer from damage due to intense external heat or thermal flux and simultaneously divert thermal energy to a complementary evaporative cooling mechanism. The compositions protect skin from external thermal fluxes, conform to skin chemistry, and are easy to apply and remove.",BUCHANAN JANICE PAIGE;;ANDERSON LAURA LYNN;;MACKEY NICOLE MARIE;;LOCHHEAD ROBERT YEATS;;UNIV SOUTHERN MISSISSIPPI,BUCHANAN JANICE PAIGE;;ANDERSON LAURA LYNN;;MACKEY NICOLE MARIE;;LOCHHEAD ROBERT YEATS,UNIVERSITY OF SOUTHERN MISSISSIPPI THE (2011-04-15),https://lens.org/085-951-177-937-18X,Granted Patent,yes,3,0,2,2,0,A61K8/18;;A61P17/02;;A61K8/042;;A61K8/19;;A61K8/20;;A61K8/23;;A61K8/24;;A61K8/29;;A61K8/34;;A61K8/41;;A61K8/8152;;A61K8/86;;A61K8/92;;A61K31/047;;A61K31/695;;A61K33/00;;A61K33/02;;A61K33/04;;A61K33/06;;A61K33/14;;A61K33/24;;A61K33/26;;A61K33/42;;A61K33/44;;A61K2800/43;;A61P39/00;;A61Q17/04;;A61Q17/04;;A61Q19/00;;F41H3/00,A61K8/02;;A61K8/18;;A61K8/19;;A61K8/20;;A61K8/23;;A61K8/24;;A61K8/34;;A61K8/41;;A61K8/92;;A61K31/047;;A61K31/695;;A61K33/00;;A61K33/02;;A61K33/04;;A61K33/06;;A61K33/14;;A61K33/42;;A61Q17/04;;A61Q19/00,,0,0,,,,ACTIVE
102,AU,A,AU 2001/016548 A,158-090-597-736-821,2001-05-14,2001,AU 2001/016548 A,2000-10-31,US 43163999 A;;US 0029977 W,1999-11-01,Freezer-to-oven dough products,,PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,,https://lens.org/158-090-597-736-821,Patent Application,no,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,EXPIRED
103,US,A1,US 2020/0019665 A1,050-598-102-190-240,2020-01-16,2020,US 201816033412 A,2018-07-12,US 201816033412 A,2018-07-12,CELL PLACEMENT IN A CIRCUIT WITH SHARED INPUTS AND OUTPUTS,"A computer-implemented method of cell placement is provided. The method includes representing a non-rectangular cell to be placed into a cell row and searching the cell row to identify existing objects that are representative of cells in the cell row that are disposable to share space with the non-rectangular cell. The method further includes determining whether a representation of the non-rectangular cell is fittable into a modified mapping of the existing objects in the cell row and, in an event the representation is fittable into the modified mapping, overlapping the representation over one or more of the portions of the existing objects.",IBM,ANDERSON BRENT A;;DARDEN LAURA R;;CHU ALBERT M;;SUESS ALEXANDER J,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-07-09),https://lens.org/050-598-102-190-240,Patent Application,yes,5,3,2,2,0,G06F30/392;;G06F30/12;;G06F30/31;;G06F30/327;;G06F30/39;;G06F30/392;;G06F30/398;;G06F2111/12;;H01L27/0207;;H01L27/0207;;H01L27/11807;;H01L27/11807;;H01L2027/11874,H01L27/02;;H01L27/118,,0,0,,,,ACTIVE
104,US,A1,US 2009/0170897 A1,075-232-667-326-927,2009-07-02,2009,US 56816605 A,2005-04-08,US 56816605 A;;GB 0408799 A;;US 59087104 P;;IB 2005000992 W,2004-04-20,Method of Treating Neuropathic Pain,The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.,PFIZER,CORRADINI LAURA;;FIELD MARK JOHN;;KINLOCK ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,,https://lens.org/075-232-667-326-927,Patent Application,yes,0,14,8,11,0,A61K31/4706;;A61K31/4709;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61K31/4709;;A61K31/4706,A61K31/4706;;A61K31/47;;A61K31/4709;;A61P25/04,514/313,0,0,,,,DISCONTINUED
105,EP,A1,EP 1227728 A1,114-231-201-165-939,2002-08-07,2002,EP 00979135 A,2000-10-31,US 0029977 W;;US 43163999 A,1999-11-01,FREEZER-TO-OVEN DOUGH PRODUCTS,,PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,THE PILLSBURY COMPANY (2004-10-27),https://lens.org/114-231-201-165-939,Patent Application,yes,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,EXPIRED
106,BR,A,BR 0015468 A,174-875-435-204-638,2002-06-25,2002,BR 0015468 A,2000-10-31,US 43163999 A;;US 0029977 W,1999-11-01,"Produtos de massa ""do-congelador-ao-forno""","""PRODUTOS DE MASSA ""DO-CONGELADOR-AO-FORNO"". A presente invenção provê produtos de massa ""do-congelador-ao-forno"", bem como métodos para a preparação dos produtos de massa. Especificamente, os produtos de massa da presente invenção incluem um sistema de fermentação química compreendendo uma pluralidade de ácidos químicos fermentantes com diferentes intervalos de temperatura dentro dos quais são ativos como fermentantes químicos. O referido sistema de fermentação química proporciona o crescimento gradativo, isto é, o crescimento que ocorre ao longo de um amplo intervalo de temperaturas e, assim sendo, durante uma porção substancial do ciclo de cozimento, dos produtos de massa da presente invenção ao serem cozidos. Proporcionando produtos de massa congelados com o referido sistema de fermentação, evita-se a necessidade de um estágio de pré-descanso antes do congelamento, um estágio de descongelamento ou um estágio intermediário de descanso antes do cozimento e, mesmo assim, o produto de massa é capaz de expansão substancial mediante cozimento, produzindo assim um produto de massa cozido com excelentes propriedades visuais e organolépticas.",PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,"GENERAL MILLS MARKETING, INC. (US) (2006-06-13)",https://lens.org/174-875-435-204-638,Patent Application,no,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,DISCONTINUED
107,WO,A8,WO 2005/102338 A8,061-130-933-516-438,2006-12-14,2006,IB 2005000992 W,2005-04-08,GB 0408799 A;;US 59087104 P,2004-04-20,METHOD OF TREATING NEUROPATHIC PAIN USING A CRTH2 RECEPTOR ANTAGONIST,The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.,PFIZER LTD;;PFIZER;;CORRADINI LAURA;;FIELD MARK JOHN;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,CORRADINI LAURA;;FIELD MARK JOHN;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,,https://lens.org/061-130-933-516-438,Patent Application,no,0,0,8,11,0,A61K31/4706;;A61K31/4709;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61K31/4709;;A61K31/4706,A61K31/4709;;A61K31/4706,,0,0,,,,PENDING
108,CA,C,CA 2389609 C,151-414-197-517-754,2006-10-03,2006,CA 2389609 A,2000-10-31,US 43163999 A;;US 0029977 W,1999-11-01,FREEZER-TO-OVEN DOUGH PRODUCTS,"The present invention provides freezer-to-oven dough products, as well as methods for preparing the dough products. Specifically, the dough products of the present invention include a chemical leavening system comprising a plurality of chemical leavening acids having different temperature ranges within which they are active as chemical leaveners. Such a chemical leavening system provides for the staged rising, i.e., rising that occurs over a wide temperature range and thus during a substantial portion of the cooking cycle, of the dough products of the present invention when cooke d. By providing frozen dough products with such a leavening system, the need for a preproofing step prior to freezing, a thawi ng step or an intervening proofing step prior to cooking is avoided, and yet, the dough product is capable of substantial expansion upon cooking, thereby producing a cooked dough product with excellent visual and organoleptic properties.",PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;REINKE JEFFREY D;;LORENCE MATTHEW W,,https://lens.org/151-414-197-517-754,Granted Patent,no,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D6/00;;A21D2/14;;A21D2/18;;A21D8/04;;A21D10/02,,0,0,,,,EXPIRED
109,AU,B2,AU 778061 B2,193-373-670-551-372,2004-11-11,2004,AU 2001/016548 A,2000-10-31,US 43163999 A;;US 0029977 W,1999-11-01,Freezer-to-oven dough products,,PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,,https://lens.org/193-373-670-551-372,Granted Patent,no,2,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,EXPIRED
110,KR,A,KR 20030027862 A,192-716-292-401-726,2003-04-07,2003,KR 20020059112 A,2002-09-28,GB 0123413 A,2001-09-28,Benzofuran Compounds,"PURPOSE: Provided is a branched benzofuran compound which is suitable for charge transport and emission inorganic electroluminescent devices and organic lasers. The compounds also have potential use in photovoltaic devices and organic thin film transistors. CONSTITUTION: A method for preparing a branched benzofuran compound comprising a core moiety which contains at least one aromatic ring and which has at least three substituted or unsubstituted benzofuran groups covalently linked thereto, is characterized by comprising the steps of (i) forming an intermediate ethynylene compound in which at least three benzene rings are each linked to the core moiety via an ethynylene bond, and where each benzene ring is substituted at the ortho position (relative to the position of the ethynylene bond) by a blocked carbonyloxy group, (ii) deblocking the carbonyloxy groups, and (iii) effecting ring closure by reaction between the deblocked carbonyloxy groups and the adjacent ethynylene bonds to form the furan rings of the benzofuran groups, whereby to produce the branched benzofuran compound.",SHARP KK,TAYLOR PETER NEIL;;ANDERSON SALLY;;BOOTH CHRISTOPHER JAMES;;VERSCHOOR GERALDINE LAURA BALL,,https://lens.org/192-716-292-401-726,Patent Application,no,6,0,6,6,0,C07D307/80;;C07D409/14;;C09K11/06;;C09K2211/1003;;C09K2211/1007;;C09K2211/1011;;C09K2211/1014;;C09K2211/1029;;C09K2211/1044;;C09K2211/1048;;C09K2211/1051;;C09K2211/1088;;C09K2211/1092;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/1135;;H10K85/655;;H10K85/6574;;H10K2102/103;;C07D407/14;;C09K11/06;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1007;;C09K2211/1088;;C07D307/80;;C07D409/14;;C09K2211/1044;;C09K2211/1014;;C09K2211/1003;;C09K2211/1048;;C09K2211/1011;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/6574;;H10K85/655;;H10K30/00;;H10K50/00;;H10K85/1135;;H10K2102/103,H01L51/50;;C07D307/80;;C07D307/81;;C07D407/14;;C07D409/14;;C07D413/14;;C09K11/06;;H01L51/00;;H01L51/30,,0,0,,,,DISCONTINUED
111,CA,A1,CA 2563707 A1,010-047-711-131-017,2005-11-03,2005,CA 2563707 A,2005-04-08,GB 0408799 A;;US 59087104 P;;IB 2005000992 W,2004-04-20,METHOD OF TREATING NEUROPATHIC PAIN USING A CRTH2 RECEPTOR ANTAGONSIT,,PFIZER INC A CORP ORGANIZED UN,FIELD MARK JOHN;;CORRADINI LAURA;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,,https://lens.org/010-047-711-131-017,Patent Application,no,0,0,8,11,0,A61K31/4706;;A61K31/4709;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61K31/4709;;A61K31/4706,A61K31/4706;;A61K31/4709;;A61P25/00;;A61P25/02;;A61P29/00,,0,0,,,,DISCONTINUED
112,US,A1,US 2011/0217247 A1,028-704-397-958-905,2011-09-08,2011,US 93262211 A,2011-03-01,US 93262211 A;;US 33918410 P,2010-03-01,Compositions and methods for protection of skin against thermal insult,"The present invention provides novel topically-applied skin and face coating and paint compositions comprising near infrared reflecting pigments and hydrogels swollen with aqueous solution and/or with simulated sweat. The invention further provides methods of making and using the compositions. The novel compositions protect the skin of the wearer from damage due to intense external heat or thermal flux and simultaneously divert thermal energy to a complementary evaporative cooling mechanism. The compositions protect skin from external thermal fluxes, conform to skin chemistry, and are easy to apply and remove.",LOCHHEAD ROBERT YEATS;;BUCHANAN JANICE PAIGE;;ANDERSON LAURA LYNN;;MACKEY NICOLE MARIE,LOCHHEAD ROBERT YEATS;;BUCHANAN JANICE PAIGE;;ANDERSON LAURA LYNN;;MACKEY NICOLE MARIE,UNIVERSITY OF SOUTHERN MISSISSIPPI THE (2011-04-15),https://lens.org/028-704-397-958-905,Patent Application,yes,3,12,2,2,0,A61K8/18;;A61P17/02;;A61K8/042;;A61K8/19;;A61K8/20;;A61K8/23;;A61K8/24;;A61K8/29;;A61K8/34;;A61K8/41;;A61K8/8152;;A61K8/86;;A61K8/92;;A61K31/047;;A61K31/695;;A61K33/00;;A61K33/02;;A61K33/04;;A61K33/06;;A61K33/14;;A61K33/24;;A61K33/26;;A61K33/42;;A61K33/44;;A61K2800/43;;A61P39/00;;A61Q17/04;;A61Q17/04;;A61Q19/00;;F41H3/00,A61K8/24;;A61K8/18;;A61K8/19;;A61K8/20;;A61K8/23;;A61K8/34;;A61K8/41;;A61K8/92;;A61K31/047;;A61K31/695;;A61K33/00;;A61K33/02;;A61K33/04;;A61K33/06;;A61K33/14;;A61K33/42;;A61P17/18;;A61Q17/04;;A61Q19/00,424/59;;424/600;;424/663;;424/709;;424/601;;514/738;;514/63;;514/669,0,0,,,,ACTIVE
113,MX,A,MX PA06011891 A,028-675-348-964-575,2007-04-24,2007,MX PA06011891 A,2005-04-08,GB 0408799 A;;US 59087104 P;;IB 2005000992 W,2004-04-20,METHOD OF TREATING NEUROPATHIC PAIN USING A CRTH2 RECEPTOR ANTAGONSIT.,The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.,PFIZER,FIELD MARK JOHN;;CORRADINI LAURA;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,,https://lens.org/028-675-348-964-575,Patent Application,no,0,0,8,11,0,A61K31/4706;;A61K31/4709;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61K31/4709;;A61K31/4706,A61K31/00;;A61K31/4706;;A61K31/4709;;A61P25/02;;A61P29/00,,0,0,,,,PENDING
114,JP,A,JP 2003176282 A,036-122-509-985-212,2003-06-24,2003,JP 2002280037 A,2002-09-25,GB 0123413 A,2001-09-28,BENZOFURAN COMPOUND,"<P>PROBLEM TO BE SOLVED: To provide an electroluminescence material which is a benzofuran compound, especially a branched-chain benzofuran compound having a light- emitting color, a high device efficiency and a high life by changing a core of the electroluminescence material and a method for producing the branched- chain benzofuran compound. <P>SOLUTION: This method for producing the branched-chain benzofuran compound comprising a core part containing at least one aromatic ring and at least three substituted or unsubstituted benzofuran groups covalently bound to the core part comprises the following steps: a step of preparing an intermediate ethynylene compound where at least three benzene rings bound through each ethynylene bonds to the core part and each benzene ring substituted with a carbonyloxy group blocked at the o-position in the intermediate ethynylene compound, a step of deblocking the carbonyloxy group and a step of carrying out a cyclizing reaction between the deblocked group and the adjacent ethynylene group, forming a furan ring of the benzofuran group and thereby producing the branched-chain benzofuran compound. <P>COPYRIGHT: (C)2003,JPO",SHARP KK,TAYLOR PETER NEIL;;ANDERSON SALLY;;BOOTH CHRISTOPHER JAMES;;VERSCHOOR GERALDINE LAURA BALL,,https://lens.org/036-122-509-985-212,Patent Application,no,0,8,6,6,0,C07D307/80;;C07D409/14;;C09K11/06;;C09K2211/1003;;C09K2211/1007;;C09K2211/1011;;C09K2211/1014;;C09K2211/1029;;C09K2211/1044;;C09K2211/1048;;C09K2211/1051;;C09K2211/1088;;C09K2211/1092;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/1135;;H10K85/655;;H10K85/6574;;H10K2102/103;;C07D407/14;;C09K11/06;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1007;;C09K2211/1088;;C07D307/80;;C07D409/14;;C09K2211/1044;;C09K2211/1014;;C09K2211/1003;;C09K2211/1048;;C09K2211/1011;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/6574;;H10K85/655;;H10K30/00;;H10K50/00;;H10K85/1135;;H10K2102/103,H01L51/50;;C07D307/80;;C07D307/81;;C07D407/14;;C07D409/14;;C07D413/14;;C09K11/06;;H01L51/00;;H01L51/30,,0,0,,,,DISCONTINUED
115,BR,A,BR PI0510043 A,128-358-221-345-212,2007-10-16,2007,BR PI0510043 A,2005-04-08,GB 0408799 A;;US 59087104 P;;IB 2005000992 W,2004-04-20,método de tratamento de dor neuropática usando antagonista de receptor crth2,MéTODO DE TRATAMENTO DE DOR NEUROPáTICA USANDO ANTAGONISTA DE RECEPTOR CRTH2. A presente invenção refere-se ao uso de um antagonista de receptor de CRTH2 na fabricação de um medicamento para o tratamento de dor neuropática e a um método para tratar dor neuropática utilizando um antagonista de receptor de CRTH2.,PFIZER,CORRADINI LAURA;;FIELD MARK JOHN;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,,https://lens.org/128-358-221-345-212,Patent Application,no,0,0,8,11,0,A61K31/4706;;A61K31/4709;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61K31/4709;;A61K31/4706,A61K31/4706;;A61K31/4709,,0,0,,,,DISCONTINUED
116,ZA,B,ZA 200203308 B,156-728-348-099-793,2003-06-25,2003,ZA 200203308 A,2002-04-25,US 43163999 A,1999-11-01,Freezer-to-oven dough products.,,PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,,https://lens.org/156-728-348-099-793,Granted Patent,no,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/14;;A21D2/02;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,EXPIRED
117,US,A1,US 2021/0389504 A1,119-840-999-744-539,2021-12-16,2021,US 201917282278 A,2019-10-01,US 201917282278 A;;US 201862740372 P;;US 2019/0054084 W,2018-10-02,CHALCOGENIDE HYBRID ORGANIC/INORGANIC POLYMERS FILMS AND COATINGS AND THE USE THEREOF,"The present invention provides certain CHIP films and coatings, as well as the preparation and uses thereof. Chalcogenide hybrid organic/inorganic polymers or CHIPs may be suitable for use in antireflection coatings for use with infrared optics, for example as applied to lenses for infrared cameras. The coatings may be applied with spin coating and have a thickness related to the quarter wavelength of the desired infrared wavelengths.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT A;;NISHANT ABHINAV;;ANDERSON LAURA;;KLEINE TRISTAN,,https://lens.org/119-840-999-744-539,Patent Application,yes,0,0,4,32,0,G02B6/1221;;G02B6/138;;C09D5/006;;C09D181/02;;C09D185/00;;G02B1/111,G02B1/111;;C09D5/00;;C09D181/02;;C09D185/00,,0,0,,,,PENDING
118,WO,A1,WO 2019/014102 A1,129-935-250-535-81X,2019-01-17,2019,US 2018/0041234 W,2018-07-09,US 201762530677 P,2017-07-10,STERILIZABLE WIRELESS COMMUNICATION DEVICES,Disclosed are devices and methods sterilization wireless communication devices. The devices and methods described involve a sterilizable wireless communication device including a communication module. The communication module includes a transceiver capable of direct wireless communication. The sterilizable wireless communication device further includes a housing having an interior sized to contain the communication module. The communication module is hermetically sealed within the housing and the housing includes a hermetic radio frequency feedthrough configured to couple to an antenna that is external to the housing.,SMART MEDICAL DEVICES INC,HOGLUND DAVID;;ANDERSON WAYNE;;PERRY JOHN;;KARCH MICHAEL;;PARK LAURA;;DOHRING EDWARD,,https://lens.org/129-935-250-535-81X,Patent Application,yes,7,1,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,A61N1/372;;A61N1/00;;A61N1/375,,0,0,,,,PENDING
119,TW,A,TW 200603802 A,136-269-258-538-523,2006-02-01,2006,TW 94112108 A,2005-04-15,GB 0408799 A,2004-04-20,Method of treating neuropathic pain,The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.,PFIZER,CORRADINI LAURA;;FIELD MARK JOHN;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,,https://lens.org/136-269-258-538-523,Patent of Addition,no,0,0,3,11,0,,A61K31/438;;A61P25/04,,0,0,,,,PENDING
120,WO,A1,WO 2005/102338 A1,147-913-277-180-807,2005-11-03,2005,IB 2005000992 W,2005-04-08,GB 0408799 A;;US 59087104 P,2004-04-20,METHOD OF TREATING NEUROPATHIC PAIN USING A CRTH2 RECEPTOR ANTAGONSIT,The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.,PFIZER LTD;;CORRADINI LAURA;;FIELD MARK JOHN;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR;;PFIZER,CORRADINI LAURA;;FIELD MARK JOHN;;KINLOCH ROSS ANDERSON;;WILLIAMS-JONES BRYN IVOR,,https://lens.org/147-913-277-180-807,Patent Application,yes,6,33,8,11,0,A61K31/4706;;A61K31/4709;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61K31/4709;;A61K31/4706,A61K31/4706;;A61K31/4709,,2,0,,,"DATABASE WPI Section Ch Week 200335, Derwent World Patents Index; Class B02, AN 2003-371742, XP002331691;;DATABASE WPI Section Ch Week 200447, Derwent World Patents Index; Class B02, AN 2004-499804, XP002331615",PENDING
121,US,B2,US 10755017 B2,170-566-068-725-292,2020-08-25,2020,US 201816033412 A,2018-07-12,US 201816033412 A,2018-07-12,Cell placement in a circuit with shared inputs and outputs,"A computer-implemented method of cell placement is provided. The method includes representing a non-rectangular cell to be placed into a cell row and searching the cell row to identify existing objects that are representative of cells in the cell row that are disposable to share space with the non-rectangular cell. The method further includes determining whether a representation of the non-rectangular cell is fittable into a modified mapping of the existing objects in the cell row and, in an event the representation is fittable into the modified mapping, overlapping the representation over one or more of the portions of the existing objects.",IBM,ANDERSON BRENT A;;DARDEN LAURA R;;CHU ALBERT M;;SUESS ALEXANDER J,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-07-09),https://lens.org/170-566-068-725-292,Granted Patent,yes,9,0,2,2,0,G06F30/392;;G06F30/12;;G06F30/31;;G06F30/327;;G06F30/39;;G06F30/392;;G06F30/398;;G06F2111/12;;H01L27/0207;;H01L27/0207;;H01L27/11807;;H01L27/11807;;H01L2027/11874,G06F30/327;;G06F30/392;;G06F30/398;;H01L27/02;;H01L27/118,,0,0,,,,ACTIVE
122,GB,A,GB 2380191 A,140-606-906-614-811,2003-04-02,2003,GB 0123413 A,2001-09-28,GB 0123413 A,2001-09-28,BENZOFURAN COMPOUNDS THEIR PREPARATION AND THEIR USE IN ELECTROLUMINESCENT AND PHOTOVOLTAIC DEVICES,"A method of preparing a branched benzofuran compound comprising a core moiety which contains at least one aromatic ring and which has at least three substituted or unsubstituted beuzofuran groups covalently linked thereto comprises the steps of <SL> <LI>(i) forming an intermediate ethynylene compound in which at least three benzene rings are each linked to the core moiety via an ethynylene bond, and where each benzene ring is substituted at the ortho position (relative to the position of the ethynylene bond) by a blocked carbonyloxy group, <LI>(ii) deblocking the carbonyloxy groups, and <LI>(iii) effecting ring closure by reaction between the deblocked carbonyloxy groups and the adjacent ethynylene bonds to form the furan rings of the beuzofuran groups, whereby to produce the branched benzofuran compound. </SL> The invention also comprises compounds of Formulae <EMI ID=1.1 HE=100 WI=130 LX=423 LY=1683 TI=CF> <PC>where each of R 1 to R 8 is independently selected from H, an aliphatic group, an aromatic group, a halogen, CN and NO 2 , and each of R' to R'' is independently selected from at least one of H, an aliphati group, an aromatic group, a halogen, CN and NO 2 . The compounds produced by the present process are used as light emitter and change transport materials in electroluminescent on photo-voltaic devices.",SHARP KK,TAYLOR PETER NEIL;;ANDERSON SALLY;;BOOTH CHRISTOPHER JAMES;;VERSCHOOR GERALDINE LAURA BALL,,https://lens.org/140-606-906-614-811,Patent Application,no,0,0,6,6,0,C07D307/80;;C07D409/14;;C09K11/06;;C09K2211/1003;;C09K2211/1007;;C09K2211/1011;;C09K2211/1014;;C09K2211/1029;;C09K2211/1044;;C09K2211/1048;;C09K2211/1051;;C09K2211/1088;;C09K2211/1092;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/1135;;H10K85/655;;H10K85/6574;;H10K2102/103;;C07D407/14;;C09K11/06;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1007;;C09K2211/1088;;C07D307/80;;C07D409/14;;C09K2211/1044;;C09K2211/1014;;C09K2211/1003;;C09K2211/1048;;C09K2211/1011;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/6574;;H10K85/655;;H10K30/00;;H10K50/00;;H10K85/1135;;H10K2102/103,H01L51/50;;C07D307/80;;C07D307/81;;C07D407/14;;C07D409/14;;C07D413/14;;C09K11/06;;H01L51/00;;H01L51/30,C2C CAA;;C2C CAB;;U1S S1411;;U1S S1927,0,0,,,,DISCONTINUED
123,US,A1,US 2003/0105343 A1,077-722-439-520-095,2003-06-05,2003,US 25443902 A,2002-09-25,GB 0123413 A,2001-09-28,Benzofuran compounds,"
   There is disclosed a method of preparing a branched benzofuran compound comprising a core moiety which contains at least one aromatic ring and which has at least three substituted or unsubstituted benzofuran groups covalently linked thereto. The method comprises the steps of 

   (i) forming an intermediate ethynylene compound in which at least three benzene rings are each linked to the core moiety via an ethynylene bond, and where each benzene ring is substituted at the ortho position (relative to the position of the ethynylene bond) by a blocked carbonyloxy group, 

   (ii) deblocking the carbonyloxy groups, and 

   (iii) effecting ring closure by reaction between the deblocked carbonyloxy groups and the adjacent ethynylene bonds to form the furan rings of the benzofuran groups, whereby to produce the branched benzofuran compound. 
",TAYLOR PETER NEIL;;ANDERSON SALLY;;BOOTH CHRISTOPHER JAMES;;VERSCHOOR GERALDINE LAURA BALLANTYNE,TAYLOR PETER NEIL;;ANDERSON SALLY;;BOOTH CHRISTOPHER JAMES;;VERSCHOOR GERALDINE LAURA BALL,SHARP KABUSHIKI KAISHA (2002-07-10),https://lens.org/077-722-439-520-095,Patent Application,yes,0,6,6,6,0,C07D307/80;;C07D409/14;;C09K11/06;;C09K2211/1003;;C09K2211/1007;;C09K2211/1011;;C09K2211/1014;;C09K2211/1029;;C09K2211/1044;;C09K2211/1048;;C09K2211/1051;;C09K2211/1088;;C09K2211/1092;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/1135;;H10K85/655;;H10K85/6574;;H10K2102/103;;C07D407/14;;C09K11/06;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1007;;C09K2211/1088;;C07D307/80;;C07D409/14;;C09K2211/1044;;C09K2211/1014;;C09K2211/1003;;C09K2211/1048;;C09K2211/1011;;Y02E10/549;;C09B11/04;;C09B57/00;;H10K85/6574;;H10K85/655;;H10K30/00;;H10K50/00;;H10K85/1135;;H10K2102/103,H01L51/50;;C07D307/80;;C07D307/81;;C07D407/14;;C07D409/14;;C07D413/14;;C09K11/06;;H01L51/00;;H01L51/30,549/462,0,0,,,,DISCONTINUED
124,AT,T1,AT E293885 T1,161-827-416-473-594,2005-05-15,2005,AT 00979135 T,2000-10-31,US 43163999 A;;US 0029977 W,1999-11-01,BACKFERTIGE GEFRORENE TEIGPRODUKTE,,PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,,https://lens.org/161-827-416-473-594,Granted Patent,no,0,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,DISCONTINUED
125,CN,A,CN 111050842 A,110-977-829-918-540,2020-04-21,2020,CN 201880056324 A,2018-07-09,US 201762530677 P;;US 2018/0041234 W,2017-07-10,STERILIZABLE WIRELESS COMMUNICATION DEVICES,Disclosed are devices and methods sterilization wireless communication devices. The devices and methods described involve a sterilizable wireless communication device including a communication module.The communication module includes a transceiver capable of direct wireless communication. The sterilizable wireless communication device further includes a housing having an interior sized to containthe communication module. The communication module is hermetically sealed within the housing and the housing includes a hermetic radio frequency feedthrough configured to couple to an antenna that isexternal to the housing.,SMART MEDICAL DEVICES INC,HOGLUND DAVID;;ANDERSON WAYNE;;PERRY JOHN;;KARCH MICHAEL;;PARK LAURA;;DOHRING EDWARD,,https://lens.org/110-977-829-918-540,Patent Application,no,0,0,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,A61N1/372;;A61N1/00;;A61N1/375,,0,0,,,,DISCONTINUED
126,EP,B1,EP 1227728 B1,098-294-358-389-754,2005-04-27,2005,EP 00979135 A,2000-10-31,US 0029977 W;;US 43163999 A,1999-11-01,FREEZER-TO-OVEN DOUGH PRODUCTS,,PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,THE PILLSBURY COMPANY (2004-10-27),https://lens.org/098-294-358-389-754,Granted Patent,yes,7,0,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/02;;A21D2/14;;A21D2/18;;A21D6/00;;A21D8/04;;A21D10/02,,0,0,,,,EXPIRED
127,WO,A1,WO 2001/032023 A1,175-308-322-353-034,2001-05-10,2001,US 0029977 W,2000-10-31,US 43163999 A,1999-11-01,FREEZER-TO-OVEN DOUGH PRODUCTS,"The present invention provides freezer-to-oven dough products, as well as methods for preparing the dough products. Specifically, the dough products of the present invention include a chemical leavening system comprising a plurality of chemical leavening acids having different temperature ranges within which they are active as chemical leaveners. Such a chemical leavening system provides for the staged rising, i.e., rising that occurs over a wide temperature range and thus during a substantial portion of the cooking cycle, of the dough products of the present invention when cooked. By providing frozen dough products with such a leavening system, the need for a preproofing step prior to freezing, a thawing step or an intervening proofing step prior to cooking is avoided, and yet, the dough product is capable of substantial expansion upon cooking, thereby producing a cooked dough product with excellent visual and organoleptic properties.",PILLSBURY CO,HANSEN LAURA M;;ANDERSON BRIAN ROBERT;;LORENCE MATTHEW W;;REINKE JEFFREY D,,https://lens.org/175-308-322-353-034,Patent Application,yes,7,15,20,20,0,A21D2/14;;A21D6/001;;A21D8/045;;A21D10/02;;A21D6/00;;A21D2/02;;A21D10/02;;A21D6/001;;A21D8/045;;A21D2/14,A21D2/14;;A21D2/18;;A21D6/00;;A21D2/02;;A21D8/04;;A21D10/02,,0,0,,,,PATENTED
128,CA,A1,CA 2310882 A1,017-490-118-161-11X,2000-12-15,2000,CA 2310882 A,2000-06-05,US 33404799 A,1999-06-15,BROADBAND AMPLIFIED WDM RING,"A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. Remote gain is provided in at least one link of the ring. In specific embodiments of the invention, the remote gain is applied preferentially to those wavelength channels most in need of amplification. In specific embodiments of the invention, the remote gain is Raman gain.",LUCENT TECHNOLOGIES INC,ANDERSON JON;;ADAMS LAURA ELLEN;;BROBERG ROBERT MARIO;;DIGIOVANNI DAVID JOHN;;ROTTWITT KARSTEN,,https://lens.org/017-490-118-161-11X,Patent Application,no,0,0,8,8,0,H04B10/27;;H04B10/2755;;H04B10/2916;;H04B10/2939;;H04J14/0206;;H04J14/0221;;H04B10/2581;;H04B10/27;;H04B10/2755;;H04J14/0206;;H04J14/0221;;H04B10/2939;;H04B10/2916,G02F1/35;;H01S3/30;;H04B10/17;;H04B10/20;;H04B10/213;;H04B10/29;;H04J14/00;;H04J14/02,,0,0,,,,DISCONTINUED
129,US,B1,US 6785472 B1,080-212-876-250-271,2004-08-31,2004,US 33404799 A,1999-06-15,US 33404799 A,1999-06-15,Broadband amplified WDM ring,"
    A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. Remote gain is provided in at least one link of the ring. In specific embodiments of the invention, the remote gain is applied preferentially to those wavelength channels most in need of amplification. In specific embodiments of the invention, the remote gain is Raman gain. 
",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;DIGIOVANNI DAVID JOHN;;ROTTWITT KARSTEN,LUCENT TECHNOLOGIES INC (1999-07-19),https://lens.org/080-212-876-250-271,Granted Patent,yes,8,26,8,8,0,H04B10/27;;H04B10/2755;;H04B10/2916;;H04B10/2939;;H04J14/0206;;H04J14/0221;;H04B10/2581;;H04B10/27;;H04B10/2755;;H04J14/0206;;H04J14/0221;;H04B10/2939;;H04B10/2916,H01S3/30;;H04B10/17;;G02F1/35;;H04B10/20;;H04B10/213;;H04B10/29;;H04J14/00;;H04J14/02,398/79;;398/59,7,4,146-075-713-659-587;;019-157-077-974-82X;;032-542-264-719-105;;098-488-165-772-824,10.1109/ofc.1996.907601;;10.1364/oaa.1997.sn4;;10.1049/cp:19971599;;10.1109/ofc.1999.766041,"A. Stentz et al., ""Raman Amplifier with Improved System Performance"", OFC '96, IEEE, 1996.*;;Hansen, P. ""Remote optical amplification extends transmission spans,"" Laser Focus World, (1998).;;Masuda, H. et al., ""Ultra-wideband Optical Amplification with a 3-dB Bandwidth of 67 nm using a partially Gain-Flattened Erbium-doped Fiber Amplifier and Raman Amplification"", Proceedings of OAA Conference (1997).;;Nissov, M. et al., ""100 Gb/s (10x10Gb/s) WDM Transmission over 7200 km Using Distributed Raman Amplification,"" ECOC Proceedings, (1997).;;Rottwitt, K. et al., ""A 92 nm Bandwidth Raman Amplifier,"" Proceedings of OFC (1998).;;Hansen, P.B. et al., ""Dense wavelength-division multiplexed transmission in 'zero-dispersion' DSF by means of hybrid Raman/erbium-doped fiber amplifiers,"" Proceedings of OFC, (1999).;;U.S. patent application Ser. No. 09/333,406, filed on Jun. 15, 1999.",EXPIRED
130,WO,A3,WO 2020/072703 A3,087-865-072-807-532,2020-06-04,2020,US 2019/0054368 W,2019-10-02,US 201862740372 P,2018-10-02,PHOTORESPONSIVE CHALCOGENIDE HYBRID ORGANIC/INORGANIC POLYMER FILMS,"The present invention provides certain CHIP films and coatings, as well as the preparation and uses thereof.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT;;NISHANT ABHINAV;;ANDERSON LAURA;;KLEINE TRISTAN;;LYONS NICHOLAS,,https://lens.org/087-865-072-807-532,Search Report,yes,5,0,4,32,0,G02B6/1221;;G02B6/138;;C09D5/006;;C09D181/02;;C09D185/00;;G02B1/111,C08L81/04;;C08G75/14;;G02B1/04,,0,0,,,,PENDING
131,TW,B,TW 484270 B,123-569-996-271-43X,2002-04-21,2002,TW 89111428 A,2000-06-12,US 33404799 A,1999-06-15,Broadband amplified WDM ring,"A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. Remote gain is provided in at least one link of the ring. In specific embodiments of the invention, the remote gain is applied preferentially to those wavelength channels most in need of amplification. In specific embodiments of the invention, the remote gain is Raman gain.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;DIGIOVANNI DAVID JOHN;;ROTTWITT KARSTEN,,https://lens.org/123-569-996-271-43X,Granted Patent,no,0,0,8,8,0,H04B10/27;;H04B10/2755;;H04B10/2916;;H04B10/2939;;H04J14/0206;;H04J14/0221;;H04B10/2581;;H04B10/27;;H04B10/2755;;H04J14/0206;;H04J14/0221;;H04B10/2939;;H04B10/2916,H01S3/30;;H04B10/17;;G02F1/35;;H04B10/20;;H04B10/213;;H04B10/29;;H04J14/00;;H04J14/02,,0,0,,,,EXPIRED
132,US,A1,US 2022/0244274 A1,155-795-135-775-296,2022-08-04,2022,US 202217591521 A,2022-02-02,US 202217591521 A;;US 202163144926 P,2021-02-02,QUANTITATIVE BIOMARKERS FOR ASSESSING MILD TRAUMATIC BRAIN INJURY AND METHODS OF USE THEREOF,"Disclosed here is a method of detecting traumatic brain injury in a subject, comprising collecting a biological sample from the subject; analyzing the biological sample to determine the level of at least one protein selected from ALDOA, PHKB, HBA-A1, DPYSL2, SYN1 and/or CKB; and determining whether the level of the at least one protein exceeds a predetermined threshold. In certain aspects, the method further comprises the step of administering a treatment to the subject if the at least one protein exceeds the predetermined threshold. The disclosed technology relates generally to brain injuries, and in particular to a panel of serum based biomarkers that can identify individuals with mild traumatic brain injury (TBI).",UNIV IOWA RES FOUND;;UNITED STATES DEPT OF VETERANS AFFAIRS,HARPER MATTHEW;;ANDERSON MICHAEL;;MEYER KACIE;;DUTCA LAURA M;;MANOHAR JOHN;;KARDON RANDY,,https://lens.org/155-795-135-775-296,Patent Application,yes,0,0,1,1,12,G01N33/6896;;G01N33/721;;G01N2333/76;;G01N2800/28;;G01N2800/40;;G01N33/6896;;G01N2333/76;;G01N2800/28;;G01N33/721,G01N33/68;;G01N33/72,,0,0,,,,PENDING
133,WO,A2,WO 2020/072703 A2,046-110-361-650-428,2020-04-09,2020,US 2019/0054368 W,2019-10-02,US 201862740372 P,2018-10-02,PHOTORESPONSIVE CHALCOGENIDE HYBRID ORGANIC/INORGANIC POLYMER FILMS,"The present invention provides certain CHIP films and coatings, as well as the preparation and uses thereof.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT;;NISHANT ABHINAV;;ANDERSON LAURA;;KLEINE TRISTAN;;LYONS NICHOLAS,,https://lens.org/046-110-361-650-428,Patent Application,yes,0,1,4,32,0,G02B6/1221;;G02B6/138;;C09D5/006;;C09D181/02;;C09D185/00;;G02B1/111,G02B6/028,,0,0,,,,PENDING
134,WO,A1,WO 2018/183702 A1,143-337-312-574-580,2018-10-04,2018,US 2018/0025178 W,2018-03-29,US 201762480403 P;;US 201762480404 P;;US 201762488451 P,2017-04-01,CHALCOGENIDE HYBRID INORGANIC/ORGANIC POLYMERS (CHIPS) FOR INFRARED OPTICAL MATERIALS AND DEVICES,"The present invention provides certain polymeric materials, precursors thereof as well as the preparation and uses thereof.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT;;HIMMELHUBER ROLAND;;KLEINE TRISTAN;;DIAZ LILIANA;;ANDERSON LAURA,,https://lens.org/143-337-312-574-580,Patent Application,yes,8,3,4,4,0,G02B1/04;;Y02P20/55;;C08F112/30;;C07C329/10;;G02B1/04,G02B1/04;;C08G75/14;;C08L81/04,,1,0,,,"DATABASE PubChem [O] 23 February 2016 (2016-02-23), XP055544538, Database accession no. 118347463",PENDING
135,AU,A,AU 2000/039385 A,023-396-973-134-354,2000-12-21,2000,AU 2000/039385 A,2000-06-08,US 33404799 A,1999-06-15,BROADBAND AMPLIFIED WDM RING,,LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;DIGIOVANNI DAVID JOHN;;ROTTWITT KARSTEN,,https://lens.org/023-396-973-134-354,Patent Application,no,0,0,8,8,0,H04B10/27;;H04B10/2755;;H04B10/2916;;H04B10/2939;;H04J14/0206;;H04J14/0221;;H04B10/2581;;H04B10/27;;H04B10/2755;;H04J14/0206;;H04J14/0221;;H04B10/2939;;H04B10/2916,G02F1/35;;H01S3/30;;H04B10/17;;H04B10/20;;H04B10/213;;H04B10/29;;H04J14/00;;H04J14/02,,0,0,,,,DISCONTINUED
136,EP,A1,EP 1061684 A1,096-131-890-441-177,2000-12-20,2000,EP 00304777 A,2000-06-06,US 33404799 A,1999-06-15,Broadband amplified WDM ring,"A fiber-optic WDM ring carries communication traffic among a plurality of nodes, each node associated with respective subscriber premises. Remote gain is provided in at least one link of the ring. In specific embodiments ot the invention, the remote gain is applied preferentially to those wavelength channels most in need of amplification. In specific embodiments of the invention, the remote gain is Raman gain.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;DIGIOVANNI DAVID JOHN;;ROTTWITT KARSTEN,,https://lens.org/096-131-890-441-177,Patent Application,yes,4,12,8,8,0,H04B10/27;;H04B10/2755;;H04B10/2916;;H04B10/2939;;H04J14/0206;;H04J14/0221;;H04B10/2581;;H04B10/27;;H04B10/2755;;H04J14/0206;;H04J14/0221;;H04B10/2939;;H04B10/2916,G02F1/35;;H01S3/30;;H04B10/17;;H04B10/20;;H04B10/213;;H04B10/29;;H04J14/00;;H04J14/02,,0,0,,,,DISCONTINUED
137,KR,A,KR 20010007375 A,132-313-041-340-081,2001-01-26,2001,KR 20000032694 A,2000-06-14,US 33404799 A,1999-06-15,Broadband amplified WDM ring,"본 발명의 광섬유 WDM 링은 각각의 노드가 각각의 가입자 건물과 연관된 복수의 노드들 사이의 통신 트래픽을 전송한다. 링의 적어도 하나의 링크에는 원격 이득이 제공된다. 본 발명의 특정 실시예들에서, 원격 이득은 증폭이 필요한 대부분의 파장 채널에 우선적으로 인가된다. 본 발명의 특정 실시예에서, 원격 이득인 라만(Raman) 이득이다.",LUCENT TECHNOLOGIES INC,ANDERSON JON;;ADAMS LAURA ELLEN;;BROBERG ROBERT MARIO;;DIGIOVANNI DAVID JOHN;;ROTTWITT KARSTEN,,https://lens.org/132-313-041-340-081,Patent Application,no,0,0,8,8,0,H04B10/27;;H04B10/2755;;H04B10/2916;;H04B10/2939;;H04J14/0206;;H04J14/0221;;H04B10/2581;;H04B10/27;;H04B10/2755;;H04J14/0206;;H04J14/0221;;H04B10/2939;;H04B10/2916,G02F1/35;;H01S3/30;;H04B10/17;;H04B10/20;;H04B10/213;;H04B10/29;;H04J14/00;;H04J14/02,,0,0,,,,EXPIRED
138,JP,A,JP 2001053687 A,133-750-715-993-540,2001-02-23,2001,JP 2000178071 A,2000-06-14,US 33404799 A,1999-06-15,OPTICAL COMMUNICATION NETWORK PROVIDED WITH WAVELENGTH DIVISION MULTIPLEX RING,"PROBLEM TO BE SOLVED: To obtain an optical ring network which can be expanded while suppressing the whole costs relatively low by using a dual ring two-way optical fiber transmission system that mutually connects a plurality of nodes and the a hub so that a plurality of WDM channels can be established in each ring. SOLUTION: A dual ring two-way optical fiber transmission system connects a series of nodes 110 to 116 to a hub 130. A distinct wavelength channel is allocated to each of the nodes 110 to 116, and the hub 130 and the nodes performs communication along a ring 101. Adjacent nodes and the hub 130 are connected by the link of a WDM ring, a pumped link is optically connected to a pump source and a signal made to pass through the pumped link is optically amplified. Then, the pumped link undergoes a different optical gain when a signal in a different wavelength channel is made to pass through a complete path between the hub 130 including the pumped link and a corresponding node.",LUCENT TECHNOLOGIES INC,ADAMS LAURA ELLEN;;ANDERSON JON;;BROBERG ROBERT MARIO;;DIGIOVANNI DAVID JOHN;;ROTTWITT KARSTEN,,https://lens.org/133-750-715-993-540,Patent Application,no,0,1,8,8,0,H04B10/27;;H04B10/2755;;H04B10/2916;;H04B10/2939;;H04J14/0206;;H04J14/0221;;H04B10/2581;;H04B10/27;;H04B10/2755;;H04J14/0206;;H04J14/0221;;H04B10/2939;;H04B10/2916,G02F1/35;;H01S3/30;;H04B10/17;;H04B10/20;;H04B10/213;;H04B10/29;;H04J14/00;;H04J14/02,,0,0,,,,DISCONTINUED
139,EP,A1,EP 3898843 A1,076-247-272-860-672,2021-10-27,2021,EP 19835852 A,2019-12-20,AU 2018/904872 A;;JP 2019050228 W,2018-12-20,SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE,,TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;MOUNTFORD SIMON;;ANDERSON BETHANY M;;SZABO MONIKA;;AURELIO LUIGI;;THOMPSON PHILIP,,https://lens.org/076-247-272-860-672,Patent Application,yes,0,0,7,7,0,C07C381/00;;C09B23/083;;G01N33/582;;A61K49/0032;;C09B23/06;;C09B23/0066;;C07D209/14;;A61K49/0052;;G01N2333/96466;;C12Q1/37;;A61K49/0052;;C07D209/30;;G01N33/582;;G01N2333/96466,C09B23/08;;A61K49/00;;C07C381/00;;C07D221/18;;G01N33/58,,0,0,,,,PENDING
140,EP,A1,EP 3672411 A1,028-398-484-926-116,2020-07-01,2020,EP 18847772 A,2018-08-15,US 201762550114 P;;IB 2018056135 W,2017-08-25,"MULTI-COMPONENT, SOIL-APPLIED, PESTICIDAL COMPOSITIONS",,VIVE CROP PROT INC,ANDERSON DARREN J;;IRWIN CALEIGH BUCHANAN;;POON GARY TIN-KEI;;GREIG KELLY LAURA SKYE,,https://lens.org/028-398-484-926-116,Patent Application,yes,0,0,5,5,0,A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01N53/00;;A01N25/04;;A01N25/10;;A01N37/46;;A01N43/50;;A01N43/54;;A01N43/90;;A01N53/00,A01N53/06;;A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01P3/00;;A01P7/04,,0,0,,,,DISCONTINUED
141,WO,A1,WO 2019/038642 A1,038-137-066-827-155,2019-02-28,2019,IB 2018056135 W,2018-08-15,US 201762550114 P,2017-08-25,"MULTI-COMPONENT, SOIL-APPLIED, PESTICIDAL COMPOSITIONS","The present disclosure describes compositions and methods for agricultural production. The formulations described herein combine polymer nanoparticles with at least 3 of 5 active compounds selected from strobilurin fungicides, pyrethroid insecticides, neonicotinoid insecticides, phenylamide fungicides and mectins and are suitable for application directly to soil. Said formulations are compatible with fertilizers, in particular, liquid fertilizers.",VIVE CROP PROT INC,ANDERSON DARREN J;;IRWIN CALEIGH BUCHANAN;;POON GARY TIN-KEI;;GREIG KELLY LAURA SKYE,,https://lens.org/038-137-066-827-155,Patent Application,yes,6,6,5,5,0,A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01N53/00;;A01N25/04;;A01N25/10;;A01N37/46;;A01N43/50;;A01N43/54;;A01N43/90;;A01N53/00,A01N53/06;;A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01P3/00;;A01P7/04,,1,0,,,See also references of EP 3672411A4,PENDING
142,WO,A1,WO 2020/072503 A1,099-170-122-282-24X,2020-04-09,2020,US 2019/0054084 W,2019-10-01,US 201862740372 P,2018-10-02,CHALCOGENIDE HYBRID ORGANIC/INORGANIC POLYMERS FILMS AND COATINGS AND THE USE THEREOF,"The present invention provides certain CHIP films and coatings, as well as the preparation and uses thereof. Chalcogenide hybrid organic/inorganic polymers or CHIPs may be suitable for use in antireflection coatings for use with infrared optics, for example as applied to lenses for infrared cameras. The coatings may be applied with spin coating and have a thickness related to the quarter wavelength of the desired infrared wavelengths.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT A;;NISHANT ABHINAV;;ANDERSON LAURA;;KLEINE TRISTAN;;LYONS NICHOLAS,,https://lens.org/099-170-122-282-24X,Patent Application,yes,2,0,4,32,0,G02B6/1221;;G02B6/138;;C09D5/006;;C09D181/02;;C09D185/00;;G02B1/111,G02B1/111;;G02B1/11;;G02B1/115,,2,2,172-134-695-465-42X;;034-085-018-016-73X,10.1364/ome.8.002510;;10.3390/ma9060497;;28773620;;pmc5456762,"BABAEIAN, M. ET AL.: ""Nonlinear optical properties of chalcogenide hybrid inorganic/organic polymers (CHIPs) using the Z-scan technique"", OPTICAL MATERIALS EXPRESS, vol. 8, no. 9, 3 August 2018 (2018-08-03), pages 2510 - 2519, XP055700494;;HEDAYATI, M. ET AL.: ""Antireflective Coatings: Conventional Stacking Layers and Ultrathin Plasmonic Metasurfaces, A Mini-Review"", MATERIALS, vol. 9, no. 6, 21 June 2016 (2016-06-21), pages 497, XP055543482",PENDING
143,AU,A8,AU 2003/239594 A8,143-792-279-428-542,2003-12-12,2003,AU 2003/239594 A,2003-05-20,US 38218102 P;;US 0316299 W,2002-05-20,"Bryostatins, bryopyrans and polyketides: compositions and methods",,HILDEBRAND MARK;;LIU HAIBIN;;ANDERSON CHRISTINE;;UNIV CALIFORNIA;;SHERMAN DAVID H;;HAYGOOD MARGO;;WAGGONER LAURA E,HAYGOOD MARGO;;ANDERSON CHRISTINE;;HILDEBRAND MARK;;WAGGONER LAURA E;;LIU HAIBIN;;SHERMAN DAVID H,,https://lens.org/143-792-279-428-542,Patent Application,no,0,0,4,4,0,C12N15/52;;C12P17/181,A61K/;;A61K48/00;;C07H21/00;;C12N15/52;;C12P17/18;;C12Q1/68,,0,0,,,,DISCONTINUED
144,CA,A1,CA 3120756 A1,020-148-938-579-225,2020-06-25,2020,CA 3120756 A,2019-12-20,AU 2018/904872 A;;JP 2019050228 W,2018-12-20,SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE,"The present invention relates to compounds of formula I bearing a sulfoxonium ylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detecting cysteine protease activity and in related diagnostic or therapeutic methods.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;MOUNTFORD SIMON;;ANDERSON BETHANY M;;SZABO MONIKA;;AURELIO LUIGI;;THOMPSON PHILIP,,https://lens.org/020-148-938-579-225,Patent Application,no,0,0,7,7,0,C07C381/00;;C09B23/083;;G01N33/582;;A61K49/0032;;C09B23/06;;C09B23/0066;;C07D209/14;;A61K49/0052;;G01N2333/96466;;C12Q1/37;;A61K49/0052;;C07D209/30;;G01N33/582;;G01N2333/96466,C09B23/08;;A61K49/00;;C07C381/00;;C07D221/18;;G01N33/58,,0,0,,,,PENDING
145,WO,A2,WO 2003/099219 A2,050-807-036-870-990,2003-12-04,2003,US 0316299 W,2003-05-20,US 38218102 P,2002-05-20,"BRYOSTATINS, BRYOPYRANS AND POLYKETIDES: COMPOSITIONS AND METHODS","The present invention provides nucleic acid molecules that encode polypeptides that catalyze the synthesis of bioactive compounds, such as polyketides including bryopyran rings, such as bryostatins. Also provided is a composition including at least one nucleic acid molecule that encodes at least one polypeptide that catalyzes at least one step in the synthesis of at least one polyketide such as a bryopyran ring, wherein said at least one nucleic acid molecule is derived from at least one marine organism.",UNIV CALIFORNIA;;HAYGOOD MARGO;;HILDEBRAND MARK;;ANDERSON CHRISTINE;;WAGGONER LAURA E;;SHERMAN DAVID H;;LIU HAIBIN,HAYGOOD MARGO;;HILDEBRAND MARK;;ANDERSON CHRISTINE;;WAGGONER LAURA E;;SHERMAN DAVID H;;LIU HAIBIN,,https://lens.org/050-807-036-870-990,Patent Application,yes,0,0,4,4,0,C12N15/52;;C12P17/181,A61K/;;A61K48/00;;C07H21/00;;C12N15/52;;C12P17/18;;C12Q1/68,,0,0,,,,PENDING
146,WO,A3,WO 2003/099219 A3,111-844-341-810-349,2005-03-03,2005,US 0316299 W,2003-05-20,US 38218102 P,2002-05-20,"BRYOSTATINS, BRYOPYRANS AND POLYKETIDES: COMPOSITIONS AND METHODS","The present invention provides nucleic acid molecules that encode polypeptides that catalyze the synthesis of bioactive compounds, such as polyketides including bryopyran rings, such as bryostatins. Also provided is a composition including at least one nucleic acid molecule that encodes at least one polypeptide that catalyzes at least one step in the synthesis of at least one polyketide such as a bryopyran ring, wherein said at least one nucleic acid molecule is derived from at least one marine organism.",UNIV CALIFORNIA;;HAYGOOD MARGO;;HILDEBRAND MARK;;ANDERSON CHRISTINE;;WAGGONER LAURA E;;SHERMAN DAVID H;;LIU HAIBIN,HAYGOOD MARGO;;HILDEBRAND MARK;;ANDERSON CHRISTINE;;WAGGONER LAURA E;;SHERMAN DAVID H;;LIU HAIBIN,,https://lens.org/111-844-341-810-349,Search Report,yes,1,0,4,4,0,C12N15/52;;C12P17/181,A61K/;;A61K48/00;;C07H21/00;;C12N15/52;;C12P17/18;;C12Q1/68,,0,0,,,,PENDING
147,WO,A1,WO 2020/130152 A1,045-126-324-783-256,2020-06-25,2020,JP 2019050228 W,2019-12-20,AU 2018/904872 A,2018-12-20,SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE,"The present invention relates to compounds of formula I bearing a sulfoxonium ylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detecting cysteine protease activity and in related diagnostic or therapeutic methods.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;MOUNTFORD SIMON;;ANDERSON BETHANY M;;SZABO MONIKA;;AURELIO LUIGI;;THOMPSON PHILIP,,https://lens.org/045-126-324-783-256,Patent Application,yes,7,0,7,7,0,C07C381/00;;C09B23/083;;G01N33/582;;A61K49/0032;;C09B23/06;;C09B23/0066;;C07D209/14;;A61K49/0052;;G01N2333/96466;;C12Q1/37;;A61K49/0052;;C07D209/30;;G01N33/582;;G01N2333/96466,A61K49/00;;C09B23/08;;C07C381/00;;C07D221/18;;G01N33/58,,44,39,056-617-253-402-123;;142-982-645-497-080;;035-836-256-373-573;;035-836-256-373-573;;082-256-450-770-517;;035-529-657-403-235;;025-752-386-752-626;;013-986-969-770-574;;082-256-450-770-517;;022-310-650-360-713;;047-196-968-347-19X;;000-560-539-699-157;;019-952-881-179-061;;019-671-579-181-979;;022-746-410-726-891;;002-026-824-618-646;;009-204-702-203-817;;047-708-808-820-941;;111-847-157-719-944;;157-134-753-975-660;;002-501-431-653-168;;169-884-383-631-075;;118-312-790-016-009;;044-738-251-930-999;;040-013-883-504-628;;023-081-280-756-197;;008-135-658-717-737;;013-955-937-709-451;;002-332-816-751-370;;064-491-971-029-043;;018-946-963-948-656;;056-617-253-402-123;;085-498-433-057-403;;128-186-505-110-572;;014-102-315-921-61X;;032-268-992-942-20X;;006-691-527-361-51X;;017-390-675-336-172;;027-056-525-447-896,21322635;;pmc3117957;;10.1021/cb100392r;;25581168;;10.1021/cb500909n;;22218294;;10.1038/nsmb.2203;;pmc3513415;;22218294;;10.1038/nsmb.2203;;pmc3513415;;10.3390/molecules19021378;;24473203;;pmc6270908;;21797256;;10.1021/ar200125k;;10.1007/s10549-007-9761-y;;17929166;;23788323;;pmc3691694;;10.1002/9780470559277.ch120235;;10.3390/molecules19021378;;24473203;;pmc6270908;;27108429;;10.1007/978-1-4939-3581-9_3;;pmc6091214;;27778287;;10.1007/978-1-4939-6439-0_11;;25274726;;pmc4180975;;10.1101/gad.249599.114;;28486971;;pmc5424360;;10.1186/s12974-017-0874-x;;20736174;;10.1074/jbc.m110.146183;;pmc2962467;;10.1002/path.4990;;29086922;;10.1038/nm.1938;;19597506;;pmc3196344;;22444589;;10.1016/j.chembiol.2011.12.021;;pmc3314226;;10.1016/j.cbpa.2011.10.012;;22098719;;pmc3237724;;pmc4429797;;10.1021/ja307083b;;23215039;;10.18632/oncotarget.4714;;26308073;;pmc4694970;;10.1111/acel.12093;;23621429;;pmc3934491;;24270187;;10.1038/nn.3588;;10.1002/path.1820;;16025436;;10.1186/1471-2202-9-80;;18700000;;pmc2527007;;8765519;;10.1021/jm950445b;;19800993;;10.1016/j.intimp.2009.09.018;;15162377;;10.1002/pros.20046;;10.1021/bi991371z;;10504234;;19433310;;10.1016/j.biocel.2009.02.019;;10.1189/jlb.0508285;;18701767;;pmc3252843;;pmc4747655;;25785540;;10.1021/jacs.5b00315;;21322635;;pmc3117957;;10.1021/cb100392r;;pmc4567178;;26325675;;10.1371/journal.pone.0137217;;24905783;;10.1146/annurev-biochem-060713-035352;;pmc2823914;;20133781;;10.1073/pnas.0907240107;;10.1016/s0021-9258(18)69135-5;;3343231;;22633413;;10.1016/j.chembiol.2012.03.012;;pmc3361968;;23971698;;10.1021/ja4056068;;pmc3826460;;17306794;;10.1016/j.expneurol.2007.01.007,"MARGOT G. PAULICK ET AL: ""Development of Activity-Based Probes for Cathepsin X"", ACS CHEMICAL BIOLOGY, vol. 6, no. 6, 28 February 2011 (2011-02-28), pages 563 - 572, XP055680043, ISSN: 1554-8929, DOI: 10.1021/cb100392r;;LECHTENBERG ET AL., ACS CHEM. BIOL., vol. 10, 2015, pages 945 - 951;;DEU, E.VERDOES, M.BOGYO, M.: ""New approaches for dissecting protease functions to improve probe development and drug discovery"", NAT. STRUCT. MOL. BIOL., vol. 19, 2012, pages 9 - 16;;DEU ET AL., NAT. STRUCT. MOL. BIOL., vol. 19, 2012, pages 9 - 16;;MARTELL ET AL.: ""Applications of Copper-Catalyzed Click Chemistry in Activity-Based Protein Profiling"", MOLECULES, vol. 19, 2014, pages 1378 - 1393, XP055612888, DOI: 10.3390/molecules19021378;;WILLEMS ET AL.: ""Bioorthogonal chemistry: Applications in activity-based protein profiling"", ACC. CHEM. RES., vol. 44, 2011, pages 718 - 729;;CHANG, X.-Z.LI, D.-Q.HOU, Y.-FWU, J.LU, J.-S.DI, G.-H.JIN, W.OU, Z.-L.SHEN, Z.-Z.SHAO, Z.-M: ""Identification of the functional role of AF1Q in the progression of breast cancer"", BREAST CANCER RES. TREAT., vol. 111, 2007, pages 65 - 78, XP019600726;;P. KOCIENSKI, THIEME, 2005;;""Mechanisms, and Structure"", 2013, WILEY, article ""March 's Advanced Organic Chemistry: Reactions"";;CAREYSUNDBERG: ""Advanced Organic Chemistry"", vol. A; B, 2000, PLENUM;;EDGINGTON, L.E.BOGYO, M.: ""In vivo imaging and biochemical characterization of protease function using fluorescent activity-based probes"", CURR. PROTOC. CHEM. BIOL., vol. 1 -27, 2013, pages 25 - 44;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;MARTELL ET AL., MOLECULES, vol. 19, 2014, pages 1378 - 1393;;EDGINGTON-MITCHELL, L.E.AND BOGYO, M.: ""Detection of Active Caspases During Apoptosis Using Fluorescent Activity-Based Probes"", METHODS MOL BIOL., vol. 1419, 2016, pages 27 - 39;;EDGINGTON-MITCHELL, L.E.BOGYO, M.VERDOES, M.: ""Live Cell Imaging and Profiling of Cysteine Cathepsin Activity Using a Quenched Activity-Based Probe"", METHODS MOL BIOL., vol. 1491, 2017, pages 145 - 159;;AKKARI, L.GOCHEVA, V.KESTER, J.C.HUNTER, K.E.QUICK, M.L.SEVENICH, L.WANG, H.-W.PETERS, C.TANG, L.H.KLIMSTRA, D.S.: ""Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix"", GENES DEV., vol. 28, 2014, pages 2134 - 2150;;ALLAN, E.R.O.CAMPDEN, R.I.EWANCHUK, B.W.TAILOR, P.BALCE, D.R.MCKENNA, N.T.GREENE, C.J.WARREN, A.L.REINHECKEL, T.YATES, R.M.: ""A role for cathepsin Z in neuroinflammation provides mechanistic support for an epigenetic risk factor in multiple sclerosis"", J NEUROINFLAMMATION, vol. 14, 2017, pages 1 - 11;;BERNHARDT, A.KUESTER, D.ROESSNER, A.REINHECKEL, T.KRUEGER, S.: ""Cathepsin X-deficient Gastric Epithelial Cells in Co-culture with Macrophages: Characterization of cytokine response and migration capability after Helicobacter pylori infection"", J. BIOL. CHEM., vol. 285, 2010, pages 33691 - 33700;;DUIVENVOORDEN, H.M.RAUTELA, JEDGINGTON-MITCHELL, L.E.SPURLING, A.GREENING, D.W.NOWELL, C.J.MOLLOY, T.J.ROBBINS, E.BROCKWELL, N.KLE: ""Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion"", J. PATHOL, vol. 243, 2017, pages 496 - 509;;EDGINGTON, L.E.BERGER, A.B.BLUM, G.ALBROW, V.E.PAULICK, M.G.LINEBERRY, N.BOGYO, M.: ""Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes"", NAT. MED., vol. 15, 2009, pages 967 - 973;;EDGINGTON, L.E.VAN RAAM, B.J.VERDOES, M.WIERSCHEM, C.SALVESEN, G.S.BOGYO, M.: ""An Optimized Activity-Based Probe for the Study of Caspase-6 Activation"", CHEM. BIOL., vol. 19, 2012, pages 340 - 352, XP028475180, DOI: 10.1016/j.chembiol.2011.12.021;;EDGINGTON, L.E.VERDOES, M.BOGYO, M.: ""Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes"", CURR. OP. CHEM. BIOL., vol. 15, 2011, pages 798 - 805, XP028338677, DOI: 10.1016/j.cbpa.2011.10.012;;EDGINGTON, L.EVERDOES, M.ORTEGA, A.WITHANA, N.P.LEE, J.SYED, S.BACHMANN, M.H.BLUM, G.BOGYO, M.: ""Functional Imaging of Legumain in Cancer Using a New Quenched Activity-Based Probe"", J. AM. CHEM. SOC., vol. 135, 2013, pages 174 - 182;;EDGINGTON-MITCHELL, L.E.RAUTELA, J.DUIVENVOORDEN, H.M.JAYATILLEKE, K.MVAN DER LINDEN, W.A.VERDOES, M.BOGYO, M.PARKER, B.S.: ""Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer"", ONCOTARGET, vol. 6, 2015, pages 27008 - 27022;;HAFNER, A.GLAVAN, G.OBERMAJER, N.ZIVIN, M.SCHLIEBS, R.KOS, J.: ""Neuroprotective role of y-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X"", AGING CELL, vol. 12, 2013, pages 604 - 614;;HUYNH, J.L.GARG, P.THIN, T.H.YOO, S.DUTTA, R.TRAPP, B.D.HAROUTUNIAN, V.ZHU, J.DONOVAN, M.J.SHARP, A.J.: ""Epigenome-wide dif ferences in pathology-free regions of multiple sclerosis-affected brains"", NAT. NEUROSCI., vol. 17, 2013, pages 121 - 130;;KRUEGER, S.KALINSKI, T.HUNDERTMARK, T.WEX, T.KüSTER, D.PEITZ, U.EBERT, M.NAGLER, D.K.KELLNER, U.MALFERTHEINER, P.: ""Up-regulation of cathepsin X inHelicobacter pylori gastritis and gastric cancer"", J. PATHOL., vol. 207, 2005, pages 32 - 42;;LEICHSENRING, A.BäCKERI., WENDTW., ANDRISKEM.SCHMITZ, B.STICHEL, C.C.LüBBERT, H.: ""Differential expression of Cathepsin S and X in the spinal cord of a rat neuropathic pain model"", BMC NEUROSCI., vol. 9, 2008, pages 80 - 13;;MEARA, J.P.RICH, D.H.: ""Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors"", J. MED. CHEM., vol. 39, 1996, pages 3357 - 3366;;NAGLER, D.K.KRAUS, S.FEIERLER, J.MENTELE, R.LOTTSPEICH, F.JOCHUM, M.FAUSSNER, A.: ""A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists"", INT. IMMUNOPHARMACO, vol. 10, 2010, pages 134 - 139, XP026826384;;NAGLER, D.K.KRUGER, S.KELLNER, AZIOMEK, EMENARD, R.BUHTZ, P.KRAMS, M.ROESSNER, A.KELLNER, U.: ""Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia"", PROSTATE, vol. 60, 2004, pages 109 - 119;;NAGLER, D.K.ZHANG, R.TARN, W.SULEA, T.PURISIMA, E.O.MENARD, R.: ""Human Cathepsin X: A Cysteine Protease with Unique Carboxypeptidase Activity"", BIOCHEM., vol. 38, 1999, pages 12648 - 12654;;OBERMAJER, N.DOLJAK, B.JAMNIK, P.FONOVIC, U.P.KOS, J: ""Cathepsin X cleaves the C-terminal dipeptide of alpha- and gamma-enolase and impairs survival and neuritogenesis of neuronal cells"", INT. J. BIOCHEM. CELL BIOL., vol. 41, 2009, pages 1685 - 1696, XP026101484, DOI: 10.1016/j.biocel.2009.02.019;;OBERMAJER, N.SVAJGER, U.BOGYO, M.JERAS, M.KOS, J.: ""Maturation of dendritic cells depends on proteolytic cleavage by cathepsin X"", J. LEUKOCYTE BIOL., vol. 84, 2008, pages 1306 - 1315;;ORESIC BENDER, KOFORI, L.VAN DER LINDEN, W.A.MOCK, E.D.DATTA, G.K.CHOWDHURY, SLI, H.SEGAL, E.SANCHEZ LOPEZ, M.ELLMAN, J.A.: ""Design of a Highly Selective Quenched Activity-Based Probe and Its Application in Dual Color Imaging Studies of Cathepsin S Activity Localization"", J. AM. CHEM. SOC., vol. 137, 2015, pages 4771 - 4777;;ORLOWSKI, G.MCOLBERT, J.D.SHARMA, S.BOGYO, M.ROBERTSON, S.A.ROCK, K.L.: ""Multiple Cathepsins Promote Pro-IL-Iβ Synthesis and NLRP3-Mediated IL-Iβ Activation"", J. IMMUNOL., vol. 195, 2015, pages 1685 - 1697;;PAULICK, M.G.BOGYO, M.: ""Development of Activity-Based Probes for Cathepsin X"", ACS CHEM. BIOL., vol. 6, 2011, pages 563 - 572;;PECAR FONOVIC, U.KOS, J.: ""Cathepsin X Cleaves Profilin 1 C-Terminal Tyr139 and Influences Clathrin-Mediated Endocytosis"", PLOS ONE, vol. 10, 2015, pages e0137217 - 13;;SANMAN, L.E.BOGYO, M.: ""Activity-Based Profiling of Proteases"", ANNU. REV. BIOCHEM., vol. 83, 2014, pages 249 - 273, XP055403896, DOI: 10.1146/annurev-biochem-060713-035352;;SEVENICH, L.SCHURIGT, U.SACHSE, K.GAJDA, M.WERNER, F.MULLER, S.VASILJEVA, O.SCHWINDE, A.KLEMM, N.DEUSSING, J.: ""Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice"", PROC. NAT. ACAD. SCI., vol. 107, 2010, pages 2497 - 2502, XP055151096, DOI: 10.1073/pnas.0907240107;;SHAW, E.: ""Peptidyl sulfonium salts. A new class of protease inhibitors"", J. BIOL. CHEM., vol. 263, 1988, pages 2768 - 2772, XP001034096;;VERDOES, M.EDGINGTON, L.E.SCHEEREN, F.A.LEYVA, M.BLUM, G.WEISKOPF, K.BACHMANN, M.H.ELLMAN, J.A.BOGYO, M.: ""A Nonpeptidic Cathepsin S Activity-Based Probe for Noninvasive Optical Imaging of Tumor-Associated Macrophages"", CHEM. BIOL., vol. 19, 2012, pages 619 - 628, XP055287983, DOI: 10.1016/j.chembiol.2012.03.012;;VERDOES, M.ORESIC BENDER, K.SEGAL, E.VAN DER LINDEN, W.A.SYED, S.WITHANA, N.P.SANMAN, L.E.BOGYO, M.: ""Improved Quenched Fluorescent Probe for Imaging of Cysteine Cathepsin Activity"", J. AM. CHEM. SOC., vol. 135, 2013, pages 14726 - 14730, XP055287988, DOI: 10.1021/ja4056068;;WENDT, W., ZHU, X.-R., LüBBERT, H., AND STICHEL, C.C.: ""Differential expression of cathepsin X in aging and pathological central nervous system of mice"", EXP. NEUROL., vol. 204, 2007, pages 525 - 540, XP022005830, DOI: 10.1016/j.expneurol.2007.01.007",PENDING
148,US,A1,US 2023/0285598 A1,144-873-119-069-983,2023-09-14,2023,US 201917416180 A,2019-12-20,AU 2018/904872 A;;JP 2019050228 W,2018-12-20,SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE,"The present invention relates to compounds of formula I bearing a sulfoxoniumylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detecting cysteine protease activity and in related diagnostic or therapeutic methods.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;MOUNTFORD SIMON;;ANDERSON BETHANY M;;SZABO MONIKA;;AURELIO LUIGI;;THOMPSON PHILIP,,https://lens.org/144-873-119-069-983,Patent Application,yes,0,0,7,7,0,C07C381/00;;C09B23/083;;G01N33/582;;A61K49/0032;;C09B23/06;;C09B23/0066;;C07D209/14;;A61K49/0052;;G01N2333/96466;;C12Q1/37;;A61K49/0052;;C07D209/30;;G01N33/582;;G01N2333/96466,A61K49/00;;C07D209/30;;G01N33/58,,0,0,,,,PENDING
149,EP,A4,EP 3672411 A4,122-245-739-182-893,2021-05-19,2021,EP 18847772 A,2018-08-15,US 201762550114 P;;IB 2018056135 W,2017-08-25,"MULTI-COMPONENT, SOIL-APPLIED, PESTICIDAL COMPOSITIONS",,VIVE CROP PROT INC,ANDERSON DARREN J;;IRWIN CALEIGH BUCHANAN;;POON GARY TIN-KEI;;GREIG KELLY LAURA SKYE,,https://lens.org/122-245-739-182-893,Search Report,no,6,0,5,5,0,A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01N53/00;;A01N25/04;;A01N25/10;;A01N37/46;;A01N43/50;;A01N43/54;;A01N43/90;;A01N53/00,A01N53/06;;A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01P3/00;;A01P7/04,,1,0,,,See also references of WO 2019038642A1,DISCONTINUED
150,US,A1,US 2020/0178520 A1,172-325-889-783-110,2020-06-11,2020,US 201816637420 A,2018-08-15,US 201816637420 A;;US 201762550114 P;;IB 2018056135 W,2017-08-25,"MULTI-COMPONENT, SOIL-APPLIED, PESTICIDAL COMPOSITIONS","The present disclosure describes compositions and methods for agricultural production. The formulations described herein enable to combine several active compounds, and are compatible with fertilizers, in particular, liquid fertilizers.",VIVE CROP PROT INC,ANDERSON DARREN J;;IRWIN CALEIGH BUCHANAN;;POON GARY TIN-KEI;;GREIG KELLY LAURA SKYE,VIVE CROP PROTECTION INC (2018-11-08),https://lens.org/172-325-889-783-110,Patent Application,yes,1,4,5,5,0,A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01N53/00;;A01N25/04;;A01N25/10;;A01N37/46;;A01N43/50;;A01N43/54;;A01N43/90;;A01N53/00,A01N25/04;;A01N25/10;;A01N37/46;;A01N43/50;;A01N43/54;;A01N43/90;;A01N53/00,,0,0,,,,ACTIVE
151,BR,A2,BR 112021011970 A2,186-946-242-060-421,2021-09-08,2021,BR 112021011970 A,2019-12-20,JP 2019050228 W;;AU 2018/904872 A,2018-12-20,Derivados de ilídeo sulfoxônio como sondas para cisteína-proteases,"derivados de ilídeo sulfoxônio como sondas para cisteínaproteases. a presente invenção diz respeito a compostos de fórmula i portando uma porção de ilídeo sulfoxônio como ogiva, ou sais dos mesmos. esses compostos podem ser usados como sondas baseadas na atividade para cisteína-proteases, tais como catepsina x, em métodos de detecção da atividade da cisteína-protease e em métodos diagnósticos ou terapêuticos relacionados.",TAKEDA PHARMACEUTICALS CO,BETHANY M ANDERSON;;EDGINGTON-MITCHELL LAURA;;AURELIO LUIGI;;SZABO MONIKA;;THOMPSON PHILIP;;MOUNTFORD SIMON,,https://lens.org/186-946-242-060-421,Patent Application,no,0,0,7,7,0,C07C381/00;;C09B23/083;;G01N33/582;;A61K49/0032;;C09B23/06;;C09B23/0066;;C07D209/14;;A61K49/0052;;G01N2333/96466;;C12Q1/37;;A61K49/0052;;C07D209/30;;G01N33/582;;G01N2333/96466,A61K49/00;;C07C381/00;;C07D221/18;;C09B23/08;;G01N33/58,,0,0,,,,PENDING
152,US,B2,US 11517013 B2,199-967-258-938-758,2022-12-06,2022,US 201816637420 A,2018-08-15,US 201816637420 A;;US 201762550114 P;;IB 2018056135 W,2017-08-25,"Multi-component, soil-applied, pesticidal compositions","The present disclosure describes compositions and methods for agricultural production. The formulations described herein enable to combine several active compounds, and are compatible with fertilizers, in particular, liquid fertilizers.",VIVE CROP PROT INC,ANDERSON DARREN J;;IRWIN CALEIGH BUCHANAN;;POON GARY TIN-KEI;;GREIG KELLY LAURA SKYE,VIVE CROP PROTECTION INC (2018-11-08),https://lens.org/199-967-258-938-758,Granted Patent,yes,202,0,5,5,0,A01N25/10;;A01N25/14;;A01N25/30;;A01N37/46;;A01N43/54;;A01N43/90;;A01N51/00;;A01N53/00;;A01N25/04;;A01N25/10;;A01N37/46;;A01N43/50;;A01N43/54;;A01N43/90;;A01N53/00,A01N25/04;;A01N25/10;;A01N37/46;;A01N43/50;;A01N43/54;;A01N43/90;;A01N53/00,,33,10,086-421-000-841-711;;045-295-507-650-04X;;024-078-909-321-449;;132-239-476-308-459;;027-190-664-259-841;;095-959-575-869-863;;136-685-301-259-451;;136-685-301-259-451;;108-461-097-386-26X;;042-626-740-850-739,10.1021/es050175e;;16190206;;10.1021/j100035a005;;10.1002/app.27078;;10.1002/ps.1566;;18366056;;10.1017/s0890037x00045735;;10.1007/s00396-009-2033-0;;10.1016/s0032-3861(00)00280-9;;10.1016/s0032-3861(00)00280-9;;10.1002/adma.200801423;;20004558;;10.1016/j.colsurfb.2009.11.007,"Cumbal et al., “Arsenic Removal Using Polymer-Supported Hydrates Iron(III) Oxide nanoparticles: Role of Donnan Membrane Effect,” Environmental Science Technology, vol. 39, No. 17, pp. 6508-6515, 2005.;;Henriet, M. and Baur, P., Evolution of deltamethrin formulations: liquid and solid lines and the fLUXX concept, Bayer CropScience Journal, 62:243-258 (2009).;;International Preliminary Report on Patentability for PCT/1809/07870 dated Jul. 7, 2011.;;International Search Report for International Application Serial No. IB2009/007870 dated Sep. 2, 2010.;;International Search Report for PCT/IB10/02341 dated Apr. 5, 2011.;;International Search Report for PCT/IB2009/06947, 4 pages (dated Feb. 2, 2010).;;International Search Report for PCT/IB2011/000626, 4 pages (dated Aug. 3, 2011).;;International Search Report for PCT/IB2012/002118, 4 pages (dated Feb. 6, 2013).;;International Search Report for PCT/IB2012/002832, 3 pages (dated May 17, 2013).;;International Search Report for PCT/IB2013/054760, 4 pages (dated Oct. 7, 2013).;;International Search Report for PCT/IB2014/058719 (3 pages), dated Jun. 19, 2014.;;International Search Report for PCT/IB2014/058816, 3 pages (dated May 28, 2014).;;International Search Report for PCT/IB2018/056135 (Multi-Component, Soil-Applied, Pesticidal Compositions, filed Aug. 15, 2018), issued by ISA/CA, 6 pages (dated Dec. 3, 2018).;;Kotov, et al. “Layer-by-Layer Self-Assembly of Polyelectrolyte-Semiconductor Nanoparticle Composite Films” J. Phys D Chem 1995, 99, pp. 13065-13069 (Aug. 1995).;;Liu, H. et al., Chitosan nanoparticles for loading of toothpaste actives and adhesion on tooth analogs, Journal of Applied Polymer Science, 106(6):4248-56 (2007).;;Liu, Y. et al., Stabilized Polymeric nanoparticles for controlled and efficient release of bifenthrin, Pest Management Science, 64(8):808-812 (2008).;;McMullen, P., Grass Herbicide Efficacy as Influenced by Adjuvant, Spray Solution pH, and Ultraviolet Light, Weed Technology, 10(1):72-77 (1996).;;Molnar, R.M. Preparation and characterization of poly (acrylic acid)-based nanoparticles, Colloid and Polymer Science, 287(6):739-744 (2009).;;Ng, W. et al., Rheological properties of methacrylic acid/ethyl acrylate co-polymer: comparison between an unmodified and hydrophobically modified system, Polymer, 42:249-259 (2001).;;Ng, W.K., et al., Rheological properties of methacrylic acid/ethyl acrylate co-polymer: comparison between an unmodified and hydrophobically modified system, Polymer, 42:249-259 (2001).;;Pham, H. et al., Polymer nanoparticles as formulation agents, Nanotechnology, 1:869-871 (2010).;;Won San Choi “Collective Behavior of Magnetic Nanoparticles in Polyelectrolyte Brushes” Advanced Materials 2008, D 20, 4504-4508 (Oct. 7, 2008).;;Written Opinion for International Application Serial No. IB2009/007870 dated Sep. 1, 2010.;;Written Opinion for PCT/IB10/02341 dated Apr. 5, 2011.;;Written Opinion for PCT/IB2009/06947, 4 pages (dated Feb. 2, 2010).;;Written Opinion for PCT/IB2011/000626, 6 pages (dated Aug. 3, 2011).;;Written Opinion for PCT/IB2012/002118, 6 pages (dated Feb. 6, 2013).;;Written Opinion for PCT/IB2012/002832, 8 pages (dated May 17, 2013).;;Written Opinion for PCT/IB2013/054760, 6 pages (dated Oct. 7, 2013).;;Written Opinion for PCT/IB2014/058719 (6 pages), dated Jun. 19, 2014.;;Written Opinion for PCT/IB2014/058816, 4 pages (dated May 28, 2014).;;Written Opinion for PCT/IB2018/056135 (Multi-Component, Soil-Applied, Pesticidal Compositions, filed Aug. 15, 2018), issued by ISA/CA, 7 pages (dated Dec. 3, 2018).;;Yoksan, R. et al., Encapsulation ofascorbyl palmitate in chitosan nanoparticles by oil-in-water emulsion and ionic gelation processes, Colloids and Surfaces B: Biointerfaces, 76(1):292-7(2010).",ACTIVE
153,CN,A,CN 113195641 A,104-292-158-125-646,2021-07-30,2021,CN 201980084516 A,2019-12-20,AU 2018/904872 A;;JP 2019050228 W,2018-12-20,SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE,"The present invention relates to compounds of formula I bearing a sulfoxonium ylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detecting cysteine protease activity and in related diagnostic or therapeutic methods.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;MOUNTFORD SIMON;;ANDERSON BETHANY M;;SZABO MONIKA;;AURELIO LUIGI;;THOMPSON PHILIP,,https://lens.org/104-292-158-125-646,Patent Application,no,2,0,7,7,0,C07C381/00;;C09B23/083;;G01N33/582;;A61K49/0032;;C09B23/06;;C09B23/0066;;C07D209/14;;A61K49/0052;;G01N2333/96466;;C12Q1/37;;A61K49/0052;;C07D209/30;;G01N33/582;;G01N2333/96466,C09B23/08;;A61K49/00;;C07C381/00;;C07D221/18;;G01N33/58,,0,0,,,,PENDING
154,AU,A1,AU 2003/239594 A1,045-700-979-534-502,2003-12-12,2003,AU 2003/239594 A,2003-05-20,US 38218102 P;;US 0316299 W,2002-05-20,"BRYOSTATINS, BRYOPYRANS AND POLYKETIDES: COMPOSITIONS AND METHODS",,HILDEBRAND MARK;;ANDERSON CHRISTINE;;WAGGONER LAURA E;;SHERMAN DAVID H;;LIU HAIBIN;;UNIV CALIFORNIA;;HAYGOOD MARGO,ANDERSON CHRISTINE;;WAGGONER LAURA E;;SHERMAN DAVID H;;LIU HAIBIN;;HAYGOOD MARGO;;HILDEBRAND MARK,,https://lens.org/045-700-979-534-502,Patent Application,no,0,0,4,4,0,C12N15/52;;C12P17/181,A61K/;;A61K48/00;;C07H21/00;;C12N15/52;;C12P17/18;;C12Q1/68,,0,0,,,,DISCONTINUED
155,AU,B2,AU 2011/213485 B2,072-095-381-189-755,2016-08-25,2016,AU 2011/213485 A,2011-02-07,AU 2010/900494 A;;US 39149110 P;;AU 2011/000124 W;;AU 2011/213485 A,2010-02-08,Compounds for treating respiratory syncytial virus infections,"The present invention relates to compounds of formula (I), its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT PTY LTD,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/072-095-381-189-755,Granted Patent,no,2,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/12;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61P31/14,,27,0,,,"CAS Registry Number 1019006-82-6, Entered STN 02 May 2008;;CAS Registry Number 1019006-78-0, Entered STN 02 May 2008;;CAS Registry Number 1019006-92-8, Entered STN 02 May 2008;;CAS Registry Number 1019006-52-0, Entered STN 02 May 2008;;CAS Registry Number 1019006-57-5, Entered STN 02 May 2008;;CAS Registry Number 1019006-62-2, Entered STN 02 May 2008;;CAS Registry Number 1019006-75-7, Entered STN 02 May 2008;;CAS Registry Number 1019001-85-4, Entered STN 02 May 2008;;CAS Registry Number 1019001-88-7, Entered STN 02 May 2008;;CAS Registry Number 1019006-25-7, Entered STN 02 May 2008;;CAS Registry Number 1019006-29-1, Entered STN 02 May 2008;;CAS Registry Number 1018998-11-2, Entered STN 02 May 2008;;CAS Registry Number 1018998-14-5, Entered STN 02 May 2008;;CAS Registry Number 1018998-54-3, Entered STN 02 May 2008;;CAS Registry Number 1019001-78-5, Entered STN 02 May 2008;;CAS Registry Number 1018997-73-3, Entered STN 02 May 2008;;CAS Registry Number 1018997-85-7, Entered STN 02 May 2008;;CAS Registry Number 1018997-90-4, Entered STN 02 May 2008;;CAS Registry Number 1018998-06-5, Entered STN 02 May 2008;;CAS Registry Number 717817-82-8, Entered STN 27 July 2004;;CAS Registry Number 903154-09-6, Entered STN 22 August 2006;;CAS Registry Number 1018992-94-3, Entered STN 02 May 2008;;CAS Registry Number 1018993-09-3, Entered STN 02 May 2008;;CAS Registry Number 1018993-12-8, Entered STN 02 May 2008;;CAS Registry Number 1018993-14-0, Entered STN 02 May 2008;;CAS Registry Number 1018993-19-5, Entered STN 02 May 2008;;CAS Registry Number 1018993-20-8, Entered STN 02 May 2008",INACTIVE
156,EP,A1,EP 2534155 A1,178-133-688-521-714,2012-12-19,2012,EP 11739283 A,2011-02-07,US 39149110 P;;AU 2010/900494 A;;AU 2011/000124 W,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,,BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/178-133-688-521-714,Patent Application,yes,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D207/333;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/34;;C07D213/79;;C07D405/12;;C07D487/14,,0,0,,,,ACTIVE
157,AU,A2,AU 2011/213485 A2,023-118-753-809-110,2012-09-13,2012,AU 2011/213485 A,2011-02-07,AU 2010/900494 A;;US 39149110 P;;AU 2011/000124 W;;AU 2011/213485 A,2010-02-08,Compounds for treating respiratory syncytial virus infections,"The present invention relates to compounds of formula (I), its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/023-118-753-809-110,Patent Application,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/12;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61P31/14,,0,0,,,,INACTIVE
158,CA,A1,CA 2789093 A1,091-986-026-937-155,2011-08-11,2011,CA 2789093 A,2011-02-07,AU 2010/900494 A;;US 39149110 P;;AU 2011/000124 W,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,"The present invention relates to compounds of formula (I), its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/091-986-026-937-155,Patent Application,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/12;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61P31/14,,0,0,,,,DISCONTINUED
159,WO,A1,WO 2011/094823 A1,021-786-240-367-784,2011-08-11,2011,AU 2011/000124 W,2011-02-07,US 39149110 P;;AU 2010/900494 A,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,"The present invention relates to compounds of formula (I), its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT;;MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/021-786-240-367-784,Patent Application,yes,2,11,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/12;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61P31/14,,29,0,,,"DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-92-8;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-82-6;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-78-0;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-75-7;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-62-2;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-57-5;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-52-0;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-29-1;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019006-25-7;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019001-88-7;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019001-85-4;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019001-78-5;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 10 18998-54-3;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018998-14-5;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018998-11-2;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018998-06-5;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018997-90-4;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018997-85-7;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018997-73-3;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018993-20-8;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018993-19-5;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018993-14-0;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018993-12-8;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018993-09-3;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1018992-94-3;;DATABASE CAS 22 August 2006 (2006-08-22), retrieved from STN Database accession no. 903154-09-6;;DATABASE CAS 27 July 2004 (2004-07-27), retrieved from STN Database accession no. 717817-82-8;;DATABASE CAS 2 May 2008 (2008-05-02), retrieved from STN Database accession no. 1019001-81-0;;See also references of EP 2534155A4",PENDING
160,US,B2,US 8604034 B2,061-760-540-083-797,2013-12-10,2013,US 201113023473 A,2011-02-08,US 201113023473 A;;AU 2010/900494 A;;US 39149110 P,2010-02-08,"Substituted imidazo[1,2-alpha]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus (RSV) infections","The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY;;BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,BIOTA SCIENTIFIC MANAGEMENT PTY LTD (2012-02-16),https://lens.org/061-760-540-083-797,Granted Patent,yes,48,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,A61K31/495,514/250;;544/115;;544/346;;544/405;;546/268.1;;548/125;;548/235;;548/247;;548/250;;548/373.1;;548/560;;549/59;;549/356;;549/469;;549/505,43,33,046-630-971-086-616;;054-269-121-291-520;;016-948-141-162-810;;040-676-588-361-123;;024-009-145-584-521;;017-995-545-398-107;;010-387-729-157-160;;117-603-551-710-486;;068-478-798-729-386;;093-587-628-895-209;;012-423-124-628-650;;066-262-034-222-897;;016-778-265-980-963;;025-307-706-461-903;;023-965-625-366-949;;030-456-764-557-92X;;032-050-196-312-977;;054-398-249-563-67X;;060-824-547-464-510;;001-751-231-254-600;;027-482-431-618-019;;027-002-404-586-140;;077-967-036-648-583;;020-045-895-650-105;;026-424-355-382-371;;043-749-387-881-820;;025-143-665-163-185;;004-674-332-017-009;;002-306-016-603-397;;017-733-731-531-741;;033-382-409-880-976;;016-482-193-120-389;;031-463-929-226-902,10.1001/jama.296.14.1731;;17032985;;10.1038/nrd1031;;12612646;;15353518;;10.1001/jama.292.10.1163;;804553;;10.1021/jm00236a014;;10.1021/jm00236a015;;10.1021/jo01258a042;;10.1039/p19760001073;;12667273;;14742189;;10.1128/aac.48.2.413-422.2004;;pmc321540;;6343860;;10.1056/nejm198306163082403;;3903239;;10.1001/jama.1985.03360210063030;;10.1001/jama.254.21.3047;;10.1016/s0040-4039(02)00350-7;;10.1016/s0957-4166(02)00220-3;;10.1021/jo01282a023;;12842618;;10.1016/s0042-6822(03)00115-6;;10.1099/0022-1317-66-10-2111;;2413163;;10.1021/jo01282a022;;6046174;;7989442;;10.1016/0166-0934(94)90124-4;;14638398;;10.1016/j.antiviral.2003.07.002;;10.1016/0040-4020(75)80278-x;;10.1080/00397919208019305;;1664843;;10.2307/30145246;;10.1086/646249;;10.1136/bmj.281.6250.1253-a;;7427656;;pmc1714608;;10.1080/00397919608002615;;10.1097/00005792-198909000-00002;;2677595;;10.1021/jm00164a051;;2299645;;7543579;;10.1021/jm00016a014;;10.1021/jo00025a047;;10.1038/89098;;11385510;;pmc7095854;;10.1006/viro.2001.1355;;12033771;;10.1086/379200;;14624384;;14730267;;10.1097/01.inf.0000108190.09824.e8;;10.1021/jm00077a008;;8258827,"Hackam, et al. JAMA, 296(14), 2006, 1731-1732.;;Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.;;Stephenson, ""New HIV prevention strategies urged,"" JAMA 292(10):1163-1164, 2004.;;CAS Registry 327979-63-5, Entered STN Mar. 19, 2001.;;CAS Registry 477867-90-6, Entered STN Dec. 31, 2002.;;CAS Registry 477886-49-0, Entered STN Dec. 31, 2002.;;Aeberli et al., ""5-Aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ols. Novel class of anorectic agents,"" J. Med. Chem. 1975, vol. 18, pp. 177-182.;;Aeberli et al., ""Anorectic agents. 2. Structural analogs of 5-(p-chlorophenyl)-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ol,"" J. Med. Chem. 1975, vol. 18, pp. 182-185.;;Aeberli et al., ""Lithium aluminum hydride reduction products from heterocycles containing an isoindolone nucleus,"" J. Org. Chem. 1969, vol. 34, pp. 1720-1726.;;Ames et al., ""Heterocyclic synthesis from o-halogeno-acids. Part III. Synthesis of 2-methylindole-4-carboxylic acid and related compounds and of some derivatives of 3-phenylisoquinolin-1(2H)-one,"" J. Chem. Soc. Perkin Trans. 1 1976, pp. 1073-1078.;;Black, ""Systematic review of the biology and medical management of respiratory syncytial virus infection,"" Respir. Care. 2003, vol. 48, pp. 209-233.;;Cianci et al., ""Orally Active Fusion Inhibitor of Respiratory Syncytial Virus,"" Antimicrob. Agents Chemother. 2004, vol. 48, pp. 413-422.;;Hall et al., ""Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study."" N. Engl. J. Med. 1983, vol. 308, pp. 1443-1447.;;Hall et al., ""Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease,"" JAMA 1985, vol. 254, pp. 3047-3051.;;Katritzky et al., ""Convenient syntheses of dihydropyrrolo[2',1':3,4]pyrazino- and dihydropyrrolo[2',1':3,4][1,4]diazepino-[2,1-alpha]isoindolones,"" Tretrahedron Let. 2002, vol. 43, pp. 2831-2833.;;Katritzky et al., ""Stereoselective syntheses of chiral (3S,9bS)-1,2,3,9b-tetrahydro-5H-imidazo[2,1-alpha]isoindol-5-ones,"" Tretrahedron Asymmetry 2002, vol. 13, pp. 933-938.;;Metlesics et al., ""Structure of the reaction product of o-benzoyl-benzoic acid with ethylenediamine,"" J. Org. Chem. 1967, vol. 32, pp. 2185-2187.;;Morton et al., ""Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay,"" Virology 2003, vol. 311, pp. 275-288.;;Mufson et al., ""Two distinct subtypes of human respiratory syncytial virus,"" J. Gen. Virol. 1985, vol. 66, pp. 2111-2124.;;Sulkowski et al., ""2,5-Benzodiazocines and intermediates,"" J. Org. Chem. 1967, vol. 32, pp. 2180-2184.;;Watanabe et al., ""MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents,"" J. Virological Methods 1994, vol. 48, pp. 257-265.;;Wyde et al., ""Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection,"" Antiviral Res. 2003, vol. 60, pp. 221-231.;;Bruggink et al., ""A study of the copper-catalysed direct arylation of beta-dicarbonyl compounds with 2-bromobenzoic acids,"" Tetrahedron 31:2607-2619, 1975.;;Epsztajn et al., ""Application of Organolithium and Related Reagents in Synthesis. Part II. Metallation of 2-Methyl- and 4-Methylnicotinic Acids. A Useful Method for Preparation of Aza-Isocoumarins,"" Synthetic Compounds 22(9):1239-1247, 1992.;;Falsey, ""Noninfluenza Respiratory Virus Infection in Long-Term Care Facilities,"" Infection Control and Hospital Epidemiology 12:602-608, 1991.;;Garvie et al., ""Outbreak of respiratory syncytial virus infection in the elderly,"" Br. Med. J. 281:1253-1254, 1980.;;Guion et al., ""The Preparation of 2-(2-OXO-2-Phenylethyl)Benzoic Acids From Dilithiated Ortho-Toluic Acid,"" Synthetic Compounds 26(9):1753-1762, 1996.;;Hertz et al., ""Respiratory Syncytial Virus-Induced Acute Lung Injury in Adult Patients with Bone Marrow Transplants: A Clinical Approach and Review of the Literature,"" Medicine 68(5):269-281, 1989.;;Kruse et al., ""Some Benzyl-Substituted Imidazoles, Triazoles, Tetrazoles, Pyridinethiones, and Structural Relatives as Multisubstrate Inhibitors of Dopamine beta-Hydroxylase. 4. Structure-Activity Relationships at the Copper Binding Site,"" J. Med. Chem. 33:781-789, 1990.;;Natsugari et al., ""Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine,"" J. Med. Chem. 38:3106-3120, 1995.;;Prasad et al., ""18-Crown-6 as a Catalyst in the Dialkylation of o-Nitrophenacyl Derivatives,"" J. Org. Chem. 56:7188-7190, 1991.;;van den Hoogen et al., ""A newly discovered human pneumovirus isolated from young children with respiratory tract disease,"" Nat. Med. 7(6):719-724, Jun. 2001.;;van den Hoogen et al., ""Analysis of the Genomic Sequence of a Human Metapneumovirus,"" Virology 295:119-132, 2002.;;van den Hoogen et al., ""Prevalence and Clinical Symptoms of Human Metapneumovirus Infection in Hospitalized Patients,"" J. Infect. Dis. 188:1571-1577, 2003.;;van den Hoogen et al., ""Clinical impact and diagnosis of human metapneumovirus infection,"" Pediatr. Infect. Dis. J. 23:S25-32, 2004.;;Yamaguchi et al., ""Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones,"" J. Med. Chem. 36:4052-4060, 1993.;;The Chemical Society of Japan, Separation of Enantiomers, Quarterly Journal, Chemical Review, 6:5, 1989.;;Non-Final Office Action dated May 26, 2010, from U.S. Appl. No. 10/585,230.;;Final Office Action dated Dec. 8, 2010, from U.S. Appl. No. 10/585,230.;;Non-Final Office Action dated Apr. 20, 2011, from U.S. Appl. No. 12/443,177.;;Final Office Action dated Nov. 8, 2011, from U.S. Appl. No. 12/443,177.;;Evans et al., ""Viral Infections of Humans,"" Epidemiology and Control, 3rd Edition, Plenum Medical Book, New York, pp. 525-544, 1989.;;Non-Final Office Action from corresponding U.S. Appl. No. 12/443,177 dated Oct. 29, 2012.",ACTIVE
161,US,A1,US 2019/0354458 A1,035-664-064-844-90X,2019-11-21,2019,US 201916528344 A,2019-07-31,US 201916528344 A;;US 201715416937 A,2017-01-26,GENERATION OF END-USER SESSIONS FROM END-USER EVENTS IDENTIFIED FROM COMPUTER SYSTEM LOGS,"One embodiment provides a method including: collecting system log files comprising a plurality of log messages representing activity within the system; generating a plurality of message templates by (i) clustering, using a clustering algorithm, the plurality of messages into groups having similar activity patterns and (ii) generating a message template for each of the groups; identifying message templates of interest, wherein a message template of interest comprises a template that potentially represents end-user events; and determining, within the message templates of interest, the message templates representing actual end-user events as opposed to system events, wherein the determining comprises (i) identifying a seed set of event types that represent known end-user events based upon identifying the event as being known to be initiated by a user and (ii) correlating the event to the known end-user event based upon a time correlation between the known end-user event and the event within the message template of interest.",IBM,ANDERSON LAURA CHALLMAN;;KIELISZEWSKI CHERYL ANN;;PEASE DAVID ALLAN;;RAMESH SRIDEVI KOUSHIK KANAGAL;;THATHACHAR JAYRAM,INTERNATIONAL BUSINESS MACHINES CORPORATION (2017-01-06),https://lens.org/035-664-064-844-90X,Patent Application,yes,2,1,4,4,0,G06F11/34;;G06F11/3075;;G06F11/3476;;G06F11/34,G06F11/30;;G06F11/34,,0,0,,,,ACTIVE
162,US,A1,US 2018/0210802 A1,096-239-288-571-109,2018-07-26,2018,US 201715416937 A,2017-01-26,US 201715416937 A,2017-01-26,GENERATION OF END-USER SESSIONS FROM END-USER EVENTS IDENTIFIED FROM COMPUTER SYSTEM LOGS,"One embodiment provides a method including: collecting, from a plurality of collaborative computing systems, system log files comprising a plurality of log messages representing activity within the system, wherein the activity within the system corresponds to system activity and end-user activity; generating a plurality of message templates, each of the plurality of message templates representing an event type by clustering the plurality of messages into groups having similar activity patterns; identifying, from the plurality of message templates, a subset of message templates representing potential end-user events; differentiating end-user events from system events, in the subset of message templates representing potential end-user events, comprising identifying a seed set of event types that represent known end-user events and correlating potential end-user events remaining after identifying the seed set of event types with the known end-user events; and grouping, based upon the differentiating, the event types representing end-user events into user sessions.",IBM,ANDERSON LAURA CHALLMAN;;KIELISZEWSKI CHERYL ANN;;PEASE DAVID ALLAN;;RAMESH SRIDEVI KOUSHIK KANAGAL;;THATHACHAR JAYRAM,INTERNATIONAL BUSINESS MACHINES CORPORATION (2017-01-06),https://lens.org/096-239-288-571-109,Patent Application,yes,0,6,4,4,0,G06F11/34;;G06F11/3075;;G06F11/3476;;G06F11/34,G06F11/30;;G06F11/34;;G06F17/30,,0,0,,,,ACTIVE
163,US,A1,US 2006/0184517 A1,048-658-420-211-916,2006-08-17,2006,US 34151206 A,2006-01-30,US 34151206 A;;US 5901405 A,2005-02-15,Answers analytics: computing answers across discrete data,"A method to derive new facts from a collection of discrete facts is provided. The discrete facts are stored in a data structure that organizes each discrete fact based on classification, value, unit, validity range, and subject. The discrete facts may be stored in an inverted index to allow efficient retrieval of values associated with each discrete fact. A discrete-fact engine is utilized in conjunction with a search engine to respond to queries. The discrete-fact engine parses a query and utilizes a collection of policies to determine whether the query involves a computational requirement. The computational requirement included in the query may trigger calculations on a set of discrete facts that match terms included the query. The result of the calculations are derived facts.",MICROSOFT CORP,ANDERSON CHRIS W;;HARRIS EDWARD D;;BUCKLEY JAMIE P;;BALDWIN LAURA J;;KERN RANDALL F,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2006-01-26),https://lens.org/048-658-420-211-916,Patent Application,yes,18,47,1,2,0,G06F16/951;;G06F16/951;;G06F16/953,G06F17/30;;G06F7/00,707/3,0,0,,,,DISCONTINUED
164,TW,A,TW 201129572 A,125-240-103-214-809,2011-09-01,2011,TW 100103938 A,2011-02-01,AU 2010/900494 A;;US 39149110 P,2010-02-08,Compounds for treating respiratory syncytial virus infections,"The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/125-240-103-214-809,Patent of Addition,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/14;;A61K31/4985;;A61P31/12,,0,0,,,,INACTIVE
165,AU,A1,AU 2011/213485 A1,158-921-467-710-003,2012-08-09,2012,AU 2011/213485 A,2011-02-07,AU 2010/900494 A;;US 39149110 P;;AU 2011/000124 W;;AU 2011/213485 A,2010-02-08,Compounds for treating respiratory syncytial virus infections,"The present invention relates to compounds of formula (I), its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/158-921-467-710-003,Patent Application,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/12;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61P31/14,,0,0,,,,INACTIVE
166,TW,B,TW I508968 B,095-320-908-967-502,2015-11-21,2015,TW 100103938 A,2011-02-01,AU 2010/900494 A;;US 39149110 P,2010-02-08,Compounds for treating respiratory syncytial virus infections,,BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/095-320-908-967-502,Granted Patent,no,1,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,,,0,0,,,,INACTIVE
167,US,B2,US 10628278 B2,138-045-102-446-315,2020-04-21,2020,US 201715416937 A,2017-01-26,US 201715416937 A,2017-01-26,Generation of end-user sessions from end-user events identified from computer system logs,"One embodiment provides a method including: collecting, from a plurality of collaborative computing systems, system log files comprising a plurality of log messages representing activity within the system, wherein the activity within the system corresponds to system activity and end-user activity; generating a plurality of message templates, each of the plurality of message templates representing an event type by clustering the plurality of messages into groups having similar activity patterns; identifying, from the plurality of message templates, a subset of message templates representing potential end-user events; differentiating end-user events from system events, in the subset of message templates representing potential end-user events, comprising identifying a seed set of event types that represent known end-user events and correlating potential end-user events remaining after identifying the seed set of event types with the known end-user events; and grouping, based upon the differentiating, the event types representing end-user events into user sessions.",IBM,ANDERSON LAURA CHALLMAN;;KIELISZEWSKI CHERYL ANN;;PEASE DAVID ALLAN;;RAMESH SRIDEVI KOUSHIK KANAGAL;;THATHACHAR JAYRAM,INTERNATIONAL BUSINESS MACHINES CORPORATION (2017-01-06),https://lens.org/138-045-102-446-315,Granted Patent,yes,13,1,4,4,0,G06F11/34;;G06F11/3075;;G06F11/3476;;G06F11/34,G06F11/30;;G06F11/34,,4,2,044-963-523-549-130;;154-828-162-353-306,10.1109/msr.2010.5463281;;10.1109/wisew.2002.1177868,"Meiyappan Nagappan, et al., “Abstracting Log Lines to Log Event Types for Mining Software System Logs”, MSR 2010, 7th IEEE Working Conference on Mining Software Repositories, May 2-3, 2010, Cape Town, South Africa, 4 pages, IEEE Digital Library.;;Adetokunbo Makanju et al., “Clustering Event Logs Using Iterative Partitioning”, KDD '09, Jun. 28-Jul. 1, 2009, Paris France, 9 pages, ACM Digital Library.;;Olfa Nasraoui et al., “Mining Web Access Logs Using Relational Competitive Fuzzy Clustering”, IFSA '99, Proceedings of the Eighth International Fuzzy Systems Association World Congress, Aug. 17-20, 1999, Taipei, Taiwan ROC, 19 pages, CiteseerX.;;Gui-Rong Xue et al., “Log Mining to Improve the Performance of Site Search”, Proceedings of the Third International Conference on Web Information Systems Engineering (Workshops), Dec. 14, 2002, 8 pages, IEEE Computer Society.",ACTIVE
168,EP,B1,EP 2534155 B1,179-837-232-945-465,2018-04-11,2018,EP 11739283 A,2011-02-07,US 39149110 P;;AU 2010/900494 A;;AU 2011/000124 W,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,,BIOTA SCIENT MANAGEMENT PTY LTD,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/179-837-232-945-465,Granted Patent,yes,4,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D207/333;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/34;;C07D213/79;;C07D405/12;;C07D487/14,,28,0,,,DATABASE CAS 02 May 2008 STN Database accession no. 1019006-92-8;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-82-6;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-78-0;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-75-7;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-62-2;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-57-5;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-52-0;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-29-1;;DATABASE CAS 02 May 2008 STN Database accession no. 1019006-25-7;;DATABASE CAS 02 May 2008 STN Database accession no. 1019001-88-7;;DATABASE CAS 02 May 2008 STN Database accession no. 1019001-85-4;;DATABASE CAS 02 May 2008 STN Database accession no. 1019001-78-5;;DATABASE CAS 02 May 2008 STN Database accession no. 10 18998-54-3;;DATABASE CAS 02 May 2008 STN Database accession no. 1018998-14-5;;DATABASE CAS 02 May 2008 STN Database accession no. 1018998-11-2;;DATABASE CAS 02 May 2008 STN Database accession no. 1018998-06-5;;DATABASE CAS 02 May 2008 STN Database accession no. 1018997-90-4;;DATABASE CAS 02 May 2008 STN Database accession no. 1018997-85-7;;DATABASE CAS 02 May 2008 STN Database accession no. 1018997-73-3;;DATABASE CAS 02 May 2008 STN Database accession no. 1018993-20-8;;DATABASE CAS 02 May 2008 STN Database accession no. 1018993-19-5;;DATABASE CAS 02 May 2008 STN Database accession no. 1018993-14-0;;DATABASE CAS 02 May 2008 STN Database accession no. 1018993-12-8;;DATABASE CAS 02 May 2008 STN Database accession no. 1018993-09-3;;DATABASE CAS 02 May 2008 STN Database accession no. 1018992-94-3;;DATABASE CAS 22 August 2006 STN Database accession no. 903154-09-6;;DATABASE CAS 27 July 2004 STN Database accession no. 717817-82-8;;DATABASE CAS 02 May 2008 STN Database accession no. 1019001-81-0,ACTIVE
169,EP,A4,EP 2534155 A4,119-833-314-123-129,2013-07-03,2013,EP 11739283 A,2011-02-07,US 39149110 P;;AU 2010/900494 A;;AU 2011/000124 W,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,,BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/119-833-314-123-129,Search Report,no,2,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61K31/4985;;A61P31/14,,1,0,,,See also references of WO 2011094823A1,ACTIVE
170,IN,A,IN 6678DEN2012 A,172-383-560-363-431,2015-10-23,2015,IN 6678DEN2012 A,2012-07-30,AU 2010/900494 A;;US 39149110 P;;AU 2011/000124 W,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,The present invention relates to compounds of formula (I) its salts isomers or prodrugs thereof useful in the treatment of viral infections in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.,BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/172-383-560-363-431,Patent Application,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/12;;A61K31/416;;A61P31/14,,0,0,,,,PENDING
171,AR,A1,AR 080146 A1,168-819-334-025-928,2012-03-14,2012,AR P110100396 A,2011-02-07,AU 2010/900494 A;;US 39149110 P,2010-02-08,COMPUESTOS PARA TRATAR INFECCIONES DEL VIRUS SINCICIAL RESPIRATORIO,"Usos en el tratamiento de viral infecciones, en particular infecciones por el virus sincicial respiratorio (RSV). La presente solicitud también se refiere a procesos para preparar los compuestos e intermediarios que se utilizan en su preparacion. Reivindicacion 1: Un compuesto con la formula (1) caracterizado porque ----- representa uniones simples o dobles dependiendo de las valencias necesarias en los átomos del anillo; cada Y se selecciona independientemente entre CH2, CH, NH y N; X se selecciona entre CH, CH2, N, NH y C=O; X1 se selecciona entre O, S, NR6, y C(R6)2 donde cada R6 se selecciona independientemente entre H, alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, cicloalquilo C3-8 opcionalmente sustituido, heterociclilo opcionalmente sustituido y arilo opcionalmente sustituido; X2 es C(R3R4) o C(R3R4)-C(R3'R4') donde cada uno de R3, R3', R4 y R4' se selecciona independientemente entre H, alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, cicloalquilo C3-8 opcionalmente sustituido, heterociclilo opcionalmente sustituido y arilo opcionalmente sustituido o dos cualesquiera de R3, R3', R4 y R4' junto con el(los) átomo(s) de carbono al cual están unidos se unen para formar un cicloalquilo C3-8 opcionalmente sustituido; R1 es un alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, cicloalquilo C3-8 opcionalmente sustituido, heterociclilo opcionalmente sustituido o arilo opcionalmente sustituido; R2 es H, R8, C(=O)R8, C(=S)R8 o S(O)2R8 donde R8 se selecciona entre alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, cicloalquilo C3-8 opcionalmente sustituido, heterociclilo opcionalmente sustituido o, arilo opcionalmente sustituido, N(R6)2, -(NR6)q(R7)qcicloalquilo opcionalmente sustituido, -(NR6)q(R7)qheterociclilo opcionalmente sustituido y -(NR6)q(R7)qarilo opcionalmente sustituido donde cada R7 se selecciona independientemente entre alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, cicloalquilo C3-8 opcionalmente sustituido, heterociclilo opcionalmente sustituido y arilo opcionalmente sustituido y q es 0 o 1; Y1 es uno o más sustituyentes opcionales; Y2 es H o uno o más R7 opcionalmente sustituidos; m y n son enteros que se seleccionan independientemente entre 0, 1, 2 y 3 donde m y n juntos son por lo menos iguales a 2; p es un entero que se selecciona entre 1, 2, 3 y 4; y donde los sustituyentes opcionales se seleccionan independientemente entre R7, R7-R7, (R7)qhalo, (R7)qCN, =O, (R7)qOR6, (R7)qOCHF2, (R7)qOCF3, (R7)qCHF2, (R7)qCF3, =S, (R7)qSR6, (R7)qSO3H, (R7)qSO2-R7, (R7)qSO2N(R6)2, (R7)qNO2, (R7)qN(R6)2, (R7)qOC(=O-R7, (R7)qC(=O)OR6, (R7)qC(=O)R6, (R7)qC(=O)N(R6)2, (R7)qNR6C(=O)-R7, (R7)qNR6SO2R7, (R7)qSi(R7)3 y (R7)qO-Si(R7)3 donde cada sustituyente opcional también puede estar sustituido opcionalmente.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;ANDRAU LAURA;;ANDERSON KELLY;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE,,https://lens.org/168-819-334-025-928,Patent Application,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,,,0,0,,,,PENDING
172,CN,A,CN 102844318 A,021-277-496-978-751,2012-12-26,2012,CN 201180015933 A,2011-02-07,AU 2011/000124 W;;AU 2010/900494 A;;US 39149110 P,2010-02-08,Compounds for treating respiratory syncytial virus infections,"The present invention relates to compounds of formula (I), its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MAN,MITCHELL JEFFREY PETER;;ANDRAU LAURA;;ANDERSON KELLY;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE,,https://lens.org/021-277-496-978-751,Patent Application,no,4,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/12;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61P31/14,,27,0,,,"CHEMICAL ABSTRACTS SERVICE: ""RN:1018993-09-3"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018993-14-0"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:903154-09-6"", 《STN REGISTRY 数据库》, 22 August 2006 (2006-08-22);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018993-12-8"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019001-88-7"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-82-6"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018998-14-5"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018997-73-3"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-75-7"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018993-20-8"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-92-8"", 《STN REGISTRY数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-52-0"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018998-54-3"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019001-78-5"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019001-85-4"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018997-85-7"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:717817-82-8"", 《STN REGISTRY 数据库》, 27 July 2004 (2004-07-27);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018998-11-2"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018992-94-3"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-25-7"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018997-90-4"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-78-0"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-57-5"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018993-19-5"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-29-1"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1019006-62-2"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02);;CHEMICAL ABSTRACTS SERVICE: ""RN:1018998-06-5"", 《STN REGISTRY 数据库》, 2 May 2008 (2008-05-02)",INACTIVE
173,SG,A1,SG 182718 A1,169-916-170-779-07X,2012-08-30,2012,SG 2012055026 A,2011-02-07,AU 2010/900494 A;;US 39149110 P;;AU 2011/000124 W,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,"The present invention relates to compounds of formula (I), its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/169-916-170-779-07X,Patent Application,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,,,0,0,,,,PENDING
174,US,B2,US 11604715 B2,038-254-803-699-492,2023-03-14,2023,US 201916528344 A,2019-07-31,US 201916528344 A;;US 201715416937 A,2017-01-26,Generation of end-user sessions from end-user events identified from computer system logs,"One embodiment provides a method including: collecting system log files comprising a plurality of log messages representing activity within the system; generating a plurality of message templates by (i) clustering the plurality of messages into groups having similar activity patterns and (ii) generating a message template for each of the groups; identifying message templates of interest and determining the message templates representing actual end-user events as opposed to system events, wherein the determining comprises (i) identifying a seed set of event types that represent known end-user events based upon identifying the event as being known to be initiated by a user and (ii) correlating the event to the known end-user event based upon a time correlation between the known end-user event and the event within the message template of interest.",IBM,ANDERSON LAURA CHALLMAN;;KIELISZEWSKI CHERYL ANN;;PEASE DAVID ALLAN;;RAMESH SRIDEVI KOUSHIK KANAGAL;;THATHACHAR JAYRAM,INTERNATIONAL BUSINESS MACHINES CORPORATION (2017-01-06),https://lens.org/038-254-803-699-492,Granted Patent,yes,21,0,4,4,0,G06F11/34;;G06F11/3075;;G06F11/3476;;G06F11/34,G06F11/30;;G06F11/34,,4,2,044-963-523-549-130;;154-828-162-353-306,10.1109/msr.2010.5463281;;10.1109/wisew.2002.1177868,"Meiyappan Nagappan, et al., “Abstracting Log Lines to Log Event Types for Mining Software System Logs”, MSR 2010, 7th IEEE Working Conference on Mining Software Repositories, May 2-3, 2010, Cape Town, South Africa, 4 pages, IEEE Digital Library.;;Adetokunbo Makanju et al., “Clustering Event Logs Using Iterative Partitioning”, KDD '09, Jun. 28-Jul. 1, 2009, Paris France, 9 pages, ACM Digital Library.;;Olfa Nasraoui et al., “Mining Web Access Logs Using Relational Competitive Fuzzy Clustering”, IFSA '99, Proceedings of the Eighth International Fuzzy Systems Association World Congress, Aug. 17-20, 1999, Taipei, Taiwan ROC, 19 pages, CiteseerX.;;Gui-Rong Xue et al., “Log Mining to Improve the Performance of Site Search”, Proceedings of the Third International Conference on Web Information Systems Engineering (Workshops), Dec. 14, 2002, 8 pages, IEEE Computer Society.",ACTIVE
175,ZA,B,ZA 201205469 B,046-328-718-637-245,2013-05-29,2013,ZA 201205469 A,2012-07-20,AU 2010/900494 A;;US 39149110 P;;AU 2011/000124 W,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,,BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,,https://lens.org/046-328-718-637-245,Granted Patent,no,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,A61P/;;A61K/;;C07D/,,0,0,,,,ACTIVE
176,US,A1,US 2011/0207728 A1,041-843-074-079-704,2011-08-25,2011,US 201113023473 A,2011-02-08,US 201113023473 A;;AU 2010/900494 A;;US 39149110 P,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,"The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY,BIOTA SCIENTIFIC MANAGEMENT PTY LTD (2012-02-16),https://lens.org/041-843-074-079-704,Patent Application,yes,25,2,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,A61K31/4985;;A61K31/5355;;A61P11/00;;A61P31/14;;C07D471/14,514/233.2;;544/346;;514/250;;544/115,2,2,046-630-971-086-616;;054-269-121-291-520,10.1001/jama.296.14.1731;;17032985;;10.1038/nrd1031;;12612646,"Hackam, et al. JAMA, 296(14), 2006, 1731-1732.;;Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.",ACTIVE
177,CA,A1,CA 3069657 A1,172-884-084-047-731,2019-01-17,2019,CA 3069657 A,2018-07-09,US 201762530677 P;;US 2018/0041234 W,2017-07-10,STERILIZABLE WIRELESS COMMUNICATION DEVICES,Disclosed are devices and methods sterilization wireless communication devices. The devices and methods described involve a sterilizable wireless communication device including a communication module. The communication module includes a transceiver capable of direct wireless communication. The sterilizable wireless communication device further includes a housing having an interior sized to contain the communication module. The communication module is hermetically sealed within the housing and the housing includes a hermetic radio frequency feedthrough configured to couple to an antenna that is external to the housing.,SMART MEDICAL DEVICES INC,HOGLUND DAVID H;;ANDERSON WAYNE;;PERRY JOHN J;;KARCH MICHAEL M;;PARK LAURA;;DOHRING EDWARD J,,https://lens.org/172-884-084-047-731,Patent Application,no,0,0,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,A61N1/372;;A61N1/00;;A61N1/375,,0,0,,,,DISCONTINUED
178,CN,A,CN 110961168 A,172-610-827-299-625,2020-04-07,2020,CN 201910857388 A,2019-09-10,US 201816147964 A,2018-10-01,BARRIER DROPLET CONFIGURATIONS AGAINST MIGRATION BETWEEN DROPLETS ON AM-EWOD DEVICES,"An electrowetting on dielectric (EWOD) device includes an EWOD device array that applies electrowetting forces and contains a non-polar fluid. A barrier droplet configuration is formed using electrowetting forces to obstruct migration of a species from a first area of the EWOD device array to a protected area of the EWOD device array. A method of operating the EWOD device includes the steps of: dispensing a source droplet into a first area of the EWOD device array, the source droplet containing a migrating species, wherein the EWOD device array includes a second area to be protected from the migrating species; and forming a barrier droplet configuration positioned between the first area and the second area of the EWOD device array that obstructs a migration pathway of the migrating speciesbetween the first area and the second area. The barrier droplet configuration includes at least one aqueous or polar barrier droplet, and the migrating species exhibits a preference for either the polar or aqueous environment of the barrier or the non-polar environment of the oil to obstruct migration.",SHARP LIFE SCIENCE EU LTD,WILSON ADAM CHRISTOPHER;;ANDERSON SALLY;;TAYLOR PETER NEIL;;BROWN CAMPBELL DONALD;;DOTHIE PAMELA ANN;;HUANG LAURA,,https://lens.org/172-610-827-299-625,Patent Application,no,27,0,5,5,0,B01L3/5027;;B01L3/502792;;B01L3/502792;;B01L2200/0605;;B01L2200/0673;;B01L2200/10;;B01L2200/141;;B01L2200/143;;B01L2300/0627;;B01L2300/0645;;B01L2300/0663;;B01L2300/161;;B01L2400/0427;;B01L2400/0427;;B01L2400/0627;;G05B15/02,B01L3/00;;G05B15/02,,0,0,,,,ACTIVE
179,MX,A,MX 2020000307 A,005-901-984-932-679,2020-08-17,2020,MX 2020000307 A,2018-07-09,US 201762530677 P;;US 2018/0041234 W,2017-07-10,STERILIZABLE WIRELESS COMMUNICATION DEVICES.,Disclosed are devices and methods sterilization wireless communication devices. The devices and methods described involve a sterilizable wireless communication device including a communication module. The communication module includes a transceiver capable of direct wireless communication. The sterilizable wireless communication device further includes a housing having an interior sized to contain the communication module. The communication module is hermetically sealed within the housing and the housing includes a hermetic radio frequency feedthrough configured to couple to an antenna that is external to the housing.,SMART MEDICAL DEVICES INC,HOGLUND DAVID H;;ANDERSON WAYNE;;PERRY JOHN J;;KARCH MICHAEL M;;PARK LAURA;;DOHRING EDWARD J,,https://lens.org/005-901-984-932-679,Patent Application,no,0,0,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,A61N1/372;;A61N1/00;;A61N1/375,,0,0,,,,PENDING
180,AU,A1,AU 2018/301337 A1,176-727-738-464-734,2020-02-13,2020,AU 2018/301337 A,2018-07-09,US 201762530677 P;;US 2018/0041234 W,2017-07-10,Sterilizable wireless communication devices,Disclosed are devices and methods sterilization wireless communication devices. The devices and methods described involve a sterilizable wireless communication device including a communication module. The communication module includes a transceiver capable of direct wireless communication. The sterilizable wireless communication device further includes a housing having an interior sized to contain the communication module. The communication module is hermetically sealed within the housing and the housing includes a hermetic radio frequency feedthrough configured to couple to an antenna that is external to the housing.,SMART MEDICAL DEVICES INC,HOGLUND DAVID H;;ANDERSON WAYNE;;PERRY JOHN J;;KARCH MICHAEL M;;PARK LAURA;;DOHRING EDWARD J,,https://lens.org/176-727-738-464-734,Patent Application,no,0,0,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,A61N1/372;;A61N1/00;;A61N1/375,,0,0,,,,ACTIVE
181,US,A1,US 2016/0046642 A1,065-434-900-152-20X,2016-02-18,2016,US 201514918156 A,2015-10-20,US 201514918156 A;;AU 2010/900494 A;;US 201314061616 A;;US 201113023473 A;;US 39149110 P,2010-02-08,Compounds for Treating Respiratory Syncytial Virus Infections,"The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY HELEN,,https://lens.org/065-434-900-152-20X,Patent Application,yes,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/34;;C07D213/79;;C07D405/12,,1,0,,,"""NO REFERENCES CITED"".",ACTIVE
182,US,A1,US 2019/0013830 A1,064-064-366-715-567,2019-01-10,2019,US 201816030203 A,2018-07-09,US 201816030203 A;;US 201762530677 P,2017-07-10,STERILIZABLE WIRELESS COMMUNICATION DEVICES,Disclosed are devices and methods sterilization wireless communication devices. The devices and methods described involve a sterilizable wireless communication device including a communication module. The communication module includes a transceiver capable of direct wireless communication. The sterilizable wireless communication device further includes a housing having an interior sized to contain the communication module. The communication module is hermetically sealed within the housing and the housing includes a hermetic radio frequency feedthrough configured to couple to an antenna that is external to the housing.,SMART MEDICAL DEVICES INC,HOGLUND DAVID H;;ANDERSON WAYNE;;PERRY JOHN J;;KARCH MICHAEL M;;PARK LAURA;;DOHRING EDWARD J,QUARTUS ENGINEERING INC (2023-07-12),https://lens.org/064-064-366-715-567,Patent Application,yes,5,13,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,H04B1/3827;;A61B17/16;;A61B34/35;;A61B50/33;;H04W4/80,,0,0,,,,DISCONTINUED
183,US,A1,US 2014/0051697 A1,183-018-429-287-73X,2014-02-20,2014,US 201314061616 A,2013-10-23,US 201314061616 A;;AU 2010/900494 A;;US 201113023473 A;;US 39149110 P,2010-02-08,COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS,"The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY HELEN,BIOTA SCIENTIFIC MANAGEMENT PTY LTD (2012-02-16),https://lens.org/183-018-429-287-73X,Patent Application,yes,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79,514/233.2;;544/346;;514/250;;548/540;;546/298;;544/115;;544/295,0,0,,,,INACTIVE
184,AU,B2,AU 2018/301337 B2,025-080-441-082-065,2024-01-25,2024,AU 2018/301337 A,2018-07-09,US 201762530677 P;;US 2018/0041234 W,2017-07-10,Sterilizable wireless communication devices,Disclosed are devices and methods sterilization wireless communication devices. The devices and methods described involve a sterilizable wireless communication device including a communication module. The communication module includes a transceiver capable of direct wireless communication. The sterilizable wireless communication device further includes a housing having an interior sized to contain the communication module. The communication module is hermetically sealed within the housing and the housing includes a hermetic radio frequency feedthrough configured to couple to an antenna that is external to the housing.,SMART MEDICAL DEVICES INC,HOGLUND DAVID H;;ANDERSON WAYNE;;PERRY JOHN J;;KARCH MICHAEL M;;PARK LAURA;;DOHRING EDWARD J,,https://lens.org/025-080-441-082-065,Granted Patent,no,0,0,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,A61N1/372;;A61N1/00;;A61N1/375,,0,0,,,,ACTIVE
185,EP,A1,EP 3632565 A1,141-075-313-134-122,2020-04-08,2020,EP 19198460 A,2019-09-19,US 201816147964 A,2018-10-01,BARRIER DROPLET CONFIGURATIONS AGAINST MIGRATION BETWEEN DROPLETS ON AM-EWOD DEVICES,"An electrowetting on dielectric (EWOD) device includes an EWOD device array that applies electrowetting forces and contains a non-polar fluid. A barrier droplet configuration is formed using electrowetting forces to obstruct migration of a species from a first area of the EWOD device array to a protected area of the EWOD device array. A method of operating the EWOD device includes the steps of: dispensing a source droplet into a first area of the EWOD device array, the source droplet containing a migrating species, wherein the EWOD device array includes a second area to be protected from the migrating species; and forming a barrier droplet configuration positioned between the first area and the second area of the EWOD device array that obstructs a migration pathway of the migrating species between the first area and the second area. The barrier droplet configuration includes at least one aqueous or polar barrier droplet, and the migrating species exhibits a preference for either the polar or aqueous environment of the barrier or the non-polar environment of the oil to obstruct migration.
",SHARP LIFE SCIENCE EU LTD,WILSON ADAM CHRISTOPHER;;ANDERSON SALLY;;TAYLOR PETER NEIL;;BROWN CAMPBELL DONALD;;DOTHIE PAMELA ANN;;HUANG LAURA,,https://lens.org/141-075-313-134-122,Patent Application,yes,11,3,5,5,0,B01L3/5027;;G05B15/02;;B01L2200/10;;B01L3/502792;;B01L2200/0673;;B01L2200/143;;B01L2300/0663;;B01L2300/0645;;B01L2300/161;;B01L2400/0427;;B01L2400/0627;;B01L3/502792;;B01L2200/0605;;B01L2200/141;;B01L2300/0627;;B01L2400/0427,B01L3/00,,2,2,036-122-420-009-020;;153-598-484-199-578,10.1016/j.snb.2017.09.071;;10.1007/s10404-007-0161-8,"CHUNQIAO LI ET AL: ""Feedback control system for large scale 2D digital microfluidic platforms"", SENSORS AND ACTUATORS B: CHEMICAL, vol. 255, 14 September 2017 (2017-09-14), NL, pages 3616 - 3622, XP055606173, ISSN: 0925-4005, DOI: 10.1016/j.snb.2017.09.071;;R.B. FAIR: ""Digital microfluidics: is a true lab-on-a-chip possible?"", MICROFLUID NANOFLUID, vol. 3, 2007, pages 245 - 281, XP019496789, doi:10.1007/s10404-007-0161-8",PENDING
186,US,A1,US 2020/0101460 A1,126-363-941-776-305,2020-04-02,2020,US 201816147964 A,2018-10-01,US 201816147964 A,2018-10-01,BARRIER DROPLET CONFIGURATIONS AGAINST MIGRATION BETWEEN DROPLETS ON AM-EWOD DEVICES,"An electrowetting on dielectric (EWOD) device includes an EWOD device array that applies electrowetting forces and contains a non-polar fluid. A barrier droplet configuration is formed using electrowetting forces to obstruct migration of a species from a first area of the EWOD device array to a protected area of the EWOD device array. A method of operating the EWOD device includes the steps of: dispensing a source droplet into a first area of the EWOD device array, the source droplet containing a migrating species, wherein the EWOD device array includes a second area to be protected from the migrating species; and forming a barrier droplet configuration positioned between the first area and the second area of the EWOD device array that obstructs a migration pathway of the migrating species between the first area and the second area. The barrier droplet configuration includes at least one aqueous or polar barrier droplet, and the migrating species exhibits a preference for either the polar or aqueous environment of the barrier or the non-polar environment of the oil to obstruct migration.",SHARP LIFE SCIENCE EU LTD,WILSON ADAM CHRISTOPHER;;ANDERSON SALLY;;TAYLOR PETER NEIL;;BROWN CAMPBELL DONALD;;DOTHIE PAMELA ANN;;HUANG LAURA,SHARP LIFE SCIENCE (EU) LIMITED (2018-09-21),https://lens.org/126-363-941-776-305,Patent Application,yes,0,0,5,5,0,B01L3/5027;;B01L3/502792;;B01L3/502792;;B01L2200/0605;;B01L2200/0673;;B01L2200/10;;B01L2200/141;;B01L2200/143;;B01L2300/0627;;B01L2300/0645;;B01L2300/0663;;B01L2300/161;;B01L2400/0427;;B01L2400/0427;;B01L2400/0627;;G05B15/02,B01L3/00,,0,0,,,,ACTIVE
187,EP,A1,EP 3651850 A1,134-911-519-169-694,2020-05-20,2020,EP 18831610 A,2018-07-09,US 201762530677 P;;US 2018/0041234 W,2017-07-10,STERILIZABLE WIRELESS COMMUNICATION DEVICES,,SMART MEDICAL DEVICES INC,HOGLUND DAVID H;;ANDERSON WAYNE;;PERRY JOHN J;;KARCH MICHAEL M;;PARK LAURA;;DOHRING EDWARD J,,https://lens.org/134-911-519-169-694,Patent Application,yes,0,0,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,A61N1/372;;A61N1/00;;A61N1/375,,0,0,,,,DISCONTINUED
188,US,B2,US 9540387 B2,039-813-719-251-921,2017-01-10,2017,US 201514918156 A,2015-10-20,US 201514918156 A;;AU 2010/900494 A;;US 201314061616 A;;US 201113023473 A;;US 39149110 P,2010-02-08,"Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections","The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY HELEN,,https://lens.org/039-813-719-251-921,Granted Patent,yes,0,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,A61K31/495;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D207/34;;C07D213/79;;C07D405/12;;C07D487/14,,0,0,,,,ACTIVE
189,US,B2,US 10913067 B2,166-300-550-442-685,2021-02-09,2021,US 201816147964 A,2018-10-01,US 201816147964 A,2018-10-01,Barrier droplet configurations against migration between droplets on AM-EWOD devices,"An electrowetting on dielectric (EWOD) device includes an EWOD device array that applies electrowetting forces and contains a non-polar fluid. A barrier droplet configuration is formed using electrowetting forces to obstruct migration of a species from a first area of the EWOD device array to a protected area of the EWOD device array. A method of operating the EWOD device includes the steps of: dispensing a source droplet into a first area of the EWOD device array, the source droplet containing a migrating species, wherein the EWOD device array includes a second area to be protected from the migrating species; and forming a barrier droplet configuration positioned between the first area and the second area of the EWOD device array that obstructs a migration pathway of the migrating species between the first area and the second area. The barrier droplet configuration includes at least one aqueous or polar barrier droplet, and the migrating species exhibits a preference for either the polar or aqueous environment of the barrier or the non-polar environment of the oil to obstruct migration.",SHARP LIFE SCIENCE EU LTD,WILSON ADAM CHRISTOPHER;;ANDERSON SALLY;;TAYLOR PETER NEIL;;BROWN CAMPBELL DONALD;;DOTHIE PAMELA ANN;;HUANG LAURA,SHARP LIFE SCIENCE (EU) LIMITED (2018-09-21),https://lens.org/166-300-550-442-685,Granted Patent,yes,11,0,5,5,0,B01L3/5027;;B01L3/502792;;B01L3/502792;;B01L2200/0605;;B01L2200/0673;;B01L2200/10;;B01L2200/141;;B01L2200/143;;B01L2300/0627;;B01L2300/0645;;B01L2300/0663;;B01L2300/161;;B01L2400/0427;;B01L2400/0427;;B01L2400/0627;;G05B15/02,B01L3/00;;G02B26/00,,2,2,153-598-484-199-578;;036-122-420-009-020,10.1007/s10404-007-0161-8;;10.1016/j.snb.2017.09.071,"Fair, R.B., “Digital microfluids: is a true lab-on-a-chip possible?” Microfluidics and Nanofluidics Jun. 2007, vol. 3, Issue 3, pp. 245-281.;;Sensors and Actuators B: Chemical Feedback control system for large scale 2D digital microfluidic platforms, Jun. 10, 2017, Chunqiao et al.",ACTIVE
190,KR,A,KR 20200050947 A,001-847-911-966-464,2020-05-12,2020,KR 20207003397 A,2018-07-09,US 201762530677 P;;US 2018/0041234 W,2017-07-10,살균가능한 무선 통신 디바이스들,살균 무선 통신 디바이스들 및 그 방법들이 개시된다. 설명된 디바이스들 및 방법들은 통신 모듈을 포함하는 살균가능한 무선 통신 디바이스를 포함한다. 통신 모듈은 직접 무선 통신을 할 수 있는 송수신기를 포함한다. 살균가능한 무선 통신 디바이스는 통신 모듈을 포함하도록 하는 크기의 내부를 갖는 하우징을 추가로 포함한다. 통신 모듈은 하우징 내에 밀폐 밀봉되고 하우징은 하우징 외부에 있는 안테나에 결합하도록 구성된 밀폐형 라디오 주파수 피드스루를 포함한다.,SMART MEDICAL DEVICES INC,HOGLUND DAVID H;;ANDERSON WAYNE;;PERRY JOHN J;;KARCH MICHAEL M;;PARK LAURA;;DOHRING EDWARD J,,https://lens.org/001-847-911-966-464,Patent Application,no,0,0,10,10,0,A61B90/90;;A61B90/98;;H04B1/3888;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;A61L2202/24;;A61B2090/0813;;A61B17/14;;A61B34/30;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B50/33;;G06F1/1656;;H04B1/385;;H04B1/3888;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/081;;A61L2/087;;A61L2/206;;A61L2/208;;A61L2/26;;H04B1/385;;H04W4/80;;A61B17/1626;;A61B2017/00221;;A61B34/35;;A61B2017/00734;;A61B50/33;;A61B90/98;;A61B90/90;;H04B1/3888;;A61L2/087;;A61L2/26;;A61L2/081;;A61L2/07;;A61B2090/0813;;A61L2/206;;A61L2/208;;A61L2202/24;;A61B34/30;;A61B17/14,H04B1/3827;;A61B34/35;;A61B90/90;;A61L2/07;;A61L2/08;;A61L2/20;;A61L2/26;;H04B1/3888,,0,0,,,,PENDING
191,US,B2,US 9163029 B2,159-978-854-580-29X,2015-10-20,2015,US 201314061616 A,2013-10-23,US 201314061616 A;;AU 2010/900494 A;;US 201113023473 A;;US 39149110 P,2010-02-08,"Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections","The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.",BIOTA SCIENT MANAGEMENT,MITCHELL JEFFREY PETER;;PITT GARY;;DRAFFAN ALISTAIR GEORGE;;MAYES PENELOPE ANNE;;ANDRAU LAURA;;ANDERSON KELLY HELEN,BIOTA SCIENTIFIC MANAGEMENT PTY LTD (2012-02-16),https://lens.org/159-978-854-580-29X,Granted Patent,yes,53,0,26,26,0,A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12;;A61P11/00;;A61P31/12;;A61P31/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;C07D487/14;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79;;C07D207/34;;C07D405/12,C07D487/14;;A61K31/407;;A61K31/4162;;A61K31/4188;;A61K31/4985;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D207/333;;C07D213/79,,40,33,040-676-588-361-123;;024-009-145-584-521;;017-995-545-398-107;;010-387-729-157-160;;117-603-551-710-486;;001-751-231-254-600;;068-478-798-729-386;;027-482-431-618-019;;027-002-404-586-140;;077-967-036-648-583;;020-045-895-650-105;;046-630-971-086-616;;093-587-628-895-209;;012-423-124-628-650;;026-424-355-382-371;;054-269-121-291-520;;066-262-034-222-897;;016-778-265-980-963;;043-749-387-881-820;;025-307-706-461-903;;023-965-625-366-949;;030-456-764-557-92X;;025-143-665-163-185;;004-674-332-017-009;;016-948-141-162-810;;032-050-196-312-977;;002-306-016-603-397;;017-733-731-531-741;;033-382-409-880-976;;016-482-193-120-389;;054-398-249-563-67X;;060-824-547-464-510;;031-463-929-226-902,804553;;10.1021/jm00236a014;;10.1021/jm00236a015;;10.1021/jo01258a042;;10.1039/p19760001073;;12667273;;10.1016/0040-4020(75)80278-x;;14742189;;10.1128/aac.48.2.413-422.2004;;pmc321540;;10.1080/00397919208019305;;1664843;;10.2307/30145246;;10.1086/646249;;10.1136/bmj.281.6250.1253-a;;7427656;;pmc1714608;;10.1080/00397919608002615;;10.1001/jama.296.14.1731;;17032985;;6343860;;10.1056/nejm198306163082403;;3903239;;10.1001/jama.1985.03360210063030;;10.1001/jama.254.21.3047;;10.1097/00005792-198909000-00002;;2677595;;10.1038/nrd1031;;12612646;;10.1016/s0040-4039(02)00350-7;;10.1016/s0957-4166(02)00220-3;;10.1021/jm00164a051;;2299645;;10.1021/jo01282a023;;12842618;;10.1016/s0042-6822(03)00115-6;;10.1099/0022-1317-66-10-2111;;2413163;;7543579;;10.1021/jm00016a014;;10.1021/jo00025a047;;15353518;;10.1001/jama.292.10.1163;;10.1021/jo01282a022;;6046174;;10.1038/89098;;11385510;;pmc7095854;;10.1006/viro.2001.1355;;12033771;;10.1086/379200;;14624384;;14730267;;10.1097/01.inf.0000108190.09824.e8;;7989442;;10.1016/0166-0934(94)90124-4;;14638398;;10.1016/j.antiviral.2003.07.002;;10.1021/jm00077a008;;8258827,"Aeberli et al., ""5-Aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindo1-5-ols. Novel class of anorectic agents,"" J Med. Chem. 18:177-182, 1975.;;Aeberli et all, ""Anorectic agents. 2. Structural analogs of 5-(p-chlorophenyl)-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ol,""J.Med.Chem. 18:182-185, 1975.;;Aeberli et al., ""Lithium aluminum hydride reduction products from heterocycles containing an isoindolone nucleus,"" J. Org. Chem 34:1720-1726, 1969.;;Ames et al., ""Heterocyclic synthesis from o-halogeno-acids. Part III. Synthesis of 2-methylindole-4-carboxylic acid and related compounds and of some derivatives of 3-pheylisoquinolin-1(2H)-one,"" J. Chem. Soc. Perkin Trans. 1 1073-1078, 1976.;;Black, ""Systemaatic review of the biology and medical management of respiratory syncytial virus infection,"" Respir. Care. 48:209-233, 2003.;;Bruggink et al., ""A study of the copper-catalysed direct arylation of beta-dicarbonyl compounds with 2-bromobenzoic acids,"" Tetrahedron 31:2607-2619, 1975.;;Cianci et al., ""Orally Active Fusion Inhibitor of Respiratory Syncytial Virus,"" Antimicrob. Agents Chemother 48:413-422, 2004.;;Epsztajn et al., ""Application of Organolithium and Related Reagents in Synthesis. Part II. Metallation of 2-Methyl- and 4-Methylnicotinic Acids. A Useful Method for Preparation of Aza-Isocoumarins,"" Synthetic Compounds 22(9):1239-1247, 1992.;;Evans et al., ""Viral Infections of Humans,"" Epidemiology and Control, 3rd Edition, Plenum Medical Book, New York, pp. 525-544, 1989.;;Falsey, ""Noninfluenza Respiratory Virus Infection in Long-Term Care Facilities,"" Infection Control and Hospital Epidemiology 12:602-608, 1991.;;Garvie et al., ""Outbreak of respiratory syncytial virus infection in the elderly,"" Br. Med. J. 281:1253-1254, 1980.;;Guion et al., ""The Preparation of 2-(2-OXO-2-Phenylethyl)Benzoic Acids From Dilithiated Ortho-Toluic Acid,"" Synthetic Compounds 26(9):1753-1762, 1996.;;Hackam et al., ""Translation of Research Evidence From Animals to Humans,"" JAMA 296(14): 1731-1732, 2006.;;Hall et al., ""Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study,"" N. Engl. J Med. 308:1443-1447, 1983.;;Hall et al., ""Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease,"" JAMA 254:3047-3051, 1985.;;Hertz et al., ""Respiratory Syncytial Virus-Induced Acute Lung Injury in Adult Patients with Bone Marrow Transplants: A Clinical Approach and Review of the Literature,"" Medicine 68(5):269-281, 1989.;;Jordan, V.C., ""Tamoxifen: A Most Unlikely Pioneering Medicine,"" Nature Reviews: Drug Discovery, 2:205-213, 2003.;;Katritzky et al., ""Convenient syntheses of dihydropyrrolo[2',1':3,4]pyrazino- and dihydropyrrolo[2',1':3,4][1,4]diazepino-[2,1-a]isoindolones,"" Tretrahedron Let. 43:2831-2833, 2002.;;Katritzky et al., ""Stereoselective syntheses of chiral (3S,9bS)-1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones,"" Tretrahedron Asymmetry 13:933-938, 2002.;;Kruse et al., ""Some Benzyl-Substituted Imidazoles, Triazoles, Tetrazoles, Pyridinethiones, and Structural Relatives as Multisubstrate Inhibitors of Dopamine beta-Hydroxylase. 4. Structure-Activity Relationships at the Copper Binding Site,"" J. Med. Chem. 33:781-789, 1990.;;Metlesics et al., ""Structure of the reaction product of o-benzoyl-benzoic acid with ethylenediamine,"" J. Org. Chem. 32:2185-2187, 1967.;;Morton et al., ""Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay,"" Virology 311:275-288, 2003.;;Mufson et al., ""Two distinct subtypes of human respiratory syncytial virus,"" J. Gen. Virol 66:2111-2124, 1985.;;Natsugari et al., ""Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine,"" J. Med. Chem. 38:3106-3120, 1995.;;Prasad et al., ""18-Crown-6 as a Catalyst in the Dialkylation of o-Nitrophenacyl Derivatives,"" J. Org. Chem. 56:7188-7190, 1991.;;Stephenson, ""New HIV prevention strategies urged,"" JAMA 292(10):1163-1164, 2004.;;Sulkowski et al., ""2,5-Benzodiazocines and intermediates,"" J. Org. Chem. 32:2180-2184, 1967.;;van den Hoogen et al., ""A newly discovered human pneumovirus isolated from young children with respiratory tract disease,"" Nat. Med. 7(6):719-724, Jun. 2001.;;van den Hoogen et al., ""Analysis of the Genomic Sequence of a Human Metapneumovirus,"" Virology 295:119-132, 2002.;;van den Hoogen et al., ""Prevalence and Clinical Symptoms of Human Metapneumovirus Infection in Hospitalized Patients,"" J. Infect. Dis. 188:1571-1577, 2003.;;van den Hoogen et al., ""Clinical impact and diagnosis of human metapneumovirus infection,"" Pediatr. Infect. Dis. J. 23:S25-32, 2004.;;Watanabe et al., ""MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents,"" J. Virological Methods 48:257-265, 1994.;;Wyde et al., ""Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection,"" Antiviral Res. 60:221-231, 2003.;;Yamaguchi et al., ""Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones,"" J. Med. Chem. 36:4052-4060, 1993.;;Non-Final Office Action dated May 26, 2010, from U.S. Appl. No. 10/585,230.;;Final Office Action dated Dec. 8, 2010, from U.S. Appl. No. 10/585,230.;;Non-Final Office Action dated Apr. 20, 2011, from U.S. Appl. No. 12/443,177.;;Final Office Action dated Nov. 8, 2011, from U.S. Appl. No. 12/443,177.;;Non-Final Office Action dated Oct. 29, 2012, from U.S. Appl. No. 12/443,177.;;Japanese Office Action dated Nov. 12, 2014 in corresponding Japanese Application No. 2012-551449.",INACTIVE
192,US,A9,US 2023/0140838 A9,067-596-968-212-007,2023-05-04,2023,US 201917416053 A,2019-12-20,AU 2018/904873 A;;JP 2019050223 W,2018-12-20,NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE,"The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;ANDERSON BETHANY M;;POOLE DANIEL P;;AURELIO LUIGI;;KASPERKIEWICZ PAULINA;;DRAG MARCIN;;BUNNETT NIGEL,,https://lens.org/067-596-968-212-007,Amended Application,yes,0,0,7,7,0,C12Q1/37;;G01N33/573;;G01N2474/10;;C09B23/0091;;C09K11/06;;C09K2211/1007;;C09K2211/1014;;C09K2211/1022;;G01N21/6428;;G01N33/559;;G01N33/573;;G01N33/582;;G01N2021/6439;;G01N2333/966;;G01N2800/06;;G01N2800/26,G01N33/573;;C09B23/01;;C09K11/06;;G01N21/64;;G01N33/559;;G01N33/58,,0,0,,,,PENDING
193,CN,A,CN 113227392 A,094-810-492-265-245,2021-08-06,2021,CN 201980084467 A,2019-12-20,AU 2018/904873 A;;JP 2019050223 W,2018-12-20,Novel activity-based probes for neutrophil elastase and their use,"The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;ANDERSON BETHANY M;;POOLE DANIEL P;;AURELIO LUIGI;;KASPERKIEWICZ PAULINA;;DRAG MARCIN;;BUNNETT NIGEL,,https://lens.org/094-810-492-265-245,Patent Application,no,5,0,7,7,0,C12Q1/37;;G01N33/573;;G01N2474/10;;C09B23/0091;;C09K11/06;;C09K2211/1007;;C09K2211/1014;;C09K2211/1022;;G01N21/6428;;G01N33/559;;G01N33/573;;G01N33/582;;G01N2021/6439;;G01N2333/966;;G01N2800/06;;G01N2800/26,C12Q1/37;;G01N33/573,,7,0,,,"LECHTENBERG BC等: ""The elastase-PK101 structure: mechanism of an ultrasensitive activity-based probe revealed"", 《ACS CHEM BIOL》, vol. 10, no. 4, pages 945 - 951, XP055674885, DOI: 10.1021/cb500909n;;KASPERKIEWICZ P等: ""Toolbox of Fluorescent Probes for Parallel Imaging Reveals Uneven Location of Serine Proteases in Neutrophils"", 《AM CHEM SOC》, vol. 139, no. 29, pages 10115 - 10125, XP055674889, DOI: 10.1021/jacs.7b04394;;EDGINGTON-MITCHELL LE等: ""Pathophysiological roles of proteases in gastrointestinal disease"", 《AM J PHYSIOL GASTROINTEST LIVER PHYSIOL》, vol. 310, no. 4, pages 234 - 239;;EDGINGTON-MITCHELL LE等: ""Fluorescent diphenylphosphonate-based probes for detection of serine protease activity during inflammation"", 《BIOORG MED CHEM LETT》, vol. 27, no. 2, pages 254 - 260, XP029862591, DOI: 10.1016/j.bmcl.2016.11.064;;ANDERSON BM等: ""Application of a chemical probe to detect neutrophil elastase activation during inflammatory bowel disease"", 《SCI REP》, vol. 9, no. 1, pages 1 - 12, XP055674913, DOI: 10.1038/s41598-019-49840-4;;KYRIAKIDI KS等: ""Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases"", 《ANN GASTROENTEROL》, vol. 29, no. 3, pages 258 - 267;;SHIOYA Y等: ""Neutrophil elastase inhibitor suppresses IL-17 based inflammation of murine experimental colitis"", 《FUKUSHIMA J MED SCI》, vol. 60, no. 1, pages 14 - 21",PENDING
194,US,A1,US 2022/0050107 A1,047-561-285-000-720,2022-02-17,2022,US 201917416053 A,2019-12-20,AU 2018/904873 A;;JP 2019050223 W,2018-12-20,NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE,"The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;ANDERSON BETHANY M;;POOLE DANIEL P;;AURELIO LUIGI;;KASPERKIEWICZ PAULINA;;DRAG MARCIN;;BUNNETT NIGEL,,https://lens.org/047-561-285-000-720,Patent Application,yes,0,0,7,7,0,C12Q1/37;;G01N33/573;;G01N2474/10;;C09B23/0091;;C09K11/06;;C09K2211/1007;;C09K2211/1014;;C09K2211/1022;;G01N21/6428;;G01N33/559;;G01N33/573;;G01N33/582;;G01N2021/6439;;G01N2333/966;;G01N2800/06;;G01N2800/26,G01N33/573;;C09B23/01;;C09K11/06;;G01N21/64;;G01N33/559;;G01N33/58,,0,0,,,,PENDING
195,CA,A1,CA 3120758 A1,140-003-428-713-301,2020-06-25,2020,CA 3120758 A,2019-12-20,AU 2018/904873 A;;JP 2019050223 W,2018-12-20,NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE,"The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;ANDERSON BETHANY M;;POOLE DANIEL P;;AURELIO LUIGI;;KASPERKIEWICZ PAULINA;;DRAG MARCIN;;BUNNETT NIGEL,,https://lens.org/140-003-428-713-301,Patent Application,no,0,0,7,7,0,C12Q1/37;;G01N33/573;;G01N2474/10;;C09B23/0091;;C09K11/06;;C09K2211/1007;;C09K2211/1014;;C09K2211/1022;;G01N21/6428;;G01N33/559;;G01N33/573;;G01N33/582;;G01N2021/6439;;G01N2333/966;;G01N2800/06;;G01N2800/26,C12Q1/37;;G01N33/573,,0,0,,,,PENDING
196,EP,A1,EP 3899013 A1,166-792-447-959-049,2021-10-27,2021,EP 19836846 A,2019-12-20,AU 2018/904873 A;;JP 2019050223 W,2018-12-20,NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE,,TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;ANDERSON BETHANY M;;POOLE DANIEL P;;AURELIO LUIGI;;KASPERKIEWICZ PAULINA;;DRAG MARCIN;;BUNNETT NIGEL,,https://lens.org/166-792-447-959-049,Patent Application,yes,0,0,7,7,0,C12Q1/37;;G01N33/573;;G01N2474/10;;C09B23/0091;;C09K11/06;;C09K2211/1007;;C09K2211/1014;;C09K2211/1022;;G01N21/6428;;G01N33/559;;G01N33/573;;G01N33/582;;G01N2021/6439;;G01N2333/966;;G01N2800/06;;G01N2800/26,C12Q1/37;;G01N33/573,,0,0,,,,PENDING
197,US,A1,US 2023/0272130 A1,172-404-810-272-04X,2023-08-31,2023,US 202318143562 A,2023-05-04,US 202318143562 A;;US 201916499689 A;;US 2018/0025178 W;;US 201762480403 P;;US 201762480404 P;;US 201762488451 P,2017-04-01,CHALCOGENIDE HYBRID INORGANIC/ORGANIC POLYMERS (CHIPS) FOR INFRARED OPTICAL MATERIALS AND DEVICES,"The present invention provides certain polymeric materials, precursors thereof as well as the preparation and uses thereof.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT A;;HIMMELHUBER ROLAND;;KLEINE TRISTAN STEPHEN;;DIAZ LILIANA RUIZ;;ANDERSON LAURA E,ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (2021-10-25),https://lens.org/172-404-810-272-04X,Patent Application,yes,0,0,4,4,0,G02B1/04;;Y02P20/55;;C08F112/30;;C07C329/10;;G02B1/04,C08F112/14;;C07C329/10;;G02B1/04,,0,0,,,,PENDING
198,US,B2,US 11685797 B2,080-671-114-670-141,2023-06-27,2023,US 201816499689 A,2018-03-29,US 201816499689 A;;US 201762488451 P;;US 201762480404 P;;US 201762480403 P;;US 2018/0025178 W,2017-04-01,Chalcogenide hybrid inorganic/organic polymers (CHIPs) for infrared optical materials and devices,"The present invention provides certain polymeric materials, precursors thereof as well as the preparation and uses thereof.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT A;;HIMMELHUBER ROLAND;;KLEINE TRISTAN STEPHEN;;DIAZ LILIANA RUIZ;;ANDERSON LAURA E,ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (2021-10-25),https://lens.org/080-671-114-670-141,Granted Patent,yes,9,0,4,4,0,G02B1/04;;Y02P20/55;;C08F112/30;;C07C329/10;;G02B1/04,C07C329/10;;C08F112/14;;G02B1/04,,3,1,036-230-457-039-168,10.1007/978-3-642-79175-8_1,"Kricheldorf, “Polymeriztion of Si-Containing Vinyl Monomers and Acetylenes,” Silicon in Polymer Synthesis (Kricheldorf, ed.) 1996. (Year: 1996).;;International Search Report and Written Opinion in International Patent Application PCT/US2018/025178 dated Jul. 11, 2018.;;PubChem CID=118347463. Create date Feb. 23, 2016 (Feb. 23, 2016) pp. 1-9, see entire document, especially p. 3.",ACTIVE
199,US,A1,US 2021/0102012 A1,104-466-123-908-306,2021-04-08,2021,US 201816499689 A,2018-03-29,US 201816499689 A;;US 201762488451 P;;US 201762480404 P;;US 201762480403 P;;US 2018/0025178 W,2017-04-01,CHALCOGENIDE HYBRID INORGANIC/ORGANIC POLYMERS (CHIPS) FOR INFRARED OPTICAL MATERIALS AND DEVICES,"The present invention provides certain polymeric materials, precursors thereof as well as the preparation and uses thereof.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT A;;HIMMELHUBER ROLAND;;KLEINE TRISTAN STEPHEN;;DIAZ LILIANA RUIZ;;ANDERSON LAURA E,ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (2021-10-25),https://lens.org/104-466-123-908-306,Patent Application,yes,1,3,4,4,0,G02B1/04;;Y02P20/55;;C08F112/30;;C07C329/10;;G02B1/04,C08F112/14;;C07C329/10;;G02B1/04,,1,1,036-230-457-039-168,10.1007/978-3-642-79175-8_1,"Kricheldorf, “Polymeriztion of Si-Containing Vinyl Monomers and Acetylenes,” Silicon in Polymer Synthesis (Kricheldorf, ed.) 1996. (Year: 1996)",ACTIVE
200,US,A1,US 2010/0109107 A1,101-299-873-788-775,2010-05-06,2010,US 38942209 A,2009-02-20,US 38942209 A;;US 11135708 P,2008-11-05,MAGNETIC STACK DESIGN WITH DECREASED SUBSTRATE STRESS,"A magnetic element and a method for making a magnetic element. The method includes patterning a first electrode material to form a first electrode on a substrate and depositing filler material on the substrate around the first electrode. The method further includes polishing to form a planar surface of filler and the first electrode. A magnetic cell is formed on the planar surface and a second electrode is formed on the magnetic cell. In some embodiments, the first electrode has an area that is at least 2:1 to the area of the magnetic cell.",SEAGATE TECHNOLOGY LLC,AHN YONGCHUL;;HUANG SHUIYUAN;;KHOUEIR ANTOINE;;ANDERSON PAUL;;JIA LILI;;HUTCHINSON CHRISTINA LAURA;;IVANOV IVAN;;DIMITROV DIMITAR,SEAGATE TECHNOLOGY LLC (2009-02-18),https://lens.org/101-299-873-788-775,Patent Application,yes,10,5,2,2,0,G11C11/161;;H10N50/01;;H10N50/10;;G11C11/161;;H10N50/01;;H10N50/10,H01L21/00;;H01L29/82,257/421;;438/3;;X257E29323;;X257E21001,0,0,,,,INACTIVE
201,WO,A1,WO 2020/130151 A1,181-994-953-671-573,2020-06-25,2020,JP 2019050223 W,2019-12-20,AU 2018/904873 A,2018-12-20,Novel activity-based probes for neutrophil elastase and their use,"The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.",TAKEDA PHARMACEUTICALS CO,EDGINGTON-MITCHELL LAURA;;ANDERSON BETHANY M;;POOLE DANIEL P;;AURELIO LUIGI;;KASPERKIEWICZ PAULINA;;DRAG MARCIN;;BUNNETT NIGEL,,https://lens.org/181-994-953-671-573,Patent Application,yes,5,0,7,7,0,C12Q1/37;;G01N33/573;;G01N2474/10;;C09B23/0091;;C09K11/06;;C09K2211/1007;;C09K2211/1014;;C09K2211/1022;;G01N21/6428;;G01N33/559;;G01N33/573;;G01N33/582;;G01N2021/6439;;G01N2333/966;;G01N2800/06;;G01N2800/26,C12Q1/37;;G01N33/573,,43,35,019-913-962-483-549;;006-523-005-480-893;;142-982-645-497-080;;035-836-256-373-573;;026-869-083-610-60X;;120-904-919-402-623;;042-855-946-932-27X;;060-494-263-831-236;;046-940-894-955-040;;104-492-876-999-651;;085-664-414-867-09X;;001-180-714-974-85X;;006-914-393-177-674;;034-808-695-458-902;;131-083-371-574-65X;;018-052-951-513-943;;068-111-541-150-124;;025-233-384-513-897;;034-422-948-041-493;;047-708-808-820-941;;114-643-858-707-676;;013-782-403-513-662;;032-079-553-835-266;;019-913-962-483-549;;097-411-798-346-428;;142-982-645-497-080;;082-256-450-770-517;;022-310-650-360-713;;047-196-968-347-19X;;082-256-450-770-517;;007-862-000-905-322;;049-163-900-490-821;;013-986-969-770-574;;004-673-927-767-891;;035-529-657-403-235,pmc6548316;;10.1021/jacs.7b04394.s001;;10.1021/jacs.7b04394;;28672107;;31527638;;10.1038/s41598-019-49840-4;;pmc6746801;;25581168;;10.1021/cb500909n;;22218294;;10.1038/nsmb.2203;;pmc3513415;;10.1124/pr.110.002733;;21079042;;pmc2993259;;16407783;;11907569;;10.1038/416291a;;pmc6077730;;10.1073/pnas.1721891115;;30012612;;pmc4995288;;27423137;;10.1111/bph.13554;;pmc4447962;;25878251;;10.1074/jbc.m115.642736;;29155217;;pmc5870895;;10.1016/j.steroids.2017.11.006;;21147616;;10.1186/2047-783x-15-s2-27;;pmc4360323;;28442313;;10.1016/j.chest.2017.03.056;;17554986;;26702140;;10.1152/ajpgi.00393.2015;;21199654;;10.1053/j.gastro.2010.12.050;;10.1007/s00535-005-1768-8;;16741610;;10.1007/bf03326409;;12572862;;10.1152/ajpgi.00292.2011;;22421620;;10.1016/j.cbpa.2011.10.012;;22098719;;pmc3237724;;18194983;;10.1136/gut.2007.140210;;10.1126/scitranslmed.3004212;;23115353;;10.1016/j.bmcl.2016.11.064;;pmc10069441;;27923620;;pmc6548316;;10.1021/jacs.7b04394.s001;;10.1021/jacs.7b04394;;28672107;;pmc3932852;;10.1073/pnas.1318548111;;24550277;;25581168;;10.1021/cb500909n;;10.3390/molecules19021378;;24473203;;pmc6270908;;27108429;;10.1007/978-1-4939-3581-9_3;;pmc6091214;;27778287;;10.1007/978-1-4939-6439-0_11;;10.3390/molecules19021378;;24473203;;pmc6270908;;pmc5900331;;29670698;;10.1021/acsmedchemlett.7b00533;;25857284;;10.1038/ncomms7722;;23788323;;pmc3691694;;10.1002/9780470559277.ch120235;;28052575;;pmc7164106;;10.1111/febs.14001;;21797256;;10.1021/ar200125k,"PAULINA KASPERKIEWICZ ET AL: ""Toolbox of Fluorescent Probes for Parallel Imaging Reveals Uneven Location of Serine Proteases in Neutrophils"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 139, no. 29, 3 July 2017 (2017-07-03), US, pages 10115 - 10125, XP055674889, ISSN: 0002-7863, DOI: 10.1021/jacs.7b04394;;BETHANY M. ANDERSON ET AL: ""Application of a chemical probe to detect neutrophil elastase activation during inflammatory bowel disease"", SCIENTIFIC REPORTS, vol. 9, no. 1, 16 September 2019 (2019-09-16), XP055674913, DOI: 10.1038/s41598-019-49840-4;;LECHTENBERG ET AL., ACS CHEM. BIOL., 2015;;DEU, E.VERDOES, M.BOGYO, M.: ""New approaches for dissecting protease functions to improve probe development and drug discovery"", NAT. STRUCT. MOL. BIOL., vol. 19, 2012, pages 9 - 16;;KORKMAZ BHORWITZ MSJENNE DEGAUTHIER F: ""Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases"", PHARMACOL REV, vol. 62, 2010, pages 726 - 759, XP055535637, DOI: 10.1124/pr.110.002733;;KOBAYASHI SDVOYICH JMBURLAK CDELEO FR: ""Neutrophils in the innate immune response"", ARCH IMMUNOL THER EXP, vol. 53, 2005, pages 505 - 517;;REEVES EPLU HJACOBS HLMESSINA CGBOLSOVER SGABELLA GPOTMA EOWARLEY AROES JSEGAL AW: ""Killing activity of neutrophils is mediated through activation of proteases by K+ flux"", NATURE, vol. 416, 2002, pages 291 - 297;;JIMENEZ-VARGAS NNPATTISON LAZHAO PLIEU TLATORRE RJENSEN DDCASTRO JAURELIO LLE GTFLYNN B: ""Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome"", PROC NATL ACAD SCI, vol. 115, 2018, pages E7438 - E7447, XP055646212, DOI: 10.1073/pnas.1721891115;;LIEU TSAVAGE EZHAO PEDGINGTON-MITCHELL LBARLOW NBRON RPOOLE DPMCLEAN PLOHMAN RJFAIRLIE DP: ""Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2"", BRIT J PHARMACOL, vol. 173, 2016, pages 2752 - 2765;;ZHAO PLIEU TBARLOW NSOSTEGNI SHAERTEIS SKORBMACHER CLIEDTKE WJIMENEZ-VARGAS NNVANNER SJBUNNETT NW: ""Neutrophil Elastase Activates Protease-activated Receptor-2 (PAR2) and Transient Receptor Potential Vanilloid 4 (TRPV4) to Cause Inflammation and Pain"", J BIOL CHEM, vol. 290, 2015, pages 13875 - 13887;;LERMAN IHAMMES SR: ""Neutrophil elastase in the tumor microenvironment"", STEROIDS, vol. 133, 2018, pages 96 - 101, XP085364156, DOI: 10.1016/j.steroids.2017.11.006;;DEMKOW UVAN OVERVELD F: ""Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment"", EUR J MED RES, vol. 2, 2010, pages 27 - 35, XP021224690, DOI: 10.1186/2047-783X-15-S2-27;;POLVERINO EROSALES-MAYOR EDALE GEDEMBOWSKY KTORRES A: ""The Role of Neutrophil Elastase Inhibitors in Lung Diseases"", CHEST, vol. 152, 2017, pages 249 - 262;;NARITA YNAOKI KHORIUCHI NHIDAOKAMOTO HKUNIKANE HWATANABE K: ""A case of legionella pneumonia associated with acute respiratory distress syndrome (ARDS) and acute renal failure treated with methylprednisolone and sivelestat] [Article in Japanese"", NIHON KOKYUKI GAKKAI ZASSHI, vol. 45, 2007, pages 413 - 8;;EDGINGTON-MITCHELL LE: ""Pathophysiological roles of proteases in gastrointestinal disease"", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 310, 2015, pages G234 - 239;;MOTTA JPMAGNE LDESCAMPS DROLLAND CDALE CSROUSSET PMARTIN LCENAC NBALLOY VHUERRE M: ""Modifying the Protease, An-tiprotease Pattern by Elafin Overexpression Protects Mice from Colitis"", GASTROENTEROL, vol. 140, 2011, pages 1272 - 1282;;MOROHOSHI YMATSUOKA KCHINEN HKAMADA NSATO THISAMATSU TOKAMOTO SINOUE NTAKAISHI HOGATA H: ""Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis"", J GASTROENTEROL, vol. 41, 2006, pages 318 - 324, XP019429495, DOI: 10.1007/s00535-005-1768-8;;KUNO YINA KNISHIWAKI TTSUZUKI TSHIMADA MIMADA ANISHIO YNOBATA KSUZUKI TANDO T: ""Possible involvement of neutrophil elastase in impaired mucosal repair in patients with ulcerative colitis"", J GASTROENTEROL, vol. 37, 2002, pages 22 - 32;;UCHIYAMA KNAITO YTAKAGI TMIZUSHIMA KHIRAI YHAYASHI NHARUSATO AINOUE KFUKUMOTO KYAMADA S: ""Serpin B 1 protects colonic epithelial cell via blockage of neutrophil elastase activity and its expression is enhanced in patients with ulcerative colitis"", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 302, 2012, pages G1163 - G1170;;EDGINGTON LEVERDOES MBOGYO M: ""Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes"", CURR OP CHEM BIOL, vol. 15, 2011, pages 798 - 805, XP028338677, DOI: 10.1016/j.cbpa.2011.10.012;;GECSE KROKA RFERRIER LLEVEQUE MEUTAMENE HCARTIER CAIT-BELGNAOUI AROSZTOCZY AIZBEKI FFIORAMONTI J: ""Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity"", GUT, vol. 57, 2008, pages 591 - 599;;MOTTA JPBERMUDEZ-HUMARAN LGDERAISON CMARTIN LROLLAND CROUSSET PBOUE JDIETRICH GCHAPMAN KKHARRAT P: ""Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis"", SCI TRANS MED, vol. 4, 2012, pages 158ra144 - 158ra144, XP002761849;;EDGINGTON-MITCHELL LEBARLOW NAURELIO LSAMHA ASZABO MGRAHAM BBUNNETT N: ""Fluorescent diphenylphosphonate-based probes for detection of serine protease activity during inflammation"", BIOORGANIC MED CHEM LETT, vol. 27, 2017, pages 254 - 260, XP029862591, DOI: 10.1016/j.bmcl.2016.11.064;;KASPERKIEWICZ PALTMAN YD'ANGELO MSALVESEN GSDRAG M: ""Toolbox of Fluorescent Probes for Parallel Imaging Reveals Uneven Location of Serine Proteases in Neutrophils"", J AM CHEM SOC, vol. 139, 2017, pages 10115 - 10125;;KASPERKIEWICZ ET AL., FEBS, 2017;;KASPERKIEWICZ PPOREBA MSNIPAS SJPARKER HWINTERBOURN CCSALVESEN GSDRAG M: ""Design of ultrasensitive probes for human neutrophil elastase through hybrid combinatorial substrate library profiling"", PROC NATL ACAD SCI, vol. 111, 2014, pages 2518 - 2523;;LECHTENBERG BCKASPERKIEWICZ PROBINSON HDRAG MRIEDL SJ: ""The Elastase-PK101 Structure: Mechanism of an Ultrasensitive Activity-based Probe Revealed"", ACS CHEM BIOL, vol. 10, 2015, pages 945 - 951;;MARTELL JWEERAPANA E: ""Applications of Copper-Catalyzed Click Chemistry in Activity-Based Protein Profiling"", MOLECULES, vol. 19, 2014, pages 1378 - 1393, XP055612888, DOI: 10.3390/molecules19021378;;WILLEMS ET AL., ACC. CHEM. RES., 2011;;WERMUTH, C.G.STAHL, P.H.: ""Pharmaceutical Salts: Properties, Selection and Use - A Handbook"", 2002, VERLAG HELVETICA CHIMICA ACTA;;EDGINGTON, BOGYO CURR PROTOC CHEM BIOL, vol. 1 -27, 2013;;CAREYSUNDBERG: ""Advanced Organic Chemistry"", vol. A and B, 2000, PLENUM;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;EDGINGTON-MITCHELL, L.E.BOGYO, M.: ""Detection of Active Caspases During Apoptosis Using Fluorescent Activity-Based Probes"", METHODS MOL BIOL., vol. 1419, 2016, pages 27 - 39;;EDGINGTON-MITCHELL, L.E.BOGYO, M.VERDOES, M.: ""Live Cell Imaging and Profiling of Cysteine Cathepsin Activity Using a Quenched Activity-Based Probe"", METHODS MOL BIOL., vol. 1491, 2017, pages 145 - 159;;MARTELL ET AL., MOLECULES, vol. 19, 2014, pages 1378 - 1393;;EDGINGTON-MITCHELL ET AL., BIOORG. MED. CHEM. LETT., 2017;;SCHULZ-FINCKE A-CBLAUT MBRAUNE AGüTSCHOW M: ""A BODIPY-Tagged Phosphono Peptide as Activity-Based Probe for Human Leukocyte Elastase"", ACS MED CHEM LETT, vol. 9, 2018, pages 345 - 350;;DAU TSARKER RSJYILDIRIM AOEICKELBERG OJENNE DE: ""Autoprocessing of neutrophil elastase near its active site reduces the efficiency of natural and synthetic elastase inhibitors"", NAT COMM, vol. 6, 2015, pages 1 - 8;;EDGINGTON LEBOGYO M: ""In vivo imaging and biochemical characterization of protease function using fluorescent activity-based probes"", CURR PROTOC CHEM BIOL, vol. 5, 2013, pages 25 - 44;;KASPERKIEWICZ PPOREBA MGROBORZ KDRAG M: ""Emerging challenges in the design of selective protease substrates, inhibitors and activity-based probes for indistinguishable proteases"", FEBS J, vol. 284, 2017, pages 1518 - 1539;;RAWLINGS NDSALVESEN G: ""Handbook of Proteolytic Enzymes"", 2012, ACADEMIC PRESS;;WILLEMS LIVAN DER LINDEN WALI NLI KYLIU NHOOGENDOORN SVAN DER MAREL GAFLOREA BIOVERKLEEFT HS: ""Bioorthogonal chemistry: Applications in activity-based protein profiling"", ACC CHEM RES, vol. 44, 2011, pages 718 - 729",PENDING
202,US,B2,US 7998758 B2,198-898-778-956-332,2011-08-16,2011,US 38942209 A,2009-02-20,US 38942209 A;;US 11135708 P,2008-11-05,Method of fabricating a magnetic stack design with decreased substrate stress,"A magnetic element and a method for making a magnetic element. The method includes patterning a first electrode material to form a first electrode on a substrate and depositing filler material on the substrate around the first electrode. The method further includes polishing to form a planar surface of filler and the first electrode. A magnetic cell is formed on the planar surface and a second electrode is formed on the magnetic cell. In some embodiments, the first electrode has an area that is at least 2:1 to the area of the magnetic cell.",SEAGATE TECHNOLOGY LLC,AHN YONGCHUL;;HAUNG SHUIYUAN;;KHOUEIR ANTOINE;;ANDERSON PAUL;;JIA LILI;;HUTCHINSON CHRISTINA LAURA;;IVANOV IVAN;;DIMITROV DIMITAR,SEAGATE TECHNOLOGY LLC (2009-02-18),https://lens.org/198-898-778-956-332,Granted Patent,yes,10,9,2,2,0,G11C11/161;;H10N50/01;;H10N50/10;;G11C11/161;;H10N50/01;;H10N50/10,H01L29/04;;H01L29/82,438/3;;257/421;;X257E29323,1,0,,,"U.S. Appl. No. 12/268,638, filed Nov. 11, 2008, Anderson.",INACTIVE
203,US,A1,US 2021/0248926 A1,011-857-592-767-581,2021-08-12,2021,US 202016786342 A,2020-02-10,US 202016786342 A,2020-02-10,PHYSICAL-VIRTUAL PATIENT SYSTEM,"A patient simulation system for healthcare training is provided. The system includes one or more interchangeable shells comprising a physical anatomical model of at least a portion of a patient's body, the shell adapted to be illuminated from within the shell to provide one or more dynamic images viewable on the outer surface of the shells; wherein the system comprises one or more imaging devices enclosed within the shell and adapted to render the one or more dynamic images on an inner surface of the shell and viewable on the outer surface of the shells; one or more interface devices located about the patient shells to receive input and provide output; and one or more computing units in communication with the image units and interface devices, the computing units adapted to provide an interactive simulation for healthcare training. In other embodiments, the shell is adapted to be illuminated from outside the shell.",UNIV CENTRAL FLORIDA RES FOUND INC,WELCH GREGORY F;;BRUDER GERD;;DAHER SALAM;;HOCHREITER JASON ERIC;;ANDERSON MINDI A;;GONZALEZ LAURA;;DIAZ DESIREE A,UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION INC (2020-02-12),https://lens.org/011-857-592-767-581,Patent Application,yes,5,0,1,1,0,G09B23/285;;G09B23/303;;G09B23/32;;G09B23/34;;H04N9/3141;;H04N9/3179;;H04N9/3194;;H04N9/3147;;H04N23/698;;G09B23/34;;A61B34/10;;H04N9/3141;;G09B23/32;;A61B2034/107;;G09B23/303;;G09B23/285;;H04N23/698,G09B23/34;;A61B34/10;;H04N5/232;;H04N9/31,,0,0,,,,PENDING
204,US,B2,US 11028543 B2,039-816-616-147-623,2021-06-08,2021,US 202016806582 A,2020-03-02,US 202016806582 A;;US 201815962802 A;;US 201762489818 P,2017-04-25,"Apparatus, system, and method for smart roadway stud control and signaling","The subject matter described herein includes a roadway stud control system including a local stud control system positioned along a first section of a roadway, a plurality of roadway studs, each roadway stud disposed on a surface of the first section of the roadway and communicably coupled to the local stud control system, wherein the local stud control system is configured to communicate a control signal to control at least one aspect of the plurality of roadway studs.",MZC FOUND INC,LANGFORD HARRIET ANDERSON;;LANGFORD A PHILIP;;ANDERSON ALAN J;;PICARD JOHN;;BEATON ALLISON KELLY;;LE FAOU GLENN;;CHURCHER LAURA;;SALISBURY JAMES;;BUDA MARIE;;MILTON ANDY;;COLBY EDWARD,MZC FOUNDATION INC (2018-07-23),https://lens.org/039-816-616-147-623,Granted Patent,yes,77,0,6,6,0,G01W1/02;;G08G1/0133;;G08G1/0175;;E01F9/559;;G08G1/052;;G08G1/167;;G08G1/164;;G08G1/0116;;G08G1/095;;G08G1/042;;H05B47/11;;H05B47/19;;G08G1/0145;;Y02B20/40;;H05B45/12;;H05B45/18;;E01F9/559;;F21W2111/02;;G08G1/052;;G08G1/167;;G08G1/166;;G08G1/164;;G08G1/048;;G08G1/0116;;G08G1/095;;F21S9/037;;F21S8/032;;G06F1/26;;F21Y2115/10;;G08G1/042;;G08G1/0175;;G01W1/02;;G08G1/0133;;H05B47/19;;H05B47/11;;H05B45/12;;H05B45/18;;H05B45/10,E01F9/559;;F21S8/00;;F21S9/03;;F21W111/02;;F21Y115/10;;G01W1/02;;G06F1/26;;G08G1/01;;G08G1/017;;G08G1/042;;G08G1/048;;G08G1/052;;G08G1/095;;G08G1/16;;H05B44/00;;H05B45/10;;H05B47/11;;H05B47/19,,1,0,,,"USPTO; Non-Final Office Action for U.S. Appl. No. 15/962,802, dated Feb. 14, 2019, 19 pages.",ACTIVE
205,US,A1,US 2018/0305876 A1,114-035-342-939-071,2018-10-25,2018,US 201815962802 A,2018-04-25,US 201815962802 A;;US 201762489818 P,2017-04-25,"APPARATUS, SYSTEM, AND METHOD FOR SMART ROADWAY STUD CONTROL AND SIGNALING","The subject matter described herein includes a roadway stud control system including a local stud control system positioned along a first section of a roadway, a plurality of roadway studs, each roadway stud disposed on a surface of the first section of the roadway and communicably coupled to the local stud control system, wherein the local stud control system is configured to communicate a control signal to control at least one aspect of the plurality of roadway studs.",MZC FOUND INC,LANGFORD HARRIET ANDERSON;;LANGFORD A PHILIP;;ANDERSON ALAN J;;PICARD JOHN;;BEATON ALLISON KELLY;;LE FAOU GLENN;;CHURCHER LAURA;;SALISBURY JAMES;;BUDA MARIE;;COLBY EDWARD;;MILTON ANDY,MZC FOUNDATION INC (2018-07-23),https://lens.org/114-035-342-939-071,Patent Application,yes,13,19,6,6,0,G01W1/02;;G08G1/0133;;G08G1/0175;;E01F9/559;;G08G1/052;;G08G1/167;;G08G1/164;;G08G1/0116;;G08G1/095;;G08G1/042;;H05B47/11;;H05B47/19;;G08G1/0145;;Y02B20/40;;H05B45/12;;H05B45/18;;E01F9/559;;F21W2111/02;;G08G1/052;;G08G1/167;;G08G1/166;;G08G1/164;;G08G1/048;;G08G1/0116;;G08G1/095;;F21S9/037;;F21S8/032;;G06F1/26;;F21Y2115/10;;G08G1/042;;G08G1/0175;;G01W1/02;;G08G1/0133;;H05B47/19;;H05B47/11;;H05B45/12;;H05B45/18;;H05B45/10,E01F9/559;;F21S8/00;;F21S9/03;;G08G1/01;;G08G1/042;;G08G1/048;;G08G1/052;;G08G1/095;;G08G1/16;;H05B37/02;;H05B44/00,,0,0,,,,ACTIVE
206,US,B2,US 10577763 B2,103-396-505-492-417,2020-03-03,2020,US 201815962802 A,2018-04-25,US 201815962802 A;;US 201762489818 P,2017-04-25,"Apparatus, system, and method for smart roadway stud control and signaling","The subject matter described herein includes a roadway stud control system including a local stud control system positioned along a first section of a roadway, a plurality of roadway studs, each roadway stud disposed on a surface of the first section of the roadway and communicably coupled to the local stud control system, wherein the local stud control system is configured to communicate a control signal to control at least one aspect of the plurality of roadway studs.",MZC FOUND INC,LANGFORD HARRIET ANDERSON;;LANGFORD A PHILIP;;ANDERSON ALAN J;;PICARD JOHN;;BEATON ALLISON KELLY;;LE FAOU GLENN;;CHURCHER LAURA;;SALISBURY JAMES;;BUDA MARIE;;COLBY EDWARD;;MILTON ANDY,MZC FOUNDATION INC (2018-07-23),https://lens.org/103-396-505-492-417,Granted Patent,yes,67,1,6,6,0,G01W1/02;;G08G1/0133;;G08G1/0175;;E01F9/559;;G08G1/052;;G08G1/167;;G08G1/164;;G08G1/0116;;G08G1/095;;G08G1/042;;H05B47/11;;H05B47/19;;G08G1/0145;;Y02B20/40;;H05B45/12;;H05B45/18;;E01F9/559;;F21W2111/02;;G08G1/052;;G08G1/167;;G08G1/166;;G08G1/164;;G08G1/048;;G08G1/0116;;G08G1/095;;F21S9/037;;F21S8/032;;G06F1/26;;F21Y2115/10;;G08G1/042;;G08G1/0175;;G01W1/02;;G08G1/0133;;H05B47/19;;H05B47/11;;H05B45/12;;H05B45/18;;H05B45/10,E01F9/559;;F21S8/00;;F21S9/03;;F21W111/02;;F21Y115/10;;G01W1/02;;G06F1/26;;G08G1/01;;G08G1/017;;G08G1/042;;G08G1/048;;G08G1/052;;G08G1/095;;G08G1/16;;H05B44/00,,0,0,,,,ACTIVE
207,US,B2,US 11753781 B2,115-142-493-339-25X,2023-09-12,2023,US 202117341026 A,2021-06-07,US 202117341026 A;;US 202016806582 A;;US 201815962802 A;;US 201762489818 P,2017-04-25,"Apparatus, system, and method for smart roadway stud control and signaling","The subject matter described herein includes a roadway stud control system including a local stud control system positioned along a first section of a roadway, a plurality of roadway studs, each roadway stud disposed on a surface of the first section of the roadway and communicably coupled to the local stud control system, wherein the local stud control system is configured to communicate a control signal to control at least one aspect of the plurality of roadway studs.",MZC FOUND INC,LANGFORD HARRIET ANDERSON;;LANGFORD A PHILIP;;ANDERSON ALAN J;;PICARD JOHN;;BEATON ALLISON KELLY;;LE FAOU GLENN;;CHURCHER LAURA;;SALISBURY JAMES;;BUDA MARIE;;COLBY EDWARD;;MILTON ANDY,MZC FOUNDATION INC (2018-07-23),https://lens.org/115-142-493-339-25X,Granted Patent,yes,81,0,6,6,0,G01W1/02;;G08G1/0133;;G08G1/0175;;E01F9/559;;G08G1/052;;G08G1/167;;G08G1/164;;G08G1/0116;;G08G1/095;;G08G1/042;;H05B47/11;;H05B47/19;;G08G1/0145;;Y02B20/40;;H05B45/12;;H05B45/18;;E01F9/559;;F21W2111/02;;G08G1/052;;G08G1/167;;G08G1/166;;G08G1/164;;G08G1/048;;G08G1/0116;;G08G1/095;;F21S9/037;;F21S8/032;;G06F1/26;;F21Y2115/10;;G08G1/042;;G08G1/0175;;G01W1/02;;G08G1/0133;;H05B47/19;;H05B47/11;;H05B45/12;;H05B45/18;;H05B45/10,E01F9/559;;F21S8/00;;F21S9/03;;F21W111/02;;F21Y115/10;;G01W1/02;;G06F1/26;;G08G1/01;;G08G1/017;;G08G1/042;;G08G1/048;;G08G1/052;;G08G1/095;;G08G1/16;;H05B45/10;;H05B45/12;;H05B45/18;;H05B47/11;;H05B47/19,,2,0,,,"USPTO; Non-Final Office Action for U.S. Appl. No. 15/962,802 dated Feb. 14, 2019, 19 pages.;;USPTO; Non-Final Office Action for U.S. Appl. No. 16/806,582 dated Sep. 21, 2020, 17 pages.",ACTIVE
208,US,A1,US 2020/0199832 A1,141-255-819-101-916,2020-06-25,2020,US 202016806582 A,2020-03-02,US 202016806582 A;;US 201815962802 A;;US 201762489818 P,2017-04-25,"APPARATUS, SYSTEM, AND METHOD FOR SMART ROADWAY STUD CONTROL AND SIGNALING","The subject matter described herein includes a roadway stud control system including a local stud control system positioned along a first section of a roadway, a plurality of roadway studs, each roadway stud disposed on a surface of the first section of the roadway and communicably coupled to the local stud control system, wherein the local stud control system is configured to communicate a control signal to control at least one aspect of the plurality of roadway studs.",MZC FOUND INC,LANGFORD HARRIET ANDERSON;;LANGFORD A PHILIP;;ANDERSON ALAN J;;PICARD JOHN;;BEATON ALLISON KELLY;;LE FAOU GLENN;;CHURCHER LAURA;;SALISBURY JAMES;;BUDA MARIE;;COLBY EDWARD;;MILTON ANDY,MZC FOUNDATION INC (2018-07-23),https://lens.org/141-255-819-101-916,Patent Application,yes,0,4,6,6,0,G01W1/02;;G08G1/0133;;G08G1/0175;;E01F9/559;;G08G1/052;;G08G1/167;;G08G1/164;;G08G1/0116;;G08G1/095;;G08G1/042;;H05B47/11;;H05B47/19;;G08G1/0145;;Y02B20/40;;H05B45/12;;H05B45/18;;E01F9/559;;F21W2111/02;;G08G1/052;;G08G1/167;;G08G1/166;;G08G1/164;;G08G1/048;;G08G1/0116;;G08G1/095;;F21S9/037;;F21S8/032;;G06F1/26;;F21Y2115/10;;G08G1/042;;G08G1/0175;;G01W1/02;;G08G1/0133;;H05B47/19;;H05B47/11;;H05B45/12;;H05B45/18;;H05B45/10,E01F9/559;;F21S8/00;;F21S9/03;;G01W1/02;;G08G1/01;;G08G1/017;;G08G1/042;;G08G1/048;;G08G1/052;;G08G1/095;;G08G1/16;;H05B44/00;;H05B45/10;;H05B47/19,,0,0,,,,ACTIVE
209,US,A1,US 2021/0292982 A1,145-097-434-858-074,2021-09-23,2021,US 202117341026 A,2021-06-07,US 202117341026 A;;US 202016806582 A;;US 201815962802 A;;US 201762489818 P,2017-04-25,"APPARATUS, SYSTEM, AND METHOD FOR SMART ROADWAY STUD CONTROL AND SIGNALING","The subject matter described herein includes a roadway stud control system including a local stud control system positioned along a first section of a roadway, a plurality of roadway studs, each roadway stud disposed on a surface of the first section of the roadway and communicably coupled to the local stud control system, wherein the local stud control system is configured to communicate a control signal to control at least one aspect of the plurality of roadway studs.",MZC FOUND INC,LANGFORD HARRIET ANDERSON;;LANGFORD A PHILIP;;ANDERSON ALAN J;;PICARD JOHN;;BEATON ALLISON KELLY;;LE FAOU GLENN;;CHURCHER LAURA;;SALISBURY JAMES;;BUDA MARIE;;COLBY EDWARD;;MILTON ANDY,MZC FOUNDATION INC (2018-07-23),https://lens.org/145-097-434-858-074,Patent Application,yes,5,0,6,6,0,G01W1/02;;G08G1/0133;;G08G1/0175;;E01F9/559;;G08G1/052;;G08G1/167;;G08G1/164;;G08G1/0116;;G08G1/095;;G08G1/042;;H05B47/11;;H05B47/19;;G08G1/0145;;Y02B20/40;;H05B45/12;;H05B45/18;;E01F9/559;;F21W2111/02;;G08G1/052;;G08G1/167;;G08G1/166;;G08G1/164;;G08G1/048;;G08G1/0116;;G08G1/095;;F21S9/037;;F21S8/032;;G06F1/26;;F21Y2115/10;;G08G1/042;;G08G1/0175;;G01W1/02;;G08G1/0133;;H05B47/19;;H05B47/11;;H05B45/12;;H05B45/18;;H05B45/10,E01F9/559;;F21S8/00;;F21S9/03;;G01W1/02;;G08G1/01;;G08G1/017;;G08G1/042;;G08G1/048;;G08G1/052;;G08G1/095;;G08G1/16;;H05B44/00;;H05B45/10;;H05B45/12;;H05B45/18;;H05B47/19,,0,0,,,,ACTIVE
210,US,A1,US 2002/0091608 A1,041-042-509-457-525,2002-07-11,2002,US 97461301 A,2001-10-10,US 97461301 A;;US 24219100 P,2000-10-20,System and method for a financial planning competition,"
   A method for a financial planning competition having at least two phases, an embodiment of the first phase including a written competition including providing a fictitious client profile to preselected teams, allowing each team thereafter to create a written financial plan based on the client profile and awarding a score. The second phase including giving high-scoring teams a revised client profile containing a change of facts to the original client profile allowing the teams to redraft the original financial plan, receiving an oral financial planning presentation from each team based upon the revised client profile for scoring and awarding a score. Any phase of the present invention may exist in a live environment or over a network, such as the Internet. The competition may also optionally include at least a third phase which is preferably styled, in one embodiment, as a game show format based on financial planning concepts. 
",ODEGAARD LAURA J.;;KAINE ORA;;ETHERIDGE JANA L;;FORD HEATHER F.;;BOWYER RUTH;;ANDERSON TERRI L.;;CANDURA DANIEL J.,ODEGAARD LAURA J;;KAINE ORA;;ETHERIDGE JANA L;;FORD HEATHER F;;BOWYER RUTH;;ANDERSON TERRI L;;CANDURA DANIEL J,AMERIPRISE FINANCIAL INC (2005-09-20);;AMERICAN EXPRESS TRAVEL RELATED SERVICES COMPANY INC (2001-10-05),https://lens.org/041-042-509-457-525,Patent Application,yes,14,40,4,4,0,G06Q40/02;;G06Q40/04;;G06Q40/06;;G09B7/00;;G09B19/18;;G06Q40/03;;G06Q40/02;;G09B7/00;;G06Q40/04;;G06Q40/06;;G09B19/18;;G06Q40/03,G06Q40/00;;G09B7/00;;G09B19/18,705/36,0,0,,,,EXPIRED
211,US,B2,US 7440919 B2,063-736-714-133-532,2008-10-21,2008,US 97461301 A,2001-10-10,US 97461301 A;;US 24219100 P,2000-10-20,System and method for a financial planning competition,"A method for a financial planning competition having at least two phases, an embodiment of the first phase including a written competition including providing a fictitious client profile to preselected teams, allowing each team thereafter to create a written financial plan based on the client profile and awarding a score. The second phase including giving high-scoring teams a revised client profile containing a change of facts to the original client profile allowing the teams to redraft the original financial plan, receiving an oral financial planning presentation from each team based upon the revised client profile for scoring and awarding a score. Any phase of the present invention may exist in a live environment or over a network, such as the Internet. The competition may also optionally include at least a third phase which is preferably styled, in one embodiment, as a game show format based on financial planning concepts.",AMERIPRISE FINANCIAL INC,ODEGAARD LAURA J;;KAINE ORA;;ETHERIDGE JANA L;;FORD HEATHER F;;BOWYER RUTH;;ANDERSON TERRI L;;CANDURA DANIEL J,AMERIPRISE FINANCIAL INC (2005-09-20);;AMERICAN EXPRESS TRAVEL RELATED SERVICES COMPANY INC (2001-10-05),https://lens.org/063-736-714-133-532,Granted Patent,yes,14,6,4,4,0,G06Q40/02;;G06Q40/04;;G06Q40/06;;G09B7/00;;G09B19/18;;G06Q40/03;;G06Q40/02;;G09B7/00;;G06Q40/04;;G06Q40/06;;G09B19/18;;G06Q40/03,G06Q40/00;;G09B7/00;;G09B19/18,705/37;;705/38,1,0,,,"Community Trust Bankcorp, Inc, Operating Results Business Editors, Business Wire: Oct. 16, 2000. p. 1.",INACTIVE
212,WO,A1,WO 2002/035428 A1,198-260-405-062-464,2002-05-02,2002,US 0131350 W,2001-10-09,US 24219100 P,2000-10-20,SYSTEM AND METHOD FOR A FINANCIAL PLANNING COMPETITION,"A method for a financial planning competition having at least two phases (e.g., steps 100, 200), the first phase (e.g., step 100) including a written competition including providing a fictitious client profile to preselected teams (e.g., steps 101, 103), allowing each team thereafter to create a written financial plan based on the client profile and awarding a score (e.g., steps 105, 107). The second phase (e.g., 200) including giving high-scoring teams a revised client profile containing a change of facts to the original client profile allowing the teams to redraft the original financial plan (e.g., steps 201, 203), receiving an oral financial planning presentation from each based upon the revised client profile for scoring and awarding a score (e.g., steps 205, 207). The competition may also optionally include at least a third phase (e.g., step 200) which is styled, in one embodiment, as a game show format.",AMERICAN EXPRESS TRAVEL RELATE,ODEGAARD LAURA J;;KAINE ORA;;ETHERIDGE JANA L;;FORD HEATHER F;;BOWYER RUTH;;ANDERSON TERRI L;;CANDURA DANIEL J,,https://lens.org/198-260-405-062-464,Patent Application,yes,3,0,4,4,0,G06Q40/02;;G06Q40/04;;G06Q40/06;;G09B7/00;;G09B19/18;;G06Q40/03;;G06Q40/02;;G09B7/00;;G06Q40/04;;G06Q40/06;;G09B19/18;;G06Q40/03,G06Q40/00;;G09B7/00;;G09B19/18,,0,0,,,,PENDING
213,ES,T5,ES 2093146 T5,000-272-308-280-31X,2003-04-16,2003,ES 92112127 T,1992-07-16,US 73158991 A,1991-07-17,ARTICULO ABSORBENTE.,"EL ARTICULO (10) INCLUYE UN ABSORBENTE (12) QUE TIENE PRIMERA (14) Y SEGUNDA (16) SUPERFICIES OPUESTAMENTE ALINEADAS Y UN EJE CENTRAL QUE SE EXTIENDE LONGITUDINALMENTE. SE SITUA UNA CUBIERTA BICOMPONENTE (24) SOBRE LA PRIMERA SUPERFICIE DEL ABSORBENTE (12) E INCLUYE UN PRIMER (26) Y UN SEGUNDO (26) MATERIALES. EL PRIMER MATERIAL (26) TIENE ABERTURAS (28) FORMADAS EN EL MISMO Y SE ALINEA A LO LARGO DEL EJE CENTRAL DEL ABSORBENTE (12) QUE SE EXTIENDE LONGITUDINALMENTE. EL SEGUNDO MATERIAL (30) NO TIENE ABERTURAS Y ESTA SUJETO A, O SITUADO ADYACENTE A LA PERIFERIA EXTERIOR DEL PRIMER MATERIAL (26). EL PRIMERO Y EL SEGUNDO MATERIALES (26, 28) COOPERAN PARA RODEAR EL ABSORBENTE. SEPARANDO EL PRIMER MATERIAL (26) Y LA PRIMERA SUPERFICIE (14) DEL ABSORBENTE (12) EXISTE UN COMPONENTE DE CONTROL DE FLUJO (18). ESTE ""MEDIO DE SEPARACION"" DIRIGE EL LIQUIDO DESDE EL CUERPO HACIA ABAJO, EN DIRECCION Z, LEJOS DE LA CUBIERTA BICOMPONENTE Y HACIA EL EXTERIOR EN LAS DIRECCIONES X E Y PARA PROPORCIONAR UN USO MAS EFICAZ DEL MATERIAL ABSORBENTE. EL ARTICULO ABSORBENTE CONTIENE ADEMAS UNA SEPARACION IMPERMEABLE A LOS LIQUIDOS (44) QUE SE SITUA JUNTO A LA SEGUNDA SUPERFICIE (16) DEL ABSORBENTE (12).",KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD,,https://lens.org/000-272-308-280-31X,Amended Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
214,WO,A1,WO 2020/191340 A1,026-960-972-430-665,2020-09-24,2020,US 2020/0023978 W,2020-03-20,US 201962820950 P,2019-03-20,CHALCOGENIDE HYBRID ORGANIC/INORGANIC POLYMERS AND METHODS FOR PRODUCING AND USING THE SAME,"The present invention provides chalcogenide hybrid organic/inorganic polymers (""CHIPs"" or organic chalcogenide polymers) and methods for producing and using the same. In particular, the chalcogenide hybrid organic/inorganic polymers of the invention comprise a hydrocarbon cyclic ring structure and one or more chalcogenide selected from the group consisting of sulfur, selenium, cyclic selenium sulfide, and a combination thereof.",UNIV ARIZONA,PYUN DONG-CHUL;;NORWOOD ROBERT;;KLEINE TRISTAN;;GLASS RICHARD;;LICHTENBERGER DENNIS;;HAMILTON MEGHAN;;LYONS NICHOLAS;;SPIRES OLIVER;;ANDERSON LAURA,,https://lens.org/026-960-972-430-665,Patent Application,yes,3,2,2,2,0,C08G75/14;;C08L81/04;;C08G75/16;;C08G79/00;;G02B1/04,C08G75/14;;C08L81/04,,2,1,007-776-044-758-255,30733431;;10.1038/s41467-019-08430-8;;pmc6367372,"WU, X ET AL.: ""Catalytic inverse vulcanization"", NATURE COMMUNICATIONS, vol. 10, 7 February 2019 (2019-02-07), pages 1 - 9, XP002796303, DOI: 10.1038/s41467-019-08430-8;;DATABASE PUBCHEM [online] 10 February 2007 (2007-02-10), XP055741861, Database accession no. 15506619",PENDING
215,AU,A,AU 2001/096684 A,049-086-839-713-451,2002-05-06,2002,AU 2001/096684 A,2001-10-09,US 24219100 P;;US 0131350 W,2000-10-20,System and method for a financial planning competition,,AMERICAN EXPRESS TRAVEL RELATE,ODEGAARD LAURA J;;KAINE ORA;;ETHERIDGE JANA L;;FORD HEATHER F;;BOWYER RUTH;;ANDERSON TERRI L;;CANDURA DANIEL J,,https://lens.org/049-086-839-713-451,Patent Application,no,0,0,4,4,0,G06Q40/02;;G06Q40/04;;G06Q40/06;;G09B7/00;;G09B19/18;;G06Q40/03;;G06Q40/02;;G09B7/00;;G06Q40/04;;G06Q40/06;;G09B19/18;;G06Q40/03,G06Q40/00;;G09B7/00;;G09B19/18,,0,0,,,,PENDING
216,ES,T3,ES 2093146 T3,031-309-256-919-951,1996-12-16,1996,ES 92112127 T,1992-07-16,US 73158991 A,1991-07-17,ARTICULO ABSORBENTE.,"EL ARTICULO (10) INCLUYE UN ABSORBENTE (12) QUE TIENE PRIMERA (14) Y SEGUNDA (16) SUPERFICIES OPUESTAMENTE ALINEADAS Y UN EJE CENTRAL QUE SE EXTIENDE LONGITUDINALMENTE. SE SITUA UNA CUBIERTA BICOMPONENTE (24) SOBRE LA PRIMERA SUPERFICIE DEL ABSORBENTE (12) E INCLUYE UN PRIMER (26) Y UN SEGUNDO (26) MATERIALES. EL PRIMER MATERIAL (26) TIENE ABERTURAS (28) FORMADAS EN EL MISMO Y SE ALINEA A LO LARGO DEL EJE CENTRAL DEL ABSORBENTE (12) QUE SE EXTIENDE LONGITUDINALMENTE. EL SEGUNDO MATERIAL (30) NO TIENE ABERTURAS Y ESTA SUJETO A, O SITUADO ADYACENTE A LA PERIFERIA EXTERIOR DEL PRIMER MATERIAL (26). EL PRIMERO Y EL SEGUNDO MATERIALES (26, 28) COOPERAN PARA RODEAR EL ABSORBENTE. SEPARANDO EL PRIMER MATERIAL (26) Y LA PRIMERA SUPERFICIE (14) DEL ABSORBENTE (12) EXISTE UN COMPONENTE DE CONTROL DE FLUJO (18). ESTE ""MEDIO DE SEPARACION"" DIRIGE EL LIQUIDO DESDE EL CUERPO HACIA ABAJO, EN DIRECCION Z, LEJOS DE LA CUBIERTA BICOMPONENTE Y HACIA EL EXTERIOR EN LAS DIRECCIONES X E Y PARA PROPORCIONAR UN USO MAS EFICAZ DEL MATERIAL ABSORBENTE. EL ARTICULO ABSORBENTE CONTIENE ADEMAS UNA SEPARACION IMPERMEABLE A LOS LIQUIDOS (44) QUE SE SITUA JUNTO A LA SEGUNDA SUPERFICIE (16) DEL ABSORBENTE (12).",KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD,,https://lens.org/031-309-256-919-951,Granted Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
217,EP,A2,EP 3995561 A2,097-138-144-641-642,2022-05-11,2022,EP 21198678 A,2021-09-23,US 202017072398 A,2020-10-16,TRANSMISSION FLUID COMPOSITIONS FOR HYBRID AND ELECTRIC VEHICLE APPLICATIONS,"A transmission fluid composition contains a major amount of a lubricating oil basestock, and a minor amount of an additive package comprising: (i) a mixture comprising two or more phosphites and/or phosphates; (ii) one or more thioester compounds; (iii) a detergent comprising calcium salicylate; and (iv) a poly(alkylene amine)-based ashless dispersant endcapped with metallocene-catalyzed PAO arms. Such a transmission fluid may be used for controlling/reducing wear in at least partially electrically-powered transmissions and/or for cooling/insulating electrical/electronic components of at least partially electrically-powered drivetrains.",INFINEUM INT LTD,NOLES JOE JNR;;GORDA KEITH RAYMOND;;KIM HAHNSOO;;WATTS RAYMOND;;KAHSAR LAURA ANDERSON;;CUNNINGHAM MATTHEW;;CHIAPPELLI MARIA;;COGEN KERRY LYNN,,https://lens.org/097-138-144-641-642,Patent Application,yes,21,0,8,8,0,C10M169/04;;C10M2223/04;;C10M2223/02;;C10M2219/022;;C10M2207/144;;C10M2215/086;;C10M2203/1006;;C10N2040/04;;C10N2030/04;;C10N2030/06;;C10N2030/10;;C10N2030/12;;C10N2030/40;;C10N2030/42;;C10N2030/44;;C10M163/00;;C10M141/10;;C10M2201/085;;C10M2223/04;;C10M2223/047;;C10M2207/262;;C10N2010/04;;C10M2215/28;;C10M2219/082;;C10N2040/04;;C10N2030/06;;C10N2030/54;;C10N2040/16;;C10N2020/02;;C10N2030/02;;C10M2219/106;;C10M2215/06;;C10M2207/026;;C10M137/04;;C10M135/24;;C10M149/22;;C10M159/18;;C10M125/26;;C10M169/04;;C10N2030/10;;C10N2030/12;;C10N2030/04;;C10N2040/04;;C10N2040/042;;C10N2030/45;;C10M129/72;;C10M133/44;;C10M135/24;;C10M137/04;;C10M169/04;;C10N2010/04;;C10N2020/02;;C10N2030/04;;C10N2030/06,C10M141/10;;C10M163/00;;C10N10/04;;C10N20/02;;C10N30/00;;C10N30/02;;C10N30/06;;C10N40/04;;C10N40/16,,2,0,,,"""Engine Oil Licensing and Certification System"", December 1996, INDUSTRY SERVICES DEPARTMENT;;C.V. SMALLHEERR. KENNEDY SMITH, LUBRICANT ADDITIVES, 1967, pages 1 - 11",PENDING
218,EP,A3,EP 3995561 A3,023-879-764-249-362,2022-08-03,2022,EP 21198678 A,2021-09-23,US 202017072398 A,2020-10-16,TRANSMISSION FLUID COMPOSITIONS FOR HYBRID AND ELECTRIC VEHICLE APPLICATIONS,"A transmission fluid composition contains a major amount of a lubricating oil basestock, and a minor amount of an additive package comprising: (i) a mixture comprising two or more phosphites and/or phosphates; (ii) one or more thioester compounds; (iii) a detergent comprising calcium salicylate; and (iv) a poly(alkylene amine)-based ashless dispersant endcapped with metallocene-catalyzed PAO arms. Such a transmission fluid may be used for controlling/reducing wear in at least partially electrically-powered transmissions and/or for cooling/insulating electrical/electronic components of at least partially electrically-powered drivetrains.",INFINEUM INT LTD,NOLES JOE JNR;;GORDA KEITH RAYMOND;;KIM HAHNSOO;;WATTS RAYMOND;;KAHSAR LAURA ANDERSON;;CUNNINGHAM MATTHEW;;CHIAPPELLI MARIA;;COGEN KERRY LYNN,,https://lens.org/023-879-764-249-362,Search Report,yes,6,0,8,8,0,C10M169/04;;C10M2223/04;;C10M2223/02;;C10M2219/022;;C10M2207/144;;C10M2215/086;;C10M2203/1006;;C10N2040/04;;C10N2030/04;;C10N2030/06;;C10N2030/10;;C10N2030/12;;C10N2030/40;;C10N2030/42;;C10N2030/44;;C10M163/00;;C10M141/10;;C10M2201/085;;C10M2223/04;;C10M2223/047;;C10M2207/262;;C10N2010/04;;C10M2215/28;;C10M2219/082;;C10N2040/04;;C10N2030/06;;C10N2030/54;;C10N2040/16;;C10N2020/02;;C10N2030/02;;C10M2219/106;;C10M2215/06;;C10M2207/026;;C10M137/04;;C10M135/24;;C10M149/22;;C10M159/18;;C10M125/26;;C10M169/04;;C10N2030/10;;C10N2030/12;;C10N2030/04;;C10N2040/04;;C10N2040/042;;C10N2030/45;;C10M129/72;;C10M133/44;;C10M135/24;;C10M137/04;;C10M169/04;;C10N2010/04;;C10N2020/02;;C10N2030/04;;C10N2030/06,C10M141/10;;C10M163/00;;C10N10/04;;C10N20/02;;C10N30/00;;C10N30/02;;C10N30/06;;C10N40/04;;C10N40/16,,0,0,,,,PENDING
219,CN,A,CN 115516497 A,001-517-278-932-223,2022-12-23,2022,CN 202180033227 A,2021-04-21,US 202016867323 A;;US 2021/0028274 W,2020-05-05,Background correction for birefringence measurements,"One example provides a computer-implemented method for reading data stored as birefringence values in a storage medium. The method includes acquiring an image of voxels of a storage medium, applying a first low-pass filter having a first cutoff frequency to the image of the voxels to obtain a first background image, applying a second low-pass filter having a second cutoff frequency to the image of the voxels to obtain a second background image, the second cutoff frequency being different from the first cutoff frequency, an enhanced background image is determined from the first background image and the second background image, a birefringence value for the enhanced background image is determined, a birefringence value for the image of the voxel is determined, and the birefringence value for the image of the voxel is corrected based on the birefringence value for the enhanced background image.",MICROSOFT TECHNOLOGY LICENSING LLC,GOMEZ DIAZ ADRIAN;;SAUCEDO D LAURA;;SCHOLZ PATRICK G;;ANDERSON PAUL N;;DREVENSKAS ROGER;;BLACK RICHARD JOHN;;CLEGG JEFFREY H,,https://lens.org/001-517-278-932-223,Patent Application,no,0,0,7,7,0,G06T5/20;;G02B27/286;;G11B7/005;;G11B7/1395;;G11B7/1275;;G11B2007/0009;;G06T5/70;;G06T5/20;;G06T2200/04;;G06T2207/20212;;G06T5/94,G06T5/00;;G02B27/00;;G06T5/20;;G11B7/00,,0,0,,,,PENDING
220,CN,A,CN 117222743 A,019-262-885-132-035,2023-12-12,2023,CN 202280019316 A,2022-01-05,US 202163133942 P;;US 2022/0011289 W,2021-01-05,GUIDE RNA DESIGN AND COMPLEXES FOR TRACAR-FREE V-TYPE Cas SYSTEMS,The invention provides a novel gRNA (guide ribonucleic acid)-ligand binding complex. The compound can be used for bringing a V-type Cas protein and an additional effector into DNA (Deoxyribonucleic Acid) for base editing. The system design allows the production of efficient module components that provide flexibility in editing DNA.,HORIZON DISCOVERY INC,MARSHALL KEVIN DAVID;;MACHADO HANY B;;ANDERSON ETHAN;;HALE ANDREW;;SMITH ANDREW;;HEMPHILL KEVIN;;A KAUFMAN;;NANTY LAURA;;RUSHTON MARK DAVID,,https://lens.org/019-262-885-132-035,Patent Application,no,0,0,6,19,0,C12N15/11;;C12N15/90;;C12N9/22;;C12N2310/20;;C12N2310/3519;;C12N2310/16;;C12N2310/315;;C12N2310/344;;C12N15/85,C12N15/90,,0,0,,,,PENDING
221,US,B2,US 10669952 B2,068-832-997-426-686,2020-06-02,2020,US 201816014706 A,2018-06-21,US 201816014706 A,2018-06-21,Diesel engine cylinder cutout control system for reduction of white smoke production,"A cylinder cutout system for an internal combustion engine is provided. The system may include a plurality of cylinders having a first pattern of cylinders and a second pattern of cylinders. Additionally, a fuel governor operatively coupled to a plurality of fuel injectors may regulate an amount of fuel received by the plurality of cylinders. The system may further include a plurality of sensors configured to collect a set of engine data and a controller communicably coupled with the plurality of fuel injectors, the fuel governor and the plurality of sensors. The controller may be programmed to detect a start-up condition of the engine and to execute a cylinder test cycle on at least a portion of the plurality of cylinders based on a positive detection of the start-up condition. The controller may activate one of the first or second patterns of cylinders based on the cylinder test cycle results.",CATERPILLAR INC,ULSTAD JAMES;;HUHN LAURA;;SMITH BLAKE LANDON;;WERE SAMUEL;;KRISHNAMURTHYGOPALAN ANAND;;SOLLARS AARON D;;ANDERSON ANDREW;;REYHART DELON R;;HART BROOKE A,CATERPILLAR INC (2018-06-12),https://lens.org/068-832-997-426-686,Granted Patent,yes,18,0,2,2,0,F02D17/02;;F02D41/0087;;F02D17/02;;F02D29/06;;F02D41/062;;F02D41/22;;F02D41/26;;F02D41/3076;;F02D41/38;;F02D2041/389;;F02D2200/021;;F02D2200/0414;;F02D2200/0414;;F02D2200/0611;;F02D2200/101;;F02D2200/1012,F02D17/02;;F02D41/26;;F02D41/30;;F02D41/38,,0,0,,,,ACTIVE
222,US,A1,US 2019/0390610 A1,118-942-012-463-984,2019-12-26,2019,US 201816014706 A,2018-06-21,US 201816014706 A,2018-06-21,Diesel Engine Cylinder Cutout Control System For Reduction Of White Smoke Production,"A cylinder cutout system for an internal combustion engine is provided. The system may include a plurality of cylinders having a first pattern of cylinders and a second pattern of cylinders. Additionally, a fuel governor operatively coupled to a plurality of fuel injectors may regulate an amount of fuel received by the plurality of cylinders. The system may further include a plurality of sensors configured to collect a set of engine data and a controller communicably coupled with the plurality of fuel injectors, the fuel governor and the plurality of sensors. The controller may be programmed to detect a start-up condition of the engine and to execute a cylinder test cycle on at least a portion of the plurality of cylinders based on a positive detection of the start-up condition. The controller may activate one of the first or second patterns of cylinders based on the cylinder test cycle results.",CATERPILLAR INC,ULSTAD JAMES;;HUHN LAURA;;SMITH BLAKE LANDON;;WERE SAMUEL;;KRISHNAMURTHYGOPALAN ANAND;;SOLLARS AARON D;;ANDERSON ANDREW;;REYHART DELON R;;HART BROOKE A,CATERPILLAR INC (2018-06-12),https://lens.org/118-942-012-463-984,Patent Application,yes,7,10,2,2,0,F02D17/02;;F02D41/0087;;F02D17/02;;F02D29/06;;F02D41/062;;F02D41/22;;F02D41/26;;F02D41/3076;;F02D41/38;;F02D2041/389;;F02D2200/021;;F02D2200/0414;;F02D2200/0414;;F02D2200/0611;;F02D2200/101;;F02D2200/1012,F02D17/02;;F02D41/26;;F02D41/30;;F02D41/38,,0,0,,,,ACTIVE
223,EP,A1,EP 1583533 A1,124-345-164-118-68X,2005-10-12,2005,EP 03751145 A,2003-10-20,IB 0304612 W;;US 42259002 P,2002-10-30,USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS,,PFIZER PROD INC,BLUMBERG LAURA COOK;;BROWN MATTHEW FRANK;;GAWECO ANDERSON SEE;;GLADUE RONALD PAUL;;HAYWARD MATTHEW MERRILL;;LUNDQUIST GREGORY DEAN;;POSS CHRISTOPHER STANLEY;;SHAVNYA ANDRE,,https://lens.org/124-345-164-118-68X,Patent Application,yes,0,1,8,8,0,A61K31/495;;A61K31/495;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P15/00;;A61P17/00;;A61P19/02;;A61P19/08;;A61P25/28;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P35/04;;A61P37/02;;Y02A50/30;;Y02A50/30,A61K31/495;;A61P37/02,,1,0,,,See references of WO 2004039376A1,DISCONTINUED
224,MX,A,MX 2008001051 A,000-516-020-953-608,2008-03-19,2008,MX 2008001051 A,2006-06-29,US 19059705 A;;US 2006/0025451 W,2005-07-26,APPLIANCE FOR DELIVERING A COMPOSITION.,"Disclosed is an appliance for treating skin or tissue, the appliance comprising a three-layer substrate having a cloth-like appearance and feel. The substrate includes a water-impermeable layer, such as a film, sandwiched between, and attached to, two fibrous layers. The fibrous layer that is adapted to contact skin includes a formulation or composition adapted to be transferred to skin or tissue of the user. Furthermore, the fibrous layer that is adapted to contact skin includes undulations that inhibit leakage of the formulation or composition.",KIMBERLY CLARK CO,HALL GREGORY K;;LEE MEEWHA;;CLOSE KENNETH B;;ANDERSON GARY V;;ARENDT JONATHAN K;;JOSEPH WAEL R;;JOHNSON KROY D;;KECK LAURA E,,https://lens.org/000-516-020-953-608,Patent Application,no,0,0,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B5/22;;B32B7/02;;B32B27/12;;C11D17/04,,0,0,,,,ACTIVE
225,US,A1,US 2023/0310055 A1,048-768-977-408-422,2023-10-05,2023,US 202318322456 A,2023-05-23,US 202318322456 A;;US 202217697739 A;;US 202163163728 P;;US 202163255385 P;;US 202163270547 P,2021-03-19,VASCULAR ABLATION,"The disclosure includes a vein ablation system, comprising a catheter having an elongated body. In some embodiments, the vein ablation system comprises an ablation device at a distal portion of the elongated body. According to some embodiments, the vein ablation system comprises a control device at a proximal portion of the elongated body. The control device may comprise an input mechanism configured to simultaneously control at least two of a longitudinal translation of the ablation device through a target vessel, a rotation of the ablation device about a central longitudinal axis, and an infusion of a chemical agent into the target vessel.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG;;HATCHER BRADY,CROSSFIRE MEDICAL INC (2022-03-18),https://lens.org/048-768-977-408-422,Patent Application,yes,6,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B18/06;;A61M5/142,,0,0,,,,PENDING
226,AU,B2,AU 770161 B2,031-787-312-762-933,2004-02-12,2004,AU 2001/068793 A,2001-09-07,US 66309500 A,2000-09-15,Gaming machine with interlinked arrangements of puzzle elements,,WMS GAMING INC,ANDERSON PETER;;BELL TARON A;;CASEY MICHAEL P;;JAFFE JOEL R;;LEDESMA LAURA R;;MASTROPIETRO MICHAEL W;;PRYZBY ERIC MICHAEL;;SMITH SHAWN A,,https://lens.org/031-787-312-762-933,Granted Patent,no,3,0,3,3,0,G07F17/32;;G07F17/3267;;G07F17/3267;;G07F17/32,G07F17/32,,0,0,,,,EXPIRED
227,US,A1,US 2004/0092529 A1,073-283-926-247-295,2004-05-13,2004,US 68699303 A,2003-10-16,US 68699303 A;;US 42259002 P,2002-10-30,Methods of using piperazine derivatives,"
    The present invention relates to compounds of the formula I 

    and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R ¹ , R ² , R ³ , R ⁴ and R ⁵ are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal. 
",PFIZER,BLUMBERG LAURA C;;BROWN MATTHEW F;;GAWECO ANDERSON S;;GLADUE RONALD P;;HAYWARD MATTHEW M;;LUNDQUIST GREGORY D;;POSS CHRISTOPHER S;;SHAVNYA ANDREI,,https://lens.org/073-283-926-247-295,Patent Application,yes,1,13,8,8,0,A61K31/495;;A61K31/495;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P15/00;;A61P17/00;;A61P19/02;;A61P19/08;;A61P25/28;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P35/04;;A61P37/02;;Y02A50/30;;Y02A50/30,A61K31/495;;A61P37/02,514/255.01,0,0,,,,DISCONTINUED
228,US,B2,US 11696793 B2,059-416-464-868-407,2023-07-11,2023,US 202217697739 A,2022-03-17,US 202217697739 A;;US 202163163728 P;;US 202163255385 P;;US 202163270547 P,2021-03-19,Vascular ablation,"The disclosure includes a vein ablation system, comprising a catheter having an elongated body. In some embodiments, the vein ablation system comprises an ablation device at a distal portion of the elongated body. According to some embodiments, the vein ablation system comprises a control device at a proximal portion of the elongated body. The control device may comprise an input mechanism configured to simultaneously control at least two of a longitudinal translation of the ablation device through a target vessel, a rotation of the ablation device about a central longitudinal axis, and an infusion of a chemical agent into the target vessel.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG;;HATCHER BRADY,CROSSFIRE MEDICAL INC (2022-03-18),https://lens.org/059-416-464-868-407,Granted Patent,yes,155,2,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61M5/142;;A61B1/06;;A61B17/00;;A61B18/00;;A61B18/06;;A61M25/10,,14,3,009-935-683-262-801;;088-322-611-635-326;;061-887-872-238-060,10.1097/01.bmsas.0000540037.59386.b0;;6497633;;10.1001/archsurg.1984.01390230053012;;1690370;;10.1016/0168-0102(90)90009-4,"Attaran, Rob—“ClariVein Animation Sequence”—youtube.com [online]—Video by user Rob Attaran—Published Feb. 13, 2018—Available from Internet <URL: https://www.youtube.com/watch?v=0R2khsxBYuk>.;;CV Technologies—“FLEBOGRIF”—cvtechnologies.in [online] - Site visited Septmber 23, 2021—Available from Internet <URL: http://cvtechnologies.in/flebogrif/>.;;Vascular Insights, LLC—“Clarivein® IC, Infusion Catheter”—clarivein.com [online]—Available at least as of 2016—Site visited Sep. 23, 2021—Available from Internet <URL: https://clarivein.com/wp-content/uploads/2015/07/IFU-001-Instruction-for-Use-IC-REV-B.pdf>.;;Balton Sp. Z O. O.—“Flebogrif Set for Varicose Veins Treatment”—youtube.com [online]—Video by user Balton Sp. z o. o.—Published Apr. 8, 2019—Available from Internet <URL: https://www.youtube.com/watch?v=d49LpQb-SQo&t=6s>.;;Venturemed Group—“FLEX Vessel Prep System”—youtube.com [online]—Video by user VentureMed Group—Published Oct. 17, 2019—Available from Internet <URL: https://www.youtube.com/watch?v=r1RwTRFbgK4>.;;Teleflex—“Arrow-Trerotola™ PTD®”—Available at least as of 2012—Retrieved Sep. 23, 2021—Available from Internet <URL: https://studylib.net/doc/8350860/arrow-trerotola%E2%84%A2-ptd%C2%AE-p>.;;La Jolla Vein and Vascular—“Watch a ClariVein Procedure”—youtube.com [online]—Video by user La Jolla Vein and Vascular—Published Aug. 17, 2017—Available from Internet <URL: https://www.youtube.com/watch?v=q2f2vThzN4o>.;;DAIC—“Trellis-8 Infusion Catheter Busts DVT Clots”—Diagnostic and Interventional Cardiology [magazine]—dicardiology.com [online]—Mar. 17, 2008—Available from Internet <URL: https://www.dicardiology.com/product/trellis-8-infusion-catheter-busts-dvt-clots>.;;NYC Surgical Associates—“Deep Vein Thrombosis Treatment With Trellis Procedure—NYC Surgical Associates”—youtube.com [online]—Video by user NYC Surgical Associates—Published Apr. 12, 2014—Available from Internet <URL: https://www.youtube.com/watch?v=50LzxuleYUc>.;;Cook Medical—“Coda® Balloon Catheter”—cookmedical.com [online]—Site visited Sep. 23, 2021—Available from Internet <URL: https://www.cookmedical.com/products/829e48bc-8fa0-43e5-9530-11ded12b6a42/>.;;Medtronic—“VenaSeal™ closure system for superficial vein therapies”—Site visited Sep. 23, 2021—Available from Internet <URL: https://www.medtronic.com/us-en/healthcare-professionals/products/cardiovascular/superficial-vein/venaseal-closure-system.html>.;;Medtronic—“VenaSeal™ Closure System VS-402”—manuals.medtronic.com [online]—Website publication date: Apr. 6, 2018—Available from Internet <URL: https://www.medtronic.com/us-en/healthcare-professionals/products/cardiovascular/superficial-vein/venaseal-closure-system.html>.;;Williams R. A., Wilson S. E.—“Sclerosant Treatment of Varicose Veins and Deep Vein Thrombosis”—Arch Surg—Nov. 1984—vol. 119, No. 11, p. 1283-1285—JAMA Surgery—<doi: 10.1001/archsurg.1984.01390230053012>.;;Rose D., Larnicol N., Duron B.—“The cat cervical dorsal root ganglia: general cell-size characteristics and comparative study of neck muscle, neck cutaneous and phrenic afferents”—Neuroscience Research—Feb. 1990—vol. 7, No. 4, p. 341-357—Elsevier Scientific Publishers Ireland Ltd.—<doi: 10.1016/0168-0102(90)90009-4>.",ACTIVE
229,AU,A,AU 2001/068793 A,155-899-801-380-47X,2002-03-21,2002,AU 2001/068793 A,2001-09-07,US 66309500 A,2000-09-15,Gaming machine with interlinked arrangements of puzzle elements,,WMS GAMING INC,ANDERSON PETER;;SMITH SHAWN A;;PRYZBY ERIC MICHAEL;;MASTROPIETRO MICHAEL W;;LEDESMA LAURA R;;JAFFE JOEL R;;CASEY MICHAEL P;;BELL TARON A,,https://lens.org/155-899-801-380-47X,Patent Application,no,0,0,3,3,0,G07F17/32;;G07F17/3267;;G07F17/3267;;G07F17/32,G07F17/32,,0,0,,,,EXPIRED
230,AU,A1,AU 2006/276792 A1,181-951-860-666-345,2007-02-15,2007,AU 2006/276792 A,2006-06-29,US 19059705 A;;US 2006/0025451 W,2005-07-26,Appliance for delivering a composition,,KIMBERLY CLARK CO,JOSEPH WAEL R;;HALL GREGORY K;;LEE MEEWHA;;ANDERSON GARY V;;JOHNSON KROY D;;KECK LAURA E;;ARENDT JONATHAN K;;CLOSE KENNETH B,,https://lens.org/181-951-860-666-345,Patent Application,no,0,0,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B5/22;;B32B7/02;;B32B27/12;;C11D17/04,,0,0,,,,INACTIVE
231,US,A1,US 2022/0296291 A1,189-365-826-307-946,2022-09-22,2022,US 202217697739 A,2022-03-17,US 202217697739 A;;US 202163163728 P;;US 202163255385 P;;US 202163270547 P,2021-03-19,VASCULAR ABLATION,"The disclosure includes a vein ablation system, comprising a catheter having an elongated body. In some embodiments, the vein ablation system comprises an ablation device at a distal portion of the elongated body. According to some embodiments, the vein ablation system comprises a control device at a proximal portion of the elongated body. The control device may comprise an input mechanism configured to simultaneously control at least two of a longitudinal translation of the ablation device through a target vessel, a rotation of the ablation device about a central longitudinal axis, and an infusion of a chemical agent into the target vessel.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG;;HATCHER BRADY,CROSSFIRE MEDICAL INC (2022-03-18),https://lens.org/189-365-826-307-946,Patent Application,yes,7,2,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B18/06,,0,0,,,,ACTIVE
232,BR,A,BR 0315777 A,022-415-326-351-584,2005-09-13,2005,BR 0315777 A,2003-10-20,US 42259002 P;;IB 0304612 W,2002-10-30,Uso de derivados de piperazina como antagonistas ccr1,"""USO DE DERIVADOS DE PIPERAZINA COMO ANTAGONISTAS CCR1"". A presente invenção refere-se com, o composto de fórmula I"" e as suas formas farmaceuticamente aceitáveis; em que X, Y, a, b, c, d, R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬ e R¬ 5¬ são como aqui definidos. Além disso, a presente invenção é também dirigida a formulações farmacêuticas compreendendo um composto de fórmula 1 e um veículo farmaceuticamente aceitável. Adicionalmente, a presente invenção é dirigida a métodos de utilização dos compostos e formulações aqui descritos para o tratamento ou prevenção de uma doença ou patologia que possa ser tratada ou prevenida por antagonização de receptores CCR1 em um mamífero.",PFIZER PROD INC,BLUMBERG LAURA COOK;;BROWN MATTHEW FRANK;;GAWECO ANDERSON SEE;;GLADUE RONALD PAUL;;HAYWARD MATTHEW MERRILL;;LUNDQUIST GREG DEAN;;POSS CHRISTOPHER STANLEY;;SHAVNYA ANDRE,,https://lens.org/022-415-326-351-584,Patent Application,no,0,0,8,8,0,A61K31/495;;A61K31/495;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P15/00;;A61P17/00;;A61P19/02;;A61P19/08;;A61P25/28;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P35/04;;A61P37/02;;Y02A50/30;;Y02A50/30,A61K31/495;;A61P37/02,,0,0,,,,DISCONTINUED
233,US,B1,US 6428412 B1,013-382-517-853-46X,2002-08-06,2002,US 66309500 A,2000-09-15,US 66309500 A,2000-09-15,Gaming machine with interlinked arrangements of puzzle elements,"
    A gaming machine is controlled by a processor in response to a wager and comprises a puzzle feature optionally triggered by a start-feature outcome of a basic game. The puzzle feature includes a plurality of arrangements of randomly-selected puzzle elements for generating respective payouts. At least one of the puzzle elements of each arrangement being shared by another one of the arrangements and contributing to the payouts generated by the respective arrangements that share the one of the puzzle elements. The puzzle elements may, for example, be letters, symbols, pictures, shaped puzzle pieces, or playing cards. 
",WMS GAMING INC,ANDERSON PETER;;BELL TARON A;;CASEY MICHAEL P;;JAFFE JOEL R;;LEDESMA LAURA R;;MASTROPIETRO MICHAEL W;;PRYZBY ERIC MICHAEL;;SMITH SHAWN A,SG GAMING INC (2015-06-29);;WMS GAMING INC (2000-09-14),https://lens.org/013-382-517-853-46X,Granted Patent,yes,10,300,3,3,0,G07F17/32;;G07F17/3267;;G07F17/3267;;G07F17/32,G07F17/32,463/9;;463/16;;463/20,0,0,,,,EXPIRED
234,EP,A1,EP 1915079 A1,154-200-682-140-132,2008-04-30,2008,EP 06774302 A,2006-06-29,US 2006/0025451 W;;US 19059705 A,2005-07-26,APPLIANCE FOR DELIVERING A COMPOSITION,,KIMBERLY CLARK CO,CLOSE KENNETH B;;JOSEPH WAEL R;;ANDERSON GARY V;;ARENDT JONATHAN K;;HALL GREGORY K;;JOHNSON KROY D;;KECK LAURA E;;LEE MEEWHA,,https://lens.org/154-200-682-140-132,Patent Application,yes,0,0,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B5/22;;B32B7/02;;B32B27/12;;C11D17/04,,0,0,,,,DISCONTINUED
235,KR,A,KR 20230158546 A,129-895-630-579-052,2023-11-20,2023,KR 20237035149 A,2022-03-18,US 202163163728 P;;US 202163255385 P;;US 202163270547 P;;US 202217697739 A;;US 2022/0020935 W,2021-03-19,혈관 절제술,"본 개시 내용은 세장형 바디를 갖는 카테터를 포함하는 혈관 절제 시스템을 포함한다. 일부 실시예에서, 혈관 절제 시스템은 세장형 바디의 원위부에 있는 절제 장치를 포함한다. 일부 실시예에 따르면, 혈관 절제 시스템은 세장형 바디의 근위부에 있는 제어 장치를 포함한다. 제어 장치는 표적 혈관을 통한 절제 장치의 종방향 병진, 중심 종축에 대한 절제 장치의 회전, 및 표적 혈관으로의 화학 작용제 주입 중 적어도 2가지를 동시에 제어하도록 구성된 입력 메커니즘을 포함할 수 있다.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE SUK;;DEAN DANNAH;;KRONE DOUG,,https://lens.org/129-895-630-579-052,Patent Application,no,0,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B17/32;;A61B17/00;;A61B17/12;;A61B17/3207;;A61B18/00;;A61B18/06;;A61B18/14;;A61M25/00;;A61M25/10,,0,0,,,,PENDING
236,DE,T8,DE 112022000007 T8,187-481-821-237-710,2023-04-06,2023,DE 112022000007 T,2022-03-18,US 202163163728 P;;US 202163255385 P;;US 202163270547 P;;US 202217697739 A;;US 2022/0020935 W,2021-03-19,GEFÄSSABLATION,,CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG;;HATCHER BRADY,"CROSSFIRE MEDICAL INC, DOVER, US (2022-11-02)",https://lens.org/187-481-821-237-710,Amended Patent,no,0,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61M25/08;;A61B17/00;;A61B18/02;;A61M5/00,,0,0,,,,PENDING
237,US,A1,US 2007/0026028 A1,199-244-986-526-699,2007-02-01,2007,US 19059705 A,2005-07-26,US 19059705 A,2005-07-26,Appliance for delivering a composition,"Disclosed is an appliance for treating skin or tissue, the appliance comprising a three-layer substrate having a cloth-like appearance and feel. The substrate includes a water-impermeable layer, such as a film, sandwiched between, and attached to, two fibrous layers. The fibrous layer that is adapted to contact skin includes a formulation or composition adapted to be transferred to skin or tissue of the user. Furthermore, the fibrous layer that is adapted to contact skin includes undulations that inhibit leakage of the formulation or composition.",CLOSE KENNETH B;;JOSEPH WAEL R;;ANDERSON GARY V;;ARENDT JONATHAN K;;HALL GREGORY K;;JOHNSON KROY D;;KECK LAURA E;;LEE MEEWHA,CLOSE KENNETH B;;JOSEPH WAEL R;;ANDERSON GARY V;;ARENDT JONATHAN K;;HALL GREGORY K;;JOHNSON KROY D;;KECK LAURA E;;LEE MEEWHA,KIMBERLY-CLARK WORLDWIDE INC (2005-09-28),https://lens.org/199-244-986-526-699,Patent Application,yes,99,32,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A01N25/34;;A41D19/00;;A61K6/00;;A61K8/02;;A61Q90/00;;B32B5/02;;B32B5/26;;B32B27/04;;B32B27/12;;B32B27/32,424/402;;442/123;;442/382;;442/394;;442/398;;424/401;;2/167,0,0,,,,DISCONTINUED
238,CA,A1,CA 2498261 A1,132-628-209-391-39X,2004-05-13,2004,CA 2498261 A,2003-10-20,IB 0304612 W;;US 42259002 P,2002-10-30,USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS,"The present invention relates to compounds of the formula (I) and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula (I) and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.",PFIZER PROD INC,BROWN MATTHEW FRANK;;LUNDQUIST GREGORY DEAN;;HAYWARD MATTHEW MERRILL;;BLUMBERG LAURA COOK;;POSS CHRISTOPHER STANLEY;;SHAVNYA ANDRE;;GLADUE RONALD PAUL;;GAWECO ANDERSON SEE,,https://lens.org/132-628-209-391-39X,Patent Application,no,0,0,8,8,0,A61K31/495;;A61K31/495;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P15/00;;A61P17/00;;A61P19/02;;A61P19/08;;A61P25/28;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P35/04;;A61P37/02;;Y02A50/30;;Y02A50/30,A61K31/495;;A61P37/02,,0,0,,,,DISCONTINUED
239,TW,A,TW 202300107 A,151-653-419-581-531,2023-01-01,2023,TW 111110191 A,2022-03-18,US 202163163728 P;;US 202163255385 P;;US 202163270547 P;;US 202217697739 A,2021-03-19,Vascular ablation,"The disclosure includes a vein ablation system, comprising a catheter having an elongated body. In some embodiments, the vein ablation system comprises an ablation device at a distal portion of the elongated body. According to some embodiments, the vein ablation system comprises a control device at a proximal portion of the elongated body. The control device may comprise an input mechanism configured to simultaneously control at least two of a longitudinal translation of the ablation device through a target vessel, a rotation of the ablation device about a central longitudinal axis, and an infusion of a chemical agent into the target vessel.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG;;HATCHER BRADY,,https://lens.org/151-653-419-581-531,Patent of Addition,no,0,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B17/12;;A61B18/00;;A61B18/02;;A61M5/14,,0,0,,,,ACTIVE
240,TW,B,TW I820640 B,097-461-107-879-432,2023-11-01,2023,TW 111110191 A,2022-03-18,US 202163163728 P;;US 202163255385 P;;US 202163270547 P;;US 202217697739 A,2021-03-19,Vascular ablation systems,,CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG;;HATCHER BRADY,,https://lens.org/097-461-107-879-432,Granted Patent,no,2,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,,,0,0,,,,ACTIVE
241,BR,A2,BR PI0613932 A2,027-902-433-361-841,2011-02-22,2011,BR PI0613932 A,2006-06-29,US 19059705 A;;US 2006/0025451 W,2005-07-26,utensìlios para aplicar uma composição,"UTENSìLIOS PARA APLICAR UMA COMPOSIçAO Um utensílio é descrito para tratar pele ou tecido, este utensílio compreende um substrato de três camadas com uma aparência e sensação tipo roupa. O substrato inclui uma camada impermeável à água, tal como um filme, colocado entre, e conectado a duas camadas fibrosas. A camada fibrosa que é adaptada para entrar em contato com a pele inclui uma fórmula ou composição adaptada para ser transferida à pele ou tecido do usuário. Além disso, a camada fibrosa que é adaptada para entrar em contato com a pele inclui ondulações que inibem vazamento da fórmula ou composição.",KIMBERLY CLARK CO,CLOSE KENNETH B;;JOSEPH WAEL R;;ARENDT JONATHAN K;;JOHNSON KROY D;;KECK LAURA E;;LEE MEEWHA;;ANDERSON GARY V;;HALL GREGORY K,,https://lens.org/027-902-433-361-841,Patent Application,no,0,0,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B5/22;;B32B7/02;;B32B27/12;;C11D17/04,,0,0,,,,DISCONTINUED
242,DE,T5,DE 112022000007 T5,046-411-593-314-430,2022-11-24,2022,DE 112022000007 T,2022-03-18,US 202163163728 P;;US 202163255385 P;;US 202163270547 P;;US 202217697739 A;;US 2022/0020935 W,2021-03-19,GEFÄSSABLATION,"Die Offenbarung umfasst ein Venenablationssystem, das einen Katheter mit einem länglichen Körper umfasst. In einigen Ausführungsformen umfasst das Venenablationssystem eine Ablationsvorrichtung an einem distalen Abschnitt des länglichen Körpers. Gemäß einigen Ausführungsformen umfasst das Venenablationssystem eine Steuervorrichtung an einem proximalen Abschnitt des länglichen Körpers. Die Steuervorrichtung kann einen Eingabevorrichtung umfassen, die so konfiguriert ist, dass sie gleichzeitig mindestens zwei der folgenden Vorgänge steuert: eine Längsverschiebung der Ablationsvorrichtung durch ein Zielgefäß, eine Drehung der Ablationsvorrichtung um eine zentrale Längsachse und eine Zuführung eines cung eines chemischen Mittels in das Zielgefäß.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG;;HATCHER BRADY,"CROSSFIRE MEDICAL INC, DOVER, US (2022-11-02)",https://lens.org/046-411-593-314-430,Patent Application,no,0,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61M25/08;;A61B17/00;;A61B18/02;;A61M5/00,,0,0,,,,PENDING
243,WO,A1,WO 2022/198039 A1,087-063-060-992-908,2022-09-22,2022,US 2022/0020935 W,2022-03-18,US 202163270547 P;;US 202217697739 A;;US 202163255385 P;;US 202163163728 P,2021-03-19,VASCULAR ABLATION,"The disclosure includes a vein ablation system, comprising a catheter having an elongated body. In some embodiments, the vein ablation system comprises an ablation device at a distal portion of the elongated body. According to some embodiments, the vein ablation system comprises a control device at a proximal portion of the elongated body. The control device may comprise an input mechanism configured to simultaneously control at least two of a longitudinal translation of the ablation device through a target vessel, a rotation of the ablation device about a central longitudinal axis, and an infusion of a chemical agent into the target vessel.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG,,https://lens.org/087-063-060-992-908,Patent Application,yes,6,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B17/12;;A61B18/00;;A61B18/02,,0,0,,,,PENDING
244,WO,A1,WO 2007/018822 A1,046-099-556-740-752,2007-02-15,2007,US 2006/0025451 W,2006-06-29,US 19059705 A,2005-07-26,APPLIANCE FOR DELIVERING A COMPOSITION,"Disclosed is an appliance for treating skin or tissue, the appliance comprising a three-layer substrate having a cloth-like appearance and feel. The substrate includes a water-impermeable layer, such as a film, sandwiched between, and attached to, two fibrous layers. The fibrous layer that is adapted to contact skin includes a formulation or composition adapted to be transferred to skin or tissue of the user. Furthermore, the fibrous layer that is adapted to contact skin includes undulations that inhibit leakage of the formulation or composition.",KIMBERLY CLARK CO;;CLOSE KENNETH B;;JOSEPH WAEL R;;ANDERSON GARY V;;ARENDT JONATHAN K;;HALL GREGORY K;;JOHNSON KROY D;;KECK LAURA E;;LEE MEEWHA,CLOSE KENNETH B;;JOSEPH WAEL R;;ANDERSON GARY V;;ARENDT JONATHAN K;;HALL GREGORY K;;JOHNSON KROY D;;KECK LAURA E;;LEE MEEWHA,,https://lens.org/046-099-556-740-752,Patent Application,yes,15,7,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B5/22;;B32B7/02;;B32B27/12;;C11D17/04,,0,0,,,,PENDING
245,AU,B2,AU 2006/276792 B2,124-725-683-898-045,2012-02-16,2012,AU 2006/276792 A,2006-06-29,US 19059705 A;;US 2006/0025451 W,2005-07-26,Appliance for delivering a composition,"Disclosed is an appliance for treating skin or tissue, the appliance comprising a three-layer substrate having a cloth-like appearance and feel. The substrate includes a water-impermeable layer, such as a film, sandwiched between, and attached to, two fibrous layers. The fibrous layer that is adapted to contact skin includes a formulation or composition adapted to be transferred to skin or tissue of the user. Furthermore, the fibrous layer that is adapted to contact skin includes undulations that inhibit leakage of the formulation or composition.",KIMBERLY CLARK CO,JOSEPH WAEL R;;HALL GREGORY K;;LEE MEEWHA;;ANDERSON GARY V;;JOHNSON KROY D;;KECK LAURA E;;ARENDT JONATHAN K;;CLOSE KENNETH B,,https://lens.org/124-725-683-898-045,Granted Patent,no,2,0,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B5/22;;B32B7/02;;B32B27/12;;C11D17/04,,0,0,,,,INACTIVE
246,CA,A1,CA 3212220 A1,155-037-704-015-068,2022-09-22,2022,CA 3212220 A,2022-03-18,US 202163163728 P;;US 202163270547 P;;US 202217697739 A;;US 202163255385 P;;US 2022/0020935 W,2021-03-19,VASCULAR ABLATION,"The disclosure includes a vein ablation system, comprising a catheter having an elongated body. In some embodiments, the vein ablation system comprises an ablation device at a distal portion of the elongated body. According to some embodiments, the vein ablation system comprises a control device at a proximal portion of the elongated body. The control device may comprise an input mechanism configured to simultaneously control at least two of a longitudinal translation of the ablation device through a target vessel, a rotation of the ablation device about a central longitudinal axis, and an infusion of a chemical agent into the target vessel.",CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG,,https://lens.org/155-037-704-015-068,Patent Application,no,0,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B18/02,,0,0,,,,PENDING
247,WO,A1,WO 2004/039376 A1,060-560-636-354-624,2004-05-13,2004,IB 0304612 W,2003-10-20,US 42259002 P,2002-10-30,USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS,"The present invention relates to compounds of the formula (I) and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula (I) and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.",PFIZER PROD INC;;BLUMBERG LAURA COOK;;BROWN MATTHEW FRANK;;GAWECO ANDERSON SEE;;GLADUE RONALD PAUL;;HAYWARD MATTHEW MERRILL;;LUNDQUIST GREGORY DEAN;;POSS CHRISTOPHER STANLEY;;SHAVNYA ANDRE,BLUMBERG LAURA COOK;;BROWN MATTHEW FRANK;;GAWECO ANDERSON SEE;;GLADUE RONALD PAUL;;HAYWARD MATTHEW MERRILL;;LUNDQUIST GREGORY DEAN;;POSS CHRISTOPHER STANLEY;;SHAVNYA ANDRE,,https://lens.org/060-560-636-354-624,Patent Application,yes,3,12,8,8,0,A61K31/495;;A61K31/495;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P15/00;;A61P17/00;;A61P19/02;;A61P19/08;;A61P25/28;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P35/04;;A61P37/02;;Y02A50/30;;Y02A50/30,A61K31/495;;A61P37/02,,0,0,,,,PENDING
248,AU,A1,AU 2003/269364 A1,068-383-754-474-72X,2004-05-25,2004,AU 2003/269364 A,2003-10-20,IB 0304612 W;;US 42259002 P,2002-10-30,USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS,,PFIZER PROD INC,GLADUE RONALD PAUL;;HAYWARD MATTHEW MERRILL;;LUNDQUIST GREGORY DEAN;;POSS CHRISTOPHER STANLEY;;SHAVNYA ANDRE;;BLUMBERG LAURA COOK;;BROWN MATTHEW FRANK;;GAWECO ANDERSON SEE,,https://lens.org/068-383-754-474-72X,Patent Application,no,0,0,8,8,0,A61K31/495;;A61K31/495;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P15/00;;A61P17/00;;A61P19/02;;A61P19/08;;A61P25/28;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P35/04;;A61P37/02;;Y02A50/30;;Y02A50/30,A61K31/495;;A61P37/02,,0,0,,,,DISCONTINUED
249,BR,A2,BR 112023018847 A2,106-701-517-582-53X,2023-12-19,2023,BR 112023018847 A,2022-03-18,US 2022/0020935 W;;US 202163163728 P;;US 202163255385 P;;US 202217697739 A;;US 202163270547 P,2021-03-19,Ablação vascular,"ablação vascular. a presente invenção fornece um sistema de ablação de veia, que compreende um cateter que tem um corpo alongado. em algumas modalidades, o sistema de ablação de veia compreende um dispositivo de ablação em uma parte distal do corpo alongado. de acordo com algumas modalidades, o sistema de ablação de veia compreende um dispositivo de controle em uma parte proximal do corpo alongado. o dispositivo de controle pode compreender um mecanismo de entrada configurado para controlar simultaneamente pelo menos duas de uma translação longitudinal do dispositivo de ablação através de um vaso alvo, uma rotação do dispositivo de ablação ao redor de um eixo geométrico longitudinal central e uma infusão de um agente químico no interior do vaso alvo.",CROSSFIRE MEDICAL INC,TSCHIDA ADAM;;PAULING AE-SUK;;HATCHER BRADY;;DEAN DANNAH;;KRONE DOUG;;ANDERSON EDWARD;;SUN JICHAO;;DUERR JOE;;ORTEGA LAURA;;BEYREIS RANDY;;NELSON SCOTT,,https://lens.org/106-701-517-582-53X,Patent Application,no,0,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B18/00;;A61B17/12;;A61B18/02,,0,0,,,,PENDING
250,EP,A1,EP 4291112 A1,105-205-574-546-78X,2023-12-20,2023,EP 22772283 A,2022-03-18,US 202163163728 P;;US 202163255385 P;;US 202163270547 P;;US 202217697739 A;;US 2022/0020935 W,2021-03-19,VASCULAR ABLATION,,CROSSFIRE MEDICAL INC,ANDERSON EDWARD;;TSCHIDA ADAM;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;DEAN DANNAH;;KRONE DOUG,,https://lens.org/105-205-574-546-78X,Patent Application,yes,0,0,13,13,0,A61M2025/105;;A61M2025/1052;;A61M25/0097;;A61M25/0074;;A61M25/0082;;A61M25/0071;;A61M25/007;;A61M25/0113;;A61B2017/320012;;A61B17/12031;;A61B17/12109;;A61B2017/1205;;A61B17/320016;;A61B17/320725;;A61B2017/00685;;A61B2017/00778;;A61B2090/0811;;A61B2090/061;;A61B2017/320004;;A61B2017/320733;;A61B17/04;;A61B17/0469;;A61B17/062;;A61B17/00234;;A61B17/12045;;A61B17/12136;;A61B18/1492;;A61B2018/0022;;A61B2018/00196;;A61B2018/00202;;A61B2018/00214;;A61B17/320016;;A61B17/12031;;A61B17/12045;;A61B17/12109;;A61B17/12136;;A61B17/00234;;A61B18/06;;A61B18/1492;;A61M25/0071;;A61M25/0074;;A61M25/0082;;A61B2017/00778;;A61B2017/320004;;A61B2017/320733;;A61B2018/00202;;A61B2018/0022;;A61M2025/105;;A61M2025/1052;;A61B18/06;;A61B2018/00404;;A61B2017/00323;;A61B2218/002;;A61B2018/00202;;A61B2018/00065;;A61B2018/0019;;A61M5/14236;;A61M2025/1086;;A61M2210/12;;A61M2205/3334;;A61M2205/05;;A61M25/0068;;A61M25/0082;;A61B17/22004;;A61B17/32002,A61B17/12;;A61B18/00;;A61B18/02,,0,0,,,,PENDING
251,KR,A,KR 20080027879 A,121-980-703-815-745,2008-03-28,2008,KR 20087001893 A,2006-06-29,US 19059705 A;;US 2006/0025451 W,2005-07-26,APPLIANCE FOR DELIVERING A COMPOSITION,"Disclosed is an appliance for treating skin or tissue, the appliance comprising a three-layer substrate having a cloth-like appearance and feel. The substrate includes a water-impermeable layer, such as a film, sandwiched between, and attached to, two fibrous layers. The fibrous layer that is adapted to contact skin includes a formulation or composition adapted to be transferred to skin or tissue of the user. Furthermore, the fibrous layer that is adapted to contact skin includes undulations that inhibit leakage of the formulation or composition. ® KIPO & WIPO 2008",KIMBERLY CLARK CO,CLOSE KENNETH B;;JOSEPH WAEL R;;ANDERSON GARY V;;ARENDT JONATHAN K;;HALL GREGORY K;;JOHNSON KROY D;;KECK LAURA E;;LEE MEE WHA,,https://lens.org/121-980-703-815-745,Patent Application,no,0,0,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12,,0,0,,,,INACTIVE
252,CN,B,CN 101227853 B,032-707-988-255-847,2012-11-14,2012,CN 200680026941 A,2006-06-29,US 2006/0025451 W;;US 19059705 A,2005-07-26,Appliance for delivering a composition,"Disclosed is an appliance for treating skin or tissue, the appliance comprising a three-layer substrate having a cloth-like appearance and feel. The substrate includes a water-impermeable layer, such as a film, sandwiched between, and attached to, two fibrous layers. The fibrous layer that is adapted to contact skin includes a formulation or composition adapted to be transferred to skin or tissueof the user. Furthermore, the fibrous layer that is adapted to contact skin includes undulations that inhibit leakage of the formulation or composition.",KIMBERLY CLARK CO,WHA LEE MEE;;CLOSE KENNETH B;;JOHNSON KROY D;;HALL GREGORY K;;KECK LAURA E;;ARENDT JONATHAN K;;JOSEPH WAEL R;;ANDERSON GARY V,,https://lens.org/032-707-988-255-847,Granted Patent,no,0,0,13,13,0,A47K7/03;;A61K8/0208;;A61Q19/00;;A61Q19/007;;B32B5/22;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;A47K7/03;;A61K8/02;;A61Q90/00;;B32B27/12;;Y10T442/678;;Y10T442/2525;;Y10T442/674;;Y10T442/66;;B32B5/022;;B32B2437/02;;B32B2307/7265;;B32B5/22;;B32B27/12;;A47K7/03;;A61K8/0208;;A61Q19/007;;A61Q19/00,A47K7/03;;A61K8/02;;A61Q90/00;;B32B5/22;;B32B7/02;;B32B27/12;;C11D17/04,,0,0,,,,INACTIVE
253,WO,A1,WO 2018/102159 A1,119-708-393-283-178,2018-06-07,2018,US 2017/0062227 W,2017-11-17,US 201662427642 P;;US 201762487597 P,2016-11-29,CARRIAGE ASSEMBLY FOR A TRANSPORT SYSTEM,A carriage assembly for a transport system includes a first body and a second body configured to moveably couple to a beam defining a transport path. The carriage assembly also includes a carrier coupled to the first body and the second body. The carrier is configured to support a container such that the carriage assembly transports the container along the transport path. The carriage assembly further includes a drive system coupled to at least one of the first body and the second body. The drive system is configured to move the carriage assembly along the transport path.,REGAL BELOIT AMERICA INC,PROPP CHRISTOPHER EDWIN E;;LOGSDON MICHAEL A;;REAMER LAURA MICHELLE;;JOHNSON JAMES P;;ODLAND SIMON ANDREW;;ANDERSON LARRY GENE;;CARRIGAN CHRISTOPHER ANDREW;;GRUBER NATHAN DANIEL,,https://lens.org/119-708-393-283-178,Patent Application,yes,10,2,3,3,0,B65G17/323;;B65G17/323;;B61B3/02;;B65G17/20;;B65G47/61;;B65G47/61;;E01B25/00;;Y02T30/00,B61B3/02;;B61B3/00;;B61B13/04;;B61B13/06;;B65G63/00;;E01B25/00,,0,0,,,,PENDING
254,US,A1,US 2019/0322456 A1,078-646-380-905-664,2019-10-24,2019,US 201716464993 A,2017-11-17,US 201716464993 A;;US 201762487597 P;;US 201662427642 P;;US 2017/0062227 W,2016-11-29,CARRIAGE ASSEMBLY FOR A TRANSPORT SYSTEM,A carriage assembly for a transport system includes a first body and a second body configured to moveably couple to a beam defining a transport path. The carriage assembly also includes a carrier coupled to the first body and the second body. The carrier is configured to support a container such that the carriage assembly transports the container along the transport path. The carriage assembly further includes a drive system coupled to at least one of the first body and the second body. The drive system is configured to move the carriage assembly along the transport path.,REGAL BELOIT AMERICA INC,PROPP CHRISTOPHER EDWIN EUGENE;;LOGSDON MICHAEL A;;REAMER LAURA MICHELLE;;JOHNSON JAMES P;;ODLAND SIMON ANDREW;;ANDERSON LARRY GENE;;CARRIGAN CHRISTOPHER ANDREW;;GRUBER NATHAN DANIEL,REGAL BELOIT AMERICA INC (2019-05-31),https://lens.org/078-646-380-905-664,Patent Application,yes,0,9,3,3,0,B65G17/323;;B65G17/323;;B61B3/02;;B65G17/20;;B65G47/61;;B65G47/61;;E01B25/00;;Y02T30/00,B65G17/32;;B65G47/61,,0,0,,,,DISCONTINUED
255,CN,A,CN 110248857 A,037-415-713-580-963,2019-09-17,2019,CN 201780084428 A,2017-11-17,US 201662427642 P;;US 201762487597 P;;US 2017/0062227 W,2016-11-29,CARRIAGE ASSEMBLY FOR A TRANSPORT SYSTEM,A carriage assembly for a transport system includes a first body and a second body configured to moveably couple to a beam defining a transport path. The carriage assembly also includes a carrier coupled to the first body and the second body. The carrier is configured to support a container such that the carriage assembly transports the container along the transport path. The carriage assembly further includes a drive system coupled to at least one of the first body and the second body. The drive system is configured to move the carriage assembly along the transport path.,REGAL BELOIT AMERICA INC,PROPP CHRISTOPHER EDWIN E;;LOGSDON MICHAEL A;;REAMER LAURA MICHELLE;;JOHNSON JAMES P;;ODLAND SIMON ANDREW;;ANDERSON LARRY GENE;;CARRIGAN CHRISTOPHER ANDREW;;GRUBER NATHAN DANIEL,,https://lens.org/037-415-713-580-963,Patent Application,no,7,0,3,3,0,B65G17/323;;B65G17/323;;B61B3/02;;B65G17/20;;B65G47/61;;B65G47/61;;E01B25/00;;Y02T30/00,B61B3/02;;B61B3/00;;B61B13/04;;B61B13/06;;B65G63/00;;E01B25/00,,0,0,,,,DISCONTINUED
256,US,A1,US 2011/0282225 A1,161-685-987-296-842,2011-11-17,2011,US 77884210 A,2010-05-12,US 77884210 A,2010-05-12,TECHNIQUES FOR REVIEWING AND ANALYZING IMPLANTABLE MEDICAL DEVICE SYSTEM DATA,"A computing device includes a memory device, a communication module, an interface, a processor, a display controller, and an input device. The communication module wirelessly receives a stream of first electrogram waveforms (EGMs) from an implantable medical device (IMD). The interface receives a stream of second EGMs. The processor stores the first and second EGMs and retrieves the stored first and second EGMs. The display controller displays the first and second EGMs together when the first and second EGMs are received. The input device is configured to receive a selection command from a user. The processor retrieves a portion of at least one of the first and second stored EGMs in response to the selection command. The display controller displays the retrieved portion of the at least one of the first and second stored EGMs while the processor concurrently stores the streams of the first and second EGMs.",ANDERSON KATHERINE H;;LACROIX TIMOTHY P;;JUSTEN MANFRED;;KOMP JOHN W;;BUTLER ARCH W;;PETERSEN CHRISTOPHER M;;DOVE LAURA K;;HOLMSTROM DAVID L;;WEBB JAMES D;;MEDTRONIC INC,ANDERSON KATHERINE H;;LACROIX TIMOTHY P;;JUSTEN MANFRED;;KOMP JOHN W;;BUTLER ARCH W;;PETERSEN CHRISTOPHER M;;DOVE LAURA K;;HOLMSTROM DAVID L;;WEBB JAMES D,MEDTRONIC INC (2010-06-03),https://lens.org/161-685-987-296-842,Patent Application,yes,4,31,1,1,0,A61B5/0006;;A61B5/283;;A61B5/0006;;A61B5/02;;A61B5/02;;A61B5/283;;A61B5/332;;A61B5/332;;A61N1/37235;;A61N1/37235,A61B5/0402,600/510,0,0,,,,DISCONTINUED
257,US,A1,US 2022/0162390 A1,163-452-085-552-582,2022-05-26,2022,US 202017441128 A,2020-03-20,US 202017441128 A;;US 201962820950 P;;US 2020/0023978 W,2019-03-20,CHALCOGENIDE HYBRID ORGANIC/INORGANIC POLYMERS AND METHODS FOR PRODUCING AND USING THE SAME,"The present invention provides chalcogenide hybrid organic/inorganic polymers (“CHIPs” or organic chalcogenide polymers) and methods for producing and using the same. In particular, the chalcogenide hybrid organic/inorganic polymers of the invention comprise a hydrocarbon cyclic ring structure and one or more chalcogenide selected from the group consisting of sulfur, selenium, cyclic selenium sulfide, and a combination thereof.",UNIV ARIZONA,PYUN DONG-CHUL ( JEFFREY );;NORWOOD ROBERT A;;KLEINE TRISTAN STEPHEN;;GLASS RICHARD S;;LICHTENBERGER DENNIS L;;HAMILTON MEGHAN O'BRIEN;;LYONS NICHOLAS;;SPIRES OLIVER;;ANDERSON LAURA E,ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (2021-09-21),https://lens.org/163-452-085-552-582,Patent Application,yes,0,0,2,2,0,C08G75/14;;C08L81/04;;C08G75/16;;C08G79/00;;G02B1/04,C08G75/16;;C08G79/00;;G02B1/04,,0,0,,,,PENDING
258,EP,B2,EP 0523683 B2,170-277-284-702-748,2002-10-09,2002,EP 92112127 A,1992-07-16,US 73158991 A,1991-07-17,Absorbent article,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,"KIMBERLY-CLARK WORLDWIDE, INC. (1998-08-03)",https://lens.org/170-277-284-702-748,Granted Patent,yes,16,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
259,CA,A1,CA 2054029 A1,155-795-892-984-466,1993-01-18,1993,CA 2054029 A,1991-10-23,US 73158991 A,1991-07-17,ABSORBENT ARTICLE EXHIBITING IMPROVED FLUID MANAGEMENT,,KIMBERLY CLARK CO,COE LOUISE C E;;ANDERSON LAURA J;;KASPAR MARK L;;MCDANIEL MARY L;;FAISON JOHN C;;DIAMOND ANDREW E;;WANEK MARY C;;OSTEEN DAVID K;;WANG KENNETH Y,,https://lens.org/155-795-892-984-466,Patent Application,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
260,DE,T2,DE 69214037 T2,006-679-975-671-392,1997-04-17,1997,DE 69214037 T,1992-07-16,US 73158991 A,1991-07-17,Absorbierender Artikel,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,"KIMBERLY-CLARK WORLDWIDE, INC., NEENAH, WIS., US (1998-08-27)",https://lens.org/006-679-975-671-392,Granted Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
261,AT,T1,AT E427985 T1,127-576-515-720-179,2009-04-15,2009,AT 00953761 T,2000-07-31,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A,1999-07-30,"FLEXIBLE BESCHICHTUNGSZUSAMMENSETZUNGEN MIT VERBESSERTER KRATZFESTIGKEIT, BESCHICHTETE OBERFLACHE UND VERFAHREN ZU DEREN HERSTELLUNG","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE;;DESAW SHAWN;;HARTMAN MARVIS;;HAYES DEBORAH;;HOCKSWENDER THOMAS;;KUSTER KYMARIE;;MAYO MICHAEL;;OLSON KURT;;SADVARY RICHARD;;SCHILLING LAURA;;SIMPSON DENNIS;;TYEBJEE SHIRYN;;WILT TRUMAN,,https://lens.org/127-576-515-720-179,Granted Patent,no,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/10;;C08J3/20;;C08K3/00;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/12;;C09D201/00,,0,0,,,,EXPIRED
262,AU,A,AU 1992/018376 A,135-246-749-627-91X,1993-01-21,1993,AU 1992/018376 A,1992-06-18,US 73158991 A,1991-07-17,AN ABSORBENT ARTICLE EXHIBITING IMPROVED FLUID MANAGMENT,,KIMBERLY CLARK CO,LOUISE CYNTHIA ELLIS COE;;LAURA JANE ANDERSON;;MARK LEONARD KASPAR;;MARY LOU MCDANIEL;;JOHN CARL FAISON;;ANDREW EDWARD DIAMOND;;MARY CHRIS WANEK;;DAVID KEITH OSTEEN;;KENNETH YIN WANG,,https://lens.org/135-246-749-627-91X,Patent Application,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
263,AU,B2,AU 654358 B2,163-164-629-183-011,1994-11-03,1994,AU 1992/018376 A,1992-06-18,US 73158991 A,1991-07-17,An absorbent article exhibiting improved fluid managment,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,,https://lens.org/163-164-629-183-011,Granted Patent,no,2,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
264,CA,C,CA 2054029 C,171-535-963-170-742,1998-05-19,1998,CA 2054029 A,1991-10-23,US 73158991 A,1991-07-17,ABSORBENT ARTICLE EXHIBITING IMPROVED FLUID MANAGEMENT,"An absorbent article is disclosed which exhibits improved fluid management. The article includes an absorbent having first and second oppositely aligned surfaces and a longitudinally extending central axis. A bicomponent cover is positioned over the first surface of the absorbent and includes a first and a second material. The first material has openings formed therein and is aligned along the longitudinally extending central axis of the absorbent. The second material is nonapertured and is secured to, or positioned adjacent to, the outer periphery of the first material. The first and second materials cooperate to enclose the absorbent. Positioned between the first material and the first surface of the absorbent is a separation means. The separation means directs fluid from the body downward, in the z direction, away from the bicomponent cover, and outward in the x and y directions to provide a more efficient use of the absorbent material. The absorbent article further contains a liquid-impermeable baffle which is positioned adjacent to the second surface of the absorbent.",KIMBERLY CLARK CO,DIAMOND ANDREW EDWARD;;OSTEEN DAVID KEITH;;WANG KENNETH YIN;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;KASPAR MARK LEONARD;;WANEK MARY CHRIS;;ANDERSON LAURA JANE;;COE LOUISE CYNTHIA ELLIS,,https://lens.org/171-535-963-170-742,Granted Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
265,EP,A1,EP 0523683 A1,150-922-868-879-807,1993-01-20,1993,EP 92112127 A,1992-07-16,US 73158991 A,1991-07-17,Absorbent article.,"The article (10) includes an absorbent (12) having first (14) and second (16) oppositely aligned surfaces and a longitudinally extending central axis. A bicomponent cover (24) is positioned over the first surface of the absorbent (12) and includes a first (26) and a second (30) material. The first material (26) has openings (28) formed therein and is aligned along the longitudinally extending central axis of the absorbent (12). The second material (30) is nonapertured and is secured to, or positioned adjacent to, the outer periphery of the first material (26). The first and second materials (26, 28) cooperate to enclose the absorbent. Separating first material (26) and the first surface (14) of the absorbent (12) is a flow control component (18). This ""separation means"" directs fluid from the body downward, in the z direction, away from the bicomponent cover, and outward in the x and y directions to provide a more efficient use of the absorbent material. The absorbent article further contains a liquid-impermeable baffle (44) which is positioned adjacent to the second surface (16) of the absorbent (12).",KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,"KIMBERLY-CLARK WORLDWIDE, INC. (1998-08-03)",https://lens.org/150-922-868-879-807,Patent Application,yes,5,33,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
266,ZA,B,ZA 924370 B,175-299-911-454-827,1993-10-13,1993,ZA 924370 A,1992-06-15,US 73158991 A,1991-07-17,An absorbent article exhibiting improved fluid management,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,,https://lens.org/175-299-911-454-827,Granted Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F5/44;;A61F13/511;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
267,US,A,US 5961505 A,177-701-476-957-539,1999-10-05,1999,US 20025194 A,1994-02-23,US 20025194 A;;US 98013792 A;;US 73158991 A,1991-07-17,Absorbent article exhibiting improved fluid management,"An absorbent article is disclosed which exhibits improved fluid management. The article includes an absorbent having first and second oppositely aligned surfaces and a longitudinally extending central axis. A bicomponent cover is positioned over the first surface of the absorbent and includes a first and a second material. The first material has openings formed therein and is aligned along the longitudinally extending central axis of the absorbent. The second material is nonapertured and is secured to, or positioned adjacent to, the outer periphery of the first material. The first and second materials cooperate to enclose the absorbent. Positioned between the first material and the first surface of the absorbent is a separation means. The separation means directs fluid from the body downward, in the z direction, away from the bicomponent cover, and outward in the x and y directions to provide a more efficient use of the absorbent material. The absorbent article further contains a liquid-impermeable baffle which is positioned adjacent to the second surface of the absorbent.",KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,KIMBERLY-CLARK WORLDWIDE INC (1996-11-30),https://lens.org/177-701-476-957-539,Granted Patent,yes,43,114,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F5/44;;A61F13/15;;A61F13/511;;A61F13/49;;A61F13/56,604/378;;604/358;;604/385.1;;604/383,0,0,,,,EXPIRED
268,DE,D1,DE 69214037 D1,090-562-307-558-869,1996-10-31,1996,DE 69214037 T,1992-07-16,US 73158991 A,1991-07-17,Absorbierender Artikel,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,"KIMBERLY-CLARK WORLDWIDE, INC., NEENAH, WIS., US (1998-08-27)",https://lens.org/090-562-307-558-869,Granted Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
269,DE,T3,DE 69214037 T3,020-318-777-523-560,2004-05-13,2004,DE 69214037 T,1992-07-16,US 73158991 A,1991-07-17,Absorbierender Artikel,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,"KIMBERLY-CLARK WORLDWIDE, INC., NEENAH, WIS., US (1998-08-27)",https://lens.org/020-318-777-523-560,Amended Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
270,EP,B1,EP 0523683 B1,071-858-474-902-19X,1996-09-25,1996,EP 92112127 A,1992-07-16,US 73158991 A,1991-07-17,Absorbent article,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,"KIMBERLY-CLARK WORLDWIDE, INC. (1998-08-03)",https://lens.org/071-858-474-902-19X,Granted Patent,yes,5,6,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
271,MX,A,MX 9201167 A,086-163-773-913-407,1993-01-01,1993,MX 9201167 A,1992-03-17,US 73158991 A,1991-07-17,UN ARTICULO ABSORBENTE QUE EXHIBE MANEJO DE FLUIDO MEJORADO.,,KIMBERLY CLARK CO,COE LOUISE CYNTHIA ELLIS;;ANDERSON LAURA JANE;;KASPAR MARK LEONARD;;MACDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;WANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,,https://lens.org/086-163-773-913-407,Patent Application,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F5/44;;A61F13/511;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,PENDING
272,KR,B1,KR 0132208 B1,017-257-613-691-678,1998-04-14,1998,KR 920012689 A,1992-07-16,US 73158991 A,1991-07-17,ABSORBENT ARTICLE EXHIBITING IMPROVED FLUID MANAGEMENT,"본 발명에는 개선된 유체 처리능을 나타내는 흡수 용품이 기재되어 있다. 본 발명의 흡수 용품은 대향하여 정렬된 제1 및 제2표면과 종방향으로 신장된 중앙축을 갖는 흡수체를 포함한다. 소정의 이성분 커버가 상기 흡수체의 제1표면상에 위치하며, 제1 및 제2 재료를 포함한다. 제1재료에는 개공이 형성되어 있으며, 흡수체의 종방향으로 신장된 중앙축을 따라 정렬된다. 제2재료는 무공성이며, 제1재료의 외곽에 고정되거나 또는 인접하여 위치한다. 제1 및 제2재료는 서로 협동하여 밀폐한다. 제1재료와 흡수체의 제1표면 사이에는 분리 수단이 위치한다. 분리 수단은 체액이 이성분 커버로부터 분리되어 z방향의 하부방향으로 흐르고, 그리고 흡수체 재료의 더 효율적인 사용을 제공하기 위해 외부방향, 즉 x 및 y 방향으로 흐르도록 한다. 본 발명의 흡수 용품은 흡수체의 제2 표면에 인접하여 위치한 액체 불투과성 배풀을 더 함유한다.",KIMBERLY CLARK CO,COE LOUSIE CYNTHIA ELLIS;;ANDERSON LAURA JAINE;;KASPAR MARK LEONARD;;MCDANIEL MARY LOU;;FAISON JOHN CARL;;DIAMOND ANDREW EDWARD;;UANEK MARY CHRIS;;OSTEEN DAVID KEITH;;WANG KENNETH YIN,,https://lens.org/017-257-613-691-678,Granted Patent,no,0,0,20,21,0,A61F13/5116;;A61F13/534;;A61F13/53713;;A61F13/53747;;A61F2013/51026;;A61F2013/51165;;A61F2013/53445;;A61F2013/53908;;A61F13/5125;;A61F2013/15878;;A61F2013/15959;;A61F2013/51028;;A61F13/15;;A61F13/534;;A61F2013/51165;;A61F2013/53908;;A61F13/5116;;A61F13/53713;;A61F13/53747;;A61F2013/53445;;A61F2013/51026;;A61F2013/15959;;A61F2013/51028;;A61F13/5125;;A61F2013/15878,A61F13/511;;A61F5/44;;A61F13/15;;A61F13/49;;A61F13/56,,0,0,,,,EXPIRED
273,US,A1,US 2022/0334599 A1,195-986-776-233-609,2022-10-20,2022,US 202217713196 A,2022-04-04,US 202217713196 A;;US 201916548043 A;;US 2018/0053226 W;;US 2017/0061195 W;;US 2018/0019570 W;;US 201862672366 P;;US 201762564175 P;;US 201862725228 P;;US 201762541637 P;;US 201762463539 P,2017-02-24,CONTROL SYSTEMS FOR UNMANNED AERIAL VEHICLES,"A method for controlling an unmanned aerial vehicle within a flight operating space. The unmanned aerial vehicle includes one or more sensor arrays on each spar. The method includes determining, using a plurality of sensor arrays, a flight path for the unmanned aerial vehicle. The method also includes receiving, by at least one sensor array of the plurality of sensor arrays, sensor data identifying at least one object in the operating space. The sensor data is transmitted over a communications bus connecting components of the UAV. The method further includes determining, by one or more processors onboard the unmanned aerial vehicle, a flight path around the at least one object. The method also includes generating, by the one or more onboard processors, a first signal to cause the unmanned aerial vehicle to navigate within the operating space around the at least one object.",FLIR DETECTION INC,JOHNSON SAMUEL A;;MISTRY SAMIR S;;TSUTSUMI ERIKA;;THOMSON CHAD;;ALEMAN JOHN;;ANDERSON BRETTON E;;BOHORQUEZ FELIPE;;BORDELON TERRANCE;;CORMAN BEN;;GONANO DION;;MAJOR LAURA;;MINERD BEN;;MITCHELL MEGAN,TELEDYNE FLIR DETECTION INC (2019-09-12);;CYPHY WORKS INC (2018-01-29),https://lens.org/195-986-776-233-609,Patent Application,yes,6,1,4,23,0,B64C27/006;;G01S13/933;;G01S15/93;;G01S17/933;;G05D1/0016;;G05D1/0866;;G05D1/106;;B64U2101/30;;B64U2201/10;;B64U2201/202;;B64U2201/20;;B64U10/16;;B64U50/19;;B64U2101/66;;B64U10/14;;B64U20/80;;B64U30/26;;G05D1/106;;B64C39/024;;G01S15/93;;G01S13/933;;G05D1/0022;;G05D1/0038;;G01S17/933;;B64U2201/20,G05D1/10;;B64C39/02;;G01S15/93;;G01S17/933;;G05D1/00,,1,0,,,"Provisional Application 62/368811, 07/29/2016",ACTIVE
274,US,B2,US 11294397 B2,045-654-861-942-864,2022-04-05,2022,US 201916548043 A,2019-08-22,US 201916548043 A;;US 2018/0053226 W;;US 2017/0061195 W;;US 2018/0019570 W;;US 201862672366 P;;US 201762564175 P;;US 201862725228 P;;US 201762541637 P;;US 201762463539 P,2017-02-24,Control systems for unmanned aerial vehicles,"A method for controlling an unmanned aerial vehicle within a flight operating space. The unmanned aerial vehicle includes one or more sensor arrays on each spar. The method includes determining, using a plurality of sensor arrays, a flight path for the unmanned aerial vehicle. The method also includes receiving, by at least one sensor array of the plurality of sensor arrays, sensor data identifying at least one object in the operating space. The sensor data is transmitted over a communications bus connecting components of the UAV. The method further includes determining, by one or more processors onboard the unmanned aerial vehicle, a flight path around the at least one object. The method also includes generating, by the one or more onboard processors, a first signal to cause the unmanned aerial vehicle to navigate within the operating space around the at least one object.",TELEDYNE FUR DETECTION INC,JOHNSON SAMUEL A;;TSUTSUMI ERIKA;;MISTRY SAMIR S;;THOMSON CHAD;;ALEMAN JOHN;;ANDERSON BRETTON E;;BOHORQUEZ FELIPE;;BORDELON TERRANCE;;CORMAN BEN;;GONANO DION;;MAJOR LAURA;;MINERD BEN;;MITCHELL MEGAN,TELEDYNE FLIR DETECTION INC (2019-09-12);;CYPHY WORKS INC (2018-01-29),https://lens.org/045-654-861-942-864,Granted Patent,yes,10,2,4,23,0,B64C27/006;;G01S13/933;;G01S15/93;;G01S17/933;;G05D1/0016;;G05D1/0866;;G05D1/106;;B64U2101/30;;B64U2201/10;;B64U2201/202;;B64U2201/20;;B64U10/16;;B64U50/19;;B64U2101/66;;B64U10/14;;B64U20/80;;B64U30/26;;G05D1/106;;B64C39/024;;G01S15/93;;G01S13/933;;G05D1/0022;;G05D1/0038;;G01S17/933;;B64U2201/20,B64C39/02;;G01S13/933;;G01S15/93;;G01S17/933;;G05D1/00;;G05D1/10,,1,0,,,"U.S. Appl. No. 62/368,811, filed Jul. 29, 2016.",ACTIVE
275,US,A1,US 2020/0218288 A1,172-195-021-141-348,2020-07-09,2020,US 201916548043 A,2019-08-22,US 201916548043 A;;US 2018/0053226 W;;US 2017/0061195 W;;US 2018/0019570 W;;US 201862672366 P;;US 201762564175 P;;US 201862725228 P;;US 201762541637 P;;US 201762463539 P,2017-02-24,CONTROL SYSTEMS FOR UNMANNED AERIAL VEHICLES,"A method for controlling an unmanned aerial vehicle within a flight operating space. The unmanned aerial vehicle includes one or more sensor arrays on each spar. The method includes determining, using a plurality of sensor arrays, a flight path for the unmanned aerial vehicle. The method also includes receiving, by at least one sensor array of the plurality of sensor arrays, sensor data identifying at least one object in the operating space. The sensor data is transmitted over a communications bus connecting components of the UAV. The method further includes determining, by one or more processors onboard the unmanned aerial vehicle, a flight path around the at least one object. The method also includes generating, by the one or more onboard processors, a first signal to cause the unmanned aerial vehicle to navigate within the operating space around the at least one object.",FLIR DETECTION INC,JOHNSON SAMUEL A;;MISTRY SAMIR S;;TSUTSUMI ERIKA;;THOMSON CHAD;;ALEMAN JOHN;;ANDERSON BRETTON E;;BOHORQUEZ FELIPE;;BORDELON TERRANCE;;CORMAN BEN;;GONANO DION;;MAJOR LAURA;;MINERD BEN;;MITCHELL MEGAN,TELEDYNE FLIR DETECTION INC (2019-09-12);;CYPHY WORKS INC (2018-01-29),https://lens.org/172-195-021-141-348,Patent Application,yes,0,35,4,23,0,B64C27/006;;G01S13/933;;G01S15/93;;G01S17/933;;G05D1/0016;;G05D1/0866;;G05D1/106;;B64U2101/30;;B64U2201/10;;B64U2201/202;;B64U2201/20;;B64U10/16;;B64U50/19;;B64U2101/66;;B64U10/14;;B64U20/80;;B64U30/26;;G05D1/106;;B64C39/024;;G01S15/93;;G01S13/933;;G05D1/0022;;G05D1/0038;;G01S17/933;;B64U2201/20,G05D1/10;;B64C39/02;;G01S15/93;;G01S17/933;;G05D1/00,,0,0,,,,ACTIVE
276,US,B2,US 11726502 B2,177-672-637-021-476,2023-08-15,2023,US 202217713196 A,2022-04-04,US 202217713196 A;;US 201916548043 A;;US 2018/0053226 W;;US 2017/0061195 W;;US 2018/0019570 W;;US 201862672366 P;;US 201762564175 P;;US 201862725228 P;;US 201762541637 P;;US 201762463539 P,2017-02-24,Control systems for unmanned aerial vehicles,"A method for controlling an unmanned aerial vehicle within a flight operating space. The unmanned aerial vehicle includes one or more sensor arrays on each spar. The method includes determining, using a plurality of sensor arrays, a flight path for the unmanned aerial vehicle. The method also includes receiving, by at least one sensor array of the plurality of sensor arrays, sensor data identifying at least one object in the operating space. The sensor data is transmitted over a communications bus connecting components of the UAV. The method further includes determining, by one or more processors onboard the unmanned aerial vehicle, a flight path around the at least one object. The method also includes generating, by the one or more onboard processors, a first signal to cause the unmanned aerial vehicle to navigate within the operating space around the at least one object.",TELEDYNE FLIR DETECTION INC,JOHNSON SAMUEL A;;MISTRY SAMIR S;;TSUTSUMI ERIKA;;THOMSON CHAD;;ALEMAN JOHN;;ANDERSON BRETTON E;;BOHORQUEZ FELIPE;;BORDELON TERRANCE;;CORMAN BEN;;GONANO DION;;MAJOR LAURA;;MINERD BEN;;MITCHELL MEGAN,TELEDYNE FLIR DETECTION INC (2019-09-12);;CYPHY WORKS INC (2018-01-29),https://lens.org/177-672-637-021-476,Granted Patent,yes,10,0,4,23,0,B64C27/006;;G01S13/933;;G01S15/93;;G01S17/933;;G05D1/0016;;G05D1/0866;;G05D1/106;;B64U2101/30;;B64U2201/10;;B64U2201/202;;B64U2201/20;;B64U10/16;;B64U50/19;;B64U2101/66;;B64U10/14;;B64U20/80;;B64U30/26;;G05D1/106;;B64C39/024;;G01S15/93;;G01S13/933;;G05D1/0022;;G05D1/0038;;G01S17/933;;B64U2201/20,B64C39/02;;G01S13/933;;G01S15/93;;G01S17/933;;G05D1/00;;G05D1/10,,2,0,,,"U.S. Appl. No. 62/368,811, filed Jul. 29, 2016.;;11. U.S. Appl. No. 62/368,811, filed Jul. 29, 2016.",ACTIVE
277,WO,A2,WO 2023/147422 A2,154-553-093-140-453,2023-08-03,2023,US 2023/0061377 W,2023-01-26,US 202263303620 P;;US 202263388728 P,2022-01-27,EXPANDABLE INTRODUCER,"An expandable introducer includes a hub and a tubular sheath coupled to the hub and extending distally from a distal end thereof. The tubular sheath defines a central lumen. A circumference of the tubular sheath includes a full thickness region having a first wall thickness and a reduced thickness region having a second wall thickness smaller than the first wall thickness. The reduced thickness region is configured to be folded such that the tubular sheath includes an unexpanded, folded state and is configured to expand to an expanded, unfolded state in response to a device passing though the central lumen. A first outer diameter of the tubular sheath in the unexpanded, folded state is smaller than a second outer diameter of the tubular sheath in the expanded, unfolded state.",MEDTRONIC INC,ANDERSON MARC;;FARRELL TIMOTHY;;MORELLI FIONNUALA;;SCIACCHITANO MARO;;NORGROVE MATTHEW;;CLARKE LUKE;;REID MARK;;COULTRY LAURA;;SAIL SHRIDHAR;;MCGUINN ALAN;;CASLEY MARK;;DESHMUKH SUSHEEL;;OGORMAN JACQUELINE;;MCAFEE PATRICIA;;MORAN CHRIS;;TROTTA ANTONIA,,https://lens.org/154-553-093-140-453,Patent Application,yes,0,0,2,2,0,A61M25/0023;;A61M2025/0024;;A61M25/0074;;A61M25/0097;;A61B17/3439;;A61M25/0045;;A61M25/0662;;A61M2025/0047;;A61B17/3415,A61M25/00;;A61B17/34;;A61M25/06,,0,0,,,,PENDING
278,WO,A3,WO 2023/147422 A3,025-830-455-797-58X,2023-09-21,2023,US 2023/0061377 W,2023-01-26,US 202263303620 P;;US 202263388728 P,2022-01-27,EXPANDABLE INTRODUCER,"An expandable introducer includes a hub and a tubular sheath (121) coupled thereto. The tubular sheath (121) defines a central lumen (103). A circumference of the tubular sheath includes a full thickness region (162) having a first wall thickness (T2) and a reduced thickness region (161) having a second wall thickness (Tl) smaller than the first wall thickness (T2). The reduced thickness region (162) is configured to be folded such that the tubular sheath includes an unexpanded, folded state and is configured to expand to an expanded, unfolded state in response to a device passing though the central lumen (103). A first outer diameter of the tubular sheath in the unexpanded, folded state is smaller than a second outer diameter of the tubular sheath in the expanded, unfolded state.",MEDTRONIC INC,ANDERSON MARC;;FARRELL TIMOTHY;;MORELLI FIONNUALA;;SCIACCHITANO MARO;;NORGROVE MATTHEW;;CLARKE LUKE;;REID MARK;;COULTRY LAURA;;SAIL SHRIDHAR;;MCGUINN ALAN;;CASLEY MARK;;DESHMUKH SUSHEEL;;OGORMAN JACQUELINE;;MCAFEE PATRICIA;;MORAN CHRIS;;TROTTA ANTONIA,,https://lens.org/025-830-455-797-58X,Search Report,yes,9,0,2,2,0,A61M25/0023;;A61M2025/0024;;A61M25/0074;;A61M25/0097;;A61B17/3439;;A61M25/0045;;A61M25/0662;;A61M2025/0047;;A61B17/3415,A61M25/00;;A61B17/34;;A61M25/06,,0,0,,,,PENDING
279,CN,A,CN 115175625 A,102-172-005-854-857,2022-10-11,2022,CN 202280001590 A,2022-02-25,US 202163154603 P;;US 202163169091 P;;US 202163176156 P;;US 202163193469 P;;US 202217679434 A;;US 2022/0018030 W,2021-02-26,Intravascular lithotripsy,"A medical device may include an elongate body, a balloon positioned at a distal end portion of the elongate body, and one or more pressure wave transmitters positioned within the balloon along a central longitudinal axis of the elongate body. The one or more pressure wave emitters may be configured to propagate pressure waves radially outward through the fluid to disrupt a calcification lesion at the targeted treatment site. At least one of the one or more pressure wave emitters may include an electron emitter including a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap therebetween, and the second electrode may include a portion of a hypotube.",QWAVE MEDICAL CORP,ANDERSON EDWARD;;HEICHEL BRADY;;BERRIS RANDY;;SCOTT NELSON;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULIN I-SHUKO;;KIEFER DARYL;;WU BRIAN;;DEAN DANA;;SIMON MARC;;GRAHAM-WORTH CURTIS;;PARKER HAGEN;;TISO TRISTAN;;HINAUX LAURENT,,https://lens.org/102-172-005-854-857,Patent Application,no,0,1,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/22;;A61B18/00;;A61B18/24;;A61B18/26,,0,0,,,,PENDING
280,JP,A,JP 2013213223 A,138-497-090-417-281,2013-10-17,2013,JP 2013144545 A,2013-07-10,US 16088802 A,2002-06-03,COATING COMPOSITION CONTAINING MODIFIED PARTICLE AND METHOD OF USING THE SAME,"PROBLEM TO BE SOLVED: To provide a coating composition having improved injury resistance and scratch resistance.SOLUTION: A coating generally includes particles that have been modified to render the particles more surface active. Particles having reactive groups on the surfaces thereof are appropriate for the modification. The surface tension of the particles is reduced by the modification. The resultant modified particles are more incompatible with a resin than unmodified counterparts. This is contrary to many art-teaching techniques in which particles are treated or reacted with compounds that make them more compatible with resin, and therefore more easily dispersed in the resin. Rendering the present particles more incompatible or more surface active causes at least some of the particles to rise to the surface of the cured coating, thus affording enhanced mar and/or scratch resistance.",PPG IND OHIO INC,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,,https://lens.org/138-497-090-417-281,Patent Application,no,4,1,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09D201/00;;B05D7/24;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04,,0,0,,,,PENDING
281,JP,A,JP 2009062548 A,129-569-598-242-033,2009-03-26,2009,JP 2008274955 A,2008-10-24,US 16088802 A,2002-06-03,COATING COMPOSITION WITH MODIFIED PARTICLE AND METHOD FOR USING THE SAME,"<P>PROBLEM TO BE SOLVED: To provide a liquid coating composition having improved mar and scratch resistance. <P>SOLUTION: The liquid coating composition comprises a resin and particles, wherein the particles which have been modified to have a surface tension lower than that of the resin are used such that at least some of the particles rise to the surface of the cured coating, thus affording enhanced mar and/or scratch resistance. The particles which have been modified to have a lower surface tension are obtained by reacting perfluorooctyl triethoxy silane to a surface of silica nanoparticles using a catalyst. <P>COPYRIGHT: (C)2009,JPO&INPIT",PPG IND OHIO INC,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,,https://lens.org/129-569-598-242-033,Patent Application,no,5,1,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09D201/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04,,0,0,,,,DISCONTINUED
282,WO,A1,WO 2003/102089 A1,162-912-985-414-554,2003-12-11,2003,US 0315153 W,2003-05-14,US 16088802 A,2002-06-03,COATING COMPOSITIONS WITH MODIFIED PARTICLES AND METHODS OF USING THE SAME,"Liquid coating compositions having improved mar and scratch resistance are disclosed. The coatings generally comprise one or more particles that have been modified to render the particles more surface active. The improved resistance is achieved without affecting the appearance or mechanical performance of the coatings. Methods for using the coatings, and the substrates coated therewith, are also disclosed.",PPG IND OHIO INC,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,,https://lens.org/162-912-985-414-554,Patent Application,yes,2,0,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,,0,0,,,,PENDING
283,AU,B8,AU 2003/241442 B8,192-618-477-307-059,2006-07-06,2006,AU 2003/241442 A,2003-05-14,US 16088802 A;;US 0315153 W,2002-06-03,Coating compositions with modified particles and methods of using the same,,PPG IND OHIO INC,O'DWYER JAMES B;;TYEBJEE SHIRYN;;MAYO MICHAEL A;;HOCKSWENDER THOMAS R;;WHITE DANIELA;;POINDEXTER LAURA E;;CARNEY JOSEPH M;;SIMPSON DENNIS A;;WHITE MICHAEL L;;SCHNEIDER JOHN R;;ANDERSON LAWRENCE G;;SADVARY RICHARD J,,https://lens.org/192-618-477-307-059,Amended Patent,no,2,0,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,,0,0,,,,EXPIRED
284,US,A1,US 2022/0338890 A1,094-892-902-587-469,2022-10-27,2022,US 202217861137 A,2022-07-08,US 202217861137 A;;US 202217679434 A;;US 202163154603 P;;US 202163169091 P;;US 202163176156 P;;US 202163193469 P,2021-02-26,INTRAVASCULAR LITHOTRIPSY,"A medical device may include an elongated body, a balloon positioned at a distal portion of the elongated body, and one or more pressure-wave emitters positioned along a central longitudinal axis of the elongated body within the balloon. The one or more pressure-wave emitters may be configured to propagate pressure waves radially outward through the fluid to fragment a calcified lesion at the target treatment site. The at least one of the one or more pressure-wave emitters may include an electronic emitter comprising a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap between the first electrode and the second electrode, and the second electrode may comprise a portion of a hypotube.",FASTWAVE MEDICAL INC,ANDERSON EDWARD;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;HATCHER BRADY;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,FASTWAVE MEDICAL INC (2022-02-28),https://lens.org/094-892-902-587-469,Patent Application,yes,2,0,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/22;;A61M25/10,,0,0,,,,ACTIVE
285,AU,A1,AU 2022/227829 A1,026-939-049-817-843,2023-09-07,2023,AU 2022/227829 A,2022-02-25,US 202163169091 P;;US 202163176156 P;;US 202163154603 P;;US 202217679434 A;;US 202163193469 P;;US 2022/0018030 W,2021-02-26,INTRAVASCULAR LITHOTRIPSY,"A medical device may include an elongated body, a balloon positioned at a distal portion of the elongated body, and one or more pressure-wave emitters positioned along a central longitudinal axis of the elongated body within the balloon. The one or more pressure- wave emitters may be configured to propagate pressure waves radially outward through the fluid to fragment a calcified lesion at the target treatment site. The at least one of the one or more pressure-wave emitters may include an electronic emitter comprising a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap between the first electrode and the second electrode, and the second electrode may comprise a portion of a hypotube.",FASTWAVE MEDICAL INC,ANDERSON EDWARD;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,,https://lens.org/026-939-049-817-843,Patent Application,no,0,0,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/22;;A61B18/00;;A61B18/24;;A61B18/26,,0,0,,,,PENDING
286,EP,A1,EP 1509578 A1,081-540-818-750-613,2005-03-02,2005,EP 03731178 A,2003-05-14,US 0315153 W;;US 16088802 A,2002-06-03,COATING COMPOSITIONS WITH MODIFIED PARTICLES AND METHODS OF USING THE SAME,,PPG IND OHIO INC,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,,https://lens.org/081-540-818-750-613,Patent Application,yes,0,0,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,,0,0,,,,DISCONTINUED
287,CA,A1,CA 2487998 A1,122-973-941-812-663,2003-12-11,2003,CA 2487998 A,2003-05-14,US 16088802 A;;US 0315153 W,2002-06-03,COATING COMPOSITIONS WITH MODIFIED PARTICLES AND METHODS OF USING THE SAME,"Liquid coating compositions having improved mar and scratch resistance are disclosed. The coatings generally comprise one or more particles that have been modified to render the particles more surface active. The improved resistance is achieved without affecting the appearance or mechanical performance of the coatings. Methods for using the coatings, and the substrates coated therewith, are also disclosed.",PPG IND OHIO INC,TYEBJEE SHIRYN;;O'DWYER JAMES B;;HOCKSWENDER THOMAS R;;WHITE DANIELA;;WHITE MICHAEL L;;MAYO MICHAEL A;;SADVARY RICHARD J;;ANDERSON LAWRENCE G;;POINDEXTER LAURA E;;CARNEY JOSEPH M;;SCHNEIDER JOHN R;;SIMPSON DENNIS A,,https://lens.org/122-973-941-812-663,Patent Application,no,0,0,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,,0,0,,,,DISCONTINUED
288,WO,A1,WO 2022/183075 A1,129-244-197-095-145,2022-09-01,2022,US 2022/0018030 W,2022-02-25,US 202163169091 P;;US 202163176156 P;;US 202163154603 P;;US 202217679434 A;;US 202163193469 P,2021-02-26,INTRAVASCULAR LITHOTRIPSY,"A medical device may include an elongated body, a balloon positioned at a distal portion of the elongated body, and one or more pressure-wave emitters positioned along a central longitudinal axis of the elongated body within the balloon. The one or more pressure- wave emitters may be configured to propagate pressure waves radially outward through the fluid to fragment a calcified lesion at the target treatment site. The at least one of the one or more pressure-wave emitters may include an electronic emitter comprising a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap between the first electrode and the second electrode, and the second electrode may comprise a portion of a hypotube.",FASTWAVE MEDICAL INC,ANDERSON EDWARD;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,,https://lens.org/129-244-197-095-145,Patent Application,yes,9,0,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/22;;A61B18/00;;A61B18/24;;A61B18/26,,0,0,,,,PENDING
289,US,B2,US 11633200 B2,144-433-101-331-083,2023-04-25,2023,US 202217861137 A,2022-07-08,US 202217861137 A;;US 202217679434 A;;US 202163154603 P;;US 202163169091 P;;US 202163176156 P;;US 202163193469 P,2021-02-26,Intravascular lithotripsy,"A medical device may include an elongated body, a balloon positioned at a distal portion of the elongated body, and one or more pressure-wave emitters positioned along a central longitudinal axis of the elongated body within the balloon. The one or more pressure-wave emitters may be configured to propagate pressure waves radially outward through the fluid to fragment a calcified lesion at the target treatment site. The at least one of the one or more pressure-wave emitters may include an electronic emitter comprising a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap between the first electrode and the second electrode, and the second electrode may comprise a portion of a hypotube.",FASTWAVE MEDICAL INC,ANDERSON EDWARD;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;HATCHER BRADY;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,FASTWAVE MEDICAL INC (2022-02-28),https://lens.org/144-433-101-331-083,Granted Patent,yes,64,0,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/00;;A61B17/22;;A61M25/10,,17,1,008-781-645-667-28X,18426268;;10.1583/07-2272.1,"Shockwave Medical—“Intravascular Lithotripsy (IVL)”—shockwavemedical.com [online]—Available at least as of Apr. 2022—Available from Internet <URL: https://shockwavemedical.com/technology/intravascular-lithotripsy-ivl/>.;;Shockwave Medical—“Shockwave M5 IVL Catheter”—shockwavemedical.com [online]—Available at least as of Apr. 2022—Available from Internet <URL: https://shockwavemedical.com/clinicians/usa/peripheral/product-specs-resources/shockwave-m5/>.;;Shockwave Medical—“Shockwave M5+”—shockwavemedical.com [online]—Available at least as of Apr. 2022—Available from Internet <URL: https://shockwavemedical.com/clinicians/usa/peripheral/product-specs-resources/shockwave-m5plus/>.;;Shockwave Medical—“Shockwave S4 IVL Catheter”—shockwavemedical.com [online]—Available at least as of Apr. 2022—Available from Internet <URL: https://shockwavemedical.com/clinicians/usa/peripheral/shockwave-s4/>.;;Marmur, Jonathan D.—“Carotid Artery Stenting”—marmur.com [online]—Available at least as of 2016—Available from Internet <URL: http://www.marmur.com/carotid-artery-stenting.html>.;;Finol E.A., Siewiorek G.M., Scotti C.M., Wholey M.H., Wholey M.H.—“Wall Apposition Assessment and Performance Comparison of Distal Protection Filters”—Journal of Endovascular Therapy—May 2008—vol. 15, No. 2, p. 177-185—Available from Internet <URL: https://www.researchgate.net/publication/5427102_Wall_Apposition_Assessment_and_Performance_Comparison_of_Distal_Protection_Filters>.;;Boston Scientific—“Peripheral Cutting Balloon™”—bostonscientific.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.bostonscientific.com/en-US/products/catheters--balloon/peripheral-cutting-balloon.html>.;;Philips—“AngioSculpt RX PTCA”—usa.philips.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.usa.philips.com/healthcare/product/HCIGTDPTCARXSB/angiosculpt-rx-ptca-scoring-balloon-catheter>.;;Cagent Vascular—“The Serration Balloon”—cagentvascular.com [online]—Available at least as of 2021—Available from Internet <URL: https://cagentvascular.com/information>.;;Trireme Medical—“Chocolate® PTCA Balloon Catheter”—qtvascular.com [online]—Available at least as of 2021—Available from Internet <URL: https://qtvascular.com/us/products/chocolate-ptca/>.;;BD (Becton, Dickinson and Company)—“Vascutrak™ PTA Dilatation Catheters”—bd.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.bd.com/en-us/products-and-solutions/products/product-families/vascutrak-pta-dilatation-catheters>.;;Boston Scientific—“FilterWire EZ™”—bostonscientific.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.bostonscientific.com/en-US/products/embolic-protection/filterwire-ez-embolic-protection-system.html>.;;Carefusion—“Introducing the AVAmax® vertebral balloon”—carefusion.com [online]—Available at least as of Apr. 1, 2010—Retrieved from Internet Archive Wayback Machine <URL: https://web.archive.org/web/20100401182423/http:/avamaxchoice.carefusion.com/>.;;Abbott Laboratories—“Abbott Accunet—Model RX—Embolic Protection System”—medical-xprt.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.medical-xprt.com/products/abbott-accunet-model-rx-embolic-protection-system-748573>.;;Medtronic—“SpiderFX Embolic Protection Device”—medtronic.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.medtronic.com/us-en/healthcare-professionals/products/cardiovascular/embolic-protection-devices/spiderfx.html>.;;Contego Medical—“Corguard® Coronary Balloon Angioplasty System with Integrated Embolic Protection”—contegomedical.com [online]—Available at least as of 2021—Available from Internet <URL: https://contegomedical.com/coronary/>.;;Contego Medical—“Paladin® Carotid PTA Balloon System with Integrated Embolic Protection”—contegomedical.com [online]—Available at least as of 2021—Available from Internet <URL: https://contegomedical.com/paladin-carotid-pta-balloon-system-u-s/>.",ACTIVE
290,US,A1,US 2003/0224174 A1,052-585-907-381-87X,2003-12-04,2003,US 16088802 A,2002-06-03,US 16088802 A,2002-06-03,Coating compositions with modified particles and methods of using the same,"
   Liquid coating compositions having improved mar and scratch resistance are disclosed. The coatings generally comprise one or more particles that have been modified to render the particles more surface active. The improved resistance is achieved without affecting the appearance or mechanical performance of the coatings. Methods for using the coatings, and the substrates coated therewith, are also disclosed. 
",WHITE DANIELA;;O'DWYER JAMES B.;;MAYO MICHAEL A.;;POINDEXTER LAURA E.;;SCHNEIDER JOHN R.;;WHITE MICHAEL L.;;SADVARY RICHARD J.;;TYEBJEE SHIRYN;;CARNEY JOSEPH M.;;ANDERSON LAWRENCE G.;;SIMPSON DENNIS A.;;HOCKSWENDER THOMAS R.,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,PPG INDUSTRIES OHIO INC (2002-08-22),https://lens.org/052-585-907-381-87X,Patent Application,yes,22,53,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,428/413,0,0,,,,EXPIRED
291,US,B2,US 6790904 B2,047-902-768-696-489,2004-09-14,2004,US 16088802 A,2002-06-03,US 16088802 A,2002-06-03,Liquid coating of film-forming resin and particles chemically modified to lower surface tension,"
    Liquid coating compositions having improved mar and scratch resistance are disclosed. The coatings generally comprise one or more particles that have been modified to render the particles more surface active. The improved resistance is achieved without affecting the appearance or mechanical performance of the coatings. Methods for using the coatings, and the substrates coated therewith, are also disclosed. 
",PPG IND OHIO INC,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,PPG INDUSTRIES OHIO INC (2002-08-22),https://lens.org/047-902-768-696-489,Granted Patent,yes,34,50,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,524/588;;523/458;;523/466;;523/467;;524/443;;524/444;;524/589;;524/590;;524/601,0,0,,,,EXPIRED
292,US,A1,US 2022/0287732 A1,171-940-117-004-031,2022-09-15,2022,US 202217679434 A,2022-02-24,US 202217679434 A;;US 202163154603 P;;US 202163169091 P;;US 202163176156 P;;US 202163193469 P,2021-02-26,INTRAVASCULAR LITHOTRIPSY,"A medical device may include an elongated body, a balloon positioned at a distal portion of the elongated body, and one or more pressure-wave emitters positioned along a central longitudinal axis of the elongated body within the balloon. The one or more pressure-wave emitters may be configured to propagate pressure waves radially outward through the fluid to fragment a calcified lesion at the target treatment site. The at least one of the one or more pressure-wave emitters may include an electronic emitter comprising a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap between the first electrode and the second electrode, and the second electrode may comprise a portion of a hypotube.",FASTWAVE MEDICAL INC,ANDERSON EDWARD;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;HATCHER BRADY;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,FASTWAVE MEDICAL INC (2022-02-28),https://lens.org/171-940-117-004-031,Patent Application,yes,0,3,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/22,,0,0,,,,ACTIVE
293,AU,A1,AU 2003/241442 A1,024-607-675-203-167,2003-12-19,2003,AU 2003/241442 A,2003-05-14,US 16088802 A;;US 0315153 W,2002-06-03,COATING COMPOSITIONS WITH MODIFIED PARTICLES AND METHODS OF USING THE SAME,,PPG IND OHIO INC,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,,https://lens.org/024-607-675-203-167,Patent Application,no,0,0,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,,0,0,,,,EXPIRED
294,CA,A1,CA 3209797 A1,174-592-365-145-168,2022-09-01,2022,CA 3209797 A,2022-02-25,US 202163154603 P;;US 202163169091 P;;US 202163176156 P;;US 202217679434 A;;US 202163193469 P;;US 2022/0018030 W,2021-02-26,INTRAVASCULAR LITHOTRIPSY,"A medical device may include an elongated body, a balloon positioned at a distal portion of the elongated body, and one or more pressure-wave emitters positioned along a central longitudinal axis of the elongated body within the balloon. The one or more pressure- wave emitters may be configured to propagate pressure waves radially outward through the fluid to fragment a calcified lesion at the target treatment site. The at least one of the one or more pressure-wave emitters may include an electronic emitter comprising a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap between the first electrode and the second electrode, and the second electrode may comprise a portion of a hypotube.",FASTWAVE MEDICAL INC,ANDERSON EDWARD;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,,https://lens.org/174-592-365-145-168,Patent Application,no,0,0,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B18/24;;A61B18/26,,0,0,,,,PENDING
295,US,B2,US 11484327 B2,076-725-029-398-661,2022-11-01,2022,US 202217679434 A,2022-02-24,US 202217679434 A;;US 202163154603 P;;US 202163169091 P;;US 202163176156 P;;US 202163193469 P,2021-02-26,Intravascular lithotripsy,"A medical device may include an elongated body, a balloon positioned at a distal portion of the elongated body, and one or more pressure-wave emitters positioned along a central longitudinal axis of the elongated body within the balloon. The one or more pressure-wave emitters may be configured to propagate pressure waves radially outward through the fluid to fragment a calcified lesion at the target treatment site. The at least one of the one or more pressure-wave emitters may include an electronic emitter comprising a first electrode and a second electrode. The first electrode and the second electrode may be arranged to define a spark gap between the first electrode and the second electrode, and the second electrode may comprise a portion of a hypotube.",FASTWAVE MEDICAL INC,ANDERSON EDWARD;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;HATCHER BRADY;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,FASTWAVE MEDICAL INC (2022-02-28),https://lens.org/076-725-029-398-661,Granted Patent,yes,50,0,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/22;;A61B17/00;;A61M25/10,,17,1,008-781-645-667-28X,18426268;;10.1583/07-2272.1,"Shockwave IVL—Downloaded on Apr. 12, 2022, from https://shockwavemedical.com/technology/intravascular-lithotripsy-ivl/.;;Shockwave M5—Downloaded on Apr. 12, 2022, from https://shockwavemedical.com/clinicians/usa/peripheral/product-specs-resources/shockwave-m5/.;;Shockwave M5+—Downloaded on Apr. 12, 2022, from https://shockwavemedical.com/clinicians/usa/peripheral/product-specs-resources/shockwave-m5plus/.;;Shockwave S4—Downloaded on Apr. 12, 2022, from https://shockwavemedical.com/clinicians/usa/peripheral/shockwave-s4/.;;Marmur, Jonathan D.—“Carotid Artery Stenting”—marmur.com [online]—Available at least as of 2016—Available from Internet <URL: http://www.marmur.com/carotid-artery-stenting.html>.;;Finol E.A., Siewiorek G.M., Scotti C.M., Wholey M.H., Wholey M.H.—“Wall Apposition Assessment and Performance Comparison of Distal Protection Filters”—Journal of Endovascular Therapy—May 2008—vol. 15, No. 2, p. 177-185—Available from Internet <URL: https://www.researchgate.net/publication/5427102_Wall_Apposition_Assessment_and_Performance_Comparison_of_Distal_Protection_Filters>.;;Boston Scientific—“Peripheral Cutting Balloon™”—bostonscientific.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.bostonscientific.com/en-US/products/catheters-balloon/peripheral-cutting-balloon.html>.;;Philips—“AngioSculpt RX PTCA”—usa.philips.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.usa.philips.com/healthcare/product/HCIGTDPTCARXSB/angiosculpt-rx-ptca-scoring-balloon-catheter>.;;Cagent Vascular—“The Serration Balloon”—cagentvascular.com [online]—Available at least as of 2021—Available from Internet <URL: https://cagentvascular.com/information>.;;Trireme Medical—“Chocolate® PTCA Balloon Catheter”—qtvascular.com [online]—Available at least as of 2021—Available from Internet <URL: https://qtvascular.com/us/products/chocolate-ptca/>.;;BD (Becton, Dickinson and Company)—“Vascutrak™ PTA Dilatation Catheters”—bd.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.bd.com/en-us/products-and-solutions/products/product-families/vascutrak-pta-dilatation-catheters>.;;Boston Scientific—“FilterWire EZ™”—bostonscientific.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.bostonscientific.com/en-US/products/embolic-protection/filterwire-ez-embolic-protection-system.html>.;;Carefusion—“Introducing the AVAmax® vertebral balloon”—carefusion.com [online]—Available at least as of Apr. 1, 2010—Retrieved from Internet Archive Wayback Machine <URL: https://web.archive.org/web/20100401182423/http:/avamaxchoice.carefusion.com/>.;;Abbott Laboratories—“Abbott Accunet—Model RX—Embolic Protection System”—medical-xprt.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.medical-xprt.com/products/abbott-accunet-model-rx-embolic-protection-system-748573>.;;Medtronic—“SpiderFX Embolic Protection Device”—medtronic.com [online]—Available at least as of 2021—Available from Internet <URL: https://www.medtronic.com/us-en/healthcare-professionals/products/cardiovascular/embolic-protection-devices/spiderfx.html>.;;Contego Medical—“Corguard® Coronary Balloon Angioplasty System with Integrated Embolic Protection”—contegomedical.com [online]—Available at least as of 2021—Available from Internet <URL: https://contegomedical.com/coronary/>.;;Contego Medical—“Paladin® Carotid PTA Balloon System with Integrated Embolic Protection”—contegomedical.com [online]—Available at least as of 2021—Available from Internet <URL: https://contegomedical.com/paladin-carotid-pta-balloon-system-u-s/>.",ACTIVE
296,AU,B2,AU 2003/241442 B2,174-395-963-450-506,2006-06-29,2006,AU 2003/241442 A,2003-05-14,US 16088802 A;;US 0315153 W,2002-06-03,Coating compositions with modified particles and methods of using the same,,PPG IND OHIO INC,O'DWYER JAMES B;;TYEBJEE SHIRYN;;MAYO MICHAEL A;;HIOCKSWENDER THOMAS R;;WHITE DANIELA;;POINDEXTER LAURA E;;CARNEY JOSEPH M;;SIMPSON DENNIS A;;WHITE MICHAEL L;;SCHNEIDER JOHN R;;ANDERSON LAWRENCE G;;SADVARY RICHARD J,,https://lens.org/174-395-963-450-506,Granted Patent,no,2,0,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04;;C09D201/00,,0,0,,,,EXPIRED
297,EP,A1,EP 4297669 A1,190-661-399-862-954,2024-01-03,2024,EP 22760544 A,2022-02-25,US 202163154603 P;;US 202163169091 P;;US 202163176156 P;;US 202163193469 P;;US 202217679434 A;;US 2022/0018030 W,2021-02-26,INTRAVASCULAR LITHOTRIPSY,,FASTWAVE MEDICAL INC,ANDERSON EDWARD;;HATCHER BRADY;;BEYREIS RANDY;;NELSON SCOTT;;SUN JICHAO;;ORTEGA LAURA;;DUERR JOE;;PAULING AE-SUK;;KIEFER DARYL;;GOH BRYAN;;DEAN DANNAH;;SIMMON MARC;;GOREHAM-VOSS CURTIS;;HAGEN PARKER;;TIESO TRISTAN;;ENO LAUREN,,https://lens.org/190-661-399-862-954,Patent Application,yes,0,0,9,12,0,A61B17/2202;;A61B17/22022;;A61B2017/22025;;A61B2017/22027;;A61B2017/22028;;A61B2017/22062;;A61B2017/00022;;A61B18/26;;A61B2017/22061;;A61B17/320725;;A61B2017/22002;;A61B2017/22024;;A61B2090/3966;;A61B2017/00455;;A61B2018/0022;;A61B18/245;;A61B2018/00154;;A61B2018/00136;;A61B2018/00791;;A61B2018/00863;;A61B2018/00702;;A61B2018/00642;;A61B2018/00857;;A61B2018/00851;;A61B2018/00767;;A61B2018/0072;;A61B2018/00761;;A61B2018/00732;;A61B2018/00708;;A61M2025/105;;A61B2017/00557;;A61B17/22022;;A61B17/2202;;A61M25/104,A61B17/22;;A61B18/00;;A61B18/24;;A61B18/26,,0,0,,,,PENDING
298,JP,A,JP 2010180418 A,156-341-893-399-584,2010-08-19,2010,JP 2010119848 A,2010-05-25,US 16088802 A,2002-06-03,COATING COMPOSITION WITH MODIFIED PARTICLE AND METHOD OF USING THE SAME,"<P>PROBLEM TO BE SOLVED: To provide coating compositions having improved mar and scratch resistance. <P>SOLUTION: The coating compositions generally include particles modified to more surface active particles. Particles having a reactive group on their surface are suitable for modification. The surface tension of the particles is reduced due to the modification. The modified particles, as the result, are more incompatible with a resin than unmodified counterparts. This is contrary to many art-teaching techniques in which particles are treated or reacted with compounds that make them more compatible with the resin, and therefore more easily dispersed in the resin. Rendering the present particles more incompatible or more surface active causes at least some of the particles to rise to the surface of the cured coating, thus affording enhanced mar and/or scratch resistance. <P>COPYRIGHT: (C)2010,JPO&INPIT",PPG IND OHIO INC,WHITE DANIELA;;O'DWYER JAMES B;;MAYO MICHAEL A;;POINDEXTER LAURA E;;SCHNEIDER JOHN R;;WHITE MICHAEL L;;SADVARY RICHARD J;;TYEBJEE SHIRYN;;CARNEY JOSEPH M;;ANDERSON LAWRENCE G;;SIMPSON DENNIS A;;HOCKSWENDER THOMAS R,,https://lens.org/156-341-893-399-584,Patent Application,no,8,1,16,16,0,C08K3/22;;C08K3/28;;C08K3/36;;C08K9/06;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;Y10T428/31511;;C09D7/00;;B82Y30/00;;Y10T428/31511;;C09D7/69;;C08K3/22;;C08K3/36;;C08K9/06;;C08K3/28;;C09D7/67;;C09D7/68;;C09D7/62,C09C1/00;;C09D201/00;;C09C3/08;;C09D5/00;;C09D7/62;;C09D161/20;;C09D183/04,,0,0,,,,PENDING
299,US,A1,US 2004/0110895 A1,024-259-033-793-865,2004-06-10,2004,US 45657603 A,2003-06-09,US 45657603 A;;US 62942000 A;;US 48904200 A;;US 48904300 A;;US 36506999 A;;US 17189899 P;;US 17189999 P,1999-07-30,"Flexible coating compositions having improved scratch resistance, coated substrates and methods related thereto","
   Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings. 
",PPG IND OHIO INC,ANDERSON LAWRENCE G;;DE SAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;NAKAJIMA MASAYUKI;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/024-259-033-793-865,Patent Application,yes,99,29,3,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C08K2201/011;;C08J3/20;;C09D7/00;;C09D183/04;;C08K3/013;;C09D7/69;;C08K3/01;;C09D7/62,C08J3/20;;C08K3/00;;C09D7/62;;C09D183/04,524 588000;;524 100000;;524 102000;;524 474000;;524 476000;;524 026000;;524 028000;;524 029000,0,0,,,,EXPIRED
300,DE,D1,DE 60041977 D1,015-794-609-131-820,2009-05-20,2009,DE 60041977 T,2000-07-31,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A;;US 0020846 W,1999-07-30,"FLEXIBLE BESCHICHTUNGSZUSAMMENSETZUNGEN MIT VERBESSERTER KRATZFESTIGKEIT, BESCHICHTETE OBERFLÄCHE UND VERFAHREN ZU DEREN HERSTELLUNG","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/015-794-609-131-820,Granted Patent,no,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/06;;C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/08;;C09D183/12;;C09D201/00;;C09D201/02,,0,0,,,,EXPIRED
301,US,B2,US 6987144 B2,125-096-594-363-548,2006-01-17,2006,US 45657603 A,2003-06-09,US 45657603 A;;US 62942000 A;;US 48904200 A;;US 48904300 A;;US 36506999 A;;US 17189899 P;;US 17189999 P,1999-07-30,"Flexible coating compositions having improved scratch resistance, coated substrates and methods related thereto","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,ANDERSON LAWRENCE G;;DE SAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;NAKAJIMA MASAYUKI;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/125-096-594-363-548,Granted Patent,yes,99,43,3,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C08K2201/011;;C08J3/20;;C09D7/00;;C09D183/04;;C08K3/013;;C09D7/69;;C08K3/01;;C09D7/62,C08L83/04;;C08J3/20;;C08K3/00;;C08L83/06;;C08L83/08;;C09D7/62;;C09D183/04,524/588;;525/100;;525/102;;525/474;;525/476;;528/26;;528/28;;528/29,40,10,157-950-869-487-234;;041-907-825-797-281;;016-304-279-678-429;;025-879-222-825-583;;086-964-510-830-941;;014-753-970-652-54X;;073-435-195-435-849;;063-483-870-667-20X;;077-422-324-372-489;;011-967-534-003-943,10.1055/s-1981-29605;;10.1007/bf00283288;;10.1002/pola.1992.080300101;;10.1002/pola.1993.080311023;;10.1016/0032-3861(95)96845-y;;10.1007/bf02693053;;10.1016/s0300-9440(97)00073-8;;10.1007/bf02693054;;10.1007/bf02700543;;10.1007/bf02697993,"Office Action of U.S. Appl. No. 09/629,422, filed Oct. 26, 2004.;;Office Action of U.S. Appl. No. 10/642,826, filed Oct. 22, 2004.;;Office Action of U.S. Appl. No. 10/795,216, filed Dec. 15, 2004.;;Office Action of U.S. Appl. No. 10/784,830, filed Dec. 15, 2004.;;Iler, Ralph K., ""The Chemistry of Silica"", Colloidal Silica-Concentrated Sols, 1979, pp. 412-414.;;Verboom et al., ""N, N'-Bis[trismethylsilyl]-urea: A Useful Silylating Agent for Alcohols and Carboxylic Acids"", Laboratory of Organic Chemistry, Twente University of Technology, Enschede, The Netherlands, Communications, pp. 807-809, Oct. 1981.;;""Surface Coatings-vol. 1: Raw Materials and Their Usage,"" 2<SUP>nd </SUP>Ed., Tafe Educational Books, New South Wales University Press Limited, New South Wales, Australia 1983.;;Chattha et al., ""High Solids Coatings from New Oligomers"", Journal of Coatings Technology, vol. 55, No. 700, pp. 39-46, May 1983.;;Degussa, No. 6, Technical Bulletin Pigments, Hydrophobic Aerosil(R) Manufacture, Properties, and Applications, 4<SUP>th </SUP>Edition, Aug. 1986.;;Williams et al., ""Polyester Oligomers of Narrowed Molecular Weight Distribution"", Water-Borne & Higher-Solids Coatings Symposium, pp. 478-512, Feb. 3-5, 1988, New Orleans, LA, USA.;;""Siloxanes With Aliphatic Isocyanate Groups, A Tetrafunctional Cross-Linking Agent"", Guangbin Zhou and Richard Fragnito, Johannes Smid, Polymer Bulletin 22, pp. 85-88 (1989), Springer-Verlag.;;Odian, G., ""Principles of Polymerization, 3rd Edition"", John Wiley & Sons; Inc. ISBN: 0471610208, pp. 19-24, Published Oct. 18, 1991.;;Greene, T. W. et al., ""Protective Groups in Organic Synthesis"", Second Edition, John Wiley & Sons, Inc., pp. 68-86; & 261-263.;;""Regioselective Rhodium-Containing Catalysts for Ring-Opening Polymerizations and Hydrosilylations"", J.V. Crivello and M. Fan, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 30, pp. 1-11 (1992), John Wiley & Sons, Inc.;;""Synthesis of Novel Organic Oligomers Containing Si-H Bonds"", T. Iwahara, M. Jusakabe, M. Chiba and K. Yonezawa, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 31, pp. 2617-2631 (1993), John Wiley & Sons, Inc.;;Schmidt, C., et al., ""Inorganic-organic Hybrid Coatings For Metal And Glass Surfaces"", PMSE, Spring 1994, pp. 347-348.;;Etranian, A. et al., ""Les Silices Greffees Ameliorent Les Revetements"", Peintures & Encres, Informations Chimie, n 371- Sep. 1995, pp. 85-88.;;Espiard et al, ""Poly(ethyl acrylate) latexes Encapsulating Nanoparticles of Silica: 3. Morphology and Mechanical Properties of Reinforced Films"", Polymer, vol. 36, No. 23, pp. 4397-4403, Elsevier Science Ltd., 1995.;;Jones, F., ""Toward Solventless Liquid Coatings"", Journal of Coatings Technology, vol. 68, No. 852, pp. 25-36, Jan. 1996.;;""Highlink(R) OG Silica Organosols,"" Clariant, Societe Francais Hoechst, BL Chimie Fine, AE/MS.22/96.;;Varerkar M.P., ""Formulating High Solids Coatings: The Solution to VOC Problem"", Paintindia, Sep. 1996, pp. 19-30.;;Misra, M., et al., ""Hybrid Inorganic-Organic UV-Curable Abrasion-Resistant Coatings"", Surface Coatings International, (12) 1998, pp. 594-595.;;Chandra et al., ""Telechelic Oligomers for High Solids Coatings"", Paintindia, Feb. 1997, pp. 35-44.;;Jones, F., ""New Technology Holds Key"", Paint & Coatings Industry, May 1997, pp. 62-64.;;Chemical Abstracts 128:62925a, Noboru et al., ""Coating Pocess Using Siloxy-Containing Vinyl Polymer Clear Coatings"", Jpn. Kokai Tokkyo Joho JP 09, 314,040, Sep. 12, 1997 (abstract).;;Azuma et al, ""Acrylic Oligomer for High Solid Automotive Top Coating System Having Excellent Acid Resistance"", Progress In Organic Coatings, vol. 32, Sep.-Dec. 1997, pp. 1-7.;;Gettwert, G., et al., ""One-Component Silicate Binder Systems for Coatings"", Surface Coatings International, (12) 1998, pp. 596-603.;;Wu, Shobing, et al, ""Effect of Siloxane Functionalized Caprolactone Polyols on Photocurable Epoxy Coatings"", Journal of Coatings Technology, vol. 70, No. 887, Dec. 1998, pp. 53-62.;;Perry, R. J., ""Applications for Cross-linked Siloxane Particles"", Chemtech, Feb. 1999, pp. 39-44.;;Frings, S., et al., ""Morphology of Hybrid Coatings Based on Polyester, Melamine Resin, and Silica and the Relation with Hardness and Scratch Resistance"", Journal of Coatings Technology, vol. 72, No. 901, Feb. 2000, pp. 83-89.;;Straehle, Dr. Wolfgang, Head of the Corporate Division, Research and Purchasing, and the Operating Division, Industrial Coating, BASF Coatings AG, Münster, Germany, ""Scratchproof Clearcoat: High Gloss for the Long Term"", www.pcimaq.com, posted Jul. 25, 2000.;;Organo Silicasol, Nissan Chemical Industries, Ltd., Nissan Chemical America Corporation webpage, http://www.snowtex.com/organo_types.html.;;Wicks, Zeno W., et al., ""Organic Coatings: Science And Technology,"" second edition, Chapter 23, pp. 433-439 (Wiley-Interscience, c1999).;;Smetankina, N.P., et al., ""Investigation of the Interrelationship Between the Compositions, Production processes, and Properties of Polyurethanes With Reticular Structures. XV. Introduction of Organosilicon Carbofunctional Glycols Into Polyurethane Lacquer Compounds"", Institute of High-Molecular Compound Chemistry of the Academy of Sciences (AS) of the Ukrainian Soviet Socialist Republic (UkrSSR) (with translation).;;Kotomkin, V. Ya, et al., ""Resistance of Polysiloxane Urethanes to the Action of Solvents and Corrosive Media"", UDS 618.(664+64):619.34 (with translation).;;Frings, S., et al., ""Preparation and Characterization of Organic-Inorganic Hybrid Coatings Based on Crosslinked Polyester Systems and Silica, Formed Via the Sol-Gel Process"", Presented at the International Waterborne, High-Solids, and Powder Coatings Symposium, Feb. 10-12, 1999, New Orleans, L.A. USA, pp. 35-43.;;U.S. Appl. No. 09/629,421, Barancyk et al., ""Coating Compositions Comprising Silyl Blocked Components, Coatings, Coated Substrates and Methods Related Thereto,"" filed Jul. 31, 2000.;;U.S. Appl. No. 09/629,422, Anderson et al., ""Scratch Resistant Dual Cure Coatings, Coated Substrates and Methods Related Thereto,"" filed Jul. 31, 2000.;;U.S. Appl. No. 09/629,443, Anderson et al., ""Coating Compositions Having Improved Scratch Resistance, Coated Substrates and Methods Related Thereto,"" filed Jul. 31, 2000.;;U.S. Appl. No. 09/629,444, Anderson et al., ""Coating Compositions Having Improved Scratch Resistance, Coated Substrates, and Methods Related Thereto,"" filed Jul. 31, 2000.",EXPIRED
302,EP,A1,EP 1228155 A1,044-074-911-022-007,2002-08-07,2002,EP 00953761 A,2000-07-31,US 0020846 W;;US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A,1999-07-30,"FLEXIBLE COATING COMPOSITIONS HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATES AND METHODS RELATED THERETO","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/044-074-911-022-007,Patent Application,yes,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/12;;C09D201/00,,0,0,,,,EXPIRED
303,CA,A1,CA 2380415 A1,097-526-024-666-057,2001-02-08,2001,CA 2380415 A,2000-07-31,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A;;US 0020846 W,1999-07-30,"FLEXIBLE COATING COMPOSITIONS HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATES AND METHODS RELATED THERETO","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating compositi on and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.</S DOAB>",PPG IND OHIO INC,DESAW SHAWN A;;HARTMAN MARVIS E;;TYEBJEE SHIRYN;;WILT TRUMAN F;;ANDERSON LAWRENCE G;;SADVARY RICHARD J;;SCHILLING LAURA E;;OLSON KURT G;;SIMPSON DENNIS A;;MAYO MICHAEL ALLEN;;NAKAJIMA MASAYUKI;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L,,https://lens.org/097-526-024-666-057,Patent Application,no,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/12;;C09D201/00,,0,0,,,,EXPIRED
304,EP,B1,EP 1228155 B1,034-620-185-595-638,2009-04-08,2009,EP 00953761 A,2000-07-31,US 0020846 W;;US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A,1999-07-30,"FLEXIBLE COATING COMPOSITIONS HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATES AND METHODS RELATED THERETO","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/034-620-185-595-638,Granted Patent,yes,8,1,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/06;;C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/08;;C09D183/12;;C09D201/00;;C09D201/02,,0,0,,,,EXPIRED
305,JP,A,JP 2006070278 A,134-431-344-274-456,2006-03-16,2006,JP 2005339500 A,2005-11-24,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A,1999-07-30,"FLEXIBLE COATING COMPOSITIONS HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATES AND METHODS RELATED THERETO","<P>PROBLEM TO BE SOLVED: To provide coating compositions which are both flexible and resistant to scratching. <P>SOLUTION: Coating compositions are provided which are formed from components comprising (a) at least one polysiloxane, (b) at least one polyol, and (c) at least one reactant comprising at least one functional group that is reactive with at least one functional group selected from the at least one reactive functional group of the at least one polysiloxane (a) and at least one functional group of at least one polyol (b), wherein each component is different. The coating which is formed from the coating compositions has at least six flexible marks according to a flexible examination method at 70°F when cured. <P>COPYRIGHT: (C)2006,JPO&NCIPI",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/134-431-344-274-456,Patent Application,no,0,1,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/04;;C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/12;;C09D201/00;;C09D201/06,,0,0,,,,DISCONTINUED
306,PT,E,PT 1228155 E,000-197-154-687-661,2009-06-03,2009,PT 00953761 T,2000-07-31,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A,1999-07-30,"FLEXIBLE COATING COMPOSITIONS HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATES AND METHODS RELATED THERETO","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,OLSON KURT G;;MAYO MICHAEL A;;WILT TRUMAN F;;HAYES DEBORAH E;;HARTMAN MARVIS E;;SADVARY RICHARD J;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;NAKAJIMA MASAYUKI;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;SCHILLING LAURA E,,https://lens.org/000-197-154-687-661,Granted Patent,no,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/06;;C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/08;;C09D183/12;;C09D201/00;;C09D201/02,,0,0,,,,EXPIRED
307,WO,A1,WO 2001/009261 A1,002-929-837-995-851,2001-02-08,2001,US 0020846 W,2000-07-31,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A,1999-07-30,"FLEXIBLE COATING COMPOSITIONS HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATES AND METHODS RELATED THERETO","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/002-929-837-995-851,Patent Application,yes,8,27,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/12;;C09D201/00,,0,0,,,,PATENTED
308,US,B1,US 6610777 B1,006-376-143-073-674,2003-08-26,2003,US 62942000 A,2000-07-31,US 62942000 A;;US 48904200 A;;US 48904300 A;;US 36506999 A;;US 17189999 P,1999-07-30,"Flexible coating compositions having improved scratch resistance, coated substrates and methods related thereto","
    Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings. 
",PPG IND OHIO INC,ANDERSON LAWRENCE G;;DE SAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;NAKAJIMA MASAYUKI;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,PGG INDUSTRIES OHIO INC (2000-11-02),https://lens.org/006-376-143-073-674,Granted Patent,yes,103,67,3,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C08K2201/011;;C08J3/20;;C09D7/00;;C09D183/04;;C08K3/013;;C09D7/69;;C08K3/01;;C09D7/62,C08J3/20;;C08K3/00;;C09D7/62;;C09D183/04,524588;;525100;;525102;;525474;;525476;;528 26;;528 28;;528 29,38,10,157-950-869-487-234;;041-907-825-797-281;;016-304-279-678-429;;025-879-222-825-583;;086-964-510-830-941;;014-753-970-652-54X;;073-435-195-435-849;;063-483-870-667-20X;;077-422-324-372-489;;011-967-534-003-943,10.1055/s-1981-29605;;10.1007/bf00283288;;10.1002/pola.1992.080300101;;10.1002/pola.1993.080311023;;10.1016/0032-3861(95)96845-y;;10.1007/bf02693053;;10.1016/s0300-9440(97)00073-8;;10.1007/bf02693054;;10.1007/bf02700543;;10.1007/bf02697993,"Chemical Abstracts AN 1996:710179, Ohsawa et al, ""One-Component thermosetting coating compositions"", Ger. Offen., 44 pp., 1996, abstract of German Patent DE 196 12 746.;;Iler, Ralph K., ""The Chemistry of Silica"", Colloidal Silica-Concentrated Sols, 1979, pp. 412-414.;;Verboom et al., ""N, N'-Bis[trismethylsilyl]-urea: A Useful Silylating Agent for Alcohols and Carboxylic Acids"", Laboratory of Organic Chemistry, Twente University of Technology, Enschede, The Netherlands, Communications, pp. 807-809, Oct. 1981.;;""Surface Coatings-vol. 1: Raw Materials and Their Usage,"" 2nd Ed., Tafe Educational Books, New South Wales University Press Limited, New South Wales, Australia 1983.;;Chattha et al., ""High Solids Coatings from New Oligomers"", Journal of Coating Technology, vol. 55, No. 700, pp. 39-46, May 1983.;;Degussa, No. 6, Technical Bulletin Pigments, Hydrophobic Aerosil(R) Manufacture, Properties, and Applications, 4th Edition, Aug. 1986.;;Williams et al., ""Polyester Oligomers of Narrowed Molecular Weight Distribution"", Water-Borne & Higher-Solids Coatings Symposium, pp. 478-512, Feb. 3-5, 1988, New Orleans, LA, USA.;;""Siloxanes With Aliphatic Isocyanate Groups, A Tetrafunctional Cross-Linking Agent"", Guangbin Zhou and Richard Fragnito, Johannes Smid, Polymer Bulletin 22, pp. 85-88 (1989), Springer-Verlag.;;Odian, G., ""Principles of Polymerization, 3rd Edition"", John Wiley & Sons; Inc. ISBN: 0471610208, pp. 19-24, Published Oct. 18, 1991.;;Greene, T. W. et al., ""Protective Groups in Organic Synthesis"", Second Edition, John Wiley & Sons, Inc., pp. 68-86; & 261-263.;;""Regioselective Rhodium-Containing Catalysts for Ring-Opening Polymerizations and Hydrosilylations"", J.V. Crivello and M. Fan, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 30, pp. 1-11 (1992), John Wiley & Sons, Inc.;;""Synthesis of Novel Organic Oligomers Containing Si-H Bonds"", T. Iwahara, M. Jusakabe, M. Chiba and K. Yonezawa, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 31, pp. 2617-2631 (1993), John Wiley & Sons, Inc.;;Schmidt, C., et al., ""Inorganic-organic Hybrid Coatings For Metal And Glass Surfaces"", PMSE, Spring 1994, pp. 347-348.;;Etranian, A. et al., ""Les Silices Greffees Ameliorent Les Revetements"", Peintures & Encres, Informations Chimie, n 371-Sep. 1995, pp. 85-88.;;Espiard et al, ""Poly(ethyl acrylate) latexes Encapsulating Nanoparticles of Silica: 3. Morphology and Mechanical Properties of Reinforced Films"", Polymer, vol. 36, No. 23, pp. 4397-4403, Elsevier Science Ltd., 1995.;;Jones, F., ""Toward Solventless Liquid Coatings"", Journal of Coatings Technology, vol. 68, No. 852, pp. 25-36, Jan. 1996.;;""Highlink(R) OG Silica Organosols,"" Clariant, Societe Francais Hoechst, BL Chimie Fine, AE/MS.22/96.;;Varerkar M.P., ""Formulating High Solids Coatings: The Solution to VOC Problem"", Paintindia, Sep. 1996, pp. 19-30.;;Misra, M., et al., ""Hybrid Inorganic-Organic UV-Curable Abrasion-Resistant Coatings"", Surface Coatings International, (12) 1998, pp. 594-595.;;Chandra et al., ""Telechelic Oligomers for High Solids Coatings"", Paintindia, Feb. 1997, pp. 35-44.;;Jones, F., ""New Technology Holds Key"", Paint & Coatings Industry, May 1997, pp. 62-64.;;Chemical Abstracts 128:62925a, Noboru et al., ""Coating Pocess Using Siloxy-Containing Vinyl Polymer Clear Coatings"", Jpn. Kokai Tokkyo Joho JP 09, 314,040, Sep. 12, 1997 (abstract).;;Azuma et al, ""Acrylic Oligomer for High Solid Automotive Top Coating System Having Excellent Acid Resistance"", Progress In Organic Coatings, vol. 32, Sep.-Dec. 1997, pp. 1-7.;;Gettwert, G., et al., ""One-Component Silicate Binder Systems for Coatings"", Surface Coatings International, (12) 1998, pp. 596-603.;;Wu, Shobing, et al, ""Effect of Siloxane Functionalized Caprolactone Polyols on Photocurable Epoxy Coatings"", Journal of Coatings Technology, vol. 70, No. 887, Dec. 1998, pp. 53-62.;;Perry, R. J., ""Applications for Cross-linked Siloxane Particles"", Chemtech, Feb. 1999, pp. 39-44.;;Frings, S., et al., ""Morphology of Hybrid Coatings Based on Polyester, Melamine Resin, and Silica and the Relation with Hardness and Scratch Resistance"", Journal of Coatings Technology, vol. 72, No. 901, Feb. 2000, pp. 83-89.;;Straehle, Dr. Wolfgang, Head of the Corporate Division, Research and Purchasing, and the Operating Division, Industrial Coating, BASF Coatings AG, Münster, Germany, ""Scratchproof Clearcoat: High Gloss for the Long Term"", www.pcimag.com, posted Jul. 25, 2000.;;Organo Silicasol, Nissan Chemical Industries, Ltd., Nissan Chemical America Corporation webpage, http://www.snowtex.com/organo_types.html.;;Wicks, Zeno W., et al., ""Organic Coatings: Science And Technology,"" second edition, Chapter 23, pp. 433-439 (Wiley-Interscience, c1999).;;Smetankina, N.P., et al., ""Investigation of the Interrelationship Between the Compositions, Production processes, and Properties of Polyurethanes With Reticular Structures. XV. Introduction of Organosilicon Carbofunctional Glycols Into Polyurethane Lacquer Compounds"", Institute of High-Molecular Compound Chemistry of the Academy of Sciences (AS) of the Ukrainian Soviet Socialist Republic (UkrSSR) (with translation).;;Kotomkin, V. Ya, et al., ""Resistance of Polysiloxane Urethanes to the Action of Solvents and Corrosive Media"", UDS 618(664+64):619.34 (with translation).;;Frings, S., et al., ""Preparation and Characterization of Organic-Inorganic Hybrid Coatings Based on Crosslinked Polyester Systems and Silica, Formed Via the Sol-Gel Process"", Presented at the International Waterborne, High-Solids, and Powder Coatings Symposium, Feb. 10-12, 1999, New Orleans, L.A. USA, pp. 35-43.;;09/629,421, Barancyk et al., ""Coating Compositions Comprising Silyl Blocked Components, Coatings, Coated Substrates and Methods Related Thereto,"" filed Jul. 31, 2000.;;09/629,422, Anderson et al., ""Scratch Resistant Dual Cure Coatings, Coated Substrates and Methods Related Thereto,"" filed Jul. 31, 2000.;;09/629,423, Anderson et al., ""Cured Coatings Having Improved Scratch-Resistance, Coated Substrates and Methods Related Thereto,"" filed Jul. 31, 2000.;;09/629,443, Anderson et al., ""Coating Compositions Having Improved Scratch Resistance, Coated Substrates and Methods Related Thereto,"" Jul. 31, 2000.;;09/629,444, Anderson et al., ""Coatings Compositions Having Improved Scratch Resistance, Coated Substrates, and Methods Related Thereto,"" filed Jul. 31, 2000.",EXPIRED
309,BR,A,BR 0012883 A,099-502-977-249-742,2002-04-09,2002,BR 0012883 A,2000-07-31,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A;;US 0020846 W,1999-07-30,"Composições de revestimento flexìveis tendo resistência a arranhadura melhorada, substratos revestidos e métodos a elas relacionados","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/099-502-977-249-742,Patent Application,no,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/12;;C09D201/00,,0,0,,,,DISCONTINUED
310,AU,A,AU 2000/066158 A,121-723-005-413-16X,2001-02-19,2001,AU 2000/066158 A,2000-07-31,US 36506999 A;;US 17189999 P;;US 17189899 P;;US 48904200 A;;US 48904300 A;;US 0020846 W,1999-07-30,"Flexible coating compositions having improved scratch resistance, coated substrates and methods related thereto","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/121-723-005-413-16X,Patent Application,no,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/12;;C09D201/00,,0,0,,,,EXPIRED
311,CA,C,CA 2380415 C,172-972-707-374-828,2007-07-17,2007,CA 2380415 A,2000-07-31,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A;;US 0020846 W,1999-07-30,"FLEXIBLE COATING COMPOSITIONS HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATES AND METHODS RELATED THERETO","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating compositi on and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.</S DOAB>",PPG IND OHIO INC,SIMPSON DENNIS A;;MAYO MICHAEL ALLEN;;HOCKSWENDER THOMAS R;;SCHILLING LAURA E;;KUSTER KYMARIE L;;SADVARY RICHARD J;;DESAW SHAWN A;;ANDERSON LAWRENCE G;;NAKAJIMA MASAYUKI;;OLSON KURT G;;TYEBJEE SHIRYN;;WILT TRUMAN F;;HARTMAN MARVIS E;;HAYES DEBORAH E,,https://lens.org/172-972-707-374-828,Granted Patent,no,0,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/06;;C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/08;;C09D183/12;;C09D201/00;;C09D201/02,,0,0,,,,EXPIRED
312,AU,B2,AU 764500 B2,018-902-295-738-981,2003-08-21,2003,AU 2000/066158 A,2000-07-31,US 36506999 A;;US 17189999 P;;US 17189899 P;;US 48904200 A;;US 48904300 A;;US 0020846 W,1999-07-30,"Flexible coating compositions having improved scratch resistance, coated substrates and methods related thereto","Coating compositions are provided which include a polysiloxane comprising at least one reactive functional group and at least one material comprising at least one reactive functional group. Also provided are multi-layer composite coatings formed from a basecoat deposited from a pigmented coating composition and a topcoat applied over the basecoat, the topcoat deposited from the aforementioned coating composition. A method for improving the scratch resistance of a coated substrate, as well as coated substrates also are provided. The compositions of the invention provide highly scratch resistant coatings, particularly highly scratch resistant color-plus-clearcoatings.",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/018-902-295-738-981,Granted Patent,no,1,0,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D161/08;;C09D163/00;;C09D175/04;;C09D183/04;;C09D183/12;;C09D201/00,,0,0,,,,EXPIRED
313,JP,A,JP 2008223034 A,122-225-103-556-919,2008-09-25,2008,JP 2008110512 A,2008-04-21,US 36506999 A;;US 17189899 P;;US 17189999 P;;US 48904200 A;;US 48904300 A,1999-07-30,"FLEXIBLE COATING COMPOSITION HAVING IMPROVED SCRATCH RESISTANCE, COATED SUBSTRATE AND METHOD RELATED THERETO","<P>PROBLEM TO BE SOLVED: To provide coating composition which are flexible and have high scratch resistance. <P>SOLUTION: The coating compositions are provided which are formed from components comprising (a) at least one polysiloxane, (b) at least one polyol, and (c) at least one reactant comprising at least one functional group that is reactive with at least one functional group selected from at least one reactive functional group of at least one polysiloxane (a) and at least one functional group of at least one polyol (b), wherein the coating which is formed from the coating compositions has at least six flexible marks according to a flexibility examination method at a temperature of 70°F when cured. <P>COPYRIGHT: (C)2008,JPO&INPIT",PPG IND OHIO INC,NAKAJIMA MASAYUKI;;ANDERSON LAWRENCE G;;DESAW SHAWN A;;HARTMAN MARVIS E;;HAYES DEBORAH E;;HOCKSWENDER THOMAS R;;KUSTER KYMARIE L;;MAYO MICHAEL ALLEN;;OLSON KURT G;;SADVARY RICHARD J;;SCHILLING LAURA E;;SIMPSON DENNIS A;;TYEBJEE SHIRYN;;WILT TRUMAN F,,https://lens.org/122-225-103-556-919,Patent Application,no,0,3,17,94,0,B82Y30/00;;C08J3/20;;C08K2201/011;;C09D7/00;;C09D183/04;;C09D7/62;;C09D7/67;;C09D7/68;;C09D7/69;;C08K3/01;;C08K3/013;;B82Y30/00;;C09D7/62,C09D183/04;;C09D183/10;;C08J3/20;;C08K3/00;;C09D7/62;;C09D133/14;;C09D161/08;;C09D163/00;;C09D167/00;;C09D171/00;;C09D175/04;;C09D183/05;;C09D183/06;;C09D183/07;;C09D183/08;;C09D183/12;;C09D201/00;;C09D201/06,,0,0,,,,PENDING
314,CA,A1,CA 3117083 A1,035-778-175-540-349,2020-04-30,2020,CA 3117083 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,INTERVENTION DRIVE SYSTEM COMPRISING AN UMBILICAL,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical (6) is manufactured from a low-density material, wherein the umbilical (6) comprises an external covering of material having a low coefficient of friction.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURICIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTONIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRES;;ALMEIDA DE SOUZA GABRIELLE;;PAIXAO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRE;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/035-778-175-540-349,Patent Application,no,0,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049,,0,0,,,,PENDING
315,BR,A2,BR 102018072062 A2,087-725-027-418-04X,2020-05-05,2020,BR 102018072062 A,2018-10-26,BR 102018072062 A,2018-10-26,sistema tracionador de intervenção compreendendo um umbilical,"sistema tracionador de intervenção compreendendo um umbilical a presente invenção está relacionada a um pig tracionador de intervenção compreendendo um umbilical. nesse cenário, a presente invenção provê um pig tracionador de intervenção compreendendo um umbilical, em que o umbilical (6) é fabricado em material de baixa densidade, e em que o umbilical (6) compreende um revestimento externo de material de baixo coeficiente de atrito.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,ANDERSON MACIEL;;DANTE AUGUSTO COUTO BARONE;;DAVID STEEVEN VILLA SALAZAR;;EDUARDO ANDRÉ PERONDI;;EDUARDO ANTONIO WINK DE MENEZES;;EDUARDO DONADEL BASSO;;FABIANO DISCONZI WILDNER;;FILIPE PAIXÃO GEIGER;;GABRIELLE ALMEIDA DE SOUZA;;HARDY LEONARDO DA CUNHA PEREIRA PINTO;;HUGO FRANCISCO LISBOA SANTOS;;IGOR MENDES URSINE KRETTLI;;JAIME ANDRÉS RIASCOS SALAS;;JOSE ABEL TICONA LARICO;;JULIANO MORATO FRANZ;;LAURA AMAYA TORRES;;LINCOLN HOMERO THOME FERREIRA;;LUCIANA PORCHER NEDEL;;MAURÍCIO GALASSI;;NEY ROBINSON SALVI DOS REIS;;RAFAEL ANTÔNIO COMPARSI LARANJA;;TIAGO BECKER,,https://lens.org/087-725-027-418-04X,Patent Application,no,0,2,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,E21B37/00;;F16L55/26,,0,0,,,,ACTIVE
316,EP,A4,EP 3872384 A4,081-339-855-920-349,2022-07-27,2022,EP 19874796 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,INTERVENTION DRIVE SYSTEM COMPRISING AN UMBILICAL,,PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURÍCIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTÔNIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRÉS;;ALMEIDA DE SOUZA GABRIELLE;;PAIXÃO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRÉ;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/081-339-855-920-349,Search Report,no,4,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049;;B08B9/055;;E21B37/00;;F16L55/26;;F16L55/30;;F16L55/46,,1,0,,,See also references of WO 2020082149A1,ACTIVE
317,US,B2,US 11920722 B2,160-120-550-814-550,2024-03-05,2024,US 17288662,2019-10-24,BR 1020180720627,2018-10-26,Intervention drive system comprising an umbilical,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical ( 6 ) is manufactured from a low-density material, wherein the umbilical ( 6 ) comprises an external covering of material having a low coefficient of friction.",PETRÓLEO BRASILEIRO S.A.—PETROBRAS;;UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL—UFRGS,Hugo Francisco Lisboa Santos;;Ney Robinson Salvi Dos Reis;;Maurício Galassi;;Lincoln Homero Thome Ferreira;;Igor Mendes Ursine Krettli;;Hardy Leonardo Da Cunha Pereira Pinto;;Tiago Becker;;Rafael Antônio Comparsi Laranja;;Luciana Porcher Nedel;;Laura Amaya Torres;;Jose Abel Ticona Larico;;Jaime Andrés Riascos Salas;;Gabrielle Almeida De Souza;;Filipe Paixão Geiger;;Fabiano Disconzi Wildner;;Eduardo Antonio Wink De Menezes;;Eduardo Donadel Basso;;David Steeven Villa Salazar;;Eduardo André Perondi;;Anderson Maciel;;Dante Augusto Couto Barone;;Juliano Morato Franz,UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL - UFRGS (2021-04-29);;PETRÓLEO BRASILEIRO S.A. - PETROBRAS (2018-10-16),https://lens.org/160-120-550-814-550,Granted Patent,yes,13,0,1,1,0,F16L55/46;;B08B9/0535;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L2101/12,B08B9/055;;B08B9/053;;F16L55/30;;F16L55/46;;F16L101/12,,0,0,,,,UNKNOWN
318,EP,B1,EP 3872384 B1,097-127-196-928-764,2023-09-13,2023,EP 19874796 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,INTERVENTION DRIVE PIG COMPRISING AN UMBILICAL,,PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURÍCIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTÔNIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRÉS;;ALMEIDA DE SOUZA GABRIELLE;;PAIXÃO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRÉ;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/097-127-196-928-764,Granted Patent,yes,15,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049;;B08B9/055;;E21B37/00;;F16L55/26;;F16L55/30;;F16L55/46,,0,0,,,,ACTIVE
319,CN,A,CN 113825939 A,138-713-719-977-475,2021-12-21,2021,CN 201980070431 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,INTERVENTION DRIVE SYSTEM COMPRISING UMBILICAL,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical (6) is manufactured from a low-density material, wherein the umbilical (6) comprises an external covering of material having a low coefficient of friction.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURICIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTÔNIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRES;;ALMEIDA DE SOUZA GABRIELLE;;PAIXAO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRE;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/138-713-719-977-475,Patent Application,no,12,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049,,1,0,,,"周云等: ""深海石油钻采隔水管浮力补偿系统的研究"", 《中国海洋平台》",ACTIVE
320,MX,A,MX 2021004349 A,081-248-854-089-764,2021-12-10,2021,MX 2021004349 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,INTERVENTION DRIVE SYSTEM COMPRISING AN UMBILICAL.,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical (6) is manufactured from a low-density material, wherein the umbilical (6) comprises an external covering of material having a low coefficient of friction.",PETROLEO BRASILEIRO SA PETROBRAS,DA CUNHA PEREIRA PINTO HARDY LEONARDO;;GALASSI MAURICIO;;SALVI DOS REIS NEY ROBINSON;;MENDES URSINE KRETTLI IGOR;;LISBOA SANTOS HUGO FRANCISCO;;THOME FERREIRA LÍNCOLN HOMERO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTONIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRÉS;;ALMEIDA DE SOUZA GABRIELLE;;PAIXÁO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRÉ;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/081-248-854-089-764,Patent Application,no,0,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049,,0,0,,,,PENDING
321,US,A1,US 2021/0396342 A1,037-291-965-403-988,2021-12-23,2021,US 201917288662 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,INTERVENTION DRIVE SYSTEM COMPRISING AN UMBILICAL,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical ( 6 ) is manufactured from a low-density material, wherein the umbilical ( 6 ) comprises an external covering of material having a low coefficient of friction.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURÍCIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTÔNIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRÉS;;ALMEIDA DE SOUZA GABRIELLE;;PAIXÃO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRÉ;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL - UFRGS (2021-04-29);;PETRÓLEO BRASILEIRO S.A. - PETROBRAS (2018-10-16),https://lens.org/037-291-965-403-988,Patent Application,yes,1,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/46;;B08B9/055,,0,0,,,,ACTIVE
322,WO,A1,WO 2020/082149 A1,145-548-278-984-772,2020-04-30,2020,BR 2019050461 W,2019-10-24,BR 102018072062 A,2018-10-26,INTERVENTION DRIVE SYSTEM COMPRISING AN UMBILICAL,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical (6) is manufactured from a low-density material, wherein the umbilical (6) comprises an external covering of material having a low coefficient of friction.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURÍCIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTÔNIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRÉS;;ALMEIDA DE SOUZA GABRIELLE;;PAIXÃO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRÉ;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/145-548-278-984-772,Patent Application,yes,12,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049,,1,0,,,See also references of EP 3872384A4,PENDING
323,EP,A1,EP 3872384 A1,187-980-667-353-719,2021-09-01,2021,EP 19874796 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,INTERVENTION DRIVE SYSTEM COMPRISING AN UMBILICAL,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical (6) is manufactured from a low-density material, wherein the umbilical (6) comprises an external covering of material having a low coefficient of friction.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURÍCIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTÔNIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRÉS;;ALMEIDA DE SOUZA GABRIELLE;;PAIXÃO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRÉ;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/187-980-667-353-719,Patent Application,yes,0,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049,,0,0,,,,ACTIVE
324,AU,A1,AU 2019/365275 A1,026-234-116-683-719,2021-05-20,2021,AU 2019/365275 A,2019-10-24,BR 102018072062 A;;BR 2019050461 W,2018-10-26,Intervention drive system comprising an umbilical,"The present invention relates to an intervention drive pig comprising an umbilical. In this scenario, the present invention provides an intervention drive pig comprising an umbilical, wherein the umbilical (6) is manufactured from a low-density material, wherein the umbilical (6) comprises an external covering of material having a low coefficient of friction.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LISBOA SANTOS HUGO FRANCISCO;;SALVI DOS REIS NEY ROBINSON;;GALASSI MAURÍCIO;;THOME FERREIRA LINCOLN HOMERO;;MENDES URSINE KRETTLI IGOR;;DA CUNHA PEREIRA PINTO HARDY LEONARDO;;BECKER TIAGO;;COMPARSI LARANJA RAFAEL ANTÔNIO;;PORCHER NEDEL LUCIANA;;AMAYA TORRES LAURA;;TICONA LARICO JOSE ABEL;;RIASCOS SALAS JAIME ANDRÉS;;ALMEIDA DE SOUZA GABRIELLE;;PAIXÃO GEIGER FILIPE;;DISCONZI WILDNER FABIANO;;WINK DE MENEZES EDUARDO ANTONIO;;DONADEL BASSO EDUARDO;;STEEVEN VILLA SALAZAR DAVID;;PERONDI EDUARDO ANDRÉ;;MACIEL ANDERSON;;COUTO BARONE DANTE AUGUSTO;;MORATO FRANZ JULIANO,,https://lens.org/026-234-116-683-719,Patent Application,no,0,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,F16L55/32;;B08B9/049,,0,0,,,,PENDING
325,BR,B1,BR 102018072062 B1,175-604-219-503-133,2023-12-12,2023,BR 102018072062 A,2018-10-26,BR 102018072062 A,2018-10-26,Sistema tracionador de intervenção compreendendo um umbilical,"sistema tracionador de intervenção compreendendo um umbilical a presente invenção está relacionada a um pig tracionador de intervenção compreendendo um umbilical. nesse cenário, a presente invenção provê um pig tracionador de intervenção compreendendo um umbilical, em que o umbilical (6) é fabricado em material de baixa densidade, e em que o umbilical (6) compreende um revestimento externo de material de baixo coeficiente de atrito.",PETROLEO BRASILEIRO SA PETROBRAS;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,MACIEL ANDERSON;;DANTE AUGUSTO COUTO BARONE;;DAVID STEEVEN VILLA SALAZAR;;EDUARDO ANDRÉ PERONDI;;EDUARDO ANTONIO WINK DE MENEZES;;EDUARDO DONADEL BASSO;;FABIANO DISCONZI WILDNER;;FILIPE PAIXÃO GEIGER;;GABRIELLE ALMEIDA DE SOUZA;;HARDY LEONARDO DA CUNHA PEREIRA PINTO;;HUGO FRANCISCO LISBOA SANTOS;;IGOR MENDES URSINE KRETTLI;;JAIME ANDRÉS RIASCOS SALAS;;JOSE ABEL TICONA LARICO;;JULIANO MORATO FRANZ;;LAURA AMAYA TORRES;;LINCOLN HOMERO THOME FERREIRA;;LUCIANA PORCHER NEDEL;;GALASSI MAURÍCIO;;NEY ROBINSON SALVI DOS REIS;;RAFAEL ANTÔNIO COMPARSI LARANJA;;BECKER TIAGO,,https://lens.org/175-604-219-503-133,Granted Patent,no,0,0,12,12,0,E21B37/00;;F16L55/26;;B08B9/049;;F16L55/30;;F16L55/46;;B08B9/055;;E21B37/00;;F16L55/26;;B08B9/055;;B08B2209/045;;B08B2209/055;;F16L55/30;;F16L55/46;;F16L2101/12;;B08B9/0535,E21B37/00;;F16L55/26,,0,0,,,,ACTIVE
326,AU,A1,AU 2003/289716 A1,018-710-980-171-366,2004-04-30,2004,AU 2003/289716 A,2003-09-12,US 41026002 P;;US 41025902 P;;US 0328227 W,2002-09-12,MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS,,INCYTE CORP,SUAREZ CHARLYN J;;SCHMIDT JEANETTE P;;WRIGHT RACHEL J;;BRUNS CHRISTOPHER M;;MARJANOVIC MIRJANA M;;SHEN FAN;;HARTHSHORNE TOINETTE A;;SUCHOROLSKI MARTIN T;;ALTUS CHRISTINA M;;PITTS STEVEN J;;ELDER LINDA V;;MOONEY ELIZABETH M;;DELEGEANE ANGELO M;;PANESAR IQBAL S;;BANVILLE STEVEN C;;REDDY THIRUPATHI P;;STEVENS KRISTIAN A;;BLANCHARD JOHN L;;PANZER SCOTT R;;WANG XINHAO;;AU ALAN P;;GERSTIN JR EDWARD H;;PERALTA CAREYNA H;;ANDERSON SCOTT B;;RIOUX PIERRE;;SHEN EDWARD J;;WU MINGHAM C;;STUVE LAURA L;;LAGACE ROBERT E;;SPIRO PETER A;;STEWART ELIZABETH A;;WINGROVE JAMES;;VITT URSULA A;;KIRTON EDWARD S;;XU YUMING;;KWONG MARY;;POLICKY JENNIFER L;;HURWITZ BONNIE L;;MA YAN;;JACKSON JENNIFER L;;GIETZEN DARRYL;;PATURY SRIKANTH;;SHI XIAOBING,,https://lens.org/018-710-980-171-366,Patent Application,no,0,0,4,4,0,C12Q1/6876;;C07K14/47;;C12Q2600/136;;C12Q2600/142;;C12Q2600/158,A61B/;;C07H21/02;;C07H21/04;;C07K14/47;;C12Q1/68,,0,0,,,,DISCONTINUED
327,AU,A8,AU 2003/289716 A8,185-468-433-996-388,2004-04-30,2004,AU 2003/289716 A,2003-09-12,US 41026002 P;;US 41025902 P;;US 0328227 W,2002-09-12,Molecules for diagnostics and therapeutics,,INCYTE CORP,PATURY SRIKANTH;;SHEN EDWARD J;;STEVENS KRISTIAN A;;GIETZEN DARRYL;;KIRTON EDWARD S;;ALTUS CHRISTINA M;;LAGACE ROBERT E;;SHI XIAOBING;;SUAREZ CHARLYN J;;KWONG MARY;;AU ALAN P;;SUCHOROLSKI MARTIN T;;PANESAR IQBAL S;;STEWART ELIZABETH A;;MA YAN;;ANDERSON SCOTT B;;BRUNS CHRISTOPHER M;;WINGROVE JAMES;;ELDER LINDA V;;REDDY THIRUPATHI P;;HARTHSHORNE TOINETTE A;;HURWITZ BONNIE L;;PERALTA CAREYNA H;;VITT URSULA A;;BLANCHARD JOHN L;;WRIGHT RACHEL J;;MOONEY ELIZABETH M;;GERSTIN JR EDWARD H;;SHEN FAN;;POLICKY JENNIFER L;;DELEGEANE ANGELO M;;RIOUX PIERRE;;JACKSON JENNIFER L;;MARJANOVIC MIRJANA M;;SPIRO PETER A;;XU YUMING;;WANG XINHAO;;WU MINGHAM C;;PANZER SCOTT R;;SCHMIDT JEANETTE P;;STUVE LAURA L;;PITTS STEVEN J;;BANVILLE STEVEN C,,https://lens.org/185-468-433-996-388,Patent Application,no,0,0,4,4,0,C12Q1/6876;;C07K14/47;;C12Q2600/136;;C12Q2600/142;;C12Q2600/158,A61B/;;C07H21/02;;C07H21/04;;C07K14/47;;C12Q1/68,,0,0,,,,DISCONTINUED
